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ABBREVIATIONS 
 
AAMI Age Associated Memory Impairment 
AchE Acetylcholinesterase 
AD Alzheimer’s Disease 
ADAS-cog Alzheimer’s Disease Assessment Scale – cognitive subscale 
ADL Barthel index for Activities of Daily Living 
ADRDA Alzheimer’s Disease and Related Disorders Association 
AE Adverse Event 
AMIPB Adult Memory and Information Processing Battery 
APA American Psychiatric Association 
BCT Brain Computed Tomography 
BDS Blessed Dementia Scale 
BDW Ba Wei Di Huang Wan* 
CCM Contemporary Clinical Manual (of Chinese medicine) 
CCSE Cognitive Capacity Screening Examination 
CDR Clinical Dementia Rating Scale 
CDR-SB Clinical Dementia Rating – Sum of the Boxes 
CEI Cognitive effect index 
CHM Chinese Herbal Medicine 
CI Confidence Interval 
CM Chinese Medicine 
CMS Clinical memory scale* 
CQVIP Chinese VIP Information (a Chinese language database) 
CSJN Cong Sheng Jiao Nang* 
CT Clinical Trial 
CT scan Computed axial Tomography scan 
CVA Cerebrovascular Accident 
DSM Diagnostic and Statistical Manual of mental disorders (various editions) 
DZHS Deng Zan Hua Su* 
EBCM Evidence Based Chinese Medicine 
EBM Evidence Based Medicine 
ECG Electrocardiograph 
FE  formula entries 
EEG Electroencephalogram 
FAQ Functional Activities Questionnaire 
GDS Global Deterioration Scale 
GIR-DDL Global Improvement Rating – Disturbance in Daily Living activities 
GIR-neur Global Improvement Rating – neurological symptoms 
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GIR-psych Global Improvement Rating – psychological symptoms 
GIR-subj Global Improvement Rating – subjective symptoms 
GTS Gou Teng San* 
HDL-C High Density Lipoprotein 
HDS Hasegawa Dementia Scale 
HDS-R Revised version of Hasegawa Dementia Scale 
HIS Hachinski Ischemic Scale 
HKBU Hong Kong Baptist University 
HM Herbal Medicine (in general) 
HNYCJN Huan Nao Yi Chong Jiao Nang* 
HXQYYZ Huo Xue Qu Yu Yi Zhi Jian Ji* 
JJDBYW Jia Jian Da Bu Yin Wan* 
JNYZ Jian Nao Yi Zhi Ke Li* 
JPTJF Jian Pi Tian Jing Fang* 
JSWW Jin Si Wei Wan* 
JWWZYZKL Jia Wei Wu Zi Yan Zong Ke Li* 
MCI Mild Cognitive Impairment 
MDA Malondialdehyde 
MeSH Medical Subject Heading 
MiD Multi-infarct Dementia 
MMSE Mini-Mental State Examination 
MMSE – R Mini-Mental State Examination – Revised in China 
MO Melissa officinalis 
MQ Memory Quotient 
MRI Magnetic Resonance Imaging 
NCJQW Niu Che Jin Qi Wan* 
NINCDS National Institute of Neurological and Communicative Disorders and Stroke 
NLBW Nao Li Bao Wan* 
NPI Neuropsychiatric Inventory 
PET Positron Emission Tomography 
PRC People’s Republic of China 
RCT Randomized Control Trial 
SF 36 36 Item Short Form Health Survey 
SLJN Shou Ling Jian Nao Jiao Nang* 
SO Salvia officinalis 
SOD Superoxide Dismutase 
SPSS Statistical Package for the Social Sciences 
TC Total Cholesterol 
 iv 
TCD Transcranial Doppler 
TG Triglycerides 
TZK Tian Zhi Ke Li* 
VaD Vascular Dementia 
WAIS Wechsler’s Adult Intelligence Scale 
WAIS-RC Wechsler Adult Intelligence Scale – Revised in China 
WMD Weighted Mean Difference 
WMS Wechsler’s Memory Scale 
XLJN Xian Long Jiao Nang* 
YGS Yi Gan San* 
YNCJ Yi Nao Chong Ji* 
YZ Yi Zhi Jiao Nang* 
Z Zarit caregiver burden scale 
ZGBCQS Zhong Guo Ben Cao Quan Shu 
ZHYD Zhong Hua Yi Dian 
ZYFJDCD Zhong Yi Fang Ji Da Ci Dian 
 
* These are Chinese herbal medicines used in various clinical trials. 
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SUMMARY 
 
This study evaluated the level and quality of evidence for the use of Chinese Herbal Medicine (CHM) 
for dementia, in particular Alzheimer’s disease (AD), and for other disorders of age-related cognitive 
impairment, in both the modern and classical clinical Chinese medicine literature. For the modern 
literature this included clinical trials using scientific methodologies and also expert recommendations. 
For the classical literature herbal formulas and individual herbs for analogous conditions were examined 
for the period up to 1911. 
 
Methods were developed for locating, retrieving, evaluating, storing and interpreting data derived from 
both clinical trials and classical literature in a manner that enabled the identification of herbs that 
showed the greatest promise of benefit in the treatment, management and/or prevention of dementia and 
related disorders.  
 
By evaluating the potential of herbs used in Chinese medicine for dementia and related conditions over 
the period of the recorded literature, this research identified specific herbs that demonstrate the best 
available levels of clinical evidence that could be investigated further as leads in the development of 
new medicines, as well as herbs and formulas that showed potential for future clinical trials. This is 
expected to facilitate future drug discovery and enable future clinical research efforts in dementia to be 
more effectively targeted.  
 
In addition, this research aimed to make a contribution to the on-going development of evidence-based 
Chinese medicine by combining evidence from a range of sources to determine the state and level of the 
best available evidence for dementia and related disorders. It was envisaged that this method could be 
adapted and applied to other diseases. 
 
The first main component of the study was two systematic reviews of the clinical research literature for 
CHMs. These found a considerable body of randomised clinical trials (RCT) of herbal medicines for AD 
and Vascular Dementia (VaD) as well as a smaller group of for Mild Cognitive Impairment (MCI) and 
Age Associated Memory Impairment (AAMI). The majority of these trials were conducted in China, 
with a much smaller number from Japan, and CHMs in the form of multi-ingredient formulas were the 
main kinds of test interventions. A large number of trials, mostly conducted in Europe and America, 
investigated single herbal medicines. Of these, extracts of Gingko biloba were by far the most frequent 
in clinical trials. Since reviews of Gingko biloba already exist these were not duplicated.  
 
The CHM studies in China mostly investigated VaD whereas those from Japan and elsewhere focused 
on AD. The reasons for this difference in research focus were not evident although population studies in 
China suggest VaD may be more the prevalent kind of dementia in that country. It was found MCI and 
AAMI had received comparative little research attention. 
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Numerous clinical studies on senile dementia (AD, VaD, MiD) were located in the searches but the 
majority were of low methodological quality. Following methodological assessment, out of 125 articles 
that reported clinical trials, only 14 satisfied all the inclusion criteria and received a score of 3 or above 
on the Jadad scale. These reported on 13 RCTs. As with the overall focus of clinical trials of dementia in 
China, the majority were for VaD. Where possible, meta-analyses were conducted on common outcome 
measures and these suggested an overall benefit for the CHMs used but not necessarily any benefit in 
excess of other intervention (see publication 1).   
 
MCI and AAMI had received relatively less research attention but when compared with the broad scope 
of dementia trials they tended to be of more recent origin. Following methodological assessment 12 
articles reporting on 10 RCTs were included. Meta-analyses were again performed where sufficient data 
were reported for common outcome measures and these suggested an overall benefit for these CHMs 
(see publication 2). The data for the test formulas that were used in the RCTs included in both systematic 
reviews were coded and entered into Statistical Package for the Social Sciences (SPSS). The resultant 
frequency data for the formulas and their constituent herbs were compared with the results derived from 
the other components of the study.  
 
The second component of the study investigated the recommendations of a sample of 23 contemporary 
clinical manuals (CCMs) for the CHM treatment of senile dementia (lao nian chi dai) and memory 
impairment (jian wang). Of these, 14 CCMs were found to provide information that was in sufficient 
detail and in a suitable format for further analyses. The herb and formula data were coded into SPSS and 
the results were compared with those derived from the RCTs to determine the extent to which the 
research literature reflected the treatment recommendations of the CCMs. Of the 148 formulas included 
in the CCMs, only 3 were similar to those used as test interventions in the RCTs and there was no exact 
match. This indicated a considerable disjunction between the interventions that were being 
recommended and those that had received clinical research attention. When the data for the individual 
herbs were compared it was evident that the formulas in the CCTs and the RCTs derived from similar 
sets of herbs. For example, six of the top ten herbs were common to both data sets. There were, however, 
a number of distinct differences between the herb lists.  
 
The third component was the development of three data sets drawn from different collections of the 
classical Chinese medicine literature for herbal formulas and individual herbs used over the period until 
1911 for disorders analogous to the modern concepts of dementia and memory loss. Firstly, 
comparisons between the available collections of the classical medical literature were undertaken to 
determine their scope and representativeness. Also, a set of search terms in Chinese were developed by 
examining a series historical discussions and undertaking trial searches of the classical literature. These 
terms referred to dementia, memory loss or impairment, and memory improvement. 
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Based on analyses of the available representative collections of classical CM books and formulas, two 
collections, the Zhong Hua Yi Dian (ZHYD) and the Zhong Yi Fang Ji Da Ci Dian (ZYFJDCD), were 
selected for comprehensive searching. It was found that the ZHYD encompassed the majority of books 
found in the other collections examined. The ZYFJDCD and the ZHYD both had the features of being 
derived from or containing large numbers of classical books (approximately 680 and 1000 books 
respectively).  
 
The ZYFJCD is a structured, edited collection of formulas in paper format which required digitalisation 
to enable searching and data classification. The ZHYD is an electronic collection in a largely 
unstructured format with a simple search function that allowed the location of single words or phases 
within the collection but no option for Boolean operators or other means of data restriction. 
Consequently, neither of these collections was suitable for text mining in the formats in which they 
presented and each had to be converted into a structured digitalised format. This involved a two stage 
process.  
 
The development of data sets involved a number of stages including searches for each of the search 
terms, data extraction and sorting, and the categorisation and rating of database entries. Firstly, the text 
data were extracted into Excel spreadsheets, then the ratings were undertaken, and then the relevant 
aspects of the data were converted into numerical formats suitable for analysis in SPSS.  
 
A series of general categorisation criteria were developed to assist in the inclusion and exclusion of 
entries from the subsequent analyses and to identify sub-groups within the data sets. Rating systems 
were developed based on the DSM IV-TR criteria for dementia (including scores for memory 
impairment, ageing and addition symptoms such as aphasia) and on the Neuropsychiatric Inventory 
(NPI). These were applied to the classical data sets of formulas derived from ZYFJCD and ZHYD. 
Ratings were undertaken by two raters working independently with disagreements being resolved by 
discussion.  
 
Data were entered into SPSS for each individual herb in each formula. Consequently, each herb entry 
received a series of numerical scores that indicated its source (book title and year, formula name), the 
search term that located it, whether it was captured under one or more of the general categorisation 
criteria, and which of the DSM IV-TR and NPI criteria it satisfied.  
 
The data set for the ZYFJCD comprised 174 formula entries and 1,676 herb entries which were entered 
into SPSS. These represented all the entries under the index terms chi dai (dementia) and jian wang 
(memory loss). The ZHYD was considerably larger. It comprised 1,450 formula entries and 13,733 
individual herb entries which represented the total population of formulas in this collection of about 
1000 classical Chinese medicine books that were indicated for one or more of a series of search terms 
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that were broadly synonymous with those used for the ZYFJCD. A separate data set was created for the 
67 books on materia medica (ben cao) included in the ZHYD. This comprised all the herbs located by 
the same series of search terms as for the total ZHYD as tokens.  
 
The data sets for the ZYFJCD and ZHYD were separately established because, although these 
collections were both derived from the classical CM literature, they differed in important ways. In the 
case of the ZYFJCD, for each of the disease index terms, each formula was included only once and was 
referenced to the first book in which it appeared, so the resultant data were a series of formulas (and their 
constituent herbs) as types. The ZHYD data set differed in that all instances of a formula indicated for a 
particular search term were extracted, so when the same formula recurred in different books it appeared 
as a separate entry in the data set. Duplications were removed to ensure multiple references to the same 
formula in the same book were not included. Consequently, the data in the ZHYD data were derived 
from formula tokens. In the case of the ZHYD ben cao data set, this comprised all the herbs indicated for 
the range of search terms in each of the 67 different ben cao, so it was also comprised of tokens. The two 
source collections also differed in scope and content since the ZYFJCD was derived mainly from books 
on formulas and therapeutics whereas the ZHYD contains a broad range of the genres of the CM 
classical literature. Despite these differences it was expected that the use of two data sets would provide 
a gauge of the reliability of the results obtained. 
 
The ratings allocated for the individual herb entries facilitated restriction of the data sets and enabled the 
selection of entries that best fit the criteria for dementia and were consequently possible examples of 
dementia, MCI or AAMI in the classical literature. Lists of herbs that comprised the herbal formulas that 
satisfied each of these criteria were produced. The high frequency items and the items that best satisfied 
all the criteria were examined in further detail.  
 
It was found that analyses of both of the classical data sets produced similar sets of high frequency herbs 
overall and similarities generally persisted when the data were progressively restricted according the 
categorisation criteria and the ratings. However, at the highest levels of restriction according to the DSM 
IV-TR criteria too few items remained for the frequency data to be meaningfully interpreted. 
Nevertheless, entries that could be considered probable instances of dementia (either AD or VaD) were 
located and substantial numbers of herbs satisfied the criteria of memory impairment and ageing. These 
constituted some of the lists suggested for further research as lead for drug development. 
 
In both data sets, entries indicated for jian wang and associated search terms predominated while those 
for chi dai and associated terms formed a much smaller subset with little or no overlap. It was also 
evident that the entries included under chi dai tended to be dissimilar to the modern conception of senile 
dementia while the entries that best satisfied the DSM IV-TR criteria were indicated for jian wang. The 
lists of herbs indicated for improving memory were very similar to those for memory impairment (jian 
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wang) with high frequency items being common to both lists.  
 
It cannot be assumed that all the herbs in a Chinese herbal formula are individually indicated for the 
primary indication of the formula. Therefore, a proportion of the high frequency herbs were likely to 
have been included for reasons other than their perceived efficacy for chi dai or jian wang. In order to 
investigate this issue, comparisons were undertaken between the results of the ben cao search and those 
derived from formulas. These indicated that the high frequency herbs in the ZYFJCD and ZHYD 
searches also tended to be indicated for jian wang in the classical ben cao. There were also some 
differences which suggested additional herbs for further research.  
 
Comparisons were made between the data obtained from the classical literature and that derived from 
the contemporary clinical manuals (CCMs) and the clinical trials. The classical data was found to be 
most similar to the jian wang subset of the CCMs at the level of the individual herb with the higher 
frequency items tending to be common to both lists.  
 
The high frequency herbs were recommended for further research with regard to drug development, and 
suggestions were also made for locating lower frequency items that may also show promise. 
Recommendations were also made regarding future research directions and the limitations of this study 
were discussed.  
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INTRODUCTION 
 
Background and need for this research 
As the global population ages, the incidence of age-related diseases, such as dementia, is expected to 
increase. Current treatments for Alzheimer’s disease (AD) and other disorders of age-related cognitive 
decline are associated with a number of limitations and there is a pressing need for new medicines and 
therapeutic approaches than can ameliorate the symptoms, slow the progression or reduce the 
incidence of these disorders. 
 
Herbal medicines and other natural products have provided the basis for many modern medicines and 
also continue to have widespread use throughout the world. A number of natural products have already 
led to the development of new drugs for dementia. Also within the systems of traditional medicine, 
herbal medicines are used for disorders of memory and cognitive decline. Therefore it is likely that 
herbal medicines will continue to be sources for drug discovery and some current herbal treatments 
will be scientifically validated in the future.  
 
Research efforts that aim to discover new drugs for dementia from herbal medicines and other natural 
produced are under way in many countries. However the number of herbal medicines is large and 
research funding is limited so strategies for determining potentially fruitful fields of research are 
always needed. 
 
Of the traditional systems of herbal medicine Chinese Herbal Medicine (CHM) is both widely used 
and in possession of a large body of literature, both scientific and traditionally based. Although there is 
a considerable body of evidence for the efficacy of CHM in the management of a number of diseases, 
evidence-based Chinese medicine remains in its infancy and there is a need for further developments 
in this field.  
 
CHM has long been used for diseases of ageing and for memory disorders. A number of Chinese herbs 
and herbal formulas have shown potential in experimental and clinical studies. However the number of 
herbs and formulas in historical and contemporary use is very large and the literature is diverse in age, 
scope and quality. In particular, there is a voluminous body of classical literature which records the 
treatment of a wide range of disorders over many centuries that may provide useful evidence to inform 
contemporary researchers and provide leads for future drug development. Consequently, approaches 
are needed that can organise and systematically evaluate the extant literature and thereby enable 
researchers access this data and apply the results in order to prioritise their efforts in the fields of both 
drug discovery and clinical research.  
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Aims of the thesis 
This study aims to apply evidence based principles and text mining techniques to the clinical 
application of Chinese herbal medicine (CHM) in the treatment of age-related dementia and associated 
disorders in order to determine which herbs and formulas constitute the best available evidence and to 
indicate directions for future drug discovery and clinical research. 
 
The specific aims of this research are to: 
 
1. Systematically evaluate the level and quality of the modern clinical evidence for the use of 
Chinese Herbal Medicine (CHM) for dementia, in particular Alzheimer’s disease (AD), and 
other age-related disorders of cognitive decline such as Mild Cognitive Impairment (MCI); 
 
2. Develop a method for identifying, searching, evaluating, storing, retrieving and interpreting 
information derived from the classical Chinese literature regarding the use of Chinese herbal 
medicine for particular signs, symptoms and diseases; and apply this methodology to dementia 
and associated disorders; 
 
3. Develop a method for rating, evaluating and interpreting evidence derived from the classical 
Chinese literature for the use of a herb or herbal formula for dementia and associated 
disorders; 
 
4. Identify herbs and herbal formulas from the classical and modern literature that are potentially 
effective for the prevention, management and treatment of AD and related disorders; and to 
indicate future directions for research in drug development and clinical trials. 
 
The research approach and components of the study 
The general approach of the study is to search the Chinese medicine literature for information on the 
clinical management of dementia and related disorders, to extract and evaluate relevant data, and use 
statistical procedures to select herbs and formulas for further research. 
 
The first main component of the study examines the modern scientific literature with a focus on 
controlled clinical trials of herbal medicines for the dementias Alzheimer’s disease (AD) and Vascular 
Dementia (VaD) as well as for Mild Cognitive Impairment (MCI) and Age Associated Memory 
Impairment (AAMI). These systematic reviews provide an evaluation of the state of the current 
clinical research evidence as well as analyses of the herbs and formulas that have been investigated.  
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The second component investigates modern Chinese medicine (CM) practice as evidenced in the herb 
andf formula recommendations of contemporary clinical manuals (CCMs) used in CM education and 
by CM practitioners to guide their practice. Comparisons are made between these recommendations 
and the herbs and formulas used in the samples of clinical trials to determine the extent to which 
clinical research endeavours have provided an evidence base for the recommendations for 
contemporary practice found in the CCMs and to identify the strengths and weakness of the 
contemporary clinical research literature.  
 
The third major component is the development of three data sets drawn from the classical Chinese 
medicine literature for herbal formulas used over the time span of the literature for disorders 
analogous to the modern concepts of dementia and memory loss. These formulas are rated according 
to criteria based on the symptoms of AD and the resultant data sets analysed to determine which 
formulas and individual herbs have the highest frequencies and longest time spans of usage for 
memory and other cognitive disorders associated with ageing. Sampling issues are addressed by 
comparisons between the sources used and other collections of the classical CM literature to determine 
their scope and representativeness. The reliability of the results is determined by comparison between 
the samples.  
 
The study makes recommendations regarding which particular herbs and formulas should be 
considered for further experimental investigation as leads in drug discovery and for future clinical 
studies. Sn approach is proposed for combining information derived from a range of classical and 
modern sources that can be applied to other diseases. 
 
Research questions 
 
The specific research questions are: 
 
1. What is the state of the modern clinical research evidence for the use of CHM in the management 
the prevention of the age-related dementias Alzheimer’s disease (AD) and Vascular Dementia 
(VaD) as well as for Mild Cognitive Impairment (MCI) and Age Associated Memory 
Impairment (AAMI)? 
 
2. What instances are there in the classical Chinese medicine literature of the use of CHM in the 
management of signs, symptoms and conditions that are similar or analogous to the modern 
clinical entities of AD, VaD, MCI or AAMI? 
 
3. How can the evidence in the classical literature be evaluated in terms of quality, reliability and 
relevance to a specific disease and in particular to dementia and related conditions? 
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4. What are the relationships between the classical CM literature, modern CM clinical practice and 
the modern clinical research literatures in terms of their approaches to the management of 
dementia and related disorders?  
 
5. Which herbs and formulae demonstrate the greatest potential for further research for AD based 
on these analyses of the classical and modern clinical data? 
 
Limitations to the scope of the study 
Considering the vast volume of literature on CM, limits were required to the type and scope of 
literature examined. With regard to the scientific literature, this was limited to clinical trials published 
in scholarly journals in Chinese, Japanese, English and German. Other forms of scientific evidence 
such as in-vivo and in-vitro studies and analyses of herbal medicines were examined as required but 
these literatures are not reviewed in this study. It was envisaged that the lists of herbs and formulas 
generated by this study would form the candidates for subsequent, more in-depth investigations of this 
kind. 
 
For the modern traditional CM literature, the investigation was limited to published specialty books on 
the clinical management of a range of psychological or neurological disorders or specifically dealing 
with dementia and associated disorders in Chinese and English. The reason was that such books 
inform both CM education and practice, are comprehensive, and tend to be considered authoritative. 
They also follow established formats and are consequently comparable in terms of scope and content. 
No such specialty books in Japanese or German could be located. Generalist books on CM 
therapeutics, books personal clinical experience and case histories, and articles in scholarly and 
professional journals are not included in this data set. 
 
The classical literature is a major focus of this study so a broad scope of works was included. There 
are, however, some limitations since only works published in collections of classical literature were 
considered and of these collections only two were selected for searching.   
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Transliteration and treatment of Chinese terms and writing style 
In the transliteration of Chinese terms and herb names the pin yin system is used. Pin yin terms are 
italicised within body text but not in tables. Chinese characters are provided in the first instances of a 
term and in other cases where greater clarity may be required. A considerable number of herb names, 
formula names, book names and personal names appear throughout the text. In order to facilitate the 
distinction between these the following approach has been adopted:  
 
• herb names are written in lower case, for example fu ling; 
• herbal formula names are written in sentence case, for example Fu ling san; and  
• book names are written in title case, for example, Shang Han Lun. 
 
Personal names are not italicised and are given in the traditional order, with family name first and with 
a hyphen used to indicate when two characters combine to form the given name, for example: Li 
Shi-Zhen, or the family name, for example: Huang-Fu Mi. Similarly, the names of places and 
institutions are not italicised. 
 
Since the focus of most of the chapters is upon the classical literature the traditional form of Chinese 
characters (fan ti 繁體) are generally used for personal names, book names, herb names, and formulas 
names. In the case of the names of modern books which use simplified characters (jian ti簡体), the 
names are written as on the book cover. 
 
Botanical and other scientific names are provided for each item of materia medica but, for space 
reasons, these are only given in the first instance or where further clarity is required. When the item is 
listed in Bensky, Clavey and Stoger (2004) [1], this is the scientific name used. The next reference 
source is the Zhong Yao Da Ci Dian (1986). Scientific names can vary considerably according to 
source so when an alternative name may be familiar to the reader this is also provided. Where there is 
dispute between sources regarding botanical nomenclature Mabberley (2007) [2] is considered 
authoritative. Latinate medical names are not used. For the vascular plants, the family is provided 
according to Bensky, Clavey and Stoger in the first instance and Mabberley where required.  
 
In general, the names of formulas and book titles are not translated, except where the translated title 
may be familiar to the reader or when a translation is considered informative. Chinese medicine 
technical terms are generally provided in pin yin with Chinese characters in the first instance and a 
gloss in parenthesis is provided for terms that may be unfamiliar to the reader. Chinese terms that are 
in common use in English, such as yin and yang and qi are not glossed. With regard to the selection of 
gloss terms, no particular glossary was considered authoritative. The reason for this was that none was 
found to be sufficiently complete for the diversity of literature consulted. This project does not aim to 
provide scholarly translations of passages from the classic medical literature. To do this for the 
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thousands of passages consulted from the broad range of text types considered over the span of 1,900 
years is a task well beyond the scope of this project. What are provided are gist translations of relevant 
sections in which the treatment of technical terms can vary according to the interpretation taken of the 
overall meaning of the passage. The focus of translation has been on identifying whether the passage 
was more or less relevant to probable dementia or a related condition, so information not directly 
related to this may be omitted.  
 
When the word ‘herb’ is used, particularly in the context of a Chinese herbal medicine (CHM) it not 
only applies to plants, but also items of materia medica of animal and mineral origin. 
 
Outline of the thesis 
 
Chapter 1 provides discussions on dementia and associated disorders, herbal medicine, drug 
discovery from natural products, and evidence-based Chinese medicine. 
 
Chapter 2 presents the methods and results of the systematic reviews of the clinical trial literature as 
well as analyses of a sample of contemporary clinical manuals. 
 
Chapter 3 provides an introduction to the classical literature of Chinese medicine and discusses the 
methods used in the selection of suitable collections of classical books for searching as well as the 
procedures used in the searches. 
 
Chapter 4 discusses the contemporary approaches to the diagnosis of dementia and the methods used 
for adapting these for application in the classification and rating of the results of the searches of the 
classical literature. 
 
Chapter 5 presents the general results of the searches of the classical literature as well as an 
evaluation of the representativeness of the collections selected. 
 
Chapter 6 presents the results of the searches and ratings of the materia medica (ben cao) literature 
and of the formula compendium Zhong Yao Fang Ji Da Ci Dian (ZYFJDCD) at the level of the 
individual herb. 
 
Chapter 7 presents the results of the electronic searches of the 1,000 classical books contained in the 
Zhong Hua Yi Dian (ZHYD) and the ratings at the level of the individual herb. 
 
Chapter 8 provides a summary and general discussion of the findings of the study and 
recommendations for future research. 
 
Chapter 9 is the conclusion and limitations of the study. 
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CHAPTER 1 
DEMENTIA, HERBAL MEDICINES, CLINICAL EVIDENCE AND 
APPROACHES TO DRUG DISCOVERY 
 
This chapter provides an overview of the diagnostic criteria for dementia and related disorders, and of 
their prevalence. The roles of herbal medicines and Chinese medicine in drug discovery and their 
potential role in dementia treatment are briefly reviewed. Some of the issues and challenges associated 
with developing evidence-based Chinese medicine are discussed and a method for integrating the 
classical literature into this evidence-base is proposed.  
 
Dementia and Mild Cognitive Impairment: prevalence and current treatments 
Dementia is a general term for a range of brain disorders characterised by multiple cognitive deficits 
such as impairment in memory [3]. Alzheimer’s disease (AD) and vascular dementia (VaD) are the 
two most common types of age-related dementia [4, 5]. AD is characterised by beta-amyloid deposits 
in the brain [6] whereas VaD and the related condition, multi-infarct Dementia (MiD), are due to 
cerebral infarcts [7-9]. However, AD and VaD show similarities in the preclinical phases [10] and 
evidence for commonality in pathology is increasing [11, 12]. These dementias are generally regarded 
as diseases of the aged, but even though their incidence increases with older age, they have been found 
in patients in their early 40s [13, 14]. 
 
It is estimated that around 24 million people world-wide have dementia. By 2040, the projection is 81 
million with much of the increase being in developing countries. About 50% of these sufferers have 
the age related cognitive disorder Alzheimer’s Disease (AD) [5]. In Europe the age-standardised 
prevalence of dementia from all causes in persons 65 years and older was 6.4%, including 4.4% for 
AD and 1.6% for VaD. The prevalence of dementia increased continuously with age and was 0.8% in 
people aged 65 to 69 years and 28.5% at age 90 years and older [15, 16]. 
 
In Australia, AD affects approximately 1% of the total population (about 200,000 people). This is 
projected to increase to 2.8% by 2050 [17]. In 2002, dementia affected 1.5% of those aged 65 to 74 
years, 6.3% of those aged 75 to 84 and 30.2% of those aged 85 years and over. The direct health costs 
of AD were estimated at A$5.6 billion [18]. Consistent with the global trend, these costs are expected 
to increase as the population ages. 
 
Like many other countries, China has an ageing population with 10% (120 million people) being aged 
60 years or over in 2000 and this is projected to increase to 400 million by 2050 [19]. The exact 
incidence of dementia in China is difficult to determine due to differences in population sampling and 
inclusion/exclusion criteria between individual studies. Studies of the elderly have found rates ranging 
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from 0.46% to 7.0% [19]. VaD appeared more prevalent than AD in China, but this was not found by 
all studies. Studies in Taiwan and Singapore have found rates of dementia ranging from 1.7% to 2.8%. 
While these rates appear relatively low, differences in methodology make comparisons between 
studies difficult [19]. Nevertheless, dementia is a significant healthcare problem in China and other 
East Asian countries and its incidence can be expected to increase as these populations age. 
 
Mild Cognitive Impairment (MCI) is a heterogeneous condition that refers to a transitional zone 
between normal ageing and somatic and psychological disorders including Alzheimer’s disease (AD), 
vascular dementia (VaD) and other clinical conditions for which cognitive decline is a feature [20-22]. 
MCI is estimated to affect between 11% and 17% of those aged 60 years and over in Europe and 
North America [23]. 
 
There remains variation in the diagnostic criteria and procedures used to determine MCI [21, 22, 24, 
25]. In addition, a number of sub-types of MCI have been identified. The type characterized by decline 
in multiple cognitive domains including memory is most likely to indicate a progression to dementia 
[21, 26, 27] with impairment in episodic memory [28, 29] and learning and retention [30] being the 
best predictors of future development of AD. However, not all those diagnosed with MCI will 
progress to dementia and a significant proportion can revert to normal functioning [31]. Age 
Associated Memory Impairment (AAMI) is a term used to characterise a decline in memory that is not 
apparently associated with neuronal degeneration and may be considered physiological [31, 32]. 
However, from a clinical perspective, the distinction between normal AAMI and MCI is more difficult 
to determine than that between MCI and AD, and consequently requires a great deal of clinical 
judgment [21]. Therefore clear differentiation between MCI and AAMI remains a challenge in clinical 
decision making and also when determining eligibility in clinical trials on age-related cognitive 
decline [21]. Due to the considerable overlap between the age-related dementias and other disorders of 
memory in ageing, this study takes a broad view and in the subsequent reviews of randomised 
controlled trials (RCTs), AD, VaD, MCI and AAMI are all considered. 
 
Cholinesterase inhibitors are currently the first-line treatment for both AD and VaD, with the addition 
of anti-hypertensive and anti-hypercholesteroleamic drugs for VaD [4, 9]. While these medications 
have been shown to be effective for patients with mild to moderate dementia, they do not halt disease 
progression and adverse effects are significant. Effective and safe treatment for AD and VaD remains 
a challenge [7, 33, 34]. Pharmacological treatment along the lines of that for AD is not recommended 
for MCI due to the inadequacy of clinical evidence of efficacy relative to risk [22, 35, 36]. 
Consequently there is a need for new, low risk interventions that can slow cognitive decline in the 
aged, improve memory and /or manage the symptoms and signs of dementia and MCI. 
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Complementary and Alternative Medicine (CAM) 
As is the case in the general population, older people use a diverse range of health care practices 
which are beyond the scope of conventional medical practice. Referred to under the umbrella term 
Complementary and Alternative Medicine (CAM), these practices include manual therapies such as 
chiropractic, vitamins and herbal medicines as well as systems of traditional medicine such as Chinese 
Medicine (CM) and Ayurveda. In the United States a study of older people found that 66.6% used at 
least one vitamin or mineral supplement and 27.4% used a non-vitamin, non-mineral dietary 
supplement including herbal medicines [37]. In Australia, a study of the elderly (65 years and older) 
found that ‘57.8%...had used at least one of 17 common forms of CAM in the 12 months preceding the 
survey’ [38]. A second study, conducted in Canberra, Australia, found that 2.8% of a sample of 60 to 
64 year olds, who were not suffering dementia or MCI, were using memory enhancement medications, 
of which the herbs gingko and bacopa (brahmi) were notable [39]. In the United States a study of 
community-dwelling AD sufferers found that 31% used a cognitive enhancement medication, most of 
which were cholinesterase inhibitors, but a small proportion used ginkgo or ginseng [40]. 
 
While CAM therapies are in widespread use and some have long histories of application in the 
management of and prevention of certain diseases, the evidence base for their safety and efficacy 
remains inadequate. However, it is increasing, and it is now possible for clinicians to make informed 
clinical decisions regarding their use in certain diseases [41-43].  
 
Herbal medicines, natural products and drug development 
Besides providing alternatives to mainstream medical approaches or complementing biomedical 
treatments for a range of disorders, over the last century natural products, including herbal medicines, 
have been the direct or indirect sources of a considerable number of modern drugs. In the period 
1989-1995, 61% of newly-approved drugs (excluding biologics) were either directly derived from or 
modelled on natural products [44]. However, less than 10% of the world’s biodiversity has been tested 
for biological activity [45], so there remains considerable scope for natural products to produce new 
drugs [46]. Future discoveries of this kind can be expected and there have been calls for increased 
linkages between CAM, ethnopharmacology and drug discovery [47-50].  
 
Of the four anti-Alzheimer’s drugs approved in the period 1981-2002 that were new chemical entities, 
one was a natural product while the others were synthetic mimics of natural products [51]. For 
example, of the cholinesterase inhibitors, galanthamine is a derivative from galanthus and narcissus 
spp. [52] and physostigmine was derived from Physostigma venenosum (Calabar bean) which was 
used as an emetic in Africa [53]. 
 
There have been calls for an increase in drug discovery endeavours in the field of bioprospecting and 
natural products research [46, 47, 51, 54]. Approaches to finding new leads for drug development 
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include high throughput screening of plant and animal products, the data mining of database entries 
and the systematic mining of historical herbal texts including those from China [48, 55]. A review of 
these various approaches found that although the random collection of botanical specimens followed 
by high throughput screening remains the industrial approach of choice, the ethnobiological approach 
has been more successful since plant-derived drug discovery efforts began [56]. In the present study an 
ethnobiological approach was taken in which the classical literature of Chinese medicine was 
examined for potential leads in the treatment of dementia and memory disorders. 
 
Herbal medicines, memory and dementia 
There is considerable research interest in the potential roles of medicines derived from natural 
products in treating or preventing cognitive disorders including the dementias [57-59]. To date there 
have been some promising developments in this area. For example, Huperzine A, isolated from the 
Chinese herb Huperzia serrata, shows promise as a cholinesterase inhibitor [60-62].  
 
Of the products derived from the Chinese materia medica, the plant Gingko biloba has received the 
most research interest as a geriatric medicine. A number of studies have suggested gingko can enhance 
memory [63-66]. Two reviews of the clinical evidence for Gingko biloba have suggested it is 
beneficial in dementia [67, 68] but other reviews have found inconclusive results for its use in 
dementia or for cognitive enhancement [69, 70]. A review of the clinical evidence for a range of 
herbal medicines found that two single herbs, Melissa officinalis and Salvia officinalis, and two 
Chinese herbal formulas, Yi gan san and Ba wei di huang wan were also potentially beneficial for AD 
[71]. Although there have been numerous experimental studies published on the effects of a wide 
range of herbs on memory and cognitive performance [72-81], the focus of the clinical research in the 
English-language literature has been on Ginkgo biloba and extracts of ginkgo are currently in 
widespread use in a number of countries [37, 82]. 
 
Experimental studies indicate that other medicinal plants can have neuroprotective properties and may 
be effective against beta-amyloid [72, 73, 83-85]. Research efforts are ongoing and certain herbs may 
prove to be the sources of future drugs for dementia and other disorders of memory, cognitions and 
ageing [53, 57, 58, 86, 87].  
 
Chinese medicine 
In China, CM is not considered a form of CAM since it is fully integrated into the national health care 
system with traditional herbal therapies reported to represent 30% to 50% of total national medication 
consumption [88]. Statistics from the Ministry of Health of the Peoples’ Republic of China indicated 
that in 2006, there were 2,665 CM hospitals and over 216,452 registered Chinese medicine 
practitioners in China [89]. Overall, it has been suggested about 40% of total healthcare in China is 
provided by CM practitioners [90].  
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CM is also a significant form of health care outside China. In Singapore, 25.3% of Chinese adults aged 
65 years and older had used CHM in the previous year [91]. In a nationwide survey conducted in 
Australia in 2005, Xue and colleagues estimated that nearly 1 in 5 Australians used Chinese medicine 
over a 12-month period. In that year approximately 7% of Australians used Chinese herbal medicine 
and over 2.1 million visits were made to Chinese herbal medicine practitioners nationally [92]. With 
the registration of CM practitioners in Victoria in 2000 and national registration set for July 2012 [93], 
CM is moving closer to becoming a mainstream practice. As this occurs, its practices are coming 
under increasing scrutiny and there is an increasing need to demonstrate that they are not only safe but 
efficacious based on scientific evidence [94, 95]. 
 
Clinical evidence and Chinese medicine 
While CM is a traditional medicine system based on accumulated clinical experience, following its 
integration into the modern medical system in China and the introduction of university based CM 
education in China, research endeavours have been increasing in both number and quality. Clinical 
studies reported in Chinese journals take a range of approaches ranging from small collections of case 
studies, large case-series studies of particular conditions, case control studies, and controlled trials 
with or without randomisation and in comparison with a placebo or other intervention. In a 
comparison of clinical studies published in major CM journals in China between the 1980s and 1990s, 
Yang (2006) [96] found a marked shift from observational studies to randomised clinical trials (RCT) 
indicating that the methodologies used in western medicine were becoming increasingly common in 
Chinese medicine. A review of the approximately 100 Chinese medicine journals as well as databases 
estimated that between 1980 and 1997, 10,000 RCTs had been published. However, in a sample of 
RCTs from 28 journals, a number of problems with the trial methodology and reporting quality were 
found [97]. 
 
With the increasing use of CM in the western world and the introduction of CM into the university 
system in countries such as Australia the need for an evidence-based approach to CM practice has 
become increasingly evident [98]. A considerable body of high quality research has now been 
conducted. In the past ten years, at least 30 randomised controlled clinical trials on CM have been 
published in leading medical journals with Science Citation Index (SCI) impact factors higher than 5.0 
(based on the 2006 SCI list). The majority of these studies have focussed on acupuncture but RCTs of 
Chinese herbal medicine have evaluated its effects on hepatitis C, irritable bowel syndrome and 
moderate to severe allergic asthma. Other studies included acupuncture and Chinese herbal medicine 
for seasonal allergic rhinitis [99-101], and moxibustion for correction of breech presentation of the 
foetus [102].  
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With the ongoing development of evidence-based approaches to Chinese medicine, systematic reviews 
of the clinical trial literature have become feasible. These include Cochrane reviews on the 
effectiveness of acupuncture for a number of clinical conditions, such as depression, induction of 
labour, lateral elbow pain, shoulder pain and fibromyalgia [103-106]. Even though the number of 
clinical studies on one condition remain, in many cases, too small to allow conclusive 
recommendations, some of the reviews provide promising evidence for the effectiveness of 
acupuncture for specific conditions, such as pain from neck disorders and idiopathic headache and 
nausea associated with chemotherapy [107-109]. Reviews on Chinese herbal medicine have found 
positive evidence in a number of disorders including type 2 diabetes, acute pancreatitis, hepatitis B, 
chemotherapy side effects and primary dysmenorrhoea [110-119]. The present study adds to this 
literature with reviews of herbal medicine for AD and VaD as well as for MCI and AAMI [120, 121]. 
 
Evidence based medicine (EBM) and Chinese medicine 
Although applying the results of scientific research to the practice of clinical medicine is not new, the 
notion of ‘Evidence based medicine’ (EBM) as a key feature of clinical practice in western medicine is 
largely a product of the 1980s and 1990s [122]. Defined broadly as ‘the conscientious, explicit, and 
judicious use of current best evidence in making decisions about the care of individual patients,’ EBM 
involves ‘integrating individual clinical expertise with the best available external clinical evidence 
from systematic research’ [123]. 
 
Currently, the highest level of clinical evidence (i.e. level 1) accepted by the National Health and 
Medical Research Council (NHMRC) in Australia is a systematic review of all available randomised 
controlled trials (RCT) [124]. Level 2 evidence is from at least one well designed RCT, level 3 derives 
from a range of other controlled trials (CT) and the lowest level (level 4) of evidence accepted is from 
case series studies. The Oxford Centre for Evidence-based Medicine also includes a fifth level of 
evidence in this hierarchy, that of expert opinion [125]. In Australia the Therapeutic Goods 
Administration (TGA), in its consideration of therapeutic claims for ‘over the counter’ (OTC) 
medicines (including herbal medicines), also includes the categories of ‘general evidence’ and 
‘supporting evidence’. General evidence includes descriptive studies, case series, opinion of expert 
committees and evidence based on reference texts, while supporting evidence includes non-human 
studies such as in-vitro and animal studies, and other non-clinical studies [126]. 
 
In each of the above hierarchies of evidence the RCT holds the highest place and the notion of EBM 
can become synonymous with evidence from RCTs and meta-analyses. Critics of EBM fear that the 
results of RCTs will be applied slavishly and this will compromise the care of individual patients 
whose needs may be outside the scope of the RCT evidence. However, proponents of EBM have 
argued that external evidence can be derived from a range of experimental approaches according to the 
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clinical question and this can include the basic sciences. Such external evidence should inform but 
cannot replace clinical expertise [123]. 
 
Within Chinese medicine there have been ongoing debates about the appropriateness and utility of 
applying EBM approaches to the clinical practice of CM. At the official level, PRC policy encourages 
the integration of western and Chinese medicine and the application of scientific methods to improve 
Chinese medicine practice; however, some fear that this approach will result in CM losing its unique 
identity [127]. The arguments for and against Evidence Based Chinese Medicine (EBCM) have been 
detailed in Shea (2006) [94] who concludes that while there are difficulties with reconciling the 
therapeutic approaches of CM, particularly the individualisation of treatment according to differential 
diagnosis, with the requirements of RCT methodology, there is no alternative but to continue with 
efficacy research.  
 
Although there is high level scientific evidence available that can support the clinical application of 
CHM in the management of a number of clinical conditions, this is mostly of recent origin and, as yet, 
is not available for the broad scope of Chinese medicine practice. Considering the large number of 
Chinese medicines in use, the complexity of multi-ingredient herbal formulas and the wide range of 
conditions for which they are employed, it is likely to be many years before high level evidence in the 
form of randomised clinical trials (RCT) is available for many of the conditions currently treated by 
Chinese medicine practitioners.  
 
Approaches to Evidence Based Chinese Medicine (EBCM) 
In its essence, EBM aims to improve clinical practice and patient care by searching for the best 
available evidence and using this to inform clinical practice. In western medicine, such evidence 
typically derives from clinical studies, epidemiological studies as well as from basic science research. 
In the absence of such evidence, practice must necessarily rely upon expert opinion based on 
accumulated clinical expertise [123]. In much of western medicine, clinical practice is also informed 
by expert opinion, but this rests on knowledge accumulated in scientific fields such as microbiology, 
chemistry and physiology over the past 150 or more years [123]. In contrast, the layer of ‘basic 
sciences’ that may provide the foundation for CM practice is considerably thinner, and the evidence 
derived from clinical trials is mostly of relatively recent origin and does not cover the full scope of 
actual practice. Therefore, CM has much catching up to do compared to western medicine, but it 
appears impractical to use RCT methodology alone to test the hundreds of CHM formulations that are 
currently in common clinical use. 
 
In order to move Chinese medicine practice onto an EBM footing it is arguable that a broad view of 
EBM is required. Such an Evidence Based Chinese Medicine (EBCM) could include systematic 
reviews of the extant clinical trial literature which include the full range of clinical trial types as well 
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as reviews of the results of in-vitro and in-vivo experimental studies. These processes are currently 
underway and when completed could be expected to provide not only evaluation of the safety and 
efficacy of certain herbal formulation for certain diseases but also insights into how these formulations 
may act which could assist clinicians in improving their practice as well a provide leads for the 
development of new medicines [128, 129]. 
 
Since much of current CM practice is informed by the traditional literature, it is arguable that 
systematic evaluations of this literature should be included in EBCM. CHM employs over 12,000 
individual species of plants and animals, singly or in combined into formulas, for the management of a 
wide range of disorders [128]. Records of the identities, properties and clinical applications of these 
items of plant, animal and mineral origin have been continuously amassed for over 2,000 years in the 
voluminous literature on ben cao (materia medica), in the similarly large collections of formulas, and 
in clinical manuals and case studies [130-132]. The history of drug discovery from natural products 
has shown that many of the items used in traditional medicine have bioactivity and a number of these 
have been developed into drugs with indications similar to those found in the traditional literature [41, 
133]. According to the established hierarchies of evidence, a finding of molecules in a traditional 
medicine whose actions are consistent with the traditional clinical indications of the medicine is not 
considered a form of clinical evidence. It is, however, a form of scientific evidence that could be 
included in an EBCM, since it can inform clinical practice as well as point the way for future clinical 
trials and drug development.  
 
Data and text mining in Chinese medicine 
With the development of electronic databases of CM literature [134], text and data mining approaches 
to research have become feasible and there is increasing interest in applying statistical procedures to 
data on Chinese herbs and formulas [135, 136]. One approach is to compare the indications of 
individual Chinese herbs with what is known of their chemical constituents derived from a range of 
databases such as NAPRLERT [137], and correlate these with the evidence from the experimental 
literature on the effects of these and similar molecules with regard to, for example, their hypertensive 
effects [128]. Another approach, used in identifying novel compounds for cancer, was to compile a 
database of anticancer formulas and examine the herbs and their constituent compounds which occur 
with high frequency with regard to their anticancer properties with the aim of developing new leads 
for drug discovery [138]. Zhou and colleagues have developed a system for integrating genomic data, 
modern disease entities and the syndromes of Chinese medicine [139]. One of the features of CHM 
that has presented difficulties for RCT research is the complexity of multi-ingredient herbal formulas 
[98]. However, the synergic action of medicines is receiving more attention in the drug discovery field 
and Chinese herbal formulas may provide leads for the development of multi-component medicines 
[140-142].  
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Some researchers have used computation approaches to investigate multi-herb formulas. Jiang and 
colleagues [143, 144] entered all the herbal formulas from the large compendium Zhong Yi Da Ci 
Dian - Fang Ji Fen Ce 中医大辞典–方剂分册 that were used to treat Spleen and Stomach disorders 
into a database together with coded information regarding their properties, actions and indications. 
They analysed the resultant 1,355 formulas in terms of frequencies of herbs for specific conditions and 
also conducted cluster analyses to determine the most common combinations. In another database 
study the combinations of herbs were compared between ancient and modern formulas [145]. Wang 
and colleagues used computational methods to examine the roles of ingredients in CHM formulas 
[146]. However, from the viewpoint of text mining much of the classical literature on Chinese 
medicine presents a number of difficulties since it remains in only semi-structured formats even when 
it has been digilatised. This is also a new field so researchers need to develop data bases and novel 
approaches to retrieval and information filtering [147].  
 
Dementia and the pre-modern Chinese literature 
Longevity has been actively pursued in China for at least 2000 years via the use of medicines and food 
stuffs [148, 149]. Classical Chinese works on materia medica and formulae record numerous 
substances and combinations of substances purported to maintain health and prolong life [150, 151]. 
Although AD, VaD and MCI are modern disease entities, and have no direct analogues in the classical 
Chinese literature, disorders of memory and cognitive deficit are referred to throughout the classical 
and modern CHM literature [152, 153]. It is likely that some of these instances referred to disorders 
that would receive the modern diagnosis of AD, VaD or MCI, and possible that the treatments 
provided for these patients were in some cases efficacious. 
 
However, the enterprise of mining the Chinese classical literature for new treatments has several 
pitfalls. The concepts and classification systems for diseases vary considerably between Chinese and 
Western medicine and have changed over time; herbs can have a variety of names with can vary 
according to region and over time such that different species can share a name and the same name can 
refer to different species [132]; and the same herb can have a range of actions and indications and 
these may also change over time [154]. Currently, the majority of traditional Chinese medicine 
classical literature remains untranslated and is largely inaccessible to Western researchers. In addition, 
the classical literature is voluminous, diverse, and poorly referenced thereby presenting obstacles to 
Chinese researchers as well. Nevertheless, the classical literature contains a multitude of accounts of 
the treatment of numerous disorders over the last 2,000 and more years. The development of a 
methodology for systematically searching this literature for data on the management of a particular 
disease will greatly facilitate access to this literature by future researchers. 
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CHAPTER 2 
SYSTEMATIC REVIEWS OF THE CLINICAL RESEARCH 
LITERATURE ON HERBAL MEDICINE FOR DEMENTIA,  
MILD COGNITIVE IMPAIRMENT AND AGE ASSOCIATED 
MEMORY IMPAIRMENT 
 
Introduction 
The systematic review of clinical trials (CTs) is a well established approach that applies the principles 
of evidence-based medicine to evaluating the efficacy and safety of a clinical intervention. Systematic 
reviews have demonstrated potential effectiveness and safety of certain single herbs and formulations 
for dementia and associated disorders.  
 
A number of reviews of the clinical evidence have suggested that the herb Gingko biloba is beneficial 
in dementia [67, 68]. The first of two Cochrane reviews included 33 trials spanning the period 1976 to 
2000 while excluding 18 trials [155]. The reviewers concluded that the evidence was inconsistent - 
trials tended to be small, methodological problems were evident, and publication bias could not be 
ruled out. However, Gingko biloba was safe and there was some evidence of efficacy. In an updated 
review the same reviewers again found this herb to be safe but found no consistent pattern in the 
results of trials [69]. Nevertheless, subsequent publications have demonstrated positive effects for 
gingko in mild dementia [156, 157]. A Cochrane review of the Chinese herbal formula Zhiling 
decoction for VaD [158] found it potentially effective but due to the small number of included trials 
and their low methodological quality no conclusive statement was made. A review of herbal medicine 
(HM) for AD found that two single herbs, Melissa officinalis (MO) and Salvia officinalis (SO), and 
two Chinese herbal formulas, Yi gan san (YGS) and Ba wei di huang wan (BDW) were potentially 
beneficial [71]. No comprehensive English language reviews of the clinical use of other herbal 
medicines for MCI or AAMI were located to December 2007. 
 
These reviews show certain limitations. They tend to focus on Gingko biloba and do not 
comprehensively examine trials on other herbal medicines. In addition, trials published in the Chinese 
language have received limited attention. Such deficiencies restrict the generalisability of findings 
concerning the applicability and safety of HM for dementia.  
 
Another limitation of the above approach to reviewing clinical trials of HMs is the focus on herbal 
formulas. In trials where only one HM is used, as is the case with Gingko biloba preparations, direct 
comparisons between trials, as well as the pooling of the results from a number of trials, is permissible. 
In contrast, when multi-herb formulas are used, comparison between trials is more problematic, as is 
the pooling of data. When the formula used in different trials is identical then the results of a number 
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of trials can be validly compared but this throws little light upon which of the component herbs 
contributes to the therapeutic effect. When the trials use formulas comprising different herbs then 
comparisons between trials may be of questionable validity. In the case of CHM, where numerous 
formulas may be used for the same condition, the formulas tend to be diverse in name and composition. 
Consequently, few trials are replications using the same formula in different samples of patients; 
rather, there are many trials each using a different formula. Nevertheless, many of the herbal 
ingredients of the formulas are common across the trials. Therefore, it may be productive to consider 
the individual herbal ingredients and conduct analysis at this level when comparing trials of multi-herb 
formulas. 
 
Scope and general features of the reviews 
As one component of the present study, two systematic reviews of randomized controlled trials (RCTs) 
of herbal medicines (HM) were conducted. The reviews were broadly based to include any kind of 
herbal medicine, not just the HMs commonly used in contemporary China since the range of herbs 
included in the subsequent investigations of the classical Chinese literature was unknown but expected 
to be diverse. However, trials on Ginkgo biloba and its extracts were excluded from these reviews 
since recent reviews were available that focussed on this herb and there appeared no need for 
duplication.  
 
The first systematic review focussed on dementia, including AD and VaD and MiD. These conditions 
were considered the closest equivalents to the traditional CM category of lao nian chi dai ‘senile 
dementia’. This review was published in Phytotherapy Research in 2009 [120]. 
 
The second review focussed on Mild Cognitive Impairment (MCI) and Age Associated Memory 
Impairment (AAMI) which were chosen as the closest equivalents to the traditional CM category of 
jian wang ‘memory loss.’ The review was published in Biogerontology in 2009 [121]. 
 
Aims of the reviews 
As is the case with systematic reviews in general, these reviews of dementia, MCI and associated 
disorders aimed to systematically evaluate the existing clinical evidence on the effects and adverse 
effects of the HMs by collecting all available RCTs and critically evaluating their methodology and 
results. However, the reviews in the present study have included an additional methodological stage by 
examining the formulas and individual herbs used in the RCTs in order to determine: 
• which herbs and formulas had received the most research attention for these conditions;  
• whether these were the same herbs and formulas as those recommended in the contemporary 
clinical literature; 
• which herbs were most frequently included in formulas for these conditions; and 
• whether these herbs were the same as the high frequency herbs found in the classical searches. 
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General method for both reviews 
The reviews were conducted in accordance with the methods detailed in the Cochrane Handbook for 
Systematic Reviews of Interventions 4.2.6 [159]. In addition, analysis at the level of the individual 
herb was added to the general methodology. 
 
Both reviews derived from searches of similar samples of the literature and followed the same search 
methodology, but they differed in two key aspects. Firstly, they focussed on different sets of 
conditions; and secondly, they differed in the scope of the RCTs included. In the case of the first trial, 
which identified a large number of RCTs, only those with high reporting quality were included. For 
the second review, the range of available studies was considerably less so the scope of inclusion was 
broadened, with all RCTs that met the general inclusion criteria being included. 
 
The development of search terms 
When searching the electronic databases the aim was to locate all controlled trials in humans and 
reviews of such controlled trials (in any language) that employed a herbal medicine as the test 
intervention in the treatment, management, and/or prevention of age-related dementia and associated 
disorders. Consequently the search strategy was intentionally broad. 
 
The search terms used by the Cochrane Dementia and Cognitive Improvement Group [160] were 
firstly examined. In addition, the medical subject heading (MeSH) terms used in the Cochrane Library 
and PubMed were used as points of departure in developing sets of additional search terms. A series of 
test searches were conducted to determine the relative inclusiveness and overlap of a range of search 
terms in two databases, PubMed (Medline) and EMBASE (via Science Direct). It was found that the 
initial sets of search terms were not sufficiently inclusive. Conversely, the sets of search terms 
designed to exclude animal and other experimental studies could also exclude relevant studies. In the 
test searches, when search terms located additional articles they were added to the list of search terms, 
and when terms were found to be unproductive they were excluded. In the test searches a number of 
other databases were included but since this approach did not result in any relevant articles that were 
not included in the other databases, this approach was later discontinued. 
 
The groups of search terms used consisted of three components: 1. interventions, 2. clinical conditions 
and 3. trial design (see below). A snowballing method was employed, that is, reference lists of 
identified trials and review articles were screened to identify other trials. The first search was for the 
first systematic review. The list of conditions was subsequently extended to capture MCI and AAMI 
more fully. The following lists of terms were applied to the second search: 
 
 
 
18 
Search terms for English language databases 
Separate lists of search terms were developed for the major English language databases PubMed and 
EMBASE (via Science Direct). The PubMed list was also used for CENTRAL and Elsevier 
BIOBASE. There were no restrictions placed upon whether these terms were found in the title, 
abstract or text.  
 
Intervention 
For PubMed: 
Medicine, Traditional OR Ethnopharmacology OR Medicine, Kampo OR Kanpo OR Medicine, 
Oriental Traditional OR Medicine, Chinese Traditional OR TCM OR T.C.M. OR Medicine, Tibetan 
Traditional OR Korean Traditional Medicine OR Japanese Traditional Medicine OR Alternative 
Medicine OR Complementary Medicine OR Phytotherapy OR Medicine, Herbal OR Herbology OR 
Plants, Medicinal OR Plant Preparations OR Plant Extracts OR Drugs, Chinese Herbal OR Materia 
Medica 
 
For EMBASE: 
Traditional Medicine OR Ethnopharmacology OR Kampo OR Kanpo OR Oriental Traditional 
Medicine OR Chinese Traditional Medicine OR TCM OR T.C.M. OR Tibetan Traditional Medicine 
OR Korean Traditional Medicine OR Japanese Traditional Medicine OR Alternative Medicine OR 
Complementary Medicine OR Phytotherapy OR Herbal Medicine OR Herbology OR Medicinal 
Plant* OR Plant Preparation* OR Plant Extract* OR Chinese Herbal Drug* OR Materia Medica 
 
Clinical condition 
For PubMed: 
Dementia OR Alzheimer Disease OR Dementia, Vascular OR Dementia, Multi-Infarct OR Lewy 
Body Disease OR Cognitive impairment OR MCI OR Cognitive decline OR AAMI OR Dement* 
OR Alzheimer* OR memory loss OR memory impairment OR memory enhancement OR memory 
improvement OR memory enhance* OR memory improve* OR senile plaque OR Amyloid plaque 
OR premature senility OR delirium OR confusion OR cerebral deterioration 
 
For EMBASE: 
Dementia OR Alzheimer Disease OR Dementia, Vascular OR Dementia, Multi-Infarct OR Lewy 
Body Disease OR Cognitive impairment OR MCI OR cognitive decline OR AAMI OR Dement* 
OR Alzheimer* OR memory loss OR memory impairment OR memory enhancement OR memory 
improvement OR memory enhance* OR memory improve* OR senile plaque OR Amyloid plaque 
OR premature senility OR delirium OR confusion OR cerebral deterioration OR (cerebr* and 
deteriorat*) 
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Study type 
The searches aimed to include all types of clinical trials and other controlled trials. They did not 
exclude animal experiments, because during the experimental searches it was found that attempting to 
exclude animal studies could also lead to the exclusion of relevant articles in which reference to 
animal studies was also made. Therefore the process of exclusion of animal studies was done 
manually. 
 
For PubMed: 
Clinical Trial OR Clinical Trial, Phase I OR Clinical Trial, Phase II OR Clinical Trial, Phase III OR 
Clinical Trial, Phase IV OR Controlled Clinical Trial OR Multicenter Study OR Randomized 
Controlled Trial OR Meta-Analysis OR random allocation OR double-blind method OR 
single-blind method OR placebo OR comparative study OR evaluation study OR follow-up study 
OR prospective study OR research design OR control group OR control OR random* OR ((singl* 
[tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR 
( placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR control* 
[tw] OR prospectiv* [tw] OR volunteer* [tw])  
 
For EMBASE: 
Controlled study OR clinical trial OR clinical study OR randomized controlled trial OR controlled 
clinical trial OR random! control! trial OR random! control! study OR controlled clinical study OR 
randomised controlled study OR random allocation OR double-blind OR single-blind OR placebo 
control! OR dummy control! OR blinding OR comparative study OR evaluation study OR follow-up 
study OR prospective study OR Multicenter Study OR Meta-Analysis 
 
Search terms for Chinese language databases 
The above approach could not be used for the Chinese language database CQVIP because the online 
system only allows the combination of two terms. Since various forms of Chinese medicine are the 
main interventions in this database, combinations of clinical condition were used as follows.  
 
Intervention 
中医 Zhong yi; 中药 Zhong yao; 草药 Cao yao; 中草药 Zhong cao yao; 中医药 Zhong yi yao 
 
Clinical condition 
轻度认知障碍 Qing du ren zhi zhang ai; 中老年认知功能减退 Zhong lao nian ren zhi gong neng 
jian tui; 老年轻度认知障碍 Lao nian qing du ren zhi zhang ai; 老年人记忆障碍 Lao nian ren ji yi 
zhang ai; 老年认知功能障碍 Lao nian ren zhi gong neng zhang ai; 轻度老年认知障碍 Qing du lao 
nian ren zhi zhang ai; 轻度认知功能障碍 Qing du ren zhi gong neng zhang ai; 阿尔兹海默病 A er 
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ci hai mo bing; 阿兹海默病 A ci hai mo bing; Alzheimer 病 Alzheimer bing; Alzheimer’s 病
Alzheimer’s bing 
 
Study type 
随机临床观察 Sui ji lin chuang guan cha; 随机临床试验 Sui ji lin chuang shi yan; 临床观察 Lin 
chuang guan cha; 随机试验 Lin chuang shi yan 
 
Search procedures for VIP Information 
 
#1. (临床观察) ti or kw. 
#2. (临床试验) ti or kw.  
#3. (随机) fulltext 
#4. #1 OR #2 
#5. #3 AND #4 
#6. ((中医) OR (中药) OR (草药)) fulltext 
#7. #5 AND #6 
#8. (痴呆) ti or kw. 
#9. (健忘) ti or kw. 
#10. (呆病) ti or kw. 
#11. (Alzheimer) ti or kw. 
#12. (Alzheimer’s) ti or kw. 
#13. (阿兹海默) ti or kw. 
#14. (阿尔兹海默) ti or kw. 
#15. (老年病) ti or kw. 
#16. (记忆损害) ti or kw. 
#17. (记忆障碍) ti or kw. 
#18. (记忆减退) ti or kw. 
#19. (认知障碍) ti or kw. 
#20. (延缓衰老) ti or kw. 
#21. (抗衰老) ti or kw. 
#22. OR #8-21 
#23. #7 AND #22 
 
Search strategy 
The following electronic databases were searched from their inception to February 2007: Cochrane 
Central Register of Controlled Trials (CENTRAL) on The Cochrane Library (2006 Issue 4), PubMed 
(1966-2007), EMBASE (1998-2007), and Elsevier BIOBASE (1994-2007). Chinese VIP Information 
(www.cqvip.com, 1989-2007) was searched in Chinese. In addition, hand searches were conducted in 
the library of Guangzhou University of Chinese Medicine in September 2007. Journals currently 
included in the Chinese VIP Information database were hand searched from their various inception 
dates until 1989 since from that year onwards these journals were included in the electronic database 
and were consequently included in the electronic searches. This approach aimed to ensure that 
similarly comprehensive searches of both English and Chinese language resources were undertaken.  
 
Study selection 
RCTs and quasi-RCTs, with or without blinding, in English, Chinese, German and Japanese were 
considered. Trial participants were required to have been diagnosed with specific conditions including 
AD, VaD or MiD for the first review and have a memory or other cognitive impairment associated 
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with age and/or other age related decline in physical or mental functioning consistent with MCI and/or 
AAMI for the second review. No restrictions were placed regarding age or gender but trials including 
healthy young participants were excluded. Any form of a single herb or herbal formulation (e.g. 
decoction, capsule, tablet, pill, powder, injection) for internal use compared with placebo, no 
intervention, or other intervention was included, irrespective of the means of administration and 
dosage. Trials of Gingko biloba and its extracts, aromatic oils for inhalation [161-164], foods and 
drinks [165, 166], and plant-derived purified compounds such as huperzine [167-169] and 
galanthamine as the principal test interventions, were excluded. Only trials assessing clinical outcomes 
relating to clinical symptoms, memory, cognitive function, activities of daily living or quality of life 
were included. The five-point scale developed by Jadad et al was used to assess methodological 
reporting quality [170].  
 
All titles and abstracts of identified articles were initially screened and full-text articles of potentially 
relevant trials were obtained. In one case [171], subsequently excluded, the authors were contacted to 
clarify the formula composition. Articles in English were read by B May and M Owens, in Chinese by 
A Yang and A Zhang, in Japanese by B May and T Tomoda, and articles in German by H Hugel (a 
second person was not required since all papers were excluded). Articles were included in the review 
based on the discussion between these researchers according to the trial selection criteria. When 
required other researchers (C Xue and CG Li) were consulted.  
 
Data extraction and methodological quality assessment 
To ensure consistency, data were extracted using a pre-defined format in Excel. These data consisted 
of trial characteristics such as: trial setting, sample size, methodological quality, inclusion and 
exclusion criteria, diagnostic criteria, characteristics of participants, intervention and outcome 
measures.  
 
The methodological quality of included trials was assessed by raters working independently using the 
Jadad criteria [170] as follows: B May and M Owens for English, A Zhang and A Yang or I Zhou for 
Chinese, and by B May and T Tomoda for Japanese. Disagreements were resolved by discussion or by 
the third party (C Xue). A score of three or above on the Jadad scale was considered good quality.  
 
Data analysis 
To assess the clinical outcomes of the included trials, only data from validated outcome measure 
instruments with continuous data were included in data analyses. For those with a comparable baseline, 
mean and standard deviation data were entered into RevMan 4.2.10, developed by The Cochrane 
Collaboration. The weighted mean difference (WMD) with a 95% confidence interval (CI) was 
calculated from trials that utilised common outcome measures. Intention-to-treat analyses were not 
practicable since raw data were not available. Therefore analyses were based on the numbers of 
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participants included by the trial authors. 
 
In addition, data on the individual herbs included in the trials together with the clinical condition, 
participant numbers, Jadad scores, and outcomes were entered into SPSS to enable investigation of 
which herbs had been included in the range of RCTs (see part 3 below). 
 
 
 
PART 1 
SYSTEMATIC REVIEW OF HERBAL MEDICINE FOR DEMENTIA 
 
This part reports the results of the first review which included RCTS for age related dementia, AD, 
Vad and MiD. 
 
Search results 
Using the search methods detailed above, a total of 1,668 articles potentially relevant to herbal 
medicine and dementia were identified. These were sorted according to a series of exclusion criteria 
(see Figure 2.1). Following initial screening, 210 articles were considered for detailed evaluation. Full 
text articles were obtained in all cases except for some of the early articles on Ginkgo biloba that were 
evaluated by Birks and Grimley Evans 2002 [155] since sufficient information was included in this 
Cochrane review. Following the next stage of exclusions, 125 articles were retained for further 
evaluation and rating. Of these, a considerable number were found to be clinical trials of low 
methodological quality so it was decided to include only those trials that scored 3 or above on the 
Jadad scale. 14 articles met all these inclusion criteria and these reported 13 distinct RCTs. Figure 2.1 
shows the process of trial inclusion and exclusion.  
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Figure 2.1: Flow chart of the clinical trial selection process in systematic review of herbal 
medicine for dementia 
 
Number of potentially
relevant articles identified
(n=1,668)
Full articles retrieved for
detailed evaluation (n=210)*
Relevant articles identified
for further analysis (n=125)
Articles excluded after screening
titles and abstracts (n=1,458)
E1: not a CT, experimental study or
systematic review of herbal medicine
(n=319)
E2: not principally related to dementia
(n=608)
E3: not principally using herbal medicine
internally in humans (n=516)
E4: not English, Chinese, German or
Japanese (n=5)
Articles excluded with reason
(n=85)
E5: Review article or not a CT (n=34)
E6: Related principally to gingko biloba
(n=43)*
E7: Clinical condition not principally
related to memory or dementia (n=8)
Articles included in the
review (n=14)**
Articles excluded with reason
(n=111)
E8: Test intervention was not principally
herbal medicine used internally in
humans (n=11)
E9: Test population was not ageing (n=9)
E10: Jadad scale less than 3 (n=85)
E11: Subjects not diagnosed with AD,
VaD or Multi-infarct dementia (n=6)
 
 
* full text was not obtained for all the articles on Ginkgo that were evaluated by Birks and Grimley Evans;  
** two articles referred to one trial, so 13 trials were included 
 
Characteristics of included trials 
The main characteristics of the included RCTs are summarized in Table 2.1. These 13 trials were 
published between 1997 and 2005 with seven in English and six in Chinese. They were conducted in 
three countries: Peoples Republic of China (PRC) (n=8), Japan (n=3), and Iran (n=2). In the 13 trials, a 
total of 1,117 subjects aged from 45 to 91 years were randomized and 1,062 were included in the data 
analyses in the original reports. The duration of the trials ranged from one to six months but in only 
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one was there a follow-up period. With respect to interventions, 11 trials used herbal combinations 
while two trials investigated extracts of single herbs (Table 2.3). Four RCTs were for AD, one was for 
a mixed group of AD and VaD, six were for VaD, one was for MiD, and the remaining trial did not 
specify the type of dementia (Table 2.1). Three trials employed differential diagnosis of Chinese 
medicine as part of the diagnostic criteria. Six trials (Iwasaki et al., 2004; Akhondzadeh et al., 2003a, 
2003b; Suzuki et al., 2005; Terazawa et al., 1997; Zhang et al., 2002) [172-176] compared herbal 
medicine with placebo control and one trial (Iwasaki et al., 2005) [177] compared herbal medicine 
with no treatment. Seven trials compared herbal medicine with a range of medications, including the 
ergoloid mesylate drug hydergine (Zhang et al., 2002; Jia and Shi, 2004; Liu et al., 2005; Luo et al., 
2001.) [176, 178-180], piracetam (Zhang et al., 2005) [181], Duxil (almitrine + raubasine) (Du et al., 
2003) [182], and the cholinesterase inhibitor huperzine A (Wang et al., 2004) [183]. Two trials used 
two interventions each - Zhang et al (2002) [176] compared a single herbal formula with hydergine 
and placebo; Suzuki et al. (2005) [184] compared two herbal formulas with placebo. In only two trials 
(Terazawa et al., 1997; Iwasaki et al., 2005) [175, 177] was sufficient quality control data provided for 
the herbal medicines (Table 2.3). All trials reported overall positive outcomes for herbal medicine but 
not necessarily in terms of superiority over pharmaceutical/active control interventions.  
 
Outcome measures used in the included trials 
A wide range of outcome measures were employed including measures of cognition, quality of life, 
reported symptoms, brain imaging, and results of various serological tests. Measures of dementia and 
cognitive function used in multiple trials were: Mini-Mental State Examination (MMSE) (9 trials), 
Barthel index for Activities of Daily Living (ADL) (4 trials), Hasegawa Dementia Scale (HDS) (3 
trials), Blessed Dementia Scale (BDS) (2 trials), the cognitive subscale of the Alzheimer’s Disease 
Assessment Scale (ADAS-cog) (2 trials) and Clinical Dementia Scale – Sum of the Boxes (CDR-SB) 
(2 trials) (see Table 2.2). Where possible, meta-analyses were conducted on the results of these 
measures but due to inadequate reporting, insufficient data was available for WMD analysis in some 
trials (Iwasaki et al., 2004; Akhondzadeh et al., 2003a, 2003b; Suzuki et al., 2005; Luo, 2001) 
[172-174]. 
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Methodological quality of included trials 
The methodological quality of all the trials included in this review ranged from 3 to 5 on the Jadad 
scale. Of the 13 trials, seven properly described the methods for randomization, 11 were double blind 
and two were single blind. The double dummy method was used in the four trials which employed 
active interventions in the control [178, 180, 182, 183]. Details of dropouts and withdrawals were 
described in nine trials. Further details are included in Table 2.2. Information on the composition, 
quality and acronyms used for herbal preparations is available in Table 2.3.  
 
Herbal medicine versus no treatment or placebo 
Iwasaki et al. (2005) [177] was a small single blind trial of the herbal formula YGS versus no 
treatment for AD/VaD. The investigators reported significant improvements in Activities of Daily 
Living (ADL) and Neuropsychiatric Index (NPI), and a range of symptoms. The WMD analysis failed 
to find a significant difference in ADL but the significant reduction in NPI was confirmed. This trial 
was complicated by allowing the use, as required, of the dopamine antagonist and antipsychotic 
tiapride hydrochloride in both groups (see Table 2.2). This medication was, however, only required for 
11 of the patients in the control group so YGS may have had a sedative effect. 
 
Of the six trials employing a placebo as control, due to insufficiencies in the reporting of outcome data, 
WMD was only possible for Zhang et al. (2002) [176]. This provided compelling evidence for Jian 
nao yi zhi ke li (JNYZ) improving MMSE and BDS in VaD. The trial was well designed and WMD 
analysis confirmed the results. One trial of Gou teng san (GTS) [Chotosan] in VaD (Terazawa et al., 
1997) [175] found significant improvements on the Global improvement rating (GIR) sub-scales in the 
areas of subjective symptoms, psychiatric symptoms and disturbance in daily living activities but not 
in neurological symptoms or on the revised version of the Hasegawa dementia scale (HDS-R). The 
HDS-R result was confirmed by WMD but the GIR data was not suitable for WMD analysis. The 
second GTS trial (Suzuki et al., 2005) [184] found significant improvements in AD patients for 
MMSE and ADL in the GTS group compared with placebo and another herbal medicine but the 
published report was brief and did not contain complete data. Although WMD analysis could not 
confirm the conclusions of these two trials, their consistent findings lend weight to the likelihood of 
GTS having some positive effects in VaD and AD. In AD patients, Iwasaki et al. (2004) [174] 
reported significant improvements in MMSE and ADL after eight weeks of BDW administration 
followed by a decline after eight weeks of wash out. However, incomplete data reporting precluded 
WMD analysis. In the two trials for AD, Akhondzadeh et al. (2003a, 2003b) [172, 173] reported 
significant improvements on ADAS-cog and CDR-SB but the results were only presented graphically 
so WMD could not be used for confirmation. While the results of only one of these six trials could be 
confirmed, they were all well designed trials so the reported results should not be discounted.  
A meta-analysis was conducted for the two trials which reported data for MMSE [176, 185]. This 
found an overall favorable effect for HM in dementia (WMD 2.02 [95% CI 0.43 to 3.61]) (Figure 2.2). 
31 
Herbal medicine versus other intervention 
For the seven trials employing an active control, data reporting was generally more comprehensive 
and this enabled confirmation of the results for six trials. However, only Zhang et al. (2002) [176] 
again presented unambiguous evidence of a treatment effect for JNYZ that was at least equivalent to 
that for hydergine in VaD patients (Table 2.2). The trial was well designed, WMD analysis confirmed 
the result for MMSE and BDS, and the inclusion of an inactive placebo lent weight to the result. The 
next most compelling trial was Jia et al. (2004) [178] since it found improvements in three validated 
outcome measures (MMSE, ADL, BDS) that indicated an effect for Cong sheng jiao nang (CSJN) that 
was at least equivalent to hydergine in VaD patients. Liu et al. (2005) [179] reported improvements in 
both the Shou ling jian nao jiao nang (SLJN) and hydergine groups on MMSE and HDS for dementia 
which were confirmed by WMD. Luo et al. (2001) [180] compared Xian long jiao nang (XLJN) with 
hydergine in VaD. They reported positive outcomes and provided numerical data for serological 
measures but not for MMSE. Zhang et al. (2005) [181] indicated that Yi zhi capsule (YZ) had a better 
effect than piracetam in MiD patients on the linguistic and operational subscales of WAIS-RC which 
was confirmed by WMD but no data were reported for the other WAIS subscales. Du et al. (2003) 
[182] suggested that Tian zhi ke li (TZK) improved scores on MMSE-R and BDS in VaD patients at 
least as much as Duxil and WMD confirmed these conclusions. Wang et al. (2004) [183] reported 
greater improvements in MMSE and HDS-R in VaD for Huo xue qu yu yi zhi jian ji (HXQYYZ) 
compared with huperzine A but WMS only confirmed this for HDS-R with MMSE showing an 
improvement but not greater than huperzine A.  
 
Five trials of HM provided data suitable for meta-analysis with MMSE as the common outcome 
measure [176, 178, 179, 182, 183]. The result favored HM (WMD 0.94 [95% CI 0.26 to 1.62]) over 
other intervention (Figure 2.2). For BDS a meta-analysis of three HM trials [176, 178, 182] found no 
significant difference between HM and other intervention (WMD -0.21 [95% CI -1.09 to 0.67]) 
(Figure 2.2). 
 
Adverse events 
Four trials [176, 178, 179, 182] reported there were no adverse events (AE) observed. Six trials listed 
AEs [172-175, 183, 185] including vomiting, nausea and abdominal pain but in two trials the only 
AEs in the HM group were post trial [174, 177]. In one trial [175] there was one case of liver 
dysfunction but it was not specified whether this was in the treatment or control group (Table 2.2). 
Otherwise the AEs were relatively mild. Three trials made no reference to AEs [180, 181, 184]. 
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Discussion 
This systematic review comprehensively searched published RCTs on herbal medicine (with exclusion of 
Ginkgo biloba) and only included trials rated three or above on Jadad’s scale. It demonstrated that the 12 
different HMs were potentially beneficial in improving symptoms associated with dementia. The number of 
trials was relatively small, involved a diverse range of herbal preparations (both single and mixed), and 
positive effects were not found for all outcome measures, but the overall positive findings indicate these 
herbal medicines warrant further investigation. For a number of the herbs and formulas used in these trials, 
corroborating evidence can be found in other trials and in experimental reports [186-190]. It is also important 
to note that all trials demonstrated an excellent safety profile for the herbal medicines examined. 
 
The 14 articles represented data from 13 RCTs. Of the six trials that compared herbal medicine with placebo, 
the overall positive outcomes and the positive meta-analysis for MMSE were promising. The results of the 
active control trials (7 in total) were more difficult to interpret since there was no means of quantifying how 
much, if any, improvement was due to the interventions and how much was due to non-specific effects. 
Nevertheless, some inferences can be made with regard to the effectiveness of the active control 
interventions. Hydergine has received considerable research attention and a Cochrane review [191] found it 
to be a well tolerated therapy for dementia or ‘age-related’ cognitive symptoms that shows significant 
treatment effects even though its efficacy in dementia remains uncertain. Piracetam has been reported to 
improve memory in animal and human experiments. Although its efficacy in dementia remains controversial, 
it has widespread use in some countries [192]. Huperzine A has been reported to improve memory in 
experimental and clinical trials in China [61].  
 
The positive meta-analysis of five trials for MMSE suggests that HM may be at least equal or even superior 
to some of the pharmaceutical interventions. However, the meta-analysis of three trials for BDS found no 
superiority of HM over the other active interventions. While these results suggest that at least part of the 
improvement in the HM groups is likely to be attributable to the HM treatment, they cannot support the 
conclusion of any superiority of the HMs over these pharmaceutical drugs.  
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Although the conclusions of the trials tend to favor HM, these data need to be interpreted with caution due to 
a number of factors. Firstly, with the exception of the formula GTS (2 trials that reported consistent 
outcomes), there is only one trial per herb or herbal mixture (11 in total). Therefore, given the relatively 
small number of subjects involved in each trial, short duration of treatment, and lack of follow up in some 
trials, the outcomes of these trials need to be accepted cautiously. Secondly, with regard to the 11 trials of 
Chinese HM, only three employed diagnostic categories according to Chinese medicine theory in the 
inclusion criteria and formula selection [178, 180, 182]. Such differentiation is a common approach and is 
considered to increase the specificity and consequent efficacy of the treatment. Consequently, the Chinese 
medicine diagnosis needs to be specified in such trials. Thirdly, data concerning the quality control of the 
herbal medicines were insufficient or not available for a number of trials. Such data are essential to 
determine whether the HM meets established specifications, where available, and to enable future 
researchers to replicate the trial. Fourthly, even though the overall quality of these trials is high, some aspects 
of methodology and reporting need improvement such as details of randomization and application of 
intention to treat in data analysis. Also, the Jadad scale does not address all aspects of methodological quality. 
For example, allocation concealment is not rated. Fifthly, the trials treated AD, VaD, MiD and 
undifferentiated dementia, and the severity of the patients’ conditions was variable. Treatment effects with 
HM may vary with the type and severity of the dementia. As yet, HM treatment does not clearly differentiate 
according to dementia type so further research is needed into this factor. Sixthly, while the meta-analyses 
provide a method of pooling and comparing data, the variability between the trials in terms of subjects, 
interventions and procedures limits this approach. Finally, only six of the trials were multi-center trials [172, 
173, 175-177, 182] which compromises the generalisability of the findings.  
 
Conclusions 
The current systematic review on high quality RCTs shows that a range of herbal preparations, either single 
herbs or herbal mixtures, are potentially beneficial for the improvement of cognitive function in various 
age-related dementias. Based on their reporting quality and confirmation of results using WMD, the best 
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available evidence is for the following formulas: Jian nao yi zhi ke li (JNYZ) (Zhang et al. 2002); Cong 
sheng jiao nang (CSJN) (Jia et al. 2004); Tian zhi ke li (TZK) (Du et al. 2003); and Huo xue qu yu yi zhi jian 
ji (HXQYYZ) (Wang et al. 2004) all which were for VaD; and for Shou ling jian nao jiao nang (SLJN) for 
dementia not specified (Liu et al. 2005). Few studies investigated AD specifically so for AD the evidence is 
less compelling, but the best available evidence would appear to be for BDW (Iwasaki et al. 2004). However, 
due to the small sample sizes for each of the herbal preparations investigated, some methodological 
weaknesses and lack of longer term follow up, these conclusion can only be tentative. There is a need for 
further multi-center trials with large sample sizes to further investigate the efficacy and safety of these and 
other herbal medicines for dementia. 
 
PART 2 
SYSTEMATIC REVIEW OF HERBAL MEDICINE FOR MILD COGNITIVE 
IMPAIRMENT (MCI) AND  
AGE ASSOCIATED MEMORY IMPAIRMENT (AAMI) 
 
Introduction 
No comprehensive English language reviews of the clinical use of herbal medicines other than Gingko biloba 
for MCI or AAMI were located to December 2007. The aims of this review and methods for searching, 
selecting trials, data extraction, rating methodological quality and approaches to data analysis are discussed 
in the general method section above. 
 
Results 
A total of 2,638 potentially relevant titles and abstracts were identified from the English and Chinese 
language electronic databases and the hand searches. Following screening, the full texts of 236 articles were 
retrieved for further examination except for a few of the trials included in the Cochrane review by Birks and 
Grimley Evans 2002 [155]. Twelve articles referring to ten different trials met all inclusion criteria (Figure 
2.3). 
40 
Figure 2.3: Flow chart of the selection process using database and hand searches for Mild Cognitive 
Impairment and Age Associated Memory Impairment 
 
Number of potentially
relevant citations identified
(n=2,638)
Full articles retrieved for
detailed evaluation (n=236)*
Journal articles included in
the review (n=12)
Citations excluded after screening
titles and abstracts (n=2,402)
E1: Not a CT, experimental study or
systematic review of herbal medicine
E2: Not principally related to memory,
ageing, cognitive impairment or dementia
E3: Not principally using herbal
medicine internally in humans
E4: Not in English, Chinese, German or
Japanese
Articles excluded with reason
(n=224)
E5: Review article or not a CT
E6: Related principally to gingko biloba
E7: Subjects not all middle aged to
elderly
E8: Subjects not all diagnosed with MCI
or AAMA
Studies included in the
review (n=10)
 
* full text was not obtained for all the papers on ginkgo that were evaluated by Birks & Grimley Evans [155]  
 
 
Characteristics of included trials 
The ten trials were published between 1999 and 2007 with one in English [193] and nine in Chinese. Nine 
were concerned with MCI and one with age related memory decline consistent with AAMI [193]. All were 
conducted in China and involved a total of 654 subjects (Table 2.4). Five trials used a double-blind design 
[194-199], three were single blind [200-202] and two were not blinded [203, 204]. Treatment durations were 
generally short and ranged from two to ten months. Two trials had follow up periods (Table 2.4). Eight 
different CHMs were investigated as the principal experimental interventions. Two trials compared CHM 
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with placebo and eight compared CHM with other interventions: the nootrophic drug piracetam, the ergoloid 
mesylate drug hydergine, the cholinesterase inhibitor donepezil and the herb Gingko biloba. 
 
Adverse event reporting was included in five trials but no adverse events were recorded. All trials reported 
overall positive outcomes for the CHMs but not necessarily in terms of superiority over the control 
interventions. 
 
Methodological quality of included trials 
The methodological quality of the included trials ranged from one to five on the Jadad scale (Table 2.5). Five 
trials properly described the randomization method, four provided appropriate details for double blinding and 
three provided details of dropouts and withdrawals. Details of the CHMs are given in Table 2.6. Five trials 
provided quality control data for the CHMs in terms of equivalence to the crude herb but without 
chromatographic or other standardization data. Seven trials provided complete lists of the ingredients of the 
CHMs, one trial [195] did not specify the ingredients and two provided incomplete lists.  
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Outline of included trials 
The ten trials are grouped below according to the type of comparison. One trial [202] included two 
interventions, placebo and piracetam. These are discussed separately. 
 
CHM versus placebo 
In a double blind RCT [194, 205], Fu (2006, 2007) compared Jia wei wu zi yan zong ke li 
(JWWZYZKL) with placebo using the Clinical Memory Scale (CMS) and reported a significant 
improvement in Memory Quotient (MQ) in the treatment group, a decline in hippocampal volume in 
the control but not in the treatment group, and a significantly greater decline in serum Beta amyloid in 
the treatment group.  
 
In a single blind RCT [202], Tian (2003) compared Jin si wei wan (JSWW) with placebo and 
piracetam (see below). In both treatment and placebo groups there was an increase in Mini-Mental 
State Examination (MMSE) scores after 12 weeks but this was only significant for the CHM group. 
This was followed by a decline but there was significantly less decline in MMSE in the CHM group 
than in placebo control at the one year follow up.  
 
CHM versus hydergine 
In a single blind RCT [201], Li (2004b) compared Huan nao yi chong jiao nang (HNYCJN) with 
hydergine. There was improvement in Cognitive Capacity Screening Examination (CCSE), Functional 
Activities Questionnaire (FAQ) and MMSE scores in the CHM group. In the hydergine group there 
was only improvement in MMSE but this was significantly less than in the CHM group.  
 
CHM versus Gingko biloba 
Wang et al (2004) compared Jia wei wu zi yan zong ke li (JWWZYZKL) with Ginkgo biloba leaf 
extract [206]. There were significant improvements in all five CMS subscales and MQ in the CHM 
group and in four subscales and MQ in the gingko group but there were no differences between groups. 
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There was an increase in superoxide dismutase (SOD) activity and decreases in malondialdehyde 
(MDA), acetylcholinesterase (AchE) and mitochondrial DNA deletion rate in both the CHM and 
Ginkgo groups with no significant differences between groups. 
 
He et al (2005, 2006) conducted a trial with a similar design to the above using Jian pi tian jing fang 
(JPTJF) compared with Yin xing ye jiao nang (a combination of gingko and piracetam) [196, 197]. 
Significant improvements in all five CMS subscales and MQ were found in the CHM group and in 
three CMS subscales and MQ in the gingko group. There were differences between the groups on two 
CMS subscales in favour of CHM but no difference in MQ.  
 
These two trials suggest that the CHMs may be equivalent or superior to gingko leaf extract in 
improving memory in MCI patients in the short term but the samples were small and the data were not 
suitable for pooling since the trial by He et al did not use gingko leaf alone. 
 
CHM versus Piracetam 
Wang and Li compared Nao li bao wan (NLBW) with piracetam in subjects with mild poor memory 
consistent with AAMI who satisfied the criteria for Liver and Kidney Yin Deficiency according to 
Chinese medicine [193]. Within the CHM group they reported significant improvement in MMSE on 
five of eight memory tasks, and four of ten sets of reported symptoms: poor memory, dream-disturbed 
sleep, tinnitus and poor hearing, and dizziness and vertigo. Compared with piracetam, there was no 
difference in MMSE but three of the memory task scores favoured CHM: immediate recall; retarded 
recall; and recognition. Of the reported symptoms, the CHM was superior on dream disturbed sleep, 
tinnitus and poor hearing.  
 
Zhu and Zhang, in a double blind RCT, also compared NLBW with piracetam in subjects meeting the 
criteria for Liver and Kidney Yin Deficiency [195]. They reported the CHM group showed greater 
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improvement on the Chinese Medicine Symptom Score and MMSE. However, the report was brief 
and no data tables were presented. 
 
Tian et al compared Jin si wei wan (JSWW) with piracetam and placebo (see above) [202]. They 
reported an increase in MMSE after 12 weeks followed by a decline at one year follow-up. There was 
no difference between CHM and piracetam but both were superior to placebo. On the Adult Memory 
and Information Processing Battery (AMIPB) the total score of memory items declined significantly 
less in the CHM group than in the piracetam group at 12-month follow up, but there was no difference 
at 12 weeks. Both groups were better than placebo.  
 
Li et al conducted a single blind trial [200] with the same design as Li et al using a combination of 
HNYCJN plus Deng zan hua su dry powder for injection compared with piracetam [201]. They found 
significant improvements on CCSE, FAQ and MMSE in the combination CHM therapy group. 
 
Gong et al compared two dosage levels of Yi nao chong ji (YNCJ) with piracetam and no treatment, in 
an unblinded RCT employing four groups (N= 126) [203]. Compared with no treatment, they reported 
that all ten subscales of Wechsler’s Memory Scale (WMS) and MQ improved significantly in the high 
dose CHM group. In the low dose CHM group six WMS subscales and MQ improved. In the 
piracetam group six WMS subscales and MQ improved. However, full numerical data were not 
provided. 
 
In an unblinded RCT, Xie compared CHM in decoction with combination therapy (donepezil + 
piracetam) [204]. The formula, Da bu yin wan, was modified according the individual presentation as 
is common practice in Chinese medicine. Subjects in both groups were given lifestyle advice and other 
medications as required. 32 of 35 subjects showed improvement or no decline in MMSE in the CHM 
group vs 24 of 34 in the combination group. However, the report was brief and complete numerical 
data were not presented.  
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Meta-analysis 
The ten trials suggest that the CHM may improve memory or slow cognitive decline in MCI and 
AAMI. However sample sizes were small, different CHMs and outcome measures were used, and the 
methodological quality varied. Considering the limitations of meta-analysis and the difficulties 
inherent in interpreting small effects [204, 207, 208] a cautious approach to combining trials was taken. 
For NLBW, two trials were conducted but one did not report complete data, thereby precluding data 
pooling. HNYCJN was also tested in two trials but in one it was used alone while in the other it was 
combined with a purified compound for injection, so these trials did not test the same intervention. 
Meta analysis was only practicable for three trials that compared CHM with piracetam and used 
MMSE as an outcome measure (Figure 2.4). This found no significant benefit for CHM over 
piracetam (WMD 0.37 [95% CI -0.21 to 0.95]) but in two trials [193, 200] both CHM and piracetam 
demonstrated a benefit over baseline.  
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Discussion 
This review found an overall benefit for the eight CHMs involved in the ten RCTs and in three trials 
the effects of the CHMs were at least equivalent to piracetam. However, variability in reporting 
quality and issues relating to the control interventions preclude firm conclusions. With regard to 
methodological reporting quality, four trials (Fu et al 2006, 2007; He et al 2005, 2006; Wang & Li 
2006; Wang et al 2004) combined the features of double blind design and a Jadad score of 3 or 
greater [194, 196-199, 205]. Of these, Fu et al [194, 205] compared JWWZYZKL with placebo and 
used a range of outcome measures including measures of memory, serum beta-amyloid and 
hippocampal volume, thereby lending weight to the possibility that the CHM had a real effect. In the 
other three trials the CHMs were compared with potentially active interventions. In the clinical setting 
in China this approach is understandable since patients are generally unwilling to participate in 
placebo controlled trials especially when they have a degenerative disease. However, the results of 
these trials need to be interpreted in light of the likely efficacy of each of the control interventions.  
 
Hydergine has received considerable research attention and a review [191] found it to be a well 
tolerated therapy for dementia or age-related cognitive symptoms that shows significant treatment 
effects even though its efficacy in dementia remains uncertain. Consequently the finding by Li et al of 
a similar level of response to both HNYCJN [201] and hydergine suggests this CHM warrants further 
research in a placebo controlled trial. 
 
Piracetam modulates neurotransmission in a range of transmitter systems, has neuroprotective and 
anticonvulsant properties, and improves neuroplasticity. It is used for a range of clinical indications 
including cognitive disorders and dementia [209]. A Cochrane review [192] concluded that the 
available evidence did not support its use in dementia or cognitive impairment. However, another 
review which also employed meta-analysis [210] found there was compelling evidence for the global 
efficacy of piracetam in a diverse group of older subjects with cognitive impairment.  
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In this review, the meta-analysis indicates an equivalent benefit for CHM and piracetam on MMSE in 
two of three trials. Of these two, the CHM tested by Wang and Li 2006 appears to have the better 
evidence of a beneficial effect [193] since another trial reported a similar finding for the same CHM 
[195]. Of the single blind trials, Tian et al 2003 is notable since it employed both placebo and 
piracetam as controls and included a 12 month follow up [202]. The results indicate there were no 
significant effects for either CHM or piracetam after three months but some benefits were evident at 
follow-up. This suggests longer trials may be needed to properly determine therapeutic benefits in this 
condition.  
 
The two unblinded trials provide weaker evidence than the others but each has features that could be 
combined into future trials. By using two CHM dosage levels, Gong et al 1999 offer one approach to 
dealing more effectively with the need to compare CHM with active control [203]. The finding of a 
dose dependant effect would seem to indicate activity for the CHM. If such an approach were adapted 
to a double blind design the evidence would be more compelling. Xie 2007 attempted to investigate a 
realistic CHM intervention by using herbs in decoction and allowing modification according to 
individual presentation [204]. The problem with this approach is that blinding cannot be applied so 
the results are subject to bias. Another approach to the issue of the mismatch between the CM 
syndrome and the diagnostic criteria for MCI was taken by [195] and [193]. In these trials, only 
patients meeting both the inclusion criteria for MCI and the CM diagnosis of Liver and Kidney Yin 
Deficiency were included, thereby ensuring that the CHM was a suitable choice, even though it was 
not adjusted according to individual and temporal variation as would be the case in typical clinical 
practice. By controlling for individual variation within the MCI category this approach allows a more 
valid comparison to be made. 
 
Conclusions 
Of the ten trials four combined double blinding with adequate reporting quality and can be considered 
high quality. Of these only one compared CHM with placebo and found a benefit for JWWZYZKL 
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for MCI [194, 205]. In two cases the same CHM was tested in two separate trials but only NLBW was 
under double blind conditions in both cases and the result of one high quality trial [193] for AAMI 
was confirmed in the meta analysis. While the evidence for efficacy of these CHMs in MCI and 
AAMI remains inconclusive, the best available evidence is for the CHMs JWWZYZKL and NLBW. 
These CHMs warrant further investigation through larger, longer-term multi-centre placebo controlled 
RCTs. 
 
 
PART 3 
ANALYSES OF THE FORMULAS AND INDIVIDUAL HERBS 
INCLUDED IN THE RCTS 
 
This part examines the procedure and results for analyzing the results of both systematic reviews at 
the level of the individual herbal ingredient. In order to determine which herbs had received research 
attention in the RCTs, the individual herbs in each of the test formulations were coded into SPSS. 
Since all but two RCTs were of Chinese or Japanese multi-herb formulations, the two herbs 
investigated by Akhondzadeh et al were excluded from these analyses.  
 
Coding and data entry procedure 
For each ingredient in each test formula the scientific name was identified. In the majority of cases 
this corresponded to the botanical name. When the same species is usually designated using more than 
one herbal name according to the part used or the method of preparation, these different forms were 
allocated separate numerical codes. Where alternate Chinese names were used for the same herb, 
these were combined under one numerical code. The resultant data was entered into SPSS with each 
herbal entry being allocated one line of data which included the identity of the RCT, year, Jadad score, 
conditions treated, outcome of trial, and the number of participants. In the cases where the trial 
formulation could be modified by the addition of herbs to treat additional symptoms, only the base 
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formula was considered. Since the aim was to allow comparison across data sets, it was decided that 
identifying herbs at the level of species was the most productive approach, so a number of herbs were 
recoded to combine them. For example, sheng di huang (dried uncooked rehmannia glutinosa root) 
was combined with shu di (dried steamed rehmannia glutinosa root) since both are forms of the root 
of the same species. However, when the herbs were derived from different parts of the plant, separate 
codes were retained. 
 
Results for individual formulas and herbs 
Herb data from 21 trials spanning the period 1997 to 2007 were included. Eleven of the RCTs were 
included in the systematic review for dementia and the remaining RCTs were from the MCI review. 
Each RCT contributed one herbal test formula to the data set. Four formulas appeared in two RCTs 
each so the data set included 17 different formulas. The formula names are summarized in Table 2.7 
below. The ingredients of each formula are listed in Table 2.3 and Table 2.6 above. 
 
The 21 formulas in Table 2.7 below resulted in 149 individual herb entries being included in the total 
data set. These were allocated 67 different codes and analysed for total frequency and frequency 
according to whether the herb was a component of formulas for two subsets of conditions: 1. AD, 
VaD or MiD; 2. MCI or AAMI. The frequency data are presented in Table 2.8 and the botanical 
names and Chinese characters for each of the herbs are listed in Appendix 4. 
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Table 2.7: Chinese herbal formulas included in the data set 
Formula name (pin yin) Formula name (Chinese) RCT Disorder 
Ba wei di huang wan 
八味地黃丸 
Iwasaki K 2004 AD+CVD 
Cong sheng jiao nang 
聰聖膠囊 
Jia Y 2004 VaD 
Gou teng san (Chotosan) 
鉤藤散 
Suzuki T 05 AD, AD+VaD 
Gou teng san (Chotosan) 
鉤藤散 
Terazawa K 1997 VaD 
Huan nao yi chong jiao nang 
還腦益聰膠囊 
Li 2004a MCI 
Huan nao yi chong jiao nang 
還腦益聰膠囊 
Li 2004b MCI 
Huo xue qu yu yi zhi jian ji 
活血祛瘀益智煎劑 
Wang LL 2004 VaD 
Jia jian da bu yin wan 
加減大補陰丸 
Xie 2007 MCI 
Jia wei wu zhi yan zong ke li 
加味五子衍宗顆粒 
Fu 2006, 2007 MCI 
Jia wei wu zhi yan zong ke li 
加味五子衍宗顆粒 
Wang XM 2004 MCI 
Jian nao yi zhi ke li 
健腦益智顆粒 
Zhang BL 2002 VaD 
Jian pi tian jing fang 
健脾填精方 
He 2005, 2006 MCI 
Jin si wei wan 
金思维丸 
Tian 2003 MCI 
Nao li bao wan 
腦力寶丸 
Wang J 06 AAMI 
Nao li bao wan 
腦力寶丸 
Zhu 2002 MCI 
Shou ling jian nao jiao nang 
首靈健腦膠囊 
Liu H 2005 Dementia 
Tian zhe ke li 
天智顆粒 
Du GY 2003 VaD 
Xian long jiao nang 
仙龍膠囊 
Luo 2001 VaD 
Yi gan san 
抑肝散 
Iwasaki K 2005 Feb AD, VaD 
Yi nao chong ji 
益腦沖劑 
Gong 1999 MCI 
Yi zhi jiao nang 
益智膠囊 
Zhang MZ 2005 MiD 
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Table 2.8: Frequencies of individual herbs for total RCT data set & two sub-sets of conditions 
Total set. 21 RCTs Freq. Subset 1. AD, VaD, MiD Freq. Subset 2. MCI, AAMI Freq. 
Shi chang pu  9 Ren shen 4 Shi chang pu 5 
Chuan xiong 8 Shi chang pu 4 Gou qi zi 5 
Ren shen 7 He shou wu 4 Chuan xiong 4 
He shou wu 7 Chuan xiong 4 Tu si zi 4 
Gou qi zi 6 Gou teng 4 Ren shen 3 
Fu ling 6 Fu ling 4 He shou wu 3 
Tu si zi 5 Gan cao 3 Huang lian 3 
Yuan zhi 5 Di huang 3 
Gou teng 4 Yuan zhi 3 
Di huang 4 Fu pen zi 2 
Wu wei zi 2 
Che qian zi 2 
Tian ma, Huang qi, Yin yang 
huo, Huang lian, Gan cao, 
Mai dong, Ju hua, Dan shen 
3 
Yin yang huo 2 
Hu lu ba 2 
Fu ling 2 
Di gu pi 2 
Fu pen zi, Wu wei zi, Che 
qian zi, Hu lu ba, San qi, Rou 
cong rong, Bai zhu, Chen pi, 
Ban xia, Fang feng, Shi gao, 
Jiang, Shui zhi, Zhi mu, Di 
gu pi 
2 
Tian ma 
Huang qi 
San qi 
Chen pi 
Ban xia  
Mai dong 
Ju hua 
Fang feng 
Shi gao 
Jiang 
Yuan zhi 
Shui zhi 
Dan shen 
2 
  
Nu zhen zi, Suo yang, Nan 
xing, Shi jue ming, Ye jiao 
teng , Yi mu cao, Du zhong, 
Huai hua, Zhi zi, Ling zhi , 
Yu jin, He ye, Di long, Lou 
lu, Chai hu, Dang gui, Shan 
zhu yu, Shan yao, Ze xie, Mu 
dan pi, Fu zi, Rou gui, gui 
zhi, Yu zhu / Huang jing , Ba 
ji tian, Hong hua, Chi shao, 
Chuan niu xi, Suan zao ren, 
Tian dong, Bai zi ren, Gui 
jia, Huang bo, Ge gen, Tao 
ren 
1 Nu zhen zi, Tu si zi, Suo 
yang, Nan xing, Gou qi zi, 
Yin yang huo, Shi jue 
ming, Ye jiao teng , Yi mu 
cao, Du zhong, Huai hua, 
Zhi zi, Ling zhi, Yu jin, 
He ye, Di long, Rou cong 
rong, Lou lu, Chai hu, 
Dang gui, Bai zhu, Di 
huang, Shan zhu yu, Shan 
yao, Ze xie, Mu dan pi, Fu 
zi, Rou gui, gui zhi , Zhi 
mu, Hong hua, Chi shao, 
Chuan niu xi, Tao ren 
1 Tian ma 
Huang qi 
Rou cong rong 
Bai zhu 
Yu zhu / huang jing 
Ba ji tian 
Mai dong 
Ju hua 
Zhi mu 
Dan shen 
Suan zao ren 
Tian dong 
Bai zi ren 
Gui jia 
Huang bo 
Ge gen 
1 
Total:149 Total:86 Total:63 
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In the first subset (AD, VaD, MiD) of the RCTs, 53 different herbs were used and 32 appeared in the 
second subset (MCI, AAMI). Of the total data set derived from the 21 RCTs, 33 herbs appeared in 
more than one RCT and 18 appeared in 3 or more. The most frequently appearing herb was shi chang 
pu 石菖蒲 (Acorus tatarinowii) which was used in 9 RCTs. This herb also had the highest frequency 
in both subsets. Chuan xiong 川芎 (Ligusticum chuanxiong) was the second most frequent overall 
and it also ranked first or second in the subsets. Ren shen 人參 (Panax ginseng) ranked third overall 
and also appeared in the top three herbs in the subsets. When the two subsets were compared there 
was considerable overlap, with 16 (50%) of the herbs in subset 2 (marked in bold in table 2.8) also 
appearing in subset 1.  
 
 
PART 4 
COMPARISONS WITH A SAMPLE OF THE CONTEMPORARY 
CLINICAL LITERATURE 
 
This part provides a comparison between the formulas and individual herbs used in the RCTs 
included in the above two systematic reviews and those recommended in contemporary clinical 
manuals (CCMs). The aim was to determine whether these RCTs had investigated a representative 
sample of the formulas and herbs currently recommended to clinicians in CM for application in senile 
dementia. 
 
Method for compiling the sample 
Searches were conducted at the Chinese medicine library of the Hong Kong Baptist University and 
the library of the Guangzhou University of Chinese Medicine for specialist books on the treatment of 
psychological and brain diseases or diseases of ageing with CM that contained sections on the 
treatment of AD, VaD, MCI, senile dementia or memory loss. These were copied. In addition, internet 
searchers were conducted for such specialist books and attempts were made to purchase of borrow 
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relevant titles. Bookshops in Hong Kong, Shenzhen, Guangzhou and Hangzhou were also searched 
for additional relevant books. These were posted to Australia. In total, 23 books were collected 
including two in English. Generalist clinical manuals that included sections on dementia were not 
included. 
 
The specialist books were examined to determine which contained comparable sections on the 
diagnosis and treatment of the above diseases using CHM. The following data from these sections 
were extracted to an Excel spreadsheet: disease name, CM syndrome (zheng 症), recommended 
formulas, and constituent herbs. With regard to the individual herbs, only those herbs that constituted 
the formulas were extracted. This included and additions or subtractions made to the formula for the 
purpose of adapting it to the treatment of chi dai or jian wang, but not the additions or subtractions 
suggested for the presence or absence of other symptoms. 
 
The procedure for entering data into SPSS and for recoding herb data was the same as for the RCT 
data in Part 3 above. 
 
Results and discussion 
Of the 23 titles, 14 were in the usual format for a CM clinical manual which typically presents the 
diagnosis and treatment in the following format: 
• Disease description and general symptoms; 
• Differential diagnosis into syndromes with associate symptoms and signs; 
• Treatment of each syndrome with guiding formula(s); and 
• Modification of the formulas by the addition and subtraction of herbs to address specific 
symptoms or individual differences in the cases. 
The other specialist books took different approaches. They provided large collections of formulas, 
focussed on case histories, or provided lists of useful herbs but no actual formulas and were therefore 
not typical treatment manuals.  
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The 14 CCMs were published between 1992 and 2007 and within these manuals there were 
discussions on the diseases AD, VaD and MCI but in all but one CCM the actual treatment sections 
were framed in terms of the traditional diagnostic categories of chi dai (dementia), lao nian chi dai 
(senile dementia) or jian wang (memory loss). In the exception, lao nian chi dai was divided into lao 
nian xing chi dai 老年性痴呆 which was analogous to AD and xue guan xing chi dai 血管性痴呆 
which was VaD. The summary results for these 14 books are provided in Appendix 1. 15 entries were 
found for chi dai (one book contained two sections) and 5 for jian wang. These yielded 216 formulas 
which had 99 different herbal formula names and there were 12 unnamed formulas.  
 
Formulas 
The higher frequency formulas are presented in Table 2.9. The most commonly used formula was 
Tong qiao huo xue tang 通竅活血湯 which appeared in 14 out of the 20 disease entries. The next 
most common were Gui pi tang 歸脾湯 and Zuo gui wan 左歸丸, appearing 13 and 10 times 
respectively, followed by Huan shao dan 還少丹 and Huang lian jie du tang 黃蓮解毒湯 (9 times 
each). When the sub-group for jian wang was considered, the most common formula was Gui pi tang 
歸脾湯 (4 times) with the following four formulas appearing three times each: Xue fu zhu yu tang 血
府逐瘀湯, Dao tan tang 導痰湯, He che da zao wan 河車大造丸 and Ren shen yang rong tang 人
參養榮湯. 
 
While formulas such as Gui pi tang were often recommended for either chi dai or jian wang, there 
were some notable differences in the recommendations for each of these conditions. The most 
common formula for chi dai, Tong qiao huo xue tang, was only recommended in one of the five 
CCMs that discussed jian wang, and neither Huang lian jie du tang nor Bu tian da zao wan received a 
recommendation. Conversely, He che da zao wan and Ren shen yang rong tang were included in three 
CCMs for jian wang but in none for chi dai. 
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Table 2.9: Higher frequency Chinese herbal formulas included in contemporary clinical 
manuals (CCMs) for chi dai and jian wang 
 
Formula name (pin yin) Formula name  Chi dai Jian wang Total 
Tong qiao huo xue tang 
通竅活血湯 
13 1 14 
Gui pi tang 
歸脾湯 
9 4 13 
Zuo gui wan 
左歸丸 
9 1 10 
Huan shao dan 
還少丹 
8 1 9 
Zhi mi tang  
指迷湯 
8 1 9 
Huang lian jie du tang 
黃蓮解毒湯 
7 0 7 
Xue fu zhu yu tang  
血府逐瘀湯 
4 3 7 
Bu tian da zao wan 
補天大造丸 
7 0 7 
Di tan tang 
涤痰湯 
4 1 5 
Ba zhen tang 
八珍湯 
4 0 4 
Bu yang huan wu tang 
補陽還五湯 
3 1 4 
Dao tan tang  
導痰湯 
1 3 4 
Qi fu yin 
七福飲 
4 0 4 
Xiao yao san 
逍遙散 
4 0 4 
Tao hong si wu tang 
桃紅四物湯 
3 1 4 
Xi xin tang 
洗心湯 
4 0 4 
Jia wei ding zhi wan/Ding zhi wan 
加味定志丸/定志丸 3 1 4 
He che da zao wan  
河車大造丸 
0 3 3 
Liu wei di huang tang/wan 
六味地黃湯/丸 1 2 3 
Ren shen yang rong tang 
人參養榮湯 
0 3 3 
Jin gui shen qi wan 
金匱腎氣丸 
3 0 3 
Tian ma gou teng yin  
天麻鉤藤飲 
3 0 3 
Wen dan tang 
溫膽湯 
2 1 3 
Zhen gan xi feng tang 
鎮肝熄風湯 
3 0 3 
Chang pu wan 
菖蒲丸 
2 0 2 
Tian wang bu xin dan 
天王補心丹 
1 1 2 
Xin shen liang jiao tang 
心腎兩交湯 
0 2 2 
You gui wan 
右歸丸 
2 0 2 
Zhuan dai wan   
轉呆丸 
2 0 2 
Bu shen yi sui tang 
補腎益髓湯 
2 0 2 
Qing xin gun tan wan 
清心滾痰丸 
2 0 2 
Totals  118 20 148 
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Of the formulas included in the RCTs discussed above (Table 2.7), only three were similar to those 
included as recommendations in the clinical manuals. Jia jian da bu yin wan 加减大補陰丸 was 
used in one RCT and a similar formula Da bu yin wan jia wei 大補陰丸加味 appeared once in the 
20 disease entries from the 14 clinical manuals. Similarly, Ba wei di huang wan 八味地黄丸 was 
used in one RCT and the related formula Liu wei di huang wan 六味地黃丸 appeared 3 times in the 
clinical manuals. Gou teng san 鉤藤散 was used in two RCTs and a similar formula Tian ma gou 
teng yin 天麻鉤藤飲 appeared three times in the clinical manuals.  
 
In short, there were large differences between the formulas investigated by the RCTs and those 
recommended in the CCTs for use by practitioners. There was no exact match between any formula 
on the two lists and only three were similar. The most commonly recommended formulas were not 
those included in clinical trials and most of the formulas that had been investigated by RCTs were not 
in the CCT recommendations. Since many of the clinical manuals were written prior to the RCTs 
being published, it was not surprising that these formulas were not recommended in the CCTs. Also, a 
number of the clinical manuals did discuss the results of clinical and experimental research, some in 
considerable detail. However, it had been expected that the clinical research would have investigated 
the formulas most commonly used in clinical practice but this was not found to be the case.  
 
From the point of view of developing an evidence base for clinical CM practice, the large number of 
different formulas in use presents a difficulty for clinical research, and it may be impractical to 
attempt to investigate all of these. However, there is an imperative to investigate the most commonly 
used treatments prior to those in less common use. The above analysis provides a summary of the 
formulas recommended for clinical practice so may be appropriate to undertake a similar analysis 
prior to selecting formulas for use in future clinical trials.  
 
Individual herbs 
Comparison between the RCTs and the contemporary clinical manuals at the level of the individual 
herbs presented some difficulties. For each formula entry in the clinical manuals there were typically 
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lists of herbs suggested for addition and subtraction when modifying the formula to the individual 
patient’s condition. So it was necessary to determine which herbs formed the total recommendation in 
the CCT and consequently which herbs should be included. The approach taken was to only include 
the herbs that comprised the base formula for jian wang or chi dai and to exclude the additions and 
subtractions that aimed to treat additional symptoms or conditions. Comparisons between subgroups 
was also problematic since the RCTs were divided into the AD, VaD, MiD group and the MCI, 
AAMI group, whereas the CCM data were divided into chi dai and jian wang. 
 
Individual herb data was extracted into SPSS from 204 formula recommendations (142 for chi dai and 
62 for jian wang). These included the unnamed formulas as well as recommendations for combined 
formulas, which were treated as one formula for data entry purposes. In some instances the herbal 
ingredients of the formulas were not listed and could not be included. These factors account for the 
lower number of formula entries in SPSS compared with the total number of formula names. In total, 
2,093 herbs were entered into SPSS under 154 different herbal names after recoding. For chi dai there 
were 1,545 entries and 136 different herbs and for jian wang there were 548 entries and 88 different 
herbs, so the consolidated results tend to reflect those for chi dai.  
 
Yuan zhi was the highest frequency herb in total, with 108 occurrences followed closely by di huang
地黃 (105), shi chang pu 石菖蒲 and fu ling 茯苓 (both 92). Dang gui 當歸 and gan cao 甘草 
had frequencies of 74 and 73 respectively, with the next grouping being bai zhu 白術 (57), ren shen 
人參 (56), suan zao ren 酸棗仁 (54) and chuan xiong 川芎 (49). For the chi dai subset the top ten 
herbs were predictably similar as follows: di huang 地黃 (75), yuan zhi 遠志 (72), shi chang pu 石
菖蒲 (70), fu ling 茯苓 (58), dang gui 當歸 (53), gan cao 甘草 (49), suan zao ren 酸棗仁 (43), 
bai zhu 白術 (42), chuan xiong 川芎 (39) and yu jin 鬱金 (38). In the case of jian wang the top 
ten were: yuan zhi 遠志 (36), fu ling 茯苓 (34), di huang 地黃 (30), ren shen 人參 (27), gan cao 
甘草 (24), shi chang pu 石菖蒲 (22), dang gui 當歸 (21), fu shen 茯神 (18), bai zhu 白術 (15) 
and dang shen 黨參 (13). More complete lists of the higher frequency herbs are in Table 2.10.  
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Table 2.10: Higher frequency herbs included in CCMs for chi dai and jian wang 
Herb name: Total set Freq Herb name: Chi dai Freq Herb name: Jian wang Freq 
Yuan zhi 108 Di huang  75 Yuan zhi 36 
Di huang  105 Yuan zhi 72 Fu ling 34 
Shi chang pu, Fu ling 92 Shi chang pu 70 Di huang 30 
Dang gui 74 Fu ling 58 Ren shen 27 
Gan cao 73 Dang gui 53 Gan cao 24 
Bai zhu 57 Gan cao 49 Shi chang pu 22 
Ren shen 56 Suan zao ren 43 Dang gui 21 
Suan zao ren 54 Bai zhu 42 Fu shen 18 
Chuan xiong 49 Chuan xiong 39 Bai zhu 15 
Yu jin (guang) 44 Yu jin (guang) 38 Dang shen 13 
Shan yao  38 Shan yao  32 Jiang  12 
Huang qi, Shan zhu yu 36 Shan zhu yu 30 
Dang shen, Tao ren 33 Ren shen 29 
Huang qi, Gui zhi/Rou gui, 
Mai dong, Suan zao ren 
11 
Ban xia, Fu shen 32 Gou qi zi 26 
Wu wei zi, Jiang 31 Huang qi 25 
Chuan xiong, Chen pi, Ban 
xia, Zhi shi 
10 
Hong hua 30 Tao ren 24 Wu wei zi, Tian dong, Tao 
ren 
9 
Gou qi zi, Chen pi, Chi 
shao, Zhi shi 
29 Hong hua, Chi shao, Gui 
jia 
23 
Da zao, Niu xi 8 
Gui jia 28 Wu wei zi, Ban xia 22 
Bai shao, Da zao, Niu xi 27 Bai shao 21 
Nan xing, Hong hua, Zhu 
sha 
7 
Gui zhi/Rou gui, Mai 
dong 31 
23 Dang shen 20 
Nan xing 22 
Dan shen, Long gu/chi  21 
Chen pi, Jiang , Da zao, 
Zhi shi, Niu xi 
19 
Yu jin (guang), Shan zhu 
yu, Shan yao, Chi shao, 
Bai shao, Jie geng (no 33) 
6 
Du zhong, Yi zhi ren 20 Long gu/chi  18 Dan shen, Bai zi ren, Gui jia 5 
Chai hu, Lu rong 18 Du zhong, Lu rong 17 
Mu dan pi, Fu zi, Ba ji 
tian 
16 Dan shen, Yi zhi ren (no 
33) 
16 
Tu si zi, Mu xiang, Long 
yan rou, Yi zhi ren 
4 
Nan xing, Chai hu 15 Huang lian, Rou cong 
rong, Tian dong, Xuan 
shen 
15 
Zhi zi, Huang lian, Mu 
dan pi, Fu zi, Fu shen 
14 
Gou qi zi, Du zhong, Chai 
hu, Ba ji tian, Di gu pi, Long 
gu/chi , Hu po, Xuan shen, 
Huang bo, Zi he che 
3 
Total: 2,093 Total: 1,545 Total: 548 
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There was considerable similarity between the herbs used for chi dai and for jian wang. In the case of 
the top 33 herbs for chi dai, 26 were included in the top 33 herbs for jian wang (in bold in Table 2.10). 
So, whereas the formula recommendations showed considerable differences between chi dai and jian 
wang, this was not the case at the level of the individual herb.  
 
Since the subgroups for the RCT and CCT data were based on different criteria, comparisons between 
the sets of individual herbs were made using the total data sets (149 and 2,093 herb entries 
respectively). Six of the top 10 herbs on either list were in common: shi chang pu 石菖蒲 (Acorus 
tatarinowii), chuan xiong 川芎 (Ligusticum chuanxiong), ren shen 人參 (Panax ginseng), fu ling 茯
苓 (Poria cocos), yuan zhi 遠志 (Polygala tenuifolia), and di huang 地黃 (Rehmannia glutinosa). 
Of the top 20 herbs in the CCT set, all but two, dang shen 黨參 (Codonopsis pilosula) and fu shen 
茯神 (Poria cocos with pine root inclusions), appeared on the RCT list but these two herbs were very 
similar to the herbs ren shen and fu ling, which were in the top 10. Of the top 31 CCT herbs, 25 
appeared in the RCT list. So, there was a high level of overlap between the RCT and CCT data sets at 
the level of the individual herb. There were, however, some differences since some of the higher 
frequency herbs on the RCT list were not amongst the higher frequency CCT herbs including: he shou 
wu 何首烏 (Polygonum multiflorum), gou teng 鉤藤 (Uncaria rhynchophylla) and tu si zi 菟絲子 
(Cuscuta chinensis).  
 
A number of caveats apply to the comparisons between the RCT and CCT data sets. While 
considerable effort was made to collect as complete data as possible, both sets are selected samples 
and the method of sampling and selection varied between the samples. The samples also vary 
considerably in size and are drawn from different textual populations. Even so, they both represent 
aspects of the contemporary CM clinical literature.  
 
As noted above, there was little commonality in the formulas recommended in the CCTs and those 
investigated in the RCTs. This suggested a major disjunction between research efforts in the field of 
CM for memory disorders and the approaches to the treatment of these disorders in the clinical 
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manuals and textbooks used by practitioners and students. This disjunction was, however, 
considerably mitigated when the herb level data was examined. Although the formulas were different 
in name and total composition, many of the same herbs appeared repeatedly in their list of 
constituents. So, when viewed from the level of the individual herb, the RCTs had investigated a 
considerable proportion of the herbs commonly used in contemporary practice.  
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CHAPTER 3 
CLASSICAL LITERATURE – INTRODUCTION AND APPROACH TO 
SEARCHING 
 
Part 1 of this chapter provides an introduction to the classical literature of CM including an overview 
of its genres and a brief outline of its history with a focus on major works in the genres of relevance to 
the chapters that follow. Part 2 discusses the processes and procedures used to select appropriate 
search terms for the classical literature and appropriate collections of literature for searching. 
 
PART 1 
INTRODUCTION TO THE CLASSICAL LITERATURE  
OF CHINESE MEDICINE 
 
Defining the classical literature 
There term ‘classical’ is used in two senses when applied to the CM literature. In the narrow sense, it 
applies to the canonical ancient works that formed the foundation of CM theory and practice. These 
fall into two groups: 
 
1. Books of uncertain authorship which were formed in the period up to and including the Han 
Dynasty 漢 (206 BC - 220 AD), namely: 
• Huang Di Nei Jing 黄帝內經 ‘Yellow Emperor’s Internal Classic’  
• Nan Jing 難經 ‘Classic of Difficulties’ 
• Shen Nong Ben Cao Jing 神農本草經 ‘Farmer God’s Materia Medica’ 
 
2. Seminal works attributable to a single author from the Eastern / Latter Han Dynasty 東/後漢 (25 - 
220 AD) or Jin Dynasty 晉 (365 - 420 AD): namely: 
• Shang Han Lun 傷寒論 ‘Treatise on Cold Damage’ and its companion work the Jin Gui Yao 
Lue (Fang Lun) 金匱要略(方論) ‘Treatise on the Essentials of the Gold(en) Chest,’ both by 
Zhang Zhong-Jing 張仲景 c. 196-214 AD 
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• Mai Jing 脈經 ‘Pulse Classic’ written c. 280 by Wang Shu-he 王叔和 (c. 210-285 AD) 
• Zhen Jiu Jia Yi Jing 針灸甲乙經 ‘Systematic Classic of Acupuncture and Moxibustion’ c. 
282 by Huang-Fu Mi 皇甫謐 (215 - c. 286). 
 
All of these works have received considerable scholarly and editorial attention over the centuries, are 
available in many editions in Chinese and have been translated into other languages including English 
[211-220].  
 
In a broader sense, the term ‘classical’ is used in contrast with ‘modern’, which from a contemporary 
viewpoint is associated with the political divide between old dynastic China and modern China. With 
the 1911 revolution, the Qing Dynasty 清代 was overthrown and the Republic of China 中華民國 
replaced it. From the point of view of medicine, however, 1912 is perhaps a more accurate endpoint 
for the classical period since it was the year the old Imperial Medical College was abolished and 
western style doctors were appointed to the President's office. In the reorganization of the education 
system in 1912 there was no official place for Chinese Medicine [221].  
 
CM did not regain official status until after the establishment of the People's Republic of China (PRC) 
中華人民共和國 in 1949. In 1950 the new health minister Li De-Quan proposed that Western and 
CM systems unite and this became official policy [221]. Since that time CM has been an integral part 
of the health care system in China.  
 
The period between 1911 and 1950 marked a low point in CM publishing that effectively demarcates 
the classical period from the modern. In the searches and statistics conducted in this study, only works 
written before 1912 will be included in the section on classical literature, although editions published 
after this date will be used for search and referencing purposes. 
 
The scope of the classical medical literature 
The classical literature on Chinese medicine is vast and diverse and despite a long history of 
publishing activity, a considerable amount remains unpublished and even uncatalogued. Nevertheless, 
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thousands of works are available in print and since many of these run into multiple volumes this 
represents a formidable corpus of literature for the researcher. 
 
Within the classic medical literature a number of genres can be identified: 
 
1. Medical classics 醫經類  
This usually includes editions of and commentaries on the Han dynasty classics: Huang Di Nei Jing, 
Nan Jing, Shan Han Lun and Jin Gui Yao Lue. 
2. Diagnostic methods 診法類  
The classic work Mai Jing is usually placed in this category as are subsequent works that focus on 
pulse diagnosis, tongue diagnosis and other aspects of diagnosis.  
3. Materia medica 本草類  
The Shen Nong Ben Cao Jing is the seminal work in this genre, which includes a vast collection of 
books that list the items of materia medica together with their properties and applications. This 
genre also includes sub-genres of works on regional medicines, the therapeutic uses of foods, and 
plants that can be eaten in times of famine. See Table 3.1 for a list of key materia medicas and the 
number of items they contain. 
4. Formula compendia 方書類  
Books in this genre are principally collections of herbal formulas, and sometimes other therapeutic 
modalities, for the treatment of disease. See Table 3.2 for a list of key formularies and the number 
of items they contain. 
5. Acupuncture, moxibustion and tui na 針灸推拿類  
The classic work Zhen Jiu Jia Yi Jing usually heads this genre which includes texts on all aspects of 
acupuncture, moxibustion and tui na (therapeutic massage) ranging from books on general theory to 
specialist treatment manuals. 
6. Comprehensive medical works 綜合醫書類 
This genre includes a diverse array of works which cover both the theory and practice of medicine. It 
also includes collections of medical works and encyclopaedias.  
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7. Clinical and specialty works 臨証各科類  
Books that focus on the treatment of specific diseases are classed under this broad genre. It usually 
includes both general works and those which focus on medical specialties such as internal medicine, 
obstetrics and gynaecology, as well as surgery, bone setting and military medicine. The treatment of 
acute febrile diseases may be included as a sub-genre or separately classified as Shang han 傷寒類 
‘Cold Damage’ and Wen bing 溫病類 ‘Warm Disease’.  
8. Medical records and cases 醫論醫案類 
This genre comprises mainly collections of the methods and case records of particular doctors but 
can also include accounts of family medical traditions.  
9. Health preservation, diet and exercise 養生食療外治類  
Books with a focus on maintaining health, achieving longevity and preventing disease all fall into 
this genre which can include discussions on food, lifestyle, exercise methods, and meditation 
methods.  
10. Medical history and biography 醫史傳記 
The genre includes variety of works on history of medicine including lists of medical works, 
accounts of medicine in various periods and the biographies of specific doctors. 
 
The above summary of the genres of classical medical works is not intended to be exhaustive and 
other genres and sub-genres can be identified. In investigating which herbs have been used for 
dementia and associated diseases during the classical period, all genres of literature other than those 
on manual methods could potentially be of use, but it was expected that compendia of materia medica 
and formulas, comprehensive medical works, and clinical and specialty works in fields such as 
internal medicine, would be of greatest relevance.  
 
Since a number of medical works are mentioned in the subsequent chapters the following section 
provides an overview of key events and works in the classical medical literature with a focus on the 
genres and texts of relevance to the present project. Since the Han dynasty classics are outlined above, 
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the focus is from the Jin dynasty onwards. For each period a number of representative works are 
outlined but this account is not intended to be exhaustive.  
 
Outline of the history of the classical literature in Chinese medicine 
This section aims to provide a brief overview of the classical persiod, broadly defined, of Chinese 
medicine with a focus on key texts in the fields of materia medica, formulary and clinical therapeutics. 
It is not intended to be a comprehensive discussion of this field.  
 
Qin Dynasty 秦代 220-201 BC, Han Dynasty 漢代 201 BC-220 AD 
The oldest and best known of the Chinese medical classics is the Huang Di Nei Jing 黄帝内經 
‘Yellow Emperor’s Internal Classic’. Although often considered to be a product of the Warring States 
Period (c. 475-221 BC), it first appears in the historical record in a catalogue of the imperial library 
compiled in the period up to 26 BC. However, its structure and content at this time are not known and 
it is likely that it differed from the received version which is now in two parts: Su Wen 素問 and 
Ling Shu 靈樞. In terms of its content, the Huang Di Nei Jing is mostly concerned with medical 
theory, diagnostics and acupuncture and contains only brief discussions of herbal medicine [148, 
222-225]. 
 
The Nan jing 難經 and the Shen Nong Ben Cao Jing 神農本草經 are also of uncertain origin but 
are thought to date from the Han Dynasty [148, 213, 223]. Whereas the Nan Jing is wholly concerned 
with medical theory and acupuncture, the Shen Nong Ben Cao Jing is a structured book of materia 
medica that contains many of the herbs used in contemporary Chinese herbal formulas. 
 
The Han dynasty classics outlined above have the distinction of being the canonical ancient works of 
CM but archeological finds of the previous 40 years have unearthed medical texts that predate these 
classic works but were unknown in the received tradition. Most notable are those found in a tomb at 
Ma wang dui 馬王堆, in Changsha, Hunan province that was closed in 168 BC. One of these was a 
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text on formulas and materia medica, now referred to as Wu Shi Er Bing Fang五十二病方 ‘Formulas 
for 52 illnesses’, which included 247 items of materia medica, a number of which are still included in 
modern ben cao [226, 227].  
 
Contemporary scholarly research indicates that the received version of the Huang Di Nei Jing is a 
corpus that incorporates numerous early works on medicine from a diversity of eras and traditions and 
parallels have been drawn between passages in the received version of the Huang Di Nei Jing and 
those found in the manuscripts unearthed at Ma wang dui [222, 226, 228].  
 
However, from the end of Eastern Han Dynasty onwards information on books becomes more reliable 
[229]. The earliest version of the Shang Han Lun 傷寒論 and its companion work the Jin Gui Yao 
Lue (Fang Lun) 金匱要略(方論) were probably compiled by Zhang Zhong-Jing 張仲景 around the 
end of the Han Dynasty. However, the received versions are likely to have undergone considerable 
editing and rearrangement. Both are principally concerned with clinical therapy and contain numerous 
formulas that remain in use in contemporary CM [148, 215, 223, 225].  
 
San Guo Period 三國 220-265 
Hua Tuo 華佗, who lived around the late Han Dynasty or early San Guo Period, is perhaps the best 
known of all figures in Chinese medicine history. Known for his skill in herbal medicine, acupuncture 
and surgery, he is one of the few doctors to receive a biography in the dynastic histories. Although 
none of the works attributed to him can be authenticated, a number of other works contain references 
to his theories and methods [230, 231].  
 
Jin Dynasty 晉代 265-420, Northern and Southern Dynasties 南北朝 c. 317-581 
During the Jin Dynasty, two systematic compilations were produced which have be accorded the 
status of classics. Huang-fu Mi 皇甫謐 compiled and oranised the extant literature on acupuncture 
into his Zhen Jiu Jia Yi Jing 針灸甲乙經 ‘Systematic Classic of Acupuncture’ (c. 282) and Wang 
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Shu-he 王叔和 compiled the Mai Jing 脈經 ‘Pulse Classic’ (c 280) which contains not only the 
details of pulse diagnosis but also substantial sections on therapeutics and herbal formulas [214, 217, 
231].  
 
Besides the Mai Jing and Zhen Jiu Jia Yi Jing mentioned above, only a few works from this period 
survive. Perhaps the best known is the Ben Cao Jing Ji Zhu 本草經集注 by the famous daoist and 
alchemist Tao Hong-Jing 陶弘景 (456-536). He combined what survived of the Han dynasty Shen 
Nong Ben Cao Jing, which contained 365 items of materia medica, with a range of other sources, also 
known as the Ming Yi Bie Lu 名醫別錄 ‘Additional notes by renowned doctors’, into the Ben Cao 
Jing Ji Zhu 本草經集注 which contains 730 herbs. He wrote the original text in red and the 
additions in black to distinguish the ancient text from the additions [130, 131, 232]. This book formed 
the model for subsequent materia medicas and also set a precedent for referencing to the source that 
was followed by many subsequent works.  
 
A regional governor, Ge Hong 葛洪 (c. 261-361), whose wife Bao Gu 鮑姑 was a practitioner of 
CM, wrote a compendium of therapeutics called Zhou Hou Bei Ji Fang 肘後備急方 c. 341 AD. It 
used a systematic arrangement according to disease, a feature followed many subsequent works [233, 
234]. 
 
Sui Dynasty 隋代 581 – 618, Tang Dynasty 唐代 618 - 907 
The Sui government set up the ‘Palace office of Pharmaceutics’ (Shang Yao Ju 尚藥局) with a staff 
of over 200. Subsequently, between 620 and 630 the Tang government set up the ‘Imperial Medical 
Administration’ (Tai Yi Shu 太醫署) and the ‘Imperial Medical College’ (Tai Yi Xue 太醫學) 
together with medical colleges (Yi Xue 醫學) in the chief provincial cities. A medical degree 
required about seven years of study depending on the disciplines studied [235, 236]. 
 
The oldest surviving version of the Nei Jing is the Huang Di Nei Jing Tai Su 黄帝内經太素 (Great 
Clarity) which was compiled and edited by the physician and official Yang Shang-Shan 楊上善 in 
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around 605 [222]. The Sui government also commissioned a team of scholars headed by the court 
physician Chao Yuan-Fang 巢元方  to create a classification system for disease names and 
symptoms. The result was the Zhu Bing Yuan Hou Lun 諸病源候論 (c. 610) in 50 volumes which 
contains descriptions of 1,720 conditions arranged according to category. This provided a standard 
which was followed by numerous subsequent works.  
 
The first official materia medica was the Xin Xiu Ben Cao 新修本草 ‘Newly Compiled Ben Cao’ 
produced by Su Jing 蘇敬 and a committee of 22 officials commissioned by the Tang government. 
Completed in 659, it was based on the Ben Cao Jing Ji Zhu but contained descriptions of 850 items of 
materia medica and contained coloured illustrations [236]. 
 
Probably the best known of the Tang dynasty medical works are the Qian Jin Yao Fang 千金要方 
‘Formulas worth 1000 Gold’ and its supplement Qian Jin Yi Fang 千金翼方 by the famous scholar 
and doctor, Sun Si-Miao 孫思邈 (c. 652 - 682). These are comprehensive multi-volume works on 
theory, therapeutics including acupuncture, and health preservation which also contain sections on 
related subjects such as medical ethics [234, 237]. His student Meng Shen 孟詵 (621-714) wrote the 
Shi Liao Ben Cao 食療本草 ‘Materia Medica of Food’ which stressed the importance of foods for 
health. It contained 227 entries and also included food restraints for pregnancy and food for infants 
[238]. 
 
Another comprehensive work was the Wai Tai Mi Yao 外臺秘要 by Wang Tao 王燾. Completed in 
752, it classified and referenced medical knowledge from a wide range of sources under 1,140 
chapters with over 6,000 formulas for diseases ranging from those of internal medicine to first aid and 
veterinary medicine [234, 235, 238]. 
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Song Dynasty 宋代 960 - 1279 
Under the Song Dynasty, state involvement in medicine further expanded into medical publishing 
with the establishment of the Jiao Zheng Yi Shu Ju 校正醫書局 ‘Bureau of Medical Books’ in 1057. 
In the period 1061-1069, teams of scholars revised, edited and published ten major medical classics 
for printing and broad distribution [239, 240]. 
  
A new official materia medica was issued in 973. Compiled by Lui Han 劉翰, Ma Zhi 馬志 and 
seven other officials, the Kai Bao Xin Xiang Ding Ben Cao 開寳新詳定本草 was essentially an 
expansion of the Xin Xiu Ben Cao to include 983 separate items of materia medica. In 1061 it was 
revised by Zhang Yu-Xi 掌禹錫, Lin Yi 林億, Su Jing 蘇敬 and others, expanded to 1,084 entries 
and issued as the Jia You Bu Ju Shen Nong Ben Cao 嘉祐補注神農本草. This was further 
supplemented c. 1061 by a collection of illustrations for 634 entries called the Ben Cao Tu Jing 本草
圖經 ‘Illustrations of Materia Medica’ under the editorship of Su Song 蘇頌 [130, 131, 239].  
 
However, the most significant ben cao of the age was a private compilation by Tang Shen-Wei 唐慎
微 (1056-1093) whose Jing Shi Zheng Lei Bei Ji Ben Cao 經史證類備急本草 ‘Materia Medica 
Based upon the Classics and Historical Works Arranged by Types for Speedy Use’ was printed 
privately around 1082 [130, 131, 238]. He consulted and referenced 248 previous books and 
expanded the number of entries to 1,746. Known mainly by its short title, Zheng Lei Ben Cao 證類本
草, Tang’s work was subsequently revised by Ai Cheng 艾晟 and re-issued as an official work in 
1108 as the Jing Shi Zheng Lei Da Guan Ben Cao 經史證類大觀本草 which itself was repeatedly 
re-issued under different titles in subsequent years [130, 131, 148, 238, 240].  
 
A feature of this period was the steady increase in the number of herbs described as each new ben cao 
was issued. These Song Dynasty works were not eclipsed until the Ming Dynasty. See Table 3.1 for a 
summary of the main ben cao and the number of individual herbs entries.  
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Table 3.1: Comprehensive classical ben cao (books on materia medica) 
Title Date Author No. entries Increase 
Shen Nong Ben Cao Jing 1st – 2nd C Anonymous 365  
Shen Nong Ben Cao Jing Ji Zhu 6th C Tao Hong-Jing 730 365 
Tang Ben Cao (Xin Xiu Ben Cao) 659 Su Jing 850 120 
Kai Bao Ben Cao eds in 973 & 974 Liu Han & Ma Zhi 984 134 
Jia You Ben Cao 1057-1061 Zhang Yu-Xi 1083 99 
Ben Cao Tu Jing c. 1061 Su Song 1186 103 
Zheng Lei Bei Ji Ben Cao c. 1082 Tang Shen-Wei 1558 372 
Da Guan Ben Cao 1108 Ai Sheng 1744 186 
Zheng He Ben Cao 1116 Cao Xiao-Zhong 1748 4 
Ben Cao Gang Mu 1578 Li Shi-Zhen 1892 144 
Adapted from Goldschmidt, A. (2009, p. 108) [240]. 
 
Numerous formula compendia were issued during the Song but the officially sponsored Tai Ping 
Sheng Hui Fang 太平聖惠方 by Wang Huai-Yin 王懷隠, Wang You 王祐 and other officials 
which was published in 992 is perhaps the most notable. Divided into 1,670 categories based on the 
Chao Yuan-Fang’s Zhu Bing Yuan Hou Lun, it was issued in 10 volumes and contains 16,834 
formulas [240]. 
 
Towards the end of the Song the first official medical encyclopedia the Sheng Ji Zong Lu 聖濟總錄
was produced. Issued between 1111 and 1117 it was in 200 volumes, covered all aspects of medicine 
and contained about 20,000 formulas [130, 240]. 
 
A simpler system for classifying diseases was proposed by Chen Yan 陳言 in his San Yin Ji Yi Bing 
Zheng Fang Lun 三因極一病證方論 published in 1174. It divided diseases into Interior, Exterior, 
and Neither interior nor exterior according to their aetiology [238, 241]. Yan Yong-He 嚴用和 
adopted this system in his 8 volume work the Ji Sheng Fang 濟生方 (c. 1253). Containing only 
about 400 formulas, it is an example of the counter trend evident from the Song onwards for privately 
produced shorter works with a practical focus.  
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Books on specialist fields also proliferated during the Song. An example is the Fu Ren Da Qian Liang 
Fang 婦人大全良方 ‘Complete Book of Good Prescriptions for Women’ by Chen Zi-Ming 陳自明 
(c. 1190-1272). Published in 1237 it discusses a range of women’s disorders under 260 categories. It 
underwent many revisions and additions and remains in print to this day [242].  
 
Jin Dynasty 金代 1115 – 1234 and Yuan Dynasty 元代 1271 - 1368 
Whereas the Tang and Song dynasties are known for the comprehensive publishing efforts and the 
establishement of an official version of medicine, the Jin and Yuan Dynasties are known for their 
innovation with the development of different therapeutic approaches, known as the ‘Jin-Yuan Schools 
of Medicine’ [243]. These are based on the writings of a number of famous doctors whose theories 
and approaches were different to that of established practice but whose approaches to therapy were 
adapted into to the later tradition. Of these the best known are Li Gao 李杲 (1180-1251) and Zhu 
Zhen-Heng 朱震亨 (1280-1358).  
 
Li Gao stressed the importance of the digestive system (i.e. Spleen) in the development of disease and 
therapy in what became known as the ‘Nourish the Earth School’ (Bu Tu Xue Pai 補土學派). Of his 
many works the Pi Wei Lun 脾胃論 ‘Treatise on the Spleen and Stomach’ and the Lan Shi Mi Zang 
蘭室秘藏 ‘Secret Collection of the Orchid Room’ are perhaps the best known [234, 238]. 
 
Zhu Zhen-Heng took the view that Yin tends to decline with age and the body becomes dry and brittle. 
Therefore in therapy it is important to preserve and strengthen Yin. This became known as the 
‘Nourish the Yin School’ (益陰學派). He wrote the Ge Zhi Yu Lun 格致餘論 ‘Treatise on 
Investigating the Properties of Things’ and his students wrote the Dan Xi Zhi Fa Xin Yao 丹溪治法
心要 ‘Heart and Essence of Dan Xi's Methods of Treatment’ [234, 238]. 
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Ming Dynasty 明代 1368 – 1644 
During this long period most of the vast number of medical works that were produced were written by 
individuals, rather than as state sponsored projects. Even so, a number of voluminous works 
eventuated.  
 
Zhu Xiao 朱櫹 (c. 1360-1425) was the fifth son of the emperor, so his publishing efforts can be 
considered offical. With a team of collaborators, he compiled a medical encyclopedia and formula 
compendium called Pu Ji Fang 普濟方, completed in 1406. It drew on many sources and preserves 
information from many books that have now been lost. In 168 volumes, it contains 61,739 
prescriptions divided into 2,175 categories. Zhu was also interested in edible plants that could be used 
as food in times of famine, so he set up an experimental garden, engaged artists to draw the plants, 
and produced the Jiu Huang Ben Cao 救荒本草 ‘Wild Food Plants for Use in Emergencies’ which 
contained 414 plants of which 276 were newly described [130, 148, 238]. 
 
Table 3.2: Comprehensive classical formula compendia and encyclopedia 
Title Date Author Number of formulas 
Qian Jin Yao Fang c. 659 Sun Si-Miao 3500 
Wai Tai Mi Yao 752 Wang Tao Over 6000 
Tai Ping Sheng Hui Fang c. 992 Wang Huai-Yin 16834 
Sheng Ji Zong Lu c. 1117 Shen Fu 20,000 
Pu Ji Fang  1406 Zhu Xiao 61739 
Adapted from Goldschmidt, A. (2009, p. 118) [240] 
 
The best known of the Ming works on medicine is the Ben Cao Gang Mu 本草綱目 which took its 
author Li Shi-Zhen 李時珍 (1518-1593) 40 years to complete during which time he visited many 
parts of China to check information. It was finished in 1578 [231]. He was denied official sponsorship 
and the book was published privately in Nanjing in 1596. Li died while the book was being prepared 
for printing but his sons and grandsons completed the work. It was presented to the emperor by his 
son Li Jian-Yuan 李建元 in 1599 but it never became an official work. It contains monographs on 
1,898 items of materia medica, 1,160 illustrations and also includes 11,096 formulas. Li quotes 952 
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previous authors and all information was referenced to the source [130, 131, 244]. Although 
numerous other ben cao were published in subsequent years, none were on the scale of the Ben Cao 
Gang Mu which remained authoritative until the modern era.  
 
Dai Si-Gong 戴思恭 (c. 1324-1405) was one of the best students of Zhu Dan-Xi. He continued the 
‘Nourish the Yin School’ into the Ming, becoming a court physician and later president of the 
Imperial Medical College. He wrote a number of voluminous books such as the Zheng Zhi Yao Jue 
證治要訣 and the Zheng Zhi Lei Fang 證治類方 [234, 236, 243]. 
 
Also notable for his prolific writings, Xue Ji 薛己 (c. 1488-1558) was the son of a well known 
doctor and became an imperial physician and finally director of the ‘Imperial Medical Academy’. He 
wrote many works such as the Nei Ke Zhai Yao 內科摘要 ‘Summary of Internal Medicine’ [234, 
238, 241]. 
 
The ‘Warming and Reinforcing School’ (溫補學派) developed in the Ming and Sun Yi-Kui 孫一奎 
(1520-1600) is considered a major proponent [243]. His best known work is the Chi Shui Xuan Zhu 
赤水玄珠 ‘Dark Pearl in the Red River’, and his sons compiled his case notes into the Sun Wen Yuan 
Yi An 孫文垣醫案 ‘Sun Wen Yuan’s Medical Records’ which is an early example of the case 
records genre which proliferated in the Ming and Qing [234, 241]. Also classified in this school is 
Zhang Jing-Yue 張景岳 (c. 1561- c. 1640), who is known for his systematic approach to diagnosis 
and syndrome differentiation. His many works were compiled by his grandson Lin Ri-Wei 林日蔚 
and published in 1624 as the Jing Yue Qian Shu 景岳全書 ‘The Complete Works of Jing Yue’ in 64 
volumes [234, 241]. 
 
Some doctors focussed on researching the classics. Wu Kun 吳崑 (c. 1551- c. 1620) is known for his 
Yi Fang Kao 醫方考 of 1584 in which he systematically analysed classical formulas and their 
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ingredients to show how they were applied. In 6 volumes it includes over 700 formulas arranged into 
44 classes and 72 categories according to disease [238, 245]. 
 
Others took a more eclectic approach. Xu Chun-Fu 徐春甫 wrote the Gu Jin Yi Tong Da Quan 古今
醫統大全 ‘Complete Book of Ancient and Modern Medicine’ in 1556. It is in 100 volumes and 
quotes about 390 sources covering a wide range of types of literature [231, 243]. Wang Ken-Tang 王
肯堂 (1549-1613) studied all the schools of Jin Yuan medicine and attempted to combined their good 
points. Between 1597 and 1598 he completed the Liu Ke Zheng Zhi Zhun Sheng 六科證治準繩 
‘Standards of Diagnosis and Treatment of Six Branches of Medicine’ published in 8 volumes in 1602. 
It had the largest circulation of any medical book of the 17th century [234, 238]. 
 
Qing Dynasty 清代 1644 - 1911 
The Qing was a somewhat contradictory period. On one hand there was a strong trend to conservatism 
in the form of the ‘Classical Formulas School’ (經方派) which focussed on the Han classics. On the 
other hand the approaches of the Jin-Yuan and Ming schools continued as the ‘Modern Formulas 
School’ (時方派) and new developments in theory and practice emerged such as those associated with 
the ‘Warm Disease School’ (Wen Bing Xue Pai 溫病學派) [234, 243]. 
 
State involvement in medical publishing was mostly in the form of encyclopaedic works. The first 
imperial encyclopedia of the era was the Gu Jin Tu Shu Ji Cheng 古今圖書集成 ‘Collection of 
Ancient and Modern Works’ which was ordered by the emperor Kang Xi 康熙 in 1686 and 
completed and printed in 1726 by Chen Meng-Lei. The whole work was in 6 divisions one of which, 
called Gu Jin Tu Shu Ji Cheng Yi Bu Quan Lu 古今圖書集成醫部全錄, dealt with medicine. It 
included 60 books beginning with the Huang Di Nei Jing Su Wen and related works [234]. 
 
The emperor Qian Long commissioned an even larger collection of literature in 1772. With a staff of 
360 it was completed in 1792 and named Qin Ding Si Ku Quan Shu 欽定四庫全書 ‘The Four 
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Literary Treasuries.’ It comprised 3,457 separate works arranged in four divisions: classics, history, 
philosophy and belles-lettres. The section on medicine, Si Ku Ti Yao Yi Jia Lei 四庫提要醫家類, 
was in the sub-section of philosophy and included 197 works in 2,266 volumes. The collection was 
never printed but seven copies were made and kept in seven pavilions around the country. One 
complete set survives [234]. 
 
Perhaps the best known of the Qing works was another imperial compilation the Yi Zong Jin Jian 
‘Golden Mirror of Medical Tradition’ by Wu Qian 吳謙 and 80 others written in 1742 on imperial 
order and was published in 1749, after which it became an official textbook [234, 238]. It contains 
extended extracts from a range of medical classics. 
 
An early proponent of the return to the classics trend in medicine was Yu Chang 喻昌 (字: Jia-yan 
嘉言)(c.1585-1664). Convinced that the works of Zhang Zhong-Jing had been distorted by later 
editors he wrote the Shang Lun Pian 尚論篇 in 1648 and in 1658 he wrote the Yi Men Fa Lu 醫門
法律 ‘Methods and Rules of Medicine’ [234].  
 
Wang Ang 汪昂 (字: Ren An 訒庵) combined methods of various schools and wrote the Yi Fang Ji 
Jie 醫方集解 which contained over 700 frequently used formulas classified into 21 categories 
according to their actions. He also produced a concise practical materia medica the Ben Cao Bei Yao 
本草備要 ‘Essential Materia Medica’ in 1682 [234]. 
 
Chen Shi-Duo 陳士鐸 (ca. 1687) wrote the Shi Shi Mi Lu 石室秘錄 ‘Secret records from the 
mountain cave’ which covers 136 therapeutic techniques, the Bian Zheng Lu 辨證錄 and the Bian 
Zheng Qi Wen 辨證奇聞 both of which contained detailed descriptions of diseases and their 
differentiation [231].  
 
88 
Zhao Xue-Min 趙學敏 (c. 1720-1805) was interested in the medical methods of itinerant doctors and 
recorded many of their formulas in his Chuan Ya Nei Pian 串雅內編 of 1759. He also aimed to 
update and correct Li Shi-Zhen’s work in his much briefer Ben Cao Gang Mu Shi Yi 本草綱目拾遺 
which was written around 1800 but not printed till 1871 [236]. 
 
Towards the end of the Qing, a number of doctors attempted to combine the methods of Chinese and 
Western medicine. Tang Zong Hai 唐宗海 (Tang Rong Chuan 唐容川) (1862-1918) advocated this 
idea in his Zhong Xi Hui Tong Yi Jing Jing Yi 中西滙通醫經精義 of 1892. However, the focus of 
his writing was on Chinese Medicine and he is best known for his discussion on the treatment of 
bleeding disorders in his Xue Zheng Lun 血証論 of 1884 [236, 238].  
 
Western medicine in China 
Throughout its history Chinese medicine has been influenced by other systems of medicine and has 
introduced new methods and substances [246]. Whereas earlier periods of intense contact, such as 
during the Tang and Yuan dynasties produced modifications to the system of medicine, it was not 
until the nineteenth and twentieth century that contact with another medical system threatened the 
basic structure of Chinese medicine. 
 
Western medicine became established in China in the Ming dynasty with the arrival of Portuguese 
traders in Macau and the establishment of the Misericordia Hospital (Santa Casa da Misericordia) by 
the the Bishop of Macau in 1569 but this was to service the foreign community [234]. The Jesuit 
priest Matteo Ricci (1552-1610) reached Beijing in 1601 where he was well received at court and was 
able to display his superior talents in calendar reform, introduce Western learning and make some 
high level converts amongst the scholars. More Jesuits followed, as did books on Western medicine. 
Johann Schrenk (1576-1630) aka Father Jean Terrenz (Terrentius), a successful scholar and physician 
from Switzerland, became a Jesuit in 1611 and went to Macau in 1621. While delayed in Hangzhou 
he wrote a short book on anatomy in Chinese then went on the Beijing where he did astronomy and 
mathematics. After his death Adam Schall passed the book on to Bi Gong-Chen who published it as 
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Tai Xi Ren Shen Shuo Gai 太西人身說概 ‘Explanations of the human body from the far west’ but it 
did not have much effect on Chinese medicine at the time [234, 236, 241].  
 
The Qing emperor Kang Xi 康熙 (reign 1661-1722) supported the Jesuits. In 1692 he had malaria 
which was treated by Fathers Gerbillon and Pereyra. It returned and he called for various remedies to 
be tried out on others to find the best one. Father de Fonteney had received cinchona bark from India 
which cured the patients. The emperor took it and was so impressed he granted the Jesuits a large 
house in the palace grounds [234]. The Jesuits remained in favour at the Chinese court under Kang Xi 
but conflict with the the Franciscans and the ‘rites controversy’ in Rome led to their decline. The 
Franciscans complained to Rome about the Jesuit approach in China which accepted Confucian ritual 
as not incompatible with Christianity. Kang Xi wrote to the pope in support of the Jesuit position but 
in 1715 the pope rejected the Jesuit argument and forbade all Christian practice of the ‘Rites and 
Ceremonies of China’. Following the dissolution of the Jesuits in 1773 their influence declined and 
the Chinese became more anti-Christian [247].  
 
English traders arrived in China in 1637 and the first trading factory was established at Canton in 
1699. The tea trade with Europe expanded rapidly after 1760 and the Americans joined the trade from 
1784. Silk and cotton textiles were also important items. The Macartney Mission of 1793 attempted, 
unsuccessfully, to have the trade expanded to other ports but the China trade and the foreign 
communities in Macau and Canton continued to grow [247]. While most Western medical practice 
was confined to these communities, a surgeon with the East India Company, Alexander Pearson 
(1780-1874), began vaccinating foreign residents and Chinese in Macau some time after 1805. He 
wrote a small pamphlet on the subject which was translated into Chinese by Sir George Thomas 
Stanton with the aid of a Chinese medical practitioner. There were many cases of smallpox over 
1805-6 and thousands were vaccinated. The pamphlet gained official recognition in 1811 and by 1813 
smallpox was under control in the Canton area. In 1818 Yao Ho-Chun, who worked in a dispensary 
set up by CoHong merchants to provide vaccination to the poor, wrote a 100 page tract on vaccination. 
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Pearson supervised this clinic but left China in 1832. By the time Yao Ho-Chun died in 1850 he had 
vaccinated over a million people. His son Yau Yam-Teng carried on his work [234]. 
 
However, the main proponents of Western medicine in China were the missionaries. The English 
missionaries Morrison and Livingstone opened a clinic in Macao in 1820 and Rev Peter Parker from 
Yale University was sent by the American Board of Commissioners for Foreign Missions to Canton 
in 1834 where he set up the Opthalmic hospital. He mainly practiced cataract surgery without 
anaethesia but is said to have introduced anaesthesia to China in his more major operations [225, 
248].  
 
Conflict over the expanding opium trade led to the Opium War of 1841-2 and the Treaty of Nanjing in 
1842 which gave Britain a large cash payment, Hong Kong, access to and consuls in five ports, and 
the removal of the CoHong monopoly on trade. However, the British were still not satisfied with these 
trading arrangements and a series of incidents created the pretext for a British and French attack on 
Canton and the Treaty of Tianjin in 1858 which opened 10 new ports, increased payments and 
allowed diplomatic residence in Beijing. A further incident led to Anglo-French forces occupying 
Beijing, burning the Summer Palace and forcing the Conventions of Beijing in 1860 which increased 
indemnities and gave Kowloon to Britain. These treaty ports provided access to China not only to 
traders but to numerous Catholic and Protestant missionaries [247]. 
 
A Mission hospital was established in Guangzhou in 1848 by the English missionary Benjamin 
Hobson. With others he produced Chinese translations of a number of works including: A New 
Treatise of Anatomy in 1851, General Foundations of Western Medicine (Xi Yi Lue Lun 西医略论) 
in 1857, Internal Medicine (2 volumes including pharmaceutics) in 1858, and Gynaecology and 
Paediatrics in 1858. Chinese were also learning Western medicine and a graduate of the Medical 
School of Edinburgh University, Huang Guan (Wong Fun) (1828-1878), began practice at the hospital 
in 1857 [236, 249, 250]. 
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From the 1870s Chinese students had been going to Europe, the USA and Japan to study Western 
scientific subjects including medicine. This was encouraged by proponents of the ‘self-strengthening 
movement’ (c. 1860 –1895) within the imperial government who aimed to strengthen China militarily 
by establishing arsenals and shipyards with western machinery. Under the slogan ‘Chinese learning for 
our foundation, Western learning for practical application’ it helped legitimise the importation and 
assimilation of western technology, particularly military technology [247].  
 
The first college of western medicine was established, with imperial sanction, in 1881 in Tianjin [251]. 
Edward Hume, from Yale University, established the Yale Hospital in Changsha, Hunan province in 
1905. This later became the Hsiangya hospital and medical school. He took an interest in Chinese 
medicine and had a Dr Wang give lectures on Chinese medicine at the medical school [248].  
 
Towards the end of the Qing a debate arose in educated circles, particularly in Shanghai, about the 
relative merits of Chinese and Western medicine. With the decline of the old Imperial Medical 
College most Chinese doctors had no formal qualifications. This was in contrast to the situation in 
Europe. With the expansion of the foreign settlements in Shanghai from the 1850s, exposure to 
Western medicine became more extensive with the opening of pharmacies selling Western drugs, the 
operation of medical servives by the foreign legations and private practice by Western and 
Western-trained practitioners [234, 248].  
 
In response to the challenges posed by Western medicine some traditional doctors began to organise. 
In 1904 the Shanghai Medical Society was established by Li Ping-Shu a member of the Shanghai 
gentry and Chen Liang-Fang a traditional practitioner. A hospital was also established by Li in 1909. 
In Chengdu a private medical college was established in 1906. In 1910 the Chinese-Western Medical 
Research Association was established by Ding Fu-Bao and a journal was issued. The aim of the 
association was the integration of Chinese and Western medicine [250]. However, following the 
establishment of the Republic of China in 1911 the old Imperial Medical College was abolished and 
western style doctors were appointed to the president's office. In the reorganization of the education 
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system in 1912 there was no place for Chinese Medicine, and so the classical period ended [250]. 
 
The organisation of materia medica 
There have been a number of changes in the way items of materia medica have been organised since 
classical times which warrant a brief discussion since they may have impacted upon the selection of 
herbs in formulas. 
 
The received version of Shen Nong Ben Cao Jing 神農本草經 is based on Tao Hong-jing’s (c 457 - 
536 AD) Jin Dynasty redaction, the Ben Cao Jing Ji Zhu 本草經集注, which discussed the structure 
of original Shen Nong Ben Cao Jing in its preface. According to Tao, the Shen Nong Ben Cao Jing 
classified all 365 herbs into three categories (san pin 三品 ) according to their therapeutic 
characteristics as in the following summary translation: 
 
Upper category medicines 上藥, are ‘Princes’ (jun) 君, 120 items 
• Mainly to nourish destiny, correspond to Heaven 主養命以應天. 
• Have no toxin 無毒, so can be consumed for a long time without damage 多服久服不傷人.  
• [People who] want to make the body light and nourish qi 欲輕身益氣, lengthen their years and 
not become senile, base their medicines on this upper category 欲輕身益氣, 不老延年者, 本上
經. 
Middle category medicines 中藥 are ‘Ministers’ (chen) 臣, 120 items 
• Mainly to nourish the body, correspond to Man, 主養性以應人. 
• Some have no toxin and some have toxin 無毒, 有毒, so you should think carefully about 
which are suitable 斟酌其宜. 
• [People who] want to treat disease, and supplement emptiness and exhaustion, base their 
medicines on this middle category 欲遏病補虛輸者, 本中經. 
Lower category medicines 下藥, are ‘Assistants’ (zuo) 佐 & ‘Aides/envoys’ (shi) 使, 125 items 
• Mainly to treat disease, correspond to Earth 主治病以應地. 
• Most have toxins 多毒, so cannot be consumed for a long period 不可久服. 
• [People who] want to eliminate cold, heat & other pathogenic factors (xie qi), break up masses 
and accumulations and cure diseases, base their medicines on this lower category 欲除寒熱邪氣
, 破積聚愈疾者, 本下經. [211, 252, 253].  
 
In this hierarchical organisation the medicinal substances are ranked according to a combination of 
their perceived safety, their usefulness in prolonging longevity and their broad therapeutic function. 
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The three-way division also reflected the prevalent cosmological division of Heaven, Man and Earth 
as well the human political structure which comprised princes or rulers (jun), their ministers (chen), 
and their assistants, aides and other minor functionaries (zuo, shi).  
 
In his supplemented version, the Ben Cao Jing Ji Zhu 本草經集注, Tao added additional medicines 
to make a total of 730 and reorganised the structure of the text under seven divisions to reflect the 
origin of the substances as follows: jewels and stones 玉石, herbs 草, trees and woods 木, insects 
and animals 蟲獸, fruits 果, vegetables 菜, and food grains 米食. Within each division he retained 
the original categories of upper, middle & lower. He also added some appendices, such as one on 
herbal combinations which included specific herbs that act as envoys for other herbs [211, 252].  
 
Tao’s arrangement according to origin formed the basis of the structure of ben cao throughout the 
classical period. Additional divisions and subdivisions were added, for example the Ben Cao Gang 
Mu contains 16 major divisions and many more subdivisions. The categories of upper, middle and 
lower were eventually dropped from the organisational structure, but references to this earlier 
structure were usually retained in the text and more appendices were added such as lists of the 
functions or applications of herbs [131, 240].  
 
In modern times the structure of ben cao has changed with herbs being organised, not under origin, 
but either according to the principal function of the herb, see for example Materia Medica [1], or in 
dictionary order according to the name of the medicine, as in the Zhong Yao Da Ci Dian 中药大词典 
[254].  
 
For the individual herbs, the Shen Nong Ben Cao Jing firstly ascribes each a flavour (i.e. sweet, bitter 
etc), a nature (i.e. hot, cold etc) and in many cases a level of toxicity. The remainder of the entry is 
concerned with its therapeutic actions plus a concluding sentence on where the plant grows or the 
item can be obtained. Subsequent ben cao until modern times have retained this general structure for 
their individual herb entries whilst adding additional information, such as alternative names, channel 
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affinity, functions, dosage range etc [211, 255]. Therefore, since the earliest times ben cao have made 
specific references not only to the general properties of each of the items of materia medica but also to 
their specific therapeutic applications. Even so, ben cao have not always been in agreement with 
regard to any of these aspects. For example, herbs may have more than one flavour and this may vary 
according to source and over time as medical theory evolved [131, 256]. Some modern books on 
materia medica accommodate these differences by including variant properties referenced to the 
sources [254, 257]. In the present project it was necessary to determine which aspects of the available 
information on individual herbs needed to be coded for analysis. Since the principal aim was to 
determine which herbs have a history of use for age-related dementia, the details of most relevance 
are the identity of the herb, whether it was indicated for disorders consistent with possible dementia, 
the source of the information and its publication year.  
 
Formula categories and construction 
Formulas have tended to be categorised according to the disease they are intended to treat since 
ancient times. The manuscript titled Wu Shi Er Bing Fang 五十二病方 ‘Prescriptions against 52 
illnesses’ (c. 206 BC) retrieved from the tombs at Ma Wang Dui 馬王堆 contains 170 prescriptions 
organised according to disease name [226, 227]. Subsequent collections including the Tang dynasty 
Qian Jin Yao Fang 千金要方 and the Song dynasty Sheng Ji Zong Lu 聖濟總錄 retained this 
general structure and it continues in contemporary compendia of formulas [252, 258]. Another 
approach has been to classify formulas according to their principal function. Variations on this 
approach have been evident since at least the Song dynasty, see the Tai Ping Hui Min He Ji Ju Fang 
太平惠民和劑局方 for example, and can also be found in contemporary works such as Formulas 
and Strategies [259]. 
 
The methods for combining the numerous ingredients that can comprise a formula has been the 
subject of a number of discussions in both ancient and modern times and the art of herbal combination, 
known as dui yao 對藥, remains an aspect of contemporary practice [260]. A key feature of this art is 
the use of herbs to address differing aspects of the disease including the root (ben 本) or underlying 
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cause(s) as perceived by the practitioner and the branch (biao 標) which usually refers to the 
presenting signs and symptoms that the patient perceives [225, 261]. In attempting to address these 
aspects, the practitioner may design a formula comprising multiple ingredients, some of which aim to 
directly alleviate the presenting symptoms while others aim to address other factors such as body 
weakness or excessive heat in the body, also, some herbs may have roles not directly connected with 
either the root or branch, such as countering the unwanted effects of certain herbs [259, 261, 262].  
 
In modern textbooks, the different roles of herbs in a formula are classified under the following 
categories: 
 
Jun 君 ‘prince’: aims to produce the leading effects of the formula in order to treat the principal 
disease or the principal syndrome.  
Chen 臣: ‘minister’: which comprise two types. The first type assists the jun to strengthen or speed 
up the action of the jun in treating the main disease or syndrome. The second type focuses on treating 
the secondary disease or syndrome. The strength of the medicinal effect of the chen is less than that of 
the jun.  
Zuo 佐 ‘assistant’: which comprise three types. One type assists the prince and/or minister by adding 
to their effects or by addressing secondary symptoms or syndromes. The second type is used to 
counteract any unwanted effects of the jun and chen medicines such as excessively strong action or 
toxicity. The third type is used to counteract or modify the jun and/or chen as well as take a role in 
supporting their actions of treating the disease or syndrome. 
Shi 使 ‘aide/envoy’: which comprise two types. The first is the ‘channel guiding herb’ (yin jing yao 
引經藥) which leads the formula into the affected channel or part of the body in order to better target 
the formulas and hence achieve an enhanced effect. The second type is the ‘harmonising herb’ (tiao 
he yao 調和藥) which aims to coordinate or modify the actions of all the herbs in the formula [259, 
262, 263].  
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It appears that the first discussions of these terms are in three passages from Su Wen 素問 chapter 74 
(ref). Since these passages are frequently quoted in contemporary books on formulas, they worth 
further discussion [259, 262, 263].  
 
Passage 1 is translated as follows:  
帝曰：方制君臣何謂也？ 
‘Huang Di asked: In formulas, what do the terms jun and chen mean?’ 
岐伯曰：主病之謂君，佐君之謂臣，應臣之謂使，非上下三品之謂也。 
‘Qi bo replied: [the herb(s) that treat] the main disease are called jun; [the ones that] assist the jun 
are called chen; [and those that] respond (comply) to [the demands of] the chen are called shi, [but 
these terms] do not refer to the upper, middle and lower class herbs of the san pin 三品 system.’ 
帝曰：三品何謂？ 
‘Huang Di asked: What are the san pin (three categories)? 
岐伯曰：所以明善惡之殊一貫也。 
‘Qi bo replied: They make clear the difference between good and bad [herbs]. [252, 253]. 
 
Although the Su Wen does not provide a detailed explanation of san pin, it appears to refer to the 
system which is found in the Shen Nong Ben Cao Jing 神農本草經. Qi Bo’s explanation regarding 
good and bad herbs seems inadequate unless it refers to herbs that are non-toxic and toxic. What is 
interesting is Qi Bo was at pains to explain that even though the terms for the roles of herbs in 
formulas that he had just described were identical to the terms used in the san pin system, the 
meanings of the terms were different in this context.  
 
While the Shen Nong Ben Cao Jing does not explicitly state that the three categories relate to the roles 
of herbs in a formula, since the categories are defined in terms of action and usage this appears to be 
implied. Moreover, in a passage in Tao’s preface there is a brief discussion on the combination of 
herbs followed by a short statement on combinations. 
 
藥有君臣佐使，以相宣攝. 合和者，宜用一君、二臣、五佐，又可一君、三臣、九佐也. 
‘Medicines comprise, jun, chen, zuo and shi, which can be combined to mutually enhance [their 
effects] and pacify [side-effects]. They can be combined as 1 jun, 2 chen and 5 zuo or as 1 jun, 3 
chen and 9 zuo.’ [252, 264]. 
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In this passage the Shen Nong Ben Cao Jing clearly specifies that the terms jun, chen, zuo do refer to 
the roles of herbs in formulas, so there appears to be a conflict between the views of Su Wen 74 and 
the Shen Nong Ben Cao Jing, with Su Wen 74 saying that the jun herbs should treat the main disease 
and the Shen Nong Ben Cao Jing saying that jun herbs should nourish destiny rather than directly treat 
the disease while the toxic zuo and shi herbs do the work of treating the disease.  
 
Su Wen chapter 74 also contains a second passage that refers to a similar classification of formulas: 
 
帝曰：非調氣而得者，治之奈何？有毒無毒，何先何后？願聞其道。 
Huang Di asked: In cases where you cannot use [the method of] tiao qi 調氣 (i.e. combining herb 
flavours, which was previously explained), how do you treat? In using toxic or non-toxic [herbs], 
which is used first and which is used later? I would like to hear the method. 
岐伯曰：有毒無毒，所治為主，適大小為制也。 
‘Qi Bo replied: In using toxic or non-toxic [herbs], the main thing is to determine [what disease] to 
treat, and accordingly to choose large or small [formulas]. 
帝曰：請言其制。 
Huang Di said: Please explain the system [to me]. 
岐伯曰：君一臣二，制之小也；君一臣三佐五，制之中也；君一臣三佐九，制之大也。 
‘Qi Bo replied: 1 jun plus 2 chen is a small [formula], 1 jun plus 3 chen and 5 zuo is a middle 
[formula], 1 jun plus 3 chen and 9 zuo is a large [formula].’  
Then follows a long list of treatment methods: 寒者熱之 ‘for cold use heat’, 熱者寒之 ‘for heat 
use cold’ etc but the passage provides no more detail on the meaning of large and small. [252, 253] 
 
The intended meaning of this passage is difficult to discern since Qi Bo does not appear to explain 
clearly Huang Di’s question regarding the use of non-toxic and toxic herbs. Instead he gives examples 
of small and large formulas and then enumerates a long list of rather generic treatment methods. 
However, if we assume that Huang Di is familiar with the san pin system of the Shen Nong Ben Cao 
Jing, the explanation seems more sufficient. For example, if the treatment aims at supplementing 
emptiness, then a small formula comprising non-toxic jun and chen herbs would be appropriate. 
Given this reading, the middle sized formula would also be of medium toxicity whereas the large 
formula would be of greater toxicity since it contains a larger proportion of zuo herbs. So the point is 
not which should be used first or last (which may also be a reference to the concept of ben and biao) 
but what the formula aims to treat.  
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While the above interpretation appears to fit with the system in the Shen Nong Ben Cao Jing, it seems 
to conflict with the first passage from Su Wen chapter 74 discussed above. The third Su Wen passage 
again refers to large and small formulas and the concepts of jun and chen as follows.  
 
帝曰：氣有多少，病有盛衰，治有緩急，方有大小，願聞其約奈何？ 
‘Huang qi said: The [pathogenic] qi can be greater or smaller, the disease can be flourishing or in 
decline, treatment can be mild or drastic/fast, formulas can be large or small. I would like to hear 
the criteria [for distinguishing these].’ 
岐伯曰：氣有高下，病有遠近，証有中外，治有輕重，適其至所為故也。 
‘Qi Bo replied: The [pathogenic] qi can be in the upper [body] or the lower [body], the disease can 
be far or near*, the syndrome can be internal or external, treatment can be light or heavy, therefore 
the [formula must be] suitable for reaching the location [of the disease].’ 
大要曰：君一臣二，奇之制也；君二臣四，偶之制也；君二臣三，奇之制也；君二臣六，偶
之制也。 
‘The Da Yao (“Essentials”) said: “1 jun and 2 chen is an odd [numbered] formula, 2 jun and 4 chen 
is an even formula, 2 jun and 3 chen is an odd formula, 2 jun and 6 chen is an even formula”’  
故曰：近者奇之，远者偶之，汗者不以奇，下者不以偶，補上治上制以緩，補下治下制以急，
急則氣味厚，緩則氣味薄，適其至所，此之謂也。 
‘That is why it is said: “for near [use] odd, for far [use] even; to induce sweating do not use odd, to 
purge do not use even.” [Medicines] to supplement the upper [body] and treat [disease of] the upper 
[body] are slow/mild, [medicines] to supplement the lower [body] and treat [disease of] the lower 
[body] are fast/drastic, the qi and flavour of drastic [medicines] is heavy, the qi and flavour of mild 
[medicines] is light, this is what is meant by “suitable for reaching the location”.’ 
病所遠而中道氣味之者，食而過之，無越其制度也。是故平氣之道，近而奇偶，制小其服也。
遠而奇偶，制大其服也。大則數少，小則數多。多則九之，少則二之。 
‘When the location of the disease is far, the qi and flavour [of the medicine] may only reach half 
way, if too much food [has been eaten], so the rules [regarding food] must not be broken. 
According to the way of “normalising qi,” when [the location of the disease] is near, odd or even 
[can be used], but [only] small formulas can be consumed. When the disease is far, odd or even 
[can be used], but [only] large formulas can be consumed. In the case of large formulas the number 
[of doses/packets] is few, in small formulas the number [of doses/packets] is many. Many is nine, 
few is two.’ 
奇之不去則偶之，是謂重方。偶之不去，則反佐以取之，所謂寒熱溫涼，反從其病也。 
‘If odd [formulas] are not effective use even, this is called the “complex method”. If even [formulas] 
are not effective select “counter assistance’, which means [using] cold, hot, warm or cool 
[medicines] contrary to [the characteristics] of the disease.’ 
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* the meaning of ‘far’ and ‘near’ is not clear but it is likely that it refers to diseases located in the trunk 
of the body which are relatively easy to reach with medicine, while ‘far’ refers to the extremities which 
can be difficult to reach and may require the use of envoy medicines. [252, 253] 
 
This third passage contains theory and terms not used in contemporary Chinese medicine. It is 
consequently difficult to translate and interpret. The concepts of odd and even formulas are not found 
in the Shen Nong Ben Cao Jing but much of the theory is consistent with that of the Shen Nong Ben 
Cao Jing. For example, it says for diseases of the four limbs (i.e. ‘far’ diseases), medicines should be 
taken on an empty stomach. Also, the notion that for ‘near’ diseases formulas should be small but 
require many doses, whereas those for ‘far’ diseases are large but require few doses, is also 
understandable if it is interpreting as follows: ‘near’ diseases tend to be due to emptiness and so small 
formulas comprised of herbs from the upper and middle categories would be appropriate, conversely 
disorders of the extremities are difficult to reach and therefore require larger formulas that include 
envoy herbs from the lower category which would be toxic, so only a few doses could be used.  
 
Of the three Su Wen passages on formulas only the first is clearly incompatible with the Shen Nong 
Ben Cao Jing view while the other two suggest a theoretical perspective consistent with the Shen 
Nong Ben Cao Jing. Unfortunately, neither the Su Wen nor the Shen Nong Ben Cao Jing provides any 
example formulas in which the roles of the individual herbs are designated. So it is problematic as to 
whether there were conflicting views on formula construction and, if there were, which viewpoint was 
dominant in ancient times. 
 
Modern texts tend to use formulas from the Shang Han Lun to illustrate the roles of herbs in terms of 
jun, chen, zuo, shi [262, 263]. In his preface, Zhang Ji does say that he used Su Wen when compiling 
the Shang Han Lun so it seems likely that he was aware of the above concepts but the terms jun, chen, 
zuo, shi are not to be found in the received text nor does he discuss formula construction [215, 252]. 
So there is no primary evidence that Zhang Ji used these principles in his formulas. In his 
nomenclature of formulas the terms da and xiao are recurrent features that are consistent with the 
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above discussions. For example, the formula Da chai hu tang has more ingredients than Xiao chai hu 
tang, but beyond this few inferences can be drawn. 
 
Sun Si-Miao in the Qian Jin Yao Fang 千金要方 paraphrases the san pin system of the Shen Nong 
Ben Cao Jing and then includes the passage from Tao Hong-jing’s preface discussed above, but with 
a minor variation as follows: 凡藥有君臣佐使，以相宣攝，合和者，宜用一君、二臣、三佐、五
使，又可一君、三臣、九佐使也 [252]. This passage differs only in that the numbers for the first 
combination of formula components is ‘1 jun, 2 chen, 3 zuo and 5 shi’ while the second is ‘1 jun, 3 
chen, 9 zuo or shi’. This suggests that variant versions of this same passage were either extant at the 
time or there are textual errors in the received versions. Interestingly, the Ben Cao Gang Mu agrees 
with Sun’s version of this passage. 
 
The above three passages from Su Wen Chapter 74 are not refereced at all. Since Sun included 
numerous Su Wen quotations in his writings, this omission appears surprising. However, it has long 
been suspected that chapter 74 was one of the chapters inserted by Wang Ping in the late Tang 
dynasty and it is notable that the above discussions on formulas are not to be found in the received 
version of the Huang Di Nei Jing Tai Su [252]. Therefore, it is likely that Sun’s apparent omission 
actually reflected the content of the Su Wen prior to Wang Ping’s subsequent editorial work [222, 
228]. 
 
Although Sun quoted concepts derived from the Shen Nong Ben Cao Jing, none of the formulas in the 
Qian Jin Yao Fang specify the roles of individual herbs so we cannot determine whether Sun actually 
employed the Shen Nong Ben Cao Jing system in his formula construction [252]. 
 
The Ben Cao Gang Mu quotes numerous sources regarding jun and chen including the first passage 
from Su Wen 74 but Li Shi-Jen does not express a view on their roles. He does, however quote Li 
Dong-Yuan who provides the following view with examples: 主病為君, 假令治風, 防風為君. 治
寒, 附子為君; 治濕, 防己為君. ‘The herb to treat the main disease is the jun, in order to treat wind, 
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fang feng is jun; to treat cold, fu zi is jun; to treat damp, fang ji is jun.’ Also, in his Pi Wei Lun, Li 
provides numerous examples of herbs that have the roles of jun, chen and zuo in the treatment of 
types of disorders [252]. However, subsequent authors seem not to have followed Li’s example since 
explicit designation of the roles of the individual herbs in formulas can seldom be found in books on 
therapeutics.  
 
Even though there is some inconsistency in the above examples, it is evident that different herbs in a 
formula are intended to take different roles. So it cannot be assumed that each of the herbs in a 
formula was included because it has an effect on a particular presenting symptom. For example, even 
when the principal disorder was jian wang, the doctor may have included herbs that had no direct 
effect on jian wang, and when jian wang was a secondary symptom it is likely that only a few herbs, 
would directly address this symptom or there may even have been no herbs included for jian wang at 
all if the focus of the formula was on the root disorder with jian wang being considered a branch. 
 
When investigating herbs within a formula in terms of their specific action on a disorder such as jian 
wang, it not possible, based on the formula alone, to determine which herbs aimed to treat the jian 
wang unless the formula author specifies this. Also, even if the roles of the herbs are specified as jun, 
chen or zuo, it may not be possible to determine which herb focuses on jian wang unless we know 
how the author conceived of these roles and whether the author considered the jian wang to be a 
principal disease or not. Therefore, there appears to be no reliable method for retrospectively 
determining the roles of the individual herbs in a formula. Consequently it provided impractical to 
attempt to code formula consituents according to their functional role. 
 
Despite these difficulties, over a range of formulas for jian wang derived from different sources it 
could be expected that herbs that focus on treating jian wang would be relatively frequent. Also, the 
ben cao do specify the applications of individual herbs and since these are used to guide prescription, 
it is likely that when a herb that was indicated in a contemporary ben cao for jian wang was included 
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in a formula, it was intended to treat jian wang even though it may also have had other functions 
besides.  
 
 
PART 2 
THE SELECTION OF SEARCH TERMS AND SAMPLES OF THE 
CLASSICAL LITERATURE 
 
This part details the procedures used in developing sets of search terms for locating references to 
possible AD or other age-related memory disorders in the classical CM literature and the approaches 
taken to selecting sources of classical CM books for searching. 
 
Selection of search terms for the classical literature 
The standard nomenclature for disease names and syndromes in modern Chinese medicine includes 
the terms chi dai 痴呆 and jian wang 健忘 [265]. However, modern clinical manuals frequently use 
terms that are more specific for dementia of the aged including lao nian chi dai 老年痴呆 ‘senile 
dementia’ or the equivalent terms lao nian qi chi dai 老年期痴呆 [266] and lao nian xing chi dai 老
年性痴呆 [267]. However, these terms alone were not expected to be sufficient when searching the 
classical literature.  
 
In order to develop a list of suitable terms, firstly, an authoritative dictionary of medical names in 
Chinese medicine was consulted. The Zhong Xi Yi Bing Ming Dui Zhao Da Ci Dian 中西医病名对
照 (2002) [268] under the entry for Alzheimer’s Disease, provided a list of equivalent terms in 
traditional Chinese medicine. Besides the usual term chi dai 痴呆, three main terms were listed: 1. 
lao ren zhi bing 老人之病 ‘diseases of the aged’; 2. jian wang 健忘 ‘frequent memory loss’ and 
lao ren jian wang 老人健忘 ‘frequent memory loss in the aged’; and 3. dai bing 呆病 which is 
equivalent to chi dai 痴呆. This book also lists dai bing 呆病 and chi dai 痴呆 as equivalents for 
‘unspecified mental retardation’ so these terms can have a broad range of meanings.  
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Next, the contents of the twenty one Chinese language CM works that focussed on mental or brain 
disorders or disorders of the aged that had been collected (see chapter 2), were examined for sections 
on dementia or memory disorders. Any discussions on classical terminology were searched for terms. 
These were listed and then examined to determine which comprised the best selection for searching 
the classical literature. Seventeen books provided such information. In order of publication year the 
results were as follows: 
 
1. Zhong Yi Jing Shen Bing Xue (1989) [269] contains sections for jian wang 健忘 and dai bing 呆
病 which it states is another term for chi dai. 
 
2. Zhong Yi Lao Nian Bing Xue (1992) [270] has a section on lao nian xing chi dai 老年性痴呆 
which states that this disorder can be classified under chi dai, xuan yun 眩暈 ‘dizziness’, xin ji 心悸 
‘palpitations’, jian wang, shi mian 失眠 ‘insomnia’; etc.  
 
3. Shi Yong Zhong Yi Nao Bing Xue (1993) [271] includes sections on chi dai and jian wang. Under 
chi dai it states that this term was first used in the Han dynasty by Hua Tuo and later terms include 
dai chi 呆痴, yu chi 愚痴, wen chi 文痴, wu chi 武痴; etc but no references for these terms were 
provided. Under jian wang a passage on shan wang 善忘 from the Su Wen was cited. 
 
4. Shi Yong Zhong Yi Lao Nian Nei Ke Bing Xue 1995 [272] under lao nian xing chi dai 老年性痴呆
states this disease is included under chi dai, jian wang, dian kuang 癲狂 ‘madness’, zhan yu 譫語 
‘delirious speech’, hun mi 昏迷 ‘stupor’, etc.  
 
5. Zhong Yi Lao Nian Bing Lin Chuang Yan Jiu (1995) [273] under the jian wang section states that 
this condition is also called shan wang 善忘, xi wang 喜忘 or duo wang 多忘. It also gives a 
number of references to shan wang from the Nei Jing. Under chi dai it notes that the Jing Yue Qian 
Shu has a section on dian kuang chi dai 癲狂痴呆 ‘madness and dementia’ but this chi dai is not 
specific to old people.  
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6. Lin Chuang Zhong Yi Nao Bing Xue (1997) [266] under lao nian qi chi dai 老年期痴呆 quotes 
passages from the Nei Jing to illustrate symptoms but provides no list of equivalent terms. However, 
it divides the disease into three stages 1. jian wang qi 健忘期 (memory loss stage), 2. hun luan qi 混
亂期 (confusion stage) and 3. chi dai qi 痴呆期 (dementia stage) according to increasing severity. 
 
7. Nao Bing Liang Fang 1500 Shou (1998) [274] in the section on lao nian xing chi dai 老年性痴呆
states this disease can appear under the terms jian wang, yu zheng 郁証 ‘depressive syndrome’, dian 
zheng 癲証 ‘withdrawal syndrome’, kuang zheng 狂証 ‘manic syndrome’, etc. It states that in the 
Jing Yue Qian Shu this disease is discussed as chi dai zheng 痴呆証 ‘dementia syndrome’ and that 
Chen Shi-Duo refers to it as dai bing 呆病.  
 
8. Zhong Yi Nao Bing Xue (1998) [275] in the section on jian wang states that the Nei Jing uses the 
terms shan wang 善忘 and xi wang 喜忘; Chao Yuan-Fang uses the term duo wang 多忘; hao 
wang 好忘 appears in the Qian Jin Yao Fang; but the term jian wang first appears in the Song 
dynasty. In the section on chi dai it states that this disease is included under liao nian dai bing 老年
呆病, wen chi 文痴, shan wang 善忘, yu yan dian dao 語言顛倒 ‘mixed up speech’, bai chi 白痴 
‘stupidity’, yu zheng 郁証, dai bing (呆病), etc. 
 
9. Lao Nian Chi Dai Zheng De Zhong Xi Yi Zhen Duan Yu Zhi Liao (1999) [276] states that lao nian 
chi dai is included under dai bing 呆病, dian zheng 癫症, chi dai, shan wang 善忘, etc. 
 
10. Xin Bian Zhong Yi Lao Nian Bing Lin Chuang Shou Ce (1999) [277] in the section on lao nian 
xing chi dai (老年性痴呆) states that this disease can be included under dai bing 呆病, dian zheng 
癲証, yu zheng 郁証, tan shi 痰濕 ‘phlegm and damp’, etc.  
 
11. Zhong Yi Shen Jing Jing Shen Bing Xue (2000) [278] contains an entry for jian wang in which it 
notes that shan wang 善忘, duo wang 多忘, hao wang 好忘 and yi wang 易忘 are synonyms. In 
the section on chi dai it notes that wen chi 文痴 and dai bing 呆病 are similar. 
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12. Shi Yong Zhong Yi Lao Nian Bing Xue (2000) [279] in the section on lao nian qi chi dai 老年期
痴呆 states that the Jia Yi Jing uses the term dai chi 呆痴 and the (Zhen jiu) Ji Sheng Jing (Song 
dynasty) refers to chi zheng 痴証.  
 
13. Shi Yong Zhong Yi Lao Nian Bing Xue (2000) [280] says that lao nian chi dai zheng 老年痴呆症 
is included under chi dai, shan wang 善忘, yu zheng 郁証, dian kuang 癲狂, etc. It then provides a 
long historical discussion that states that prior to the Ming dynasty the terms wen chi 文痴 and wu 
chi 武痴 were used but they were not clear. Wen chi 文痴 was used to mean dian zheng 癲証 
‘withdrawal syndrome’ while wu chi 武痴 meant kuang zheng 狂証 ‘manic syndrome’ but these 
were not really equivalent to chi dai (p 406). 
 
14. Lao Nian Chi Dai Zhong Yi Fang Zhi (2002) [281] states that in Chinese medicine chi dai is 
characterized by the symptoms dai 呆, sha 傻, yu 愚 and ben 笨 and is called dai bing 呆病 or 
chi bing 痴病.  
 
15. Shen Jing Ke Zhuan Bing (2005) [282] notes that lao nian qi chi dai 老年期痴呆 can be 
included under dai zheng 呆証, dian zheng 癲証, shan wang 善忘, chi dai 痴呆, yu zheng 郁証, 
etc.   
 
16. Lao Nian Qi Chi Dai Xiao Fang 200 Shou (2006) [283] states this disease can be included under 
dai bing 呆病, dai sha 呆傻, wen chi 文痴, jian wang, shan wang 善忘, yu zheng 郁証, dian 
kuang 癲狂, xu lao (虛勞) ‘debility’, etc. 
 
17. Gu Jin Zhong Yi Nao Bing Bian Zhi Jing Yao (2007) [284] in the section on lao nian qi chi dai 老
年期痴呆 states this disorder can be included under dai zheng 呆証, dian zheng 癲証, shan wang 善
忘, chi dai 痴呆, yu zheng 郁証, etc. 
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This survey of specialist works found considerable diversity in the depth and approach to discussing 
the nomenclature traditionally used in Chinese medicine. Nevertheless, there was considerable 
overlap in the terms mentioned between the books surveyed but no definitive list was evident.  
 
Since the aim of the searches was to identify instances in the classical literature that were likely 
references to disorders that would now be classified as AD, VaD or MCI, it was necessary to identify 
terms that would be likely to include such instances but were not so broadly inclusive as to locate too 
many instances of other kinds of disorders which would make the resultant data sets unwieldy. In 
short, the more specific the search terms, the more likely they were to isolate instances suitable for 
inclusion. 
 
The characters that appeared most commonly in the above survey of books were chi 痴, dai 呆, 
wang 忘, dian 癲 and yu 郁. Of these dian was discarded as having too broad a meaning for use as 
a search term since it can refer to a wide range of types of madness, particularly in combination with 
kuang i.e. 癲狂. Similarly, yu was considered excessively broad with its association of depression. 
Other terms that appeared infrequently also tended to be too non-specific. Xu lao 虛勞 can include 
numerous disorders of exhaustion and debility, and while zhan yu 譫語 ‘delirious speech’ and hun 
mi 昏迷 ‘stupor’ may be symptoms of dementia, they are only some of the symptoms, are not 
specific to dementia, and may be present in a wide range of other disorders. The resultant terms based 
on the main three characters are summarised in Table 3.3 below. 
 
Table 3.3: Three main groups of search terms 
chi:  chi dai 痴呆, dai chi 呆痴, yu chi 愚痴, wen chi 文痴, wu chi 武痴;  
bai chi 白痴; chi bing 痴病 
dai:  dai bing 呆病, dai zheng 呆証, dai sha 呆傻 
wang:  jian wang 健忘, shan wang 善忘, duo wang 多忘, xi wang 喜忘, hao wang 好忘,  
yi wang 易忘, yi wang遺忘 
 
Whereas chi and dai occurred together, wang did not occur with either of these but always with a 
preceding character as a modifier. To further investigate the origins and meanings of these terms, the 
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ancient dictionary the Shuo Wen Jie Zi 說文解字 (c. 121 AD) [223] and the comprehensive 
dictionary Ci Hai 辭海 [285] were consulted.  
 
According to the Ci Hai, chi痴 is a variant of the ancient character chi 癡 which appears in the Shuo 
Wen Jie Zi [286]. The fundamental meaning is ‘not intelligent, not smart (bu hui ye 不慧也)’ and as a 
disease it refers to having this characteristic. The later variant chi 痴 appears in the Ji Yun 集韵 
(c.1037). By combining the character zhi 知 (knowledge) with the disease radical, it provides the 
image of a disease that affects knowledge or learning. In common parlance chi 痴 refers to idiocy, 
foolishness or dotage [285]. This term has not changed its fundamental meaning since the Han 
dynasty. 
 
The Ci Hai lists the character dai 呆 as a variant of dai 獃 and states it has a similar meaning to chi
癡 (chi dai, ji ben bu ling min ye 癡呆，滯笨不靈敏也) [285]. In the Yuan dynasty dai referred to a 
child in common parlance, in the sense of not having adult knowledge. However, neither character 
appears in the Shuo Wen Jie Zi. Both chi and dai have essentially the same meaning and refer to 
foolish, simple or idiotic people. In the medical literature dai is combined with bing 病 ‘disease’ to 
indicate the disease has the characteristics of dai. So dai bing appears to be essentially an equivalent 
term to chi dai.  
 
The character wang 忘 appears in the Shuo Wen Jie Zi meaning ‘not remember / recognise / 
distinguish’ (bu zhi ye不識也) [286] (p 220). In modern Chinese it remains the main word meaning 
‘forget’ so there has been little change over time. The character jian 健 qualifies the basic meaning 
to indicate it is constant or regular. In each of the other terms the qualifying characters have similar 
meanings. Duo 多 indicates that forgetting is frequent. Yi 易 means it is easy to forget. In shan 
wang 善忘 the first character usually means ‘good’ or ‘well able to’, but in this case it just indicates 
that forgetting is easy. The hao 好 in hao wang also means ‘good’ but in this case simply indicates 
frequency. Similarly, the xi 喜 in xi wang 喜忘 generally means ‘like/enjoy,’ but in this case it 
refers to something which is done a lot.  
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Besides the above terms which refer to disorders in need of alleviation, terms referring to the actions 
of medicines are also of relevance since they can indicate that they are intended for memory disorders. 
The main term for this function is qiang ji 強記 ‘strengthen memory’. 
 
Sampling and searching the classical literature 
Whereas search procedures are well established for medical databases and for systematic reviews of 
the clinical trial literature, in the case of the classical Chinese medical literature no established 
methodologies could be located. Since the aims of the searches are to determine which herbs have a 
history of usage for the search conditions, both from the point of view of frequent use as well as long 
established use, an approach that could satisfy these aims needed to be developed. 
 
It was evident from the outset that the scope of the classical literature was too vast to be searched in 
its entirety therefore a method for selecting books suitable for data extraction was required. Random 
sampling was not feasible for a number of reasons as follows: 
Firstly, there is no electronic database for the classical literature so the approach used to search the 
modern clinical literature was not feasible. 
Secondly, the total population of the classical literature was not available in any one place for random 
sampling. 
Thirdly, different genres were expected to more productive than others so these would require specific 
focus, and hence a broadly based random sampling approach could miss the key sections.  
 
Specific sampling of certain genres could be an option but it was not evident what constituted a single 
‘sample’ since books are of vastly different sizes and so are the pages or paragraphs. Therefore any 
attempt to take samples from a wide range of books could run into major difficulties. 
 
A number of options were considered as approaches to generating a sample. One possible approach 
was to select a range well known books from various time periods, look up the search terms in the 
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contents or indices and copy the relevant sections. Such an approach could plausibly generate a 
representative sample. After examining a range of texts it became evident that classical books tend to 
be poorly indexed or not indexed at all, so finding a relevant section in a large book can be 
problematic. Of the genres, the materia medicas usually have comprehensive tables of contents but 
these tend to focus on the herb names, although some contain reference lists of symptoms and 
diseases e.g. Ben Cao Gang Mu. Some formula compendia contain appendices that list herbs and/or 
formulas under diseases and symptoms, but these tend to be the exception. Clinical manuals tend to be 
classified according to disease so these would appear a suitable option, but there is no standardized 
format for listing, particularly when it comes to psychological disorders which may appear under 
other categories. For example, jian wang can appear under lao disorders (debility), dian kuang 
(madness) etc so many categories would need to be searched. Despite these difficulties, these three 
genres appeared the most promising and formed the focus of the preliminary hand searches. One 
option to dealing with the inadequacies of classical indexing that was considered was to scan books to 
text and then search the files. However, a preliminary attempt to do this revealed the limitations of 
OCR (Optical Character Recognition) software in dealing with classical texts in different formats. 
Setting up the pages was time consuming and characters were often missed, so such an enterprise 
would be excessively time consuming. Besides this, there were likely to be copyright issues 
associated with some texts. 
 
Locating collections of classical literature in Australia proved problematic. A considerable number of 
editions of major classical works had been collected in the past, more were purchased and others were 
located on the internet. However, it was evident that these would not constitute a sufficiently large or 
representative sample since some key works, e.g. Pu Ji Fang, proved difficult to locate or were 
prohibitively expensive to buy. Inquiries revealed that a CD of classical literature had been published 
in China so orders were placed with bookshops and other attempts were made to locate a copy.  
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It was apparent that reliance upon local resources was not likely to be sufficient to generate a 
satisfactory sample. So contact was made with the Hong Kong Baptist University which was known 
to possess a substantial collection of books in its Chinese Medicine Library. Permission was obtained 
to visit the library and use its resources.  
 
Searches at the Hong Kong Baptist University’s Chinese Medicine Library 
From November 26 to December 1, 2006 research was conducted in the Chinese Medicine Library at 
the Hong Kong Baptist University (HKBU). Searching all the literature contained in this library 
proved to be a considerable task and all the planned searches could not be completed in the time 
available. Nevertheless, considerable progress was made. 
 
The following collections were searched: 
 
1. Zhong Guo Ben Cao Quan Shu 中國本草全書 
This is a collection of over 1,500 books on materia medica and related topics, including multiple 
editions of some titles in facsimile [287]. As its title suggests, it is a comprehensive work on this 
genre that is published in 401 large volumes. Unfortunately there is no index to this collection and no 
electronic list of the books contained in this collection was available, so the first step was to catalogue 
the book titles and enter these into an Excel spreadsheet with the help of Angela Yang. It was not 
feasible to enter every book title but all of the titles other than those in the division for regional 
materia medicas (843 titles) were entered in order to gain a view of the scope of this collection. While 
the collection focuses on ben cao it also contains many works that would usually be classed under 
formula compendia, as well as books on agriculture. 
 
Searches of samples of the collection found that some books have tables of contents but others do not, 
some books are clearly printed whereas others are facsimiles of rare editions in block printed format 
with the result that characters can be blurred. As regards searching the titles in this collection, the 
initial approach was to only search those books that cannot be obtained or accessed elsewhere or in 
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another format. Hand searches were conducted of the Daoist part of the section on Buddhist and 
Daoist Materia Medica 佛道本草 (Fu Dao Ben Cao). This section was chosen because works of this 
type are not widely available – none could be located in the other collections examined.  
 
Most texts had no table of contents so the only possible strategy was to search every page. The terms 
wang 健, dai 呆 and chi 痴 were used since these three characters encompass all the main terms 
used for dementia and it proved too difficult to visually scan pages for a larger number of terms. 
When a table of contents was available, only those sections in which a reference was likely were 
searched, for example any sections on internal medicine, any sections on longevity, age or longevity, 
mental states etc. Sections on external medicine, gynaecology etc were skipped. However, few texts 
provided opportunities for this approach since tables of contents, when available, mostly related to 
categories of material medica only. It was found that it took 2-3 minutes per page to visually scan for 
the search terms. 30 texts were hand searched without finding a reference. Two references were, 
however, found in the text Ai Cun Yi Jue 隘村醫訣. These were copied.  
 
This method of search was very time consuming, generated few references and also caused 
considerable eyestrain. It was found not to be feasible to search the whole work by hand. So, hand 
searching this collection was abandoned as an approached to generating a sample. It was concluded 
that the best approach to using this work is as a source for checking or contextualising references that 
are found via other approaches.  
 
2. Zhong Yi Fang Ji Da Ci Dian 中醫方劑大辭典  
This large compendium of formulas was published in 1994 in 11 volumes was located in the HKBU 
library [288]. It is well indexed and includes an index of disease and symptom names which contained 
the terms 痴呆 chi dai and健忘 jian wang. All the formula references to these two terms were 
located and copied. These subsequently formed the basis of classical data set 1. 
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3. Yi Fang Lei Ju 醫方類聚 
A 2002 edition of this multi-volume classical formula compendium was located [289]. This work, 
which dates back to 1447, has been republished in the classic format and print style. The table of 
contents was searched and the sections for 健忘 jian wang were located and copied. Data entry from 
this search into Excel was commenced but the book presented a number of difficulties. Firstly, the 
classical format made the location of references difficult, secondly, formula names only were 
provided in numerous cases and thirdly, references to source books were frequently abbreviated 
which made it difficult to reference the source work to obtain the ingredients. Moreover, since the 
previously mentioned formula compendium Zhong Yi Fang Ji Da Ci Dian (ZYFJDCD) was found to 
have referenced the Yi Fang Lei Ju, it was likely that this search would duplicate what was available 
from this other source. Therefore, further data entry from this source was abandoned. 
 
4. Si Ku Yi Xue Cong Shu 四庫醫學叢書 
The section of the Qing dynasty encyclopoedia the Si Ku Quan Shu 四庫全書 ‘The Complete Four 
Literary Treasuries’ which deals with medicine i.e. 四庫全書-子部-醫家類 is available in modern 
edition. Republished in 1991 it comprises about 100 titles spanning the scope of classical medicine 
[290]. As a sample, it provides a collection of key works of mostly pre-Qing origin that had been 
selected by the experts of the time. The 1991 edition examined was printed as a facsimile in 
traditional format so it has the attribute of authenticity but its utility is limited since there is no 
overarching indexing system which allows searching, and the tables of contents of individual titles 
suffer from the general limitations of classical texts discussed above. 
 
5. Zhong Guo Yi Xue Da Cheng 中國醫學大成 
A later collection of medical literature is the Zhong Guo Yi Xue Da Cheng ‘Great Compendium of 
Chinese Medicine’ which was first published in 1936 and again in 1990 [291]. It comprises 50 
volumes containing 136 titles, mostly from the Ming and Qing but with a number from the Song, Jin 
and Yuan dynasties, as well as a few Japanese works. The format is classical in style and since there 
113 
is no indexing system beyond that available in the original works, this collection again presented 
difficulties as a source for searching.  
 
6. Ming Qing Ming Yi Quan Shu Da Cheng 明清名醫全書大成 
A modern collection of classical literature is the Ming Qing Ming Yi Quan Shu Da Cheng ‘Complete 
Collection of the Works of Famous Doctors from the Ming and Qing’ [292]. Published in 1999 it 
comprises about 238 titles which are published as parts of collections of the works of 30 famous 
doctors from the Ming and Qing. This represents a valuable research resource and it appears to 
complement the previously discussed resources since it fills out the Ming and Qing components of the 
classical literature. However, again there is no indexing system which allows comprehensive 
searching. 
 
7. Zhong Hua Yi Dian 中華醫典 
The HKBU had a computer in which the CD ROM Zhong Hua Yi Dian ‘Enclyclopaedia of 
Traditional Chinese Medicine’ was installed. This was examined and trial searches conducted. It was 
found that it was the third edition which contains 689 books [293]. The same edition had recently 
been purchased via RMIT University but the search function turned up surprisingly few references, so 
it had appeared not to be a suitable source for this project. However, the CD at HKBU found 
considerably more hits so it became apparent that the CD previously purchased was not functioning 
properly. As a result of the trial searches at HKBU it became evident that electronic searches of the 
Zhong Hua Yi Dian (ZHYD) were a feasible approach to obtaining a comprehensive data set since a 
search term appeared to locate all instances of the term in the CD. In order to obtain the best data set 
possible from this CD, attempts were made to purchase the fourth edition of the CD which contains 
1,000 books [252]. It proved unavailable in Hong Kong and Shenzhen but was obtained from Taiwan 
in 2007.  
 
A second round of hand searches of the classical and modern clinical literature were undertaken at the 
library Guangzhou TCM University and again at HKBU in September 2007.  
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Conclusions drawn from trial searches of the classical literature 
It was found that conducting hand searches of pages or even a selection of pages of a text was too 
time consuming to be a practical strategy for generating a sample. The references required tended to 
be located in specific sections of books and references were not spread throughout the text, so a 
random sampling approach was highly likely to miss the relevant section. Targeted searching based 
on tables of contents was a more productive approach but due to the inconsistent referencing systems 
of classical texts this approach was also cumbersome and time consuming as well as being likely to 
miss numerous references.  
 
Using a modern formula compendium derived from a wide variety of classical and modern works 
which has a detailed indexing system, such as Zhong Yi Fang Ji Da Ci Dian, was found to be a 
practical approach. However, the degree to which this sample is representative of the literature was 
unknown, nor were the nature of any biases in the selection of extracts for inclusion. Examination of 
the list of source books revealed a wide spread of the classical literature which also includes some 
major Japanese works, so the book appeared to derive from a broad sample of classical books. 
However, the procedures used for searching these sources and selecting formulas for inclusion in the 
work are not specified.  
 
In the case of the Zhong Hua Yi Dian, the availability of an electronic search facility that can search 
the whole or a section of a single CD containing 1,000 titles overcomes the problem of the indexing 
inadequacies of these texts. As with the Zhong Yi Fang Ji Da Ci Dian, the criteria for including the 
books in the CD is not specified but an examination of the list of titles showed a wide selection of 
works spanning the whole classical literature. Since the CD includes the total text of each book, there 
can be no selection bias of the type possible in ZYFJDCD. Also, the CD contains specific categories 
of books likely to contain useful references such as categories for ‘clinical medicine and specialties’ 
臨證各科類, ‘materia medica’ 本草類, ‘formula compendia’ 方書類, ‘health preservation and food’ 
養生食療, ‘medical records and cases’ 醫論醫案. However, the search function in the CD is not 
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sophisticated since it only allows one field to be searched at one time and there is no way of limiting 
the search using Boolean operators. Therefore a search of a term such as jian wang turns up all 
instances of the term, each of which needs to be examined individually to determine whether it is a 
useful reference. This was in contrast with an organised source such as Zhong Yi Fang Ji Da Ci Dian 
in which all the jian wang references link to a formula for which jian wang is a key indication.   
 
Visits to bookshops in China and Hong Kong proved useful since specialist works in addition to those 
found in the libraries were obtained. It had been envisaged that these specialist clinical manuals would 
contain a range of classical references, which could, in turn, be consulted as sources and that this 
would constitute a well selected, i.e. by modern experts, sample of classical literature. However, in 
the process of collecting these books it became evident that such works are not widely available and 
that the older works are not typically held in bookshops since there was little overlap between 
bookshop holdings and the books in the HKBU and Guangzhou University library collections. 
Therefore there was no available method to determine how representative was the sample of specialist 
works that was collected. Also, using a two-stage process was likely to be problematic since the 
referencing in these books was often less than adequate so locating a passage in the source text was 
difficult and time consuming. 
 
Selecting sources for systematic searching 
The trial searches demonstrated the impracticality of hand searching a number of the compendia of 
classical literature discussed above. It was also evident that a sampling process was not feasible. 
Nevertheless, two major sources were located for which comprehensive searches appeared practicable 
and which encompassed a large number of classical books. These sources were distinctly different 
with Zhong Yi Fang Ji Da Ci Dian being a collection of formulas derived from other books which had 
been categorized under disease/symptom names, whereas the Zhong Hua Yi Dian 4th edition is a 
collection of texts with no such system of categorization. For each source there were advantages and 
limitations but on the basis of the trial searches it could not be determined which was the more useful 
for this project. Consequently, it was resolved to search both sources and compare the results.  
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Another important consideration was the issue of individual herb versus formula. When a text 
specifies that a particular herb is indicated for a particular condition, direct inferences can be drawn 
from this information but when a multi-herb formula is indicated for a condition it cannot be inferred 
that all the herbs in the formula are indicated for the condition. Since the aim was to identify 
individual herbs, it was important to be able to determine whether a herb is likely to have been 
included for its action on chi dai or jian wang rather than for another function. Consequently it was 
necessary to include a specific search of the ben cao literature to determine which herbs are 
specifically indicated for these and other associated search terms. This provided a means of determing 
whether the high frequency herbs found in the searches of formulas were individually indicated for 
the search terms as well. 
 
Eventually, three searches were conducted. 
 
1. The first was a hand search of the formulas and their constituent herbs in the Zhong Yi Fang Ji Da 
Ci Dian (ZYFJDCD). This was expected to provide a population of formulas for which chi dai or 
jian wang were major indications.  
 
2. The second was an electronic search of the individual herbs in the ben cao section of the Zhong 
Hua Yi Dian (ZHYD) which contains 67 titles. This replaced the originally proposed search of the 
Zhong Guo Ben Cao Quan Shu and focussed on individual herbs, rather than formulas. It aimed to 
locate all the herbs listed in the ben cao literature for which the selected search terms were an 
indication, but not necessarily the primary indication. 
 
3. The third search was an electronic search of the entire text of the Zhong Hua Yi Dian to locate all 
formulas for which chi dai, jian wang and associated terms were at least one indication. It was 
expected that this search would identify not only formulas that had these as major indication but 
also those for which these were additional indications. It should also locate any instances of these 
disorders in texts that would not usually be searched for these disorders and thereby overcome the 
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problems associated with finding such references in the broad scope of the largely unreferenced 
classical literature. 
 
In the case of the individual herb search, only the ben cao sections of the ZHYD CD were searched. 
Since the same set of search terms where used, the same hits were also found in the search of the 
whole CD. In the whole CD search, individual herb entries were also extracted but this search was 
focused on formula entries, so the extraction of individual herb entries at the same time proved a 
complication, particularly as many were just passing references or components of lists. Consequently, 
it was decided that a more systematic approach was to select the ben cao section and to extract entries 
from this. In this approach the source population of books would be the ben cao literature and the 
population would be an uncontaminated one. 
 
Comparison of sources 
While there are considerable similarities in the searches of sources one and three, there are also a 
number of differences which make the searches distinct but may make them complementary.  
 
In the Zhong Yi Fang Ji Da Ci Dian each formula appears only once for the particular condition and it 
is referenced to the oldest of the sources consulted, plus notes taken from other sources. This search 
should indicate when a formula was first used for the condition. In contrast, the Zhong Hua Yi Dian 
search is accumulative so the same formula may recur in different books over a long period for the 
same indication. This would provide a measure of the period of time the formula was in use. It was 
considered plausible that this recurrence could be interpreted as a measure of the regard the authors 
had for the formula since they repeatedly considered it worthy of inclusion in collections. 
 
Presumably, the editors of the ZYFJDCD selected formulas for inclusion according to their own 
judgements. These judgements may have considered their contemporary utility, the status of the 
source work or the clarity of the text associated with the formulas. For instance, since the ZYFJDCD 
recorded not only the formula name and ingredients but also the ‘main indications’ 主治 and 
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‘actions’ 功用, it seems likely that formulas for which this information was available would be more 
likely to be selected for inclusion. In contrast, in the electronic search of the Zhong Hua Yi Dian all 
formulas that are associated with the search terms can be included so the resultant data set should not 
contain any selection bias based on editorial judgement. 
 
Determining the representativeness of the sources 
The two sources were selected since they satisfied the criteria of being derived from large numbers of 
classical books and being practicable to search. However, there was no available method of 
determining how representative either source is as a sample of the total corpus of extant classical 
literature. In order to obtain a measure of this, comparisons were made between the ZHYD and the 
ZYFJDCD and other collections of classical literature to determine the degree of overlap. 
 
At the outset, comparing the lists of books which comprised various collections appeared a straight 
forward task. This was not borne out in reality, so a number of criteria for inclusion needed to be 
developed: 
 
1. The aim of the searches was to locate herbs and formulas used over a long period so the 
informational content of the collection in this regard was the key concern. From this point of view, 
variant editions of the same book that contained the same key content were considered as the same 
book. So when two collections contained different editions they were considered to overlap.  
2. When a work was known to be subsumed within a larger work, then it was scored as included. 
3. In cases where there were discrepancies between the title, authorship and/or publication date, the 
procedure was to examine the text where possible or to consult other sources to determine whether 
the variant information applied to the same book or not.  
4. When books had different titles and different author attributions but had essentially the same 
content, this was treated as overlap. For example, the Si Ku Quan Shu 四庫全書 contains the 
Zheng Lei Pu Ji Ben Shi Fang 政類普濟本事方 which is attributed to the Song dynasty author 
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Xu Shu-Wei 許叔微 whereas the ZHYD contains the Lei Zheng Pu Ji Ben Shi Fang Shi Yi 類證
普濟本事方釋義 which is Qing dynasty version with commentary by Ye Gui 葉桂.  
 
In the case of the Ben Cao sections of the ZHYD the comparison was with the ben cao section of the 
Zhong Guo Ben Cao Quan Shu 中國本草全書 since these were both samples derived from the 
population of ben cao literature. 
 
Search, data extraction and data entry procedures 
Procedures for searching the sources, extracting and recording data and for data entry were developed 
and documented prior to each search. Since the searches were different, there were differences in the 
procedures used. 
 
ZYFJDCD search 
The aims of the hand search of the ZYFJDCD were to determine:  
 
1. Which formulas had been listed in the classical literature as indicated for the treatment of chi dai 
and jian wang; 
2. In which books were these formulas listed and what were the dates of these books;  
3. Which diseases and symptoms were these formulas indicated for; 
4. Which herbs constituted these formulas; 
5. Which of the herbs which constituted these formulas were more or less frequently listed; 
6. Whether there was any change in the herbs listed over the timeframe of the entries. 
 
The search and data extraction procedure followed the following steps: 
 
1. The indices of the ZYFJDCD were examined for dementia related terms. The two most relevant 
were chi dai and jian wang; 
2. Each of the entries was located in the ZYFJDCD and the page photocopied; 
120 
3. The following information was extracted from the photocopied entries into Excel in Chinese: book 
title (in characters and pin yin), each of the herbs that comprised the formula (in characters and pin 
yin), functions and indications of the formula (in characters). The index term was also entered into 
Excel as was an ID number. The dosages of the individual herbs were not entered, nor were any 
administration instructions or other information not directly pertinent to the indications of the 
formula; 
4. The authorship and date of the book was determined (see below) and this information was entered 
in the Excel spreadsheet; 
5. The entries were checked against the paper files by a second researcher (Apple) and any errors or 
omissions corrected. 
 
Ben cao search 
The aims of this electronic search of the ben cao section of the ZHYD CD where to determine:  
1. Which herbs had been listed in the classical ben cao literature as indicated for the treatment of chi 
dai, jian wang and associated terms;  
2. In which books were these herbs listed and under which disease names; 
3. Which herbs were more or less frequently listed; 
4. Whether there was any change in the herbs listed over the timeframe of the entries. 
 
The search and data extraction procedure involved a number of steps as follows: 
 
1. Each of the search terms was entered into the search window in the CD, the ben cao section was 
selected and the total number of hits per term was recorded. 
2. The search results were displayed and the sections read to determine whether they were instances 
of a herb being indicated for the search term.  
3. When this was the case, the relevant text was extracted into a Word file and then the herb name, 
book name and search term was entered into an Excel spreadsheet in Chinese. When the search term 
appeared more than once under the entry for a particular herb, it was treated as one entry in the Excel 
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file. When two search terms (e.g. jian wang and duo wang) appeared under the same herb entry, it 
was treated as one entry but both search terms were listed under the herb entry. When a search hit was 
associated with a list of herbs for the condition, each of the herbs was entered separately even when 
the list was under the section for only one of the herbs. The reason for this was that in the smaller ben 
cao, not every herb is listed for every condition in each section due to space limitations, so following 
an indication for a herb, there can be a list of other herbs also indicated for that condition, and some of 
these herbs may not have separate entries in that ben cao, or this condition may not appear under the 
herb entry for all of the herbs on the list. 
4. The entries were checked against the Word files or CD by a second researcher (BM) and any errors 
or omissions corrected. 
5. The authorship and date of the ben cao was determined (see below) and this information was 
entered in the Excel. 
 
ZHYD search 
The aims of this electronic search of the complete CD where to determine: 
 
1. Which formulas had been listed in the classical literature as indicated for the treatment of chi dai 
and jian wang and associated terms; 
2. In which books were these formulas listed and what were the dates of these books;  
3. Which diseases and symptoms were these formulas indicated for; 
4. Which herbs constituted these formulas; 
4. Which of the herbs which constituted these formulas were more or less frequently listed; 
5. Whether there was any change in the herbs listed over the timeframe of the entries. 
 
The search and data extraction procedure involved the following steps: 
 
1. Each of the search terms was entered into the search window in the CD, the whole ZHYD was 
selected and the total number of hits per term was recorded; 
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2. For each term, the hits were examined on the CD one by one, the reference was listed in an excel 
file together with an indication as whether it should be included or excluded according to the 
following inclusion criteria: 
1. the entry was in a book concerned with herbal medicine, not acupuncture etc.  
2. the entry was associated with the treatment of one or more of the search terms  
3. the entry was associated with a herb or herbal formula; 
3. The screen images of the CD showing the hits were copied (using the print screen function) into a 
Word file and those hits which satisfied the inclusion criteria also had the relevant pages extracted as 
text and copied to the Word file following the screen image;  
4. The entries that contained herbs and/or formulas were extracted into Excel in Chinese. The 
following information was included:  
1. book title (in characters and pin yin),  
2. each of the herbs that comprised the formula (in characters and pin yin), 
3. the functions and indications of the formula (in characters),  
4. any other relevant parts of the extract.  
5. The search term was also entered into Excel, as was an ID number. The dosages of the individual 
herbs were included where available but this was not a necessary aspect, any administration 
instructions or other information pertinent to the indications of the formula was also entered; 
6. The entries were checked against the Word files or CD Rom by a second researcher (Iris) and any 
errors or omissions corrected. 
7. Entries were removed that were not relevant to the conditions. These were mainly items picked up 
by the search terms but upon examination of the entry the term turned out to be not relevant to the 
actual formula use.  
8. When the ingredients section listed a formula name plus modifications, attempts were made to 
locate the ingredients of the formula elsewhere in the text and fill in ingredients in the spreadsheet. 
When there was a reference to another book, this was followed up for the ingredients.  
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9. Duplicates were removed by sorting the spreadsheet to find formula entries that occur twice for the 
same disorder in the same book. Since duo wang, jian wang, xi wang etc are synonymous terms, the 
search results overlapped. A duplicate could be exactly the same reference (i.e. same book and section) 
or a repeat reference (i.e. same book, same formula with the same indications but in different section 
of the book) that was found by more than one search term. When the same formula, with the same 
indications was found in different books, these were treated as different entries.  
10. Entries that are for single herbs rather than formulas were identified. When these had no formula 
names and were not single-herb formulas, these were excluded. 
11. Formulas for which ingredients were either incomplete or absent were identified. Further attempts 
were made to identify the ingredients by searching the source texts. When the formula was a well 
known one, it was assumed that the author had considered its composition self-evident, so the 
ingredients of the most well known classical version of the formula were entered. Cross referencing 
with the same formula in other books in the database was another approach. When the ingredient lists 
were consistent over a number of references without any major discrepancies, then these ingredients 
were included. When these approaches failed the entry was excluded. 
12. The authorship and date of the book was determined (see below) and this information was entered 
in the Excel. 
 
Coding procedures for ZYFJDCD and ZHYD searches 
To prepare the extracted data for entry into SPSS the following numerical codes were allocated: 
 
1. Each formula was allocated a number. When two formulas had the same name but different 
ingredients, different numbers were allocated. The same number was only applied to identical 
formulas. 
2. Each herb was allocated a separate number. The aim was to numerically identify all the distinct 
items of material medica rather than all the names used. When a herb appeared under different names 
but was evidently the same herb, then the same number was allocated for example, shan yao and shu 
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yu. When a herb typically has distinctly different forms, such as different methods of preparation such 
as sheng di huang (unprocessed rehmannia) and shu di huang (steamed rehmannia), these were given 
different numbers. When different parts of the plant are used as different medicines, e.g. rou gui 
(cinnamon bark) and gui zhi (cinnamon twigs) these were given different codes.  
3. The codes and names of the formulas and herbs were recorded in a spreadsheet. 
 
Coding was not required for the ben cao search since SPSS was not needed for this data set, but the 
nomenclature for the individual herbs was made consistent with that for the other searches.  
 
Recoding of some of the herb codes was undertaken prior to the final analyses in SPSS. The aim of 
this was to facilitate the identification of high frequency items of materia medica at the level of the 
species. When the same species was separately identified as different items of materia medica 
according to the processing method, for example processed di huang (shu di huang) and unprocessed 
di huang (sheng di huang), these were allocated the same code and renamed with a more general 
appellation, in the case ‘di huang’. In other cases, different parts of the plant were designated as 
separate items of materia medica, such as gui zhi and rou gui (see above), but also not differenctiated 
in some formulas, for example simply gui was written, then these were recoded in to one item.  
 
Determining book dates 
Besides identifying which formulas and their ingredients have been used in the classical literature for 
the search term conditions, it was of interest to determine the dates of these references. Dating 
classical books can be problematic for a number of reasons. In some cases the authorship is unclear, 
as is when the book first appeared. Published editions typically reference the book to a dynasty 
without any clear date. In other cases the author may be known but there are no clear dates regarding 
the author’s birth or death or when the book was written or first published. Some books have very 
similar names or may be known under multiple names, also, authors can frequently be known by 
different names. Books can also appear as edited editions or revisions with the result that there are 
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multiple authors from varied time periods. Since books may not have been published in a formal way 
until long after the completion date, there may be large discrepancies between the completion date 
and the publication date. Also the dates given in various sources can vary without any reason being 
given for how the date was determined. 
 
The aims of including dates for the books were to determine wheter use of the herbs had varied over 
time, so the most useful date is that of the completion of the original book since this indicates that the 
formula was employed for a particular condition at that time. In practical terms, obtaining an accurate 
date may not be possible, so an approximation may need to be used. From the point of view of 
statistical analysis, which will employ comparisons between blocks of time rather than between 
individual books, an approximate date is better than no date, and the aim was not to investigate in 
detail the dates of individual books. Therefore, the following procedures were employed to determine 
a date for entry into the database. 
 
In the case of the ZYFJDCD data set, the primary reference was the appendix of books which 
included authors and dates. This was considered the most consistent approach for this data set and this 
approach was able to provide dates for most books. The appendix did not however, specify whether 
the date given was the publication date of the edition used or the completion date. When referenced 
against other sources, discrepancies were found, but unless these were considerable, or an error 
identified, the date given in the appendix was entered. As mentioned previously, the appendix of 680 
books proved to be incomplete, so for books not included, dates were obtained from other sources 
with the same priorities as for the CD Rom results (see below). 
 
In the case of the ZHYD, the included titles had no publication dates. In the majority of cases, an 
author and dynasty was written on the cover page but for some books this information was missing or 
illegible. Consequently, a procedure for allocating authorship and dates was required as follows: 
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Firstly, the WHO International Standard Terminologies [294] was consulted since this is both 
authoritative and of recent publication. Unfortunately the book list is far from complete. The next 
source was the appendix to the ZYFJDCD. When this was unsuccessful, specialist works on medical 
history [131, 232, 295] and the famous books and famous doctors sections of the ZHYD were 
searched. Finally, internet searches were conducted and the most consistently recurring date was used. 
In many cases a number of methods were used and in some cases these resulted in conflicting dates so 
a judgement on the most plausible date was required.  
 
In a number of cases, no clear date could be obtained so the following procedures were used for 
approximation. When the year of death of the author was known, this date was used since it was the 
last date the book could have been worked on – assuming the book was not completed by descendents, 
and even in this case the material contained would have been collected by the author. In cases where 
this date is unknown, but the date of another work by the same author is known, then this date was 
used as the best approximation. When the reign period or dynasty was all that was known, then the 
last year of the period is given as the date.  
 
By following these procedures, dates suitable for entry into SPSS were obtained for all references. In 
the majority of cases, a number of sources were consulted prior to determining the best estimate. 
Since the procedure varied slightly between the two data sets, care was taken to avoid any large 
differences, i.e. over plus/minus 10 years. Since analyses are of grouped data, differences in dates of 
this order would not be expected to affect the overall results. 
 
Data entry into SPSS 
The Excel spreadsheets were organized according the entry, with each line of data representing a 
single entry, which, after the exclusion process, was equivalent to a single formula. In contrast, the 
SPSS data editor was organized at the level of the individual herb, with each line representing one of 
the herbs in one of the formulas. For example, when a single entry in the Excel spreadsheet was for a 
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formula comprising six herbs, this would result in six lines of data in SPSS. This approach was to 
facilitate statistical analysis at the level of the individual herb. 
 
For each line of data in SPSS, an individual code was allocated. The name of the source book, the 
formula code, the herb code, the codes for the search term and the source of the entry (ZHYD, 
ZYFJDCD etc), plus the codes for the ratings (see chapter 4) were all entered, so that every herb in 
every formula in every data set had an individual line of data in SPSS. Not all the information 
included in the spreadsheet was entered into SPSS. Excel contained text about the formula indications 
and actions which was not feasible to code. Essentially, the Excel spreadsheets retained all the verbal 
information for the entries while the SPSS data editors contained a summary of the key aspects in 
numerical form. The system of cross-referencing allowed both databases to be reconciled. 
 
Planned data analyses 
Since the principal aim was to generate lists of herbs to enable the prioritisation of research effors, the 
main focus of the analyses was at the level of the individual herb entry, with frequency data providing 
lists in descending order of herbs most frequently used and the years of the books indicating whether 
these data were only derived from a particular period in the history of Chinese medicine or 
represented a long period of use.  
 
Comparing three different data sets that had differing characterisitics but were all derived from the 
classical literature, was expected to provide an indication of the reliability of the results, but an 
appropriate statistical procedure for measuring this was not evident. The populations that comprised 
each of the data sets were, in a sense, samples of a hypothetical total population of all formulas used 
for the conditions represented by the search terms, but the populations differed in key features. In the 
ZYFJDCD each formula only occurred once, so it was a population of types, but in the ZHYD each 
formula could recur many times depending on how many books it was mentioned in, so it was a 
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population of tokens. Combining a population of types with one of tokens appeared an invalid 
approach, so these data sets were analysed separately. 
 
It was planned to use the criteria data (see chapter 4) to categorise the individual herbs according to 
how well they fit the modern conception of dementia using the select cases function in SPSS to 
remove components of the data set and then to undertake analyses on the remaining cases. 
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Figure 3.1: Summary of stages in the selection and search process 
This summary applies primarily to the ZHYD CD ROM search. In the other searches, some stages 
were not necessary. 
 
Examine specialist books for
classical terms
Assess candidate terms for
relevance to modern concepts of
dementia, MCI etc
Select list of search terms
Investigate options for classical
literature sources
Compare available literature
sources and conduct trial searches
Select sources for systematic
searches
Apply search terms to sources
and calculate no. of hits
Select passages from books for
relevance to herbs and
formulas
Copy relevant passages into
Word files
Select sections of passages
suitable as formula entries into
Excel
Enter entries into Excel in
appropriate fields
Sort Excel files to remove
duplicates
Edit Excel files and add
missing information, incl. book
authorship and year
Assign code numbers to
individual herbs and formulas
Rate entries according to
criteria
Enter data into SPSS as
individual herb entries
Conduct analyses in SPSS
Remove entries with
insufficient information
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Limitations of the searches and data sets 
In the case of the ZHYD 4th edition it had a number of limitations as a database. Firstly, the search 
function tended to be slow and may falsely return zero hits so searches needed to be repeated to 
determine an accurate number. Secondly, the search did not locate words in the headers to pages, so 
when the required information was only located in the page header, it did not register as a hit. Thirdly, 
the conversion to text function did not include the page header which contains the reference 
information, so this had to be entered separately, which was time consuming. Fourthly, the title pages 
of books can appear as fuzzy or unclear images with the result that author names and dynasties are 
illegible, since these pages cannot be copied as text and the information on the cover is not duplicated 
elsewhere in the file, this makes it difficult to verify the identity of the book. Since the texts are 
classical, a number of characters are not typically included in the type sets of modern word processing 
programs. Therefore, when an extract is copied as text, these characters can blank out or be omitted. 
There is no index of authors or list of book dates and most books contain no preface providing 
information as to the history of the book, its editorial history or the edition which is included in the 
CD. 
 
The ZYFJDCD also presents some difficulties. Book names are frequently abbreviated which makes 
their identity difficult to determine. An index of book names with dates is provided in volume 11 but 
it contains inaccuracies as well as a number of omissions. The entries are referenced to the book but 
not to the section, so they can be difficult to locate in the original work. In the editorial process, herb 
names have been partially standardised and text extracts may be abbreviated so exact matches may 
not be found with editions of the original works. Nevertheless, in all cases where the entry was 
checked with the source text, the differences did not affect the overall meaning. 
 
Expected characteristics of the data sets 
There was expected to be considerable overlap between the two data sets for formulas with the 
majority of the ZYFJDCD entries also appearing in the ZHYD since the ZHYD was derived from a 
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larger spread of the classical literature. The ZHYD data set was also expected to be larger since it was 
an accumulative set which allowed the same formula to be included each time it appeared in a 
different book. It was also expected to be more diverse in its composition since the formulas included 
had not been selected by editors, as in the ZYFJDCD, but were the total results of electronic searches.  
 
In terms of ease of data set creation, it was evident that searching the ZYFJDCD was a much simpler 
and faster procedure that searching the ZHYD which required a lengthy process of data sorting. 
However, it was only possible to use the set index terms in the ZYFJDCD and the search results 
would not provide an indication of how frequently the same formula was included in different works.  
 
Since the formulas collected into the ZYFJDCD had been selected by editors, it was expected that 
they would prove a more focused set with regard to treating jian wang or chi dai as a primary 
condition compared with the formulas located in the ZHYD search since the latter included all 
formulas for which the search term was at least one of the indications but not necessarily a primary 
indication. 
 
A feature common to both these data sets was they included both formulas and their individual 
ingredients. At the level of the individual herb entry, the items were essentially components of the 
clusters of herbs that formed the formula. Also, the number of herbs in a formula was variable so the 
relation between the numbers of formulas and the numbers of herbs was not fixed. While the resultant 
data set enabled analysis at both the level of formula and individual herb, care needed to be taken  
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CHAPTER 4 
DIAGNOSTIC CRITERIA AND THE DEVELOPMENT OF RATING 
SYSTEMS 
 
The first part of this chapter discusses contemporary diagnostic criteria for dementia and its associated 
symptoms. Part 2 details the approach taken to adapting these systems for rating information derived 
from the classical Chinese medicine literature. 
 
PART 1 
THE DIAGNOSIS OF DEMENTIA AND  
THE CATEGORISATION OF SYMPTOMS 
 
Diagnostic Criteria for Alzheimer’s Disease 
The two main approaches to the clinical diagnosis of AD are those developed by the American 
Psychiatric Association (APA) and those by the combined efforts of the National Institute of 
Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer’s Disease and 
Related Disorders Association (ADRDA) [3, 296]. Both of these sets of criteria are used 
internationally and there is considerable overlap between them. Whereas the NINCDS-ADRDA 
Alzheimer’s Criteria are specifically designed for AD, those developed by the APA form one 
component of the Diagnostic and Statistical Manual (DSM) which provides a classification of 
numerous psychiatric disorders.  
 
The NINCDS-ADRDA Criteria 
The NINCDS-ADRDA Alzheimer’s Criteria divide the diagnosis into Possible, Probable and Definite 
AD. A clinical diagnosis of Possible or Probable AD requires the presence of both cognitive 
impairment and a suspected dementia syndrome to be confirmed by neuropsychological testing. For 
the diagnosis of Definite AD, histopathologic confirmation (i.e. microscopic examination of brain 
tissue) is additionally required. The NINCDS-ADRDA criteria are tabulated below. 
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Table 4.1: NINCDS-ADRDA Alzheimer’s Criteria 
I. Criteria for the clinical diagnosis of Probable Alzheimer’s Disease: 
• Dementia established by clinical examination, and documented by a standard test of cognitive 
function (e.g. Mini-Mental State Examination, Blessed Dementia Scale, etc.), and confirmed by 
neuropsychological tests. 
• Significant deficiencies in two or more areas of cognition, for example, word comprehension and 
task-completion ability. 
• Progressive deterioration of memory and other cognitive functions. 
• No disturbance of consciousness (e.g. delirium, drowsiness, stupor or coma). 
• Onset from age 40 to 90, typically after age 65. 
• No other diseases or disorders that could account for the progressive loss of memory and 
cognition.  
 
II. The diagnosis of Probable Alzheimer’s Disease is supported by: 
• Progressive deterioration of specific cognitive functions: language (aphasia), motor skills (apraxia), 
and perception (agnosia). 
• Impaired activities of daily living and altered patterns of behaviour. 
• A family history of similar problems, particularly if confirmed by neurological testing. 
• The following laboratory results: 
- Normal cerebrospinal fluid (lumbar puncture test). 
- Normal electroencephalogram (EEG) test of brain activity. 
- Evidence of cerebral atrophy in a series of CT scans.  
 
III. Other clinical features consistent with Probable Alzheimer’s Disease after exclusion of causes for 
other dementias: 
• Plateaus in the course of illness progression. 
• CT scan findings normal for the person's age. 
• Associated symptoms of depression, insomnia, incontinence, delusions, illusions, hallucinations, 
weight loss, sexual disorders, and catastrophic verbal, emotional, or physical outbursts. 
• Other neurological abnormalities, especially in advanced disease: including: increased muscle tone, 
myoclonus, or a shuffling gait.  
 
IV. Features that make the diagnosis of Probable Alzheimer’s Disease uncertain or unlikely:  
• Sudden apopleptic onset. 
• Focal neurologic findings such as hemiparesis, sensory loss, visual field defects, and 
incoordination early in the course of the illness 
• Seizures or gait problems at the onset or very early in the course of the illness.  
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V. Criteria for the clinical diagnosis of Possible Alzheimer’s Disease: 
• May be made on the basis of Dementia syndrome in the absence of other neurologic, psychiatric or 
systemic disorders sufficient to cause dementia, and in the presence of variations in the onset, in 
the presentation, or in the clinical course; 
• May be made in the presence of a second systemic or brain disorder sufficient to produce dementia, 
which is not considered to be the cause of the dementia; and  
• Should be used in research studies when a single, gradually progressive severe cognitive deficit is 
identified in the absence of other identifiable cause. 
 
VI. Criteria for the diagnosis of Definite Alzheimer’s Disease: 
• The clinical criteria for Probable Alzheimer’s Disease, and 
• Histopathologic evidence obtained from autopsy or biopsy. 
 
VII. Classification of Alzheimer’s Disease for research purposes should specify features that may 
differentiate subtypes of the disorder, such as:  
• Familial occurrence, 
• Onset before age of 65, 
• Presence of trisomy 21, and 
• Coexistence of other relevant conditions such as Parkinson’s Disease.  
 
Adapted from McKhann, G. et al. Clinical Diagnosis of Alzheimer’s Disease: Report of the 
NINCDS/ADRDA Work Group [296] 
 
In summary, for a clinical diagnosis of Probable AD, the presence of cognitive deficits needs to be 
confirmed by tests, and behavioural symptoms of insidious onset of dementia with progression are 
required in the absence of other disorders that could account for progressive memory and other 
cognitive deficits. The main disorders that require exclusion are manic-depressive disorder, 
Parkinson’s disease, multi-infarct dementia and drug intoxication, and less commonly, thyroid disease, 
pernicious anemia, luetic brain disease and other chronic infections of the nervous system, subdural 
dematoma, occult hydrocephalus, Huntington’s disease, Creutzfeld-Jakob disease and brain tumours. 
For a diagnosis of Definite AD, not only do the criteria for Probable AD need to be met but there 
needs to be histopathologic confirmation by brain biopsy or autopsy [296]. 
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In 2007, Dubois et al proposed a revision of the criteria for Probable AD based on progress in 
imaging and the identification of biomarkers for AD and other dementias. Three clinical criteria have 
been proposed as follows: 
1. Gradual and progressive change in memory function at disease onset reported by patients or 
informants for a period greater than 6 months; and 
2. Objective evidence of significantly impaired memory on testing; and 
3. Episodic memory impairment can be isolated or associated with other cognitive changes at onset 
of AD or as AD advances [297]. 
 
In this system, the core focus is upon clinical evidence of a progressive decline in episodic memory, 
with the supportive features being derived from imaging (i.e. MRI, PET), tests of cerebrospinal fluid 
(i.e. for beta amyloid, tau) and genetic evidence. 
 
The DSM Criteria 
The Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM IV-TR) includes AD in 
the section on Delirium, Dementia, Amnestic Disorders, and Cognitive Disorder Not Otherwise 
Specified. A number of dementias are classified as follows: Dementia of the Alzheimer’s Type, 
Vascular Dementia, Dementia Due to HIV Disease, Dementia Due to Head Trauma, Dementia Due to 
Parkinson’s Disease, Dementia Due to Huntington’s Disease, Dementia Due to Pick’s Disease, 
Dementia Due to Creutzfeldt-Jakob Disease, Dementia Due to Other General Medical Conditions, 
Substance-Induced Persisting Dementia, and Dementia Due to Multiple Etiologies [3].  
 
The specific diagnostic criteria for Probable AD are as follows: 
A. The development of multiple cognitive deficits manifested by both:  
(1) Memory impairment (impaired ability to learn new information or to recall previously learned 
information), and 
(2) One (or more) of the following cognitive disturbances:  
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(a) aphasia (language disturbance),  
(b) apraxia (impaired ability to carry out motor activities despite intact motor function),  
(c) agnosia (failure to recognize or identify objects despite intact sensory function), or  
(d) disturbance in executive functioning (i.e., planning, organizing, sequencing, abstracting).  
B. The cognitive deficits in Criteria A1 and A2 each cause significant impairment in social or 
occupational functioning and represent a significant decline from a previous level of functioning.  
C. The course is characterized by gradual onset and continuing cognitive decline.  
D. The cognitive deficits in Criteria A1 and A2 are not due to any of the following:  
(1) Other central nervous system conditions that cause progressive deficits in memory and 
cognition (e.g., cerebrovascular disease, Parkinson's disease, Huntington's disease, subdural 
hematoma, normal-pressure hydrocephalus, brain tumour),  
(2) Systemic conditions that are known to cause dementia (e.g., hypothyroidism, vitamin B12 or 
folic acid deficiency, niacin deficiency, hypercalcemia, neurosyphilis, HIV infection), or  
(3) Substance-induced conditions.  
E. The deficits do not occur exclusively during the course of a delirium.  
F. The disturbance is not better accounted for by another Axis I disorder (e.g. Major Depressive 
Disorder, Schizophrenia).  
Adapted from DSM IV-TR [3]  
 
Comparison of the NINCDS-ADRDA and the DSM IV-TR criteria for AD 
Both the NINCDS-ADRDA and the DSM IV-TR criteria show considerable similarities and a few 
differences. Firstly, the NINCDS-ADRDA divide the diagnosis into three levels of certainty - 
Possible, Probable and Definite - with histological findings being required for the higher level of 
certainty, whereas the focus of the DSM IV-TR criteria is upon the clincal diagnosis of probable AD. 
Secondly, DSM IV-TR criteria do not include a specific reference to age of onset. These differences 
mostly appear to be reflections of the differing uses of these systems. An imperative of the DSM 
IV-TR is that it enables psychiatrists to classify patients into disease categories based on information 
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that can be obtained in a range of clincal settings. In this regard, the DSM IV-TR, with its focus on 
memory disorder plus at least one of four sets of other clinical indications of cognitive disorder, offers 
a more practical approach to the retrospective classification of sets of symptoms (derived from the 
Chinese clinical literature) as examples of Possible or Probable AD. These four symptom categories 
are examined in more detail below in order to enable matching with similar Chinese terms. 
 
Aphasia (language disturbance) generally develops after several years. It is a deterioration of 
language function that can include: difficulty producing the names of individuals and objects; vague 
or empty speech, with long circumlocutory phrases and excessive use of terms of indefinite reference 
such as ‘thing’ and ‘it’. Comprehension of spoken and written language and repetition of language 
may also be compromised. In the advanced stages of dementia, individuals may be mute or have a 
deteriorated speech pattern characterized by echolalia (i.e. echoing what is heard) or palilalia (i.e. 
repeating sounds or words over and over). Language is tested by asking the individual to name objects 
in the room (e.g. tie, dress, desk, lamp) or body parts (e.g. nose, chin, shoulder), to follow commands 
(‘Point at the door and then at the table’), or to repeat phrases (‘no ifs, ands, or buts’). Slurred speech 
is more likely to occur in dementia that is associated with subcortical pathology such as Parkinson's 
disease, Huntington's disease, and some cases of Vascular Dementia [3]. 
 
Apraxia is impaired ability to execute motor activities despite intact motor abilities, sensory function, 
and comprehension of the required task. This generally develops after several years. The person is 
impaired in their ability to pantomime the use of objects (e.g. combing hair) or to execute known 
motor acts (e.g. waving goodbye). Apraxia may contribute to deficits in cooking, dressing, and 
drawing. Motor skill disturbances may be tested by asking the individual to execute motor functions 
(e.g., to show how to brush teeth, to copy intersecting pentagons, to assemble blocks, or to arrange 
sticks in specific designs) [3]. 
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Agnosia is failure to recognize or identify objects despite intact sensory function. The person may 
have normal visual acuity but lose the ability to recognize objects such as chairs or pencils. 
Eventually they may be unable to recognize family members or even their own reflection in the mirror. 
Similarly, they may have normal tactile sensation, but be unable to identify objects placed in their 
hands by touch alone (e.g., a coin or keys) [3]. 
 
Disturbances in executive functioning involve reduced ability to think abstractly and to plan, initiate, 
sequence, monitor, and stop complex behaviour. Impairment in abstract thinking may be manifested 
by the individual having difficulty coping with novel tasks and avoiding situations that require the 
processing of new and complex information. The ability to abstract can be formally assessed by 
asking the person to find similarities or differences between related words. Executive dysfunction is 
also evident in a reduced ability to shift mental sets, to generate novel verbal or nonverbal information, 
and to execute serial motor activities. Tests for executive function include asking the individual to 
count to 10, recite the alphabet, subtract serial 7s, state as many animals as possible in 1 minute, or 
draw a continuous line consisting of alternating m's and n's [3]. 
 
Besides the symptoms required for a diagnosis (see above), the DSM IV-TR lists and comments on a 
number of features and disorders associated with dementia. These include: 
Spatial disorientation: The individual may become spatially disoriented and have difficulty with 
spatial tasks. Visuospatial functioning can be assessed by asking the individual to copy drawings, 
such as a circle, overlapping pentagons, and a cube. 
Poor judgment and poor insight: Individuals may exhibit little or no awareness of memory loss or 
other cognitive abnormalities. They may make unrealistic assessments of their abilities and make 
plans that are not congruent with their deficits and prognosis (e.g. planning to start a new business). 
They may underestimate the risks involved in activities (e.g., driving). 
Violence: Occasionally, they may harm others by becoming violent. 
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Suicidal behaviour: This may occur, particularly in early stages when the individual is more capable 
of carrying out a plan of action. 
Motor disturbances of gait: This can lead to falls. 
Disinhibited behaviour: This includes making inappropriate jokes, neglecting personal hygiene, 
exhibiting undue familiarity with strangers, or disregarding conventional rules of social conduct. 
Slurred speech: May occur but is mainly associated with subcortical pathology such as Parkinson's 
disease, Huntington's disease, and some cases of Vascular Dementia. 
Anxiety, mood, and sleep disturbances: The multiple cognitive impairments of dementia are 
associated with these disorders. 
Delusions: These are common, especially those involving themes of persecution (e.g. that misplaced 
possessions have been stolen). 
Hallucinations: These can occur in all sensory modalities, but visual hallucinations are most 
common. 
Delirium: This is distinct from dementia but is frequently superimposed on dementia because the 
underlying brain disease may increase susceptibility to confusional states that may be produced by 
medications or other concurrent general medical conditions [3]. 
 
The progressive symptomatology of AD 
The above two diagnostic approaches focus on key features of AD that enable the clinician to reach a 
differential diagnosis rather than provide a description of the range of symptoms that occur in AD as 
the disease progresses. The NINCDS-ADRDA Alzheimer’s Criteria note that as the disease 
progresses patients may become apathetic or show irritability, agitation, paranoid ideas, sleep 
disorders or incontinence. In the very advanced stages they may become mute and lose all ability to 
communicate [296].  
 
In the Merk Manual, AD is divided into early, intermediate and severe stages. Besides memory, 
learning and language disorders, in the early stages there are personality changes, mood swings, 
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irritability, hostility, and agitation. In the intermediate stage the person requires assistance with 
bathing, eating, dressing, or toileting and there can be more severe behavioural disorganization such 
as wandering, agitation, hostility, uncooperativeness, or physical aggressiveness. The person can lose 
all sense of time and place and often get lost. In the severe stage the person is unable to walk or to 
perform any activity of daily living, is usually totally incontinent, may be unable to swallow and eat 
and is at risk of malnutrition, pneumonia (especially from aspiration), and pressure sores. Recent and 
remote memory is completely lost and the person eventually becomes mute [4]. 
 
Neuropsychiatric Inventory (NPI) 
The Neuropsychiatric Inventory (NPI) was developed by Cummings et al (1994) [298] to assess a 
wide range of behavioural disorders encountered in patients suffering from a variety of dementias. It 
is a validated, standardised questionnaire designed to be administered to care givers of dementia 
patients and includes symptoms and behaviours that could be observed and remarked upon by 
non-specialists. Unlike the DSM IV-TR, it does not aim to result in a diagnosis but rather provides a 
framework for assessing the range and severity of psychopathology in the patient.  
 
The NPI has been validated in a number of languages including Chinese and has been used in the 
assessment of dementia and MCI patients in a number of countries [299-305]. It comprises 12 items 
each referring to a group of symptoms and/or behaviours and is intended to be administered by a 
clinician to a caregiver rather than to the patient. For each symptom group, a range of response 
options are available. In Cummings et al (2002)[306, 307] there are the options of yes or no for 
whether the symptom had been present in the past month, followed by a scale from 1 to 3 of symptom 
severity, followed by a scale from 0-5 of how much distress the caregiver experiences because of the 
symptom . The items and questions are summarised in Table 4.2 below. 
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Table 4.2: The Neuropsychiatric Inventory (NPI) Questionnaire 
NPI category Descriptors from NPI questionnaire 
1. Delusions Does the patient believe that others are stealing from him or her, or planning 
to harm him or her in some way? 
2. Hallucinations Does the patient act as if he or she hears voices? Does he or she talk to 
people who are not there? 
3. Agitation or 
aggression 
Is the patient stubborn and resistive to help from others? 
4. Depression or 
dysphoria 
Does the patient act as if he or she is sad or in low spirits? Does he or she 
cry? 
5. Anxiety Does the patient become upset when separated from you? Does he or she 
have any other signs of nervousness, such as shortness of breath, sighing, 
being unable to relax, or feelings excessively tense? 
6. Elation or euphoria Does the patient seem to feel too good or act excessively happy? 
7. Apathy or 
indifference 
Does the patient seem less interested in his or her usual activities and the 
activities and plans of others? 
8. Disinhibition Does the patient seem to act impulsively? For example, does the patient talk 
to strangers as if he or she knows them, or does the patient say things that 
may hurt people’s feelings? 
9. Irritability or 
lability 
Is the patient impatient or cranky? Does he or she have difficulty coping 
with delays or waiting for planned activities? 
10. Motor disturbance Does the patient engage in repetitive activities, such as pacing around the 
house, handling buttons, wrapping string, or doing other things repeatedly? 
11. Nighttime 
behaviours 
Does the patient awaken you during the night, rise too early in the morning, 
or take excessive naps during the day? 
12. Appetite and 
eating 
Has the patient lost or gained weight, or had a change in the food he or she 
likes? 
Adapted from: Cummings, J.L. et al (2002) [307] 
 
Whereas the DSM IV-TR criteria provide a means of assessing the likelihood of AD based on a few 
criteria, the NPI provides a means of categorising a wide range of symptoms that have been noted by 
clinicians and caregivers in dementia patients. There are considerable similarities between the 
symptom categories of the NPI and the additional symptoms described by the NINCDS-ADRDA and 
DSM IV-TR. However, neither of these diagnostic systems provides a clear categorisation of these 
additional symptoms that is comparable with the NPI.  
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A number of studies have investigated the prevalence of the NPI symptom categories. Mega et al 
(1996) found that these non-cognitive behavioral symptoms were present in 88% of a population of 
AD patients and that Apathy (72%) was the most frequent followed by Agitation (60%) and Anxiety 
(48%) [304]. In a comparison between AD patients in Los Angeles, Taiwan and Hong Kong, Chow et 
al 2002 found that Anxiety (58%) was reported more frequently and Apathy (35%) less frequently in 
the Chinese samples compared with the Los Angeles sample [301]. However a comparative study of 
nursing home residents with dementia in Sydney and Shanghai, found only minor differences between 
the two populations, with Apathy and Agitation being the most prevalent and Elation the least [300]. 
While apathy may be a symptom for which medication does not appear to be needed, compared with 
anxiety or aggression, a French study Robert et al (2008) found that in MCI patients it was associated 
with a higher rate of progression to AD [308]. 
 
 
PART 2 
THE DEVELOPMENT OF RATING SYSTEMS FOR ENTRIES FROM 
THE CLASSICAL LITERATURE 
 
Applying modern diagnostic criteria to references in the classical literature 
The retrospective analysis of historical reports presents numerous difficulties. While a condition may 
be labelled as chi dai or jian wang it cannot simply be inferred that this refers to a clinical entity 
analogous to ‘dementia’ or ‘memory loss’ in the modern sense. The extent to which it was possible to 
be confident that an instance of chi dai or jian wang was referring to a condition that would be 
considered AD was completely dependent upon the information provided in the text and there was no 
plausible means of obtaining additional information. Therefore, the approach taken was a series of 
inclusion and exclusion criteria to enable an assessment of the likelihood of the classical passage 
being an instance of AD or an associated disorder.  
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AD is a complex disorder in which a wide range of psychiatric and physical symptoms can occur. Of 
these, the established diagnostic criteria focus on those which most reliably differential AD from 
other similar disorders. For modern clinicians, such an approach has clear advantages, but what may 
be notable or obvious to a contemporary psychiatrist trained in the DSM IV-TR, may not be noticed 
or remarked upon by an untrained person writing a description of the symptoms of the same patient. 
While some criteria such as memory loss and language disturbance are exceedingly salient, others 
such as ‘disturbances in executive functioning’ are abstract concepts that the the untrained observer 
may notice but find difficult to write a description of.  
 
Besides the self evident facts that neither psychological nor histological tests were available in 
pre-modern China, the retrospective diagnosis of references to AD in the classical Chinese literature 
faces a number of issues. 
 
AD is a modern diagnostic entity whose incidence in modern populations is increasing but it is not 
known what the incidence of this disease was in pre-modern China, or even whether the disease was 
present at all, as no references could be located. However, as the review in chapter 3 has shown, there 
are disease names in the classical medical literature that refer to disorders of memory and/or cognition 
which were used by Chinese doctors to categorise patients. While it is likely that actual instances of 
AD would have been categorised under these names it is also likely that a range on non-AD disorders 
would have been similarly categorised.  
 
Assuming that AD did exist in pre-modern China, since it tends to be a disease of old age there is the 
issue of how often this disease presented as a medical disorder for treatment, and how many 
references remain in the historical record. As remarked upon earlier, longevity has long been pursued 
in Chinese culture but demographic estimates of the age makeup of historical populations proved 
difficult to obtain. In an analysis of the ages of 241 Chinese emperors from 221 BC to 1911, Zhao, et 
al (2006) found their ages at death ranged from two to 89 years with a mean of 41.3 years, however, 
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this was considerably younger than samples of buddhist monks (mean 66.9 years) and doctors (mean 
75.1 years) [309]. On the basis of the ages of the monks and doctors it appears that amongst those in 
the educated population who did not lead an extravagent or risky lifestyle there was a considerable 
proportion who made it into their 60s and 70s and may have developed AD.  
 
It cannot be expected that pre-modern descriptions of AD disease would conceptualise this disease in 
modern terms or intentionally include descriptions of the symptoms and signs sufficient to fit the 
modern diagnostic criteria for AD and enable a retrospective diagnosis of probable or possible AD. 
This is particularly the case for symptoms such as apraxia and agnosia which are difficult to describe. 
Besides this, the taxonomies of diseases vary considerably between western and Chinese medicine 
and also between the modern and classical versions of these two systems. Although diagnostic 
categories were codified early in the history of medicine in China (see chapter 3), these varied over 
time, so what was included under one name in one era may have been included under another name in 
another era. However, historians have been able to at least tentatively identify some diseases of the 
past [310-312]. It is hoped that some descriptions from the classical literature with be sufficiently 
detailed to allow the idenfication of instances of possible AD. 
 
The symptoms of diseases can be difficult to translate from one language to another. Some symptoms 
that appear in Chinese texts do not have direct English equivalents. Conversely, symptoms that are 
described in the English literature may not appear in the Chinese clinical literature. In the case of 
psychological symptoms and signs, there are likely to be even greater differences in the way different 
cultures judge, interpret and report on these, and this poses a number of issues when attempting to 
interpret historical reports in order to determine the modern diagnostic category. As is the case with 
disease categories, the scope of inclusion can be difficult to determine and it is also likely to have 
varied over time. In practical terms, it was not possible to determine the scope of inclusion for all 
terms over all periods so the approach taken was to interpret a term broadly and err on the side of 
inclusion unless there was contrary evidence. 
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Despite the above difficulties, it was considered feasible to adapt modern diagnostic criteria and apply 
statistical procedures that allow the inclusion and exclusion of cases in order to increase the likelihood 
that the data included was drawn from cases that could possibly have been instances of AD and 
related disorders. To do this the following three approaches were taken: 
• A series of criteria were developed for the general categorisation of an entry in the literature 
• Systems were developed for categorising and rating an entry according to the DSM IV-TR criteria 
and the NPI and 
• Scoring procedures were developed to provide numerical data suitable for statistical analysis 
 
General categorisation criteria 
Even though a condition may have been designated as chi dai or jian wang in an entry in the literature, 
further details may throw doubt on whether the condition could have been actually referring to age 
related dementia and whether the instance should be included in a particular analysis of the data. 
Eight criteria were used as listed in table 4.3. A number of these were based on the diagnostic systems 
for AD discussed above (i.e. 1, 2, 3, 4, 6), whereas others were developed according to the 
requirements of this project. For example, when the entry was from a book that was dated as post 
1911, it was excluded under code 5. This is because the focus of this project is on classical literature. 
 
Table 4.3: General categorisation criteria 
Criterion Code 
1. Child, young person 1 
2. Acute condition 2 
3. Mental disorder unlike dementia 3 
4. Physical disease unlike dementia (eg seizures, fever, head injury, loss of eyesight) 4 
5. Modern literature (post 1911) 5 
6. Mention of cerebro-vascular accident 6 
7. To improve memory only, not for disease, good for study, or due to over reading/study 7 
8. Disorder of women only 8 
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In cases where the entry clearly indicated the formula was for a child or a young person, then the 
condition was not an age-related dementia and needed to be excluded. Such cases may have referred 
to a congenital condition, a psychosis, a febrile disease or the consequences of an accident or other 
unidentifiable cause. Since dementia has an insidious onset and is a long term condition, acute 
conditions or other conditions with a rapid onset were unlikely candidates. These were excluded but 
cases of an acute complication of a chronic condition were included. When there was sufficient 
information in the description to indicate that the mental disorder described was not consistent with 
dementia, and appeared more like a manic-depressive psychosis, congenital disorder, delirium 
associated with fever, etc, then these were categorised as criterion 3. When the disorder was directly 
associated with a physical disorder, such as an injury, fever, ongoing epilepsy or other disorder that 
appeared primarily physical, then this was classed as criterion 4. When there was mention of 
symptoms or a condition (such as zhong feng 中風) which were consistent with a cerebrovascular 
accident (CVA), the case may have been VaD and a code of 6 was allocated. If the condition was 
specific to women, such as a post-partum disorder then it was excluded under code 8, but when 
gynaecological symptoms were simply part of the overall symptomology of the condition, they were 
not excluded. In a number of entries the formula was intended for improving memory but there was 
no mention of a disorder, nor was it explicitly stated that the formula was for assisting study or 
treating the consequences of excessive study. Such cases were identified under criterion 7.  
 
The above criteria were not intended to represent a scale and the numerical values were simply codes 
to be used by the raters when reading the full entry. The scoring of these categorisation criteria was 
done concurrently with and according to similar procedures to the rating described below.  
 
Approach to interpreting historical reports in terms of similarity to AD 
The main modern approaches to making a clinical diagnosis of probable dementia, and Alzheimer’s 
disease (AD) in particular, are to apply the criteria specified by either the NINCDS-ADRDA or the 
DSM IV-TR as outlined above. However, a considerable portion of these modern diagnostic criteria 
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for AD relies upon testing, so these criteria needed to be excluded and only those criteria that could be 
observed by a Chinese doctor unaware of the modern approach could be taken into consideration. 
Taking this viewpoint, the DSM IV-TR was preferable to the NINCDS-ADRDA criteria since it relies 
less upon the results of tests. 
 
The entries derived from the ZYFJDCD were examined to determine whether it was feasible to apply 
the DSM IV-TR criteria to specific formula entries under the categories of chi dai and jian wang. It 
was found that while memory loss/impairment was frequently mentioned or described no description 
of a progressive decline could be located. Mentions of the age of a patient were not found but there 
were occasional indications that the person was in middle or old age. The four symptom groups – 
aphasia, apraxia, agnosia, and disturbance in executive functioning proved problematic. Of these 
groups, language disorders of a type that could be considered to fall within the meaning of the modern 
term aphasia appeared occasionally in the literature. In the case of the other symptom groups, these 
are concepts that require a modern understanding of the characteristics of AD so references to these 
were not expected. Nevertheless, a few examples included terms or descriptions of symptoms that 
appeared to indicate conditions for which the modern terms apraxia, agnosia or disturbance in 
executive functioning could have been applied. It was concluded that the DSM IV-TR could be 
adapted to rate and sort the formula entries in the database, and the following modified version was 
used as the basis for the development of further systems of scoring. 
 
Modified version of the DSM IV-TR in English and Chinese 
In this modified version, the DSM IV-TR criteria are divided into two groups. 
Group 1. Primary criteria 
1.1. Memory impairment (impaired ability to learn new information or to recall previously learned 
information) 記憶的損傷 (無法學習新事物或無法回憶以前學習的事物); plus 
1.2. Middle to old age 壯年至老年; plus one (or more) of the following cognitive disturbances 至少
有下列一個的認知障礙: 
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Group 2: Symptom groups 2.1-2.4 
2.1. Aphasia (language disturbance) 失語症 (言語障礙), or 
2.2. Apraxia (impaired ability to carry out motor activities despite intact motor function) 失用症 (雖
無運動中心損傷，但有運動能力有障礙), or 
2.3. Agnosia (failure to recognise or identify objects despite intact sensory function) 認識不能 (感
覺中心雖無損傷，但認識或分辨事物有障礙), or 
2.4. Disturbance in executive functioning (i.e. planning, organizing, sequencing, abstracting) 執行功
能障礙 (即計劃、組織、排序、摘錄). 
Adapted from [152, 313] 
 
The above system is a simplified version of the DSM IV-TR to which the criterion of age was added. 
In combination with the general categorisation criteria discussed above, the main inclusion and 
exclusion criteria of the DSM IV-TR are encompassed.  
 
Testing the modified DSM rating system 
The above system was applied to rating the ZYFJDCD entries to determine its utility and whether it 
could be used by Chinese native speakers to categorise the data set. To facilitate accuracy and 
consistency the raters were provided with a Chinese version of the DSM IV-TR criteria and instructed 
on the aims of the rating processes (see Appendix 2). Through a process of discussion further 
refinements were made to the rating system to allow for more accurate categorisation of the entries as 
well as enable statistical analysis. These were mostly in terms of ranking the criteria of memory and 
age. These are discussed below.  
 
Developing the DSM criteria into a scoring system 
Besides providing a means of identifying which instances from the classical literature more or less 
satisfied the DSM IV-TR criteria, the purpose of rating the entries was to provide a means for sorting 
large data sets using statistical procedures. For this, a check-the-boxes system was not considered 
sufficient and a more fine-grained process needed to be developed that reflected the features of the 
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classical literature, allowed an assessment according to the DSM IV-TR criteria and provided 
numerical scores suitable for data entry into SPSS. 
 
The first criterion was whether the disease name was consistent. The terms used in Chinese have been 
discussed above and the search process itself only included instances which could have been dementia 
based on the Chinese terms used. In a considerable number of instances, the disease name was the 
only information provided so there was no other means of determining whether the entry should be 
included or not. In such cases the approach taken was inclusion, since there was no reason to exclude 
the entry. It was found to be impractical to code every single search term separately, particularly when 
the same item may have been found by a number of different search terms, so terms were coded as 
either the chi dai group or the jian wang group according to the primary condition. 
 
Progressive decline in memory function is the key symptom in AD. It is also a symptom that is likely 
to be remarked upon and recorded in the literature. Not all forms of memory loss are, however, 
indicative of AD or MCI. For example, sudden memory loss after head trauma is quite 
uncharacteristic of AD even when it occurs in an elderly person, so such instances needed to be 
identified and excluded. Conversely, impairments in episodic memory are very characteristic of AD 
and such instances require specific attention.  
 
In the case of formulas that aim to strengthen memory the situation is less clear cut, since these may 
be aimed at those suffering from pathological memory loss in old age but may also be aimed at those 
seeking better memory, such as students studying for exams. In order to distinguish the types of 
references to memory the scoring system in Table 4.4 was developed.  
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Table 4.4: Scoring for memory 
Category Score 
No mention of memory 0 
Function of improve memory (qiang ji etc) without explicit indication that there is a memory 
disorder 
1 
Memory impairment (jian wang, duo wang, shan wang, xi wang etc) as a disease or symptom 2 
Description of memory disorder consistent with dementia 3 
 
Since AD is a disorder associated with ageing, instances of chi dai or jian wang in young people are 
most likely to refer to another condition and need to be excluded. However, the age of the patient is 
not commonly mentioned in the classical literature. In some cases it is specifically mentioned that the 
person is elderly or young. In others, some inferences as to age can be drawn. For example, when the 
book is on longevity, it can be inferred that the contents are at least intended for a mature adult and 
the formulas are probably intended for an older person. In cases where the formula name indicates it 
is intended to promote longevity, or its functions and indications indicate it is to treat disorders of age 
or to regain youthfulness, then the level of confidence with which we can infer it is a geriatric formula 
is greater, but still less than in cases where the formula is specifically indicated for old people. To 
reflect this variation in confidence the following scoring system for the age component of the DSM 
IV-TR criteria was developed (see table 4.5) 
 
Table 4.5: Scoring for Age 
Category Score 
No reference to old age or longevity 0 
Longevity referred to book name 1 
Promote longevity as a formula action/function, or in the formula name 2 
Indicated for older people 3 
 
In the case of the four group 2 symptoms – aphasia, apraxia, agnosia, and disturbance in executive 
functioning – a symptom from only one of these groups is needed to satisfy the criteria for probable 
AD. The approach taken to scoring these symptoms was to identify any instances of symptoms that 
could plausibly fit each category and code these as 1 to 4 (see Table 4.6).  
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Table 4.6: Group 2 symptoms 
Category Code 
Aphasia 1 
Apraxia 2 
Agnosia 3 
Disturbance in executive functioning  4 
 
In cases where more than one symptom within a category appeared, no additional score was added. 
Also, a graduated score of confidence of fit was not used since it was found to be impractical to judge 
whether a particular symptom or a description of a condition fitted a category more or less well than 
another. 
 
Scoring procedure for DSM criteria 
An instruction sheet for raters was developed that included the modified DSM criteria above in 
English and Chinese, the scoring tables and instructions for use (see Appendix 2). Two Chinese native 
speakers who were familiar with the terminology used in Chinese medicine and fluent in English were 
instructed in the NPI criteria how to use the rating system. They worked separately to assign scores to 
each of the classical book entries in an Excel spreadsheet. Any disagreements were resolved by 
discussion, with a third person being brought in when agreement could not be reached. This was 
similar to the method used in determining a Jadad score and was familiar to the research students 
 
In order to improve consistency in scoring between raters and across data sets, a cumulative tally was 
kept of each of the terms in the classical source that was assigned a particular score. This tally was 
used by raters to inform their decision making.  
 
Developing the NPI criteria into a scoring system 
A validated Chinese version of the NPI has been developed [302], and the full form was obtained 
upon request from Dr Vivian Leung of the Chinese University of Hong Kong. In the Chinese form 
there are Chinese equivalents for each of the 12 symptom categories, an explanation in Chinese of the 
meaning and scope of the category, as well as translations for the descriptive sentences used guide 
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users (see table 4.7 for the main terms). The terms used were in modern Chinese so there were a 
number of issues to be considered when applying the Chinese NPI to classical texts.  
 
One issue was the difficulty in distinguishing between categories. Following discussion with native 
Chinese speakers it was apparent that finding suitable ways of translating certain categories was not 
straightforward and different people interpreted them differently. In the case of the DSM IV-TR 
criteria this issue was present to some degree but memory impairment is a straight forward concept 
and the group two symptom categories are so broad and abstract and their descriptors so unlike 
commonplace terms that once defined there were few issues with individual interpretation of their 
meaning. There were, of course, issues with determining whether a passage from a classical text 
should be included or not but this was a separate issue to that of sharing a common interpretation of 
the criteria themselves. 
 
In order to determine which categories were the most difficult to define a short workshop was 
conducted with research students from the CM department at RMIT University (4 Chinese native 
speakers and 3 English native speakers). Prior to the workshop the participants received two papers in 
English for pre-reading: 
1. Fuh J-L et al (2005) Neuropsychiatric profiles in patients with Alzheimer’s disease and vascular 
dementia [314]. 
2. Cummings, J.L. et al (2002) Guidelines for managing Alzheimer’s disease: Part 1. Assessment 
[307]. 
At the beginning of the workshop, the structure, meaning and purposes of the NPI were explained and 
there was a discussion on the issues associated with the translation of psychiatric symptoms, and how 
to describe mental states. Following this, the students were given a sheet listing the 12 NPI symptom 
categories and asked to write down as many words as they could think of that could be used by 
patients, clinicians or caregivers to describe the category in Chinese and/or English. The terms were 
collated to investigate the level of agreement. 
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Table 4.7: The 12 NPI criteria in Chinese and English 
Criterion Pin yin Chinese characters English 
1 Wang xiang 
妄想 
Delusions 
2 Huan jue 
幻覺 
Hallucinations 
3 Fan zao/Gong gi xing wei 
煩燥/攻擊行為 
Agitation or aggression 
4 Yi yu/Qing xu di luo 
抑鬱/情緒低落 
Depression or dysphoria 
5 Jiao lu 
焦慮 
Anxiety 
6 Qing xu gao zhang/Xin kuai 
情緒高漲/欣快 
Euphoria 
7 Qing xu dan mo/Leng mo 
情緒淡漠/冷漠 
Apathy or indifference 
8 Yi zhi jie chu 
抑制解除 
Disinhibition 
9 Yi nu/Qing xu bo dong 
易怒/情緒波動 
Irritability or lability 
10 Yi chang de dong zuo xing wei 
異常的動作行為 
Motor disturbance 
11 Shui mian 
睡眠 
Night time behaviour 
12 Shi yu huo Yin shi shi tiao 
食慾或飲食失調 
Appetite and eating 
 
The results of this workshop tended to confirm earlier views. Categories 1 and 2 were not clearly 
distinguished, with the terms wang xiang 妄想 and huan jue 幻覺 being used for both. Categories 3 
and 9 were also somewhat unclear with yi nu 易怒 ‘easily angered’ being applied to both. The 
English speakers also considered these categories difficult to distinguish. Consequently, additional 
efforts were made to explain and distinguish these categories when instructing raters. In the case of 3 
and 9 the distinction was made more explicit with ‘easily angered’ being placed in criterion 2 and 
‘emotional lability’ being the focus for category 9. 
 
Scoring procedure for NPI 
A rating sheet was developed based on the Chinese version of the NPI and the associated descriptors 
(see Appendix 2). Two Chinese native speakers who were familiar with the terminology used in 
Chinese medicine were instructed in the NPI criteria how to use the rating system. They worked 
separately to assign scores to each of the classical book entries in a excel spreadsheet. Any 
disagreements were resolved by discussion, with a third person being brought in when agreement 
could not be reached. This was similar to the method used in determining a Jadad score and was 
familiar to research students. 
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The procedure was to assign an NPI code (1-12 as per table 4.7) to the entry whenever there was a 
symptom or a description in the entry that fitted the NPI criterion. The raters could take into account 
not only a particular Chinese term but also a sentence and the overall context in determining whether 
a particular NPI category was applicable. However, a particular term could only be assigned to one 
category. When a number of terms were judged as belonging to the same category only one score was 
given since there seemed to be no logical reason for assigning the same code more than once in a 
particular entry. In order to achieve as much consistency in the scoring as possible a series of 
instructions were provided in addition to a summary of the Chinese version of the NPI (see Appendix 
2). As was the case for the DSM criteria a tally of the terms found in the classical literature and the 
codes allocated was kept by the raters to assist with consistency in decision making. 
 
Data entry into SPSS 
For each of the scoring systems described above, the scoring was inputted into the Excel databases 
which held the extracts from the classical texts. The next step was to code this information into SPSS. 
For the general categorisation criteria and the NPI, there was a separate variable for each category and 
the SPSS scores were 1 for the presence of a symptom and 0 for its absence. For the DSM criteria 
separate variables were used for memory and ageing with scores of 0-3 being entered but the group 
two symptoms were scored under four variables using 1 or 0 to indicate presence or absence of a 
symptom.  
 
Approaches to analysis 
The general categorisation codes were to be used to exclude entries that were unlikely to represent 
possible instances of dementia, such as acute conditions, and to allow sub-group analyses of the 
possible CVA group and the memory aid formulas.  
 
By using the scoring system adapted from the DSM IV-TR it was expected that the data set of herb 
entries could be categorised to include only those entries which satisfied various combinations of 
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these criteria however, it was unknown whether any items would satisfy these criteria at the highest 
level of restriction, i.e. memory = 3, ageing = 3, and at least one group 4 symptom, because such 
information may not be present in the entries derived from the searches of the classical literature, or it 
may be present in too low a frequency to be useful for the project. It was expected that the memory 
scores would be the most frequent, so the gradation in the scores was expected to provide a means of 
distinguishing between groups of herbs intended to improve memory and those for treating memory 
disorders similar to the disorders of episodic memory characteristic of AD.  
 
Since Chinese herbal formulas typically aim to address the spectrum of symptoms in a patient, even 
though dementia or memory loss may be found as symptoms in the searches, these conditions may not 
have been the sole focus of the formula. Preliminary searches found that some classical entries 
contained considerable detail regarding symptoms, so by capturing this in a systematic fashion using 
the NPI criteria it was expected that this would facilitate the sorting of the data set and compensate for 
the excessive restriction that the modified DSM IV-TR scoring system was suspected to produce. 
 
By categorising the range of symptoms for the formula entries in the database according to the NPI, it 
was expected that differences in the herbs used for different NPI symptom groups would emerge. For 
example, it was expected that the herbs used when there was anxiety would differ from those used 
when there was apathy. Since apathy appears to be a stronger predictor of progression to AD in MCI 
patients, it may also be the case that patients with jian wang (memory loss) and apathy would be a 
better match to probable AD than those that satisfied the DSM IV-TR criteria according to the scoring 
system adopted. Also, using two different approaches to scoring may provide a means of assessing the 
validity of the results. The main planned analysis for the NPI scores was to generate frequency lists of 
herbs that satisfied each of the criteria and compare these with the lists generated using the DSM 
IV-TR criteria.  
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CHAPTER 5 
CHARACTERISTICS AND GENERAL RESULTS FOR THE THREE 
CLASSICAL SEARCHS AND  
ANALYSIS OF THE REPRESENTATIVENESS OF THE SAMPLES 
 
Part one of this chapter discusses the characteristics of the three data sets and reports the consolidated 
results for each of the three searches, including the frequency results for the search terms. The results 
for the individual herbs and the ratings are presented in chapters 6 and 7. The second part of theis 
chapter provides the results of the comparison between collections of classical books to determine the 
representativeness of the sources selected for searching.  
PART 1 
CHARACTERISTICS OF THE THREE DATA SETS AND 
CONSOLIDATED SEARCH RESULTS 
 
Characteristics of the ZYFJDCD and summary search results 
The Zhong Yi Fang Ji Da Ci Dian (ZYFJDCD) contains about 97,000 individual entries, each of 
which refers to at least one herbal formula. It is indexed according to disease and symptom names. 
Under the terms chi dai 痴呆 and jian wang 健忘 are listed 16 and 149 entries respectively. All the 
entries for these two terms were copied and the information for each formula was extracted into an 
Excel spreadsheet. No duplicate entries were found but in some cases more than one formula was 
listed under one entry. In total, the 165 entries copied resulted in 174 formula entries in the Excel 
spreadsheet (see Table 5.1). When these formula entries were entered into SPSS, they resulted in 
1,676 herb entries. The average number of herbs per formula was 10.4. 
Table 5.1: Results for each search term for the ZYFJDCD 
Search term:  
pin yin  
Chinese characters No. entries copied  No. formula entries extracted 
to Excel 
chi dai 
痴呆 
16 16 
jian wang 
健忘 
149 158 
Totals  165 174 
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The appendix of book titles in volume 11 of ZYFJDCD lists 680 different titles with authors and dates; 
however this list was found to be incomplete since seven titles located in the searches were not listed 
in this appendix. In total, 75 different source books provided the 174 formula entries (FE). Of these, 
12 books were post-1911, 3 listed under chi dai and 9 under jian wang. These were subsequently 
removed from the analyses, so the remaining 162 formulas derived from 63 classical books (i.e. 
pre-1911) formed the classical data set. The most frequently sourced books are listed in Table 5.2. 
 
Table 5.2: Most frequently sourced books in the ZYFJDCD sample 
Book title (Pin yin, Chinese characters) Year* No. FE 
Bian Zheng Lu 辨證錄 1687 17 
Sheng Ji Zong Lu 聖濟總錄 1111 15 
Bei Ji Qian Jin Yao Fang 備急千金要方 c 650 10 
Tai Ping Sheng Hui Fang 太平聖惠方 992 10 
Gu Jin Yi Tong Da Quan 古今醫統大全 1556 7 
Yang Shi Jia Cang Fang 楊氏家藏方 1178 6 
Pu Ji Fang 普濟方 1390 5 
Ji Feng Pu Ji Fang 雞峰普濟方 1133 5 
Za Bing Yuan Liu Xi Zhu 雜病源流犀燭 1773 4 
Zheng Zhi Zhun Sheng 證治準繩 1602 3 
Shi Shi Mi Lu 石室秘錄  1687 3 
Fu Shou Jing Fang 扶壽精方 1534 3 
Gu Jin Yi Jian 古今醫鑒 1577 3 
Gu Jin Yu Lan 古今錄驗 c 1087 3 
* According to the appendix in vol. 11;  FE formula entries 
 
The earliest book was the Bei Ji Qian Jin Yao Fang (c. 650 AD) by Sun Si-Miao and the most recent 
was the Qian Jia Miao Fang 千家妙方 published in 1982. The majority of entries were derived from 
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books from the Tang dynasty to the Qing dynasty but there were few items after the 18th century. As 
would be expected large works such as Tai Ping Sheng Hui Fang and Pu Ji Fang contributed 
considerable numbers of formulas, but it was surprising that the largest number of formulas came 
from the much smaller Bian Zheng Lu.  
 
All of the formulas in the 174 entries had names. Yuan zhi wan 遠志丸 had the highest frequency at 
5 entries followed by Ding zhi wan 定志丸 and Tian wang bu xin dan 天王補心丹, both with 4 
entries. All formula names with a frequency (F) of 2 or more are listed in Table 5.3. A number of 
formulas had similar names. Some varied according to whether the formula was intended as a 
decoction or a pill such as Yang xin tang ‘Nourish heart decoction’ and Yang xin wan ‘Nourish heart 
pill’. Others indicated modification of a base formula, such as Jia wei ding zhi wan ‘Modified ding 
zhi wan’. One formula, Du shu wan, indicated by its name that it was intended to assist with study. 
 
Even though two formulas had the same name this did not mean that the ingredients were identical. 
For example, all five Yuan zhi wan contained the herb yuan zhi and there was considerable overlap in 
the other ingredients but none of the formulas were identical in composition. Therefore the formula 
name was not a reliable indication of formula ingredients.  
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Table 5.3: Most frequent formulas in the ZYFJDCD  
Formula name (Pin yin, characters) Frequency (F) in ZYFJDCD Inclusion in CCMs (F) 
Yuan zhi wan 遠志丸 5 Yes (1) 
Ding zhi wan 定志丸 4 Yes (1) 
Tian wang bu xin dan 天王補心丹 4 Yes (2) 
Tian wang bu xin wan 天王補心丸 3 No 
Jia wei ding zhi wan 加味定志丸 3 Yes (3) & Ding zhi wan (1) 
Zhuang yuan wan 狀元丸 3 No 
Shu yu wan 薯蕷丸 3 No 
Fu shen wan 茯神丸 3 Yes (1) & Fu shen tang (1) 
An shen ding zhi wan 安神定志丸 2 No 
Da ding xin tang 大定心湯 2 Yes (1) 
Du shu wan 讀書丸 2 Yes (1) 
Gui pi tang 歸脾湯 2 Yes (13) 
Hu po duo mei wan 琥珀多寐丸 2 No 
Mai men dong yin 麥門冬飲 2 No 
Ren shen wan 人參丸 2 Yes (1) 
Yang xin tang 養心湯 2 No 
Yang xin wan 養心丸 2 No 
CCMs: Contemporary clinical manuals 
 
When compared to the list of 99 different formulas derived from the sample of contemporary clinical 
manuals (CCM) of Chinese medicine there was a degree of overlap, but mostly for the low frequency 
items in the CCM sample. Gui pi tang had high frequency of occurrence on both lists, being the 
second most common recommendation in the CCMs. Variants on Ding zhi wan were also frequent on 
both lists but the most frequent formula on the CCM list, Tong qiao huo xue tang did not appear in the 
ZYFJDCD at all, nor did Zuo gui wan which ranked third.  
 
Characteristics of the Zhong Hua Yi Dian (ZHYD) 
The Zhong Hua Yi Dian 4th edition is a CD-Rom with a search function divided into two parts. The 
main part is the Zhong Hua Yi Dian proper, which contains the full text of 1,000 books. It has a table 
of contents for these titles organised into sections and subsections. The main sections and the numbers 
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of titles in each are presented below. The second part comprises sections on famous medicines (ming 
yao 名藥), famous doctors (ming yi 名醫), famous books (ming zhu 名著), famous formulas (ming 
fang 名方), famous quotations (ming yan 名言) and terminology (ming ci 名詞), all of which are 
arranged in dictionary format. Unfortunately, the two parts are independent. The second part is not a 
dictionary of the books and formulas contained in the first part and therefore this part was seldom 
useful for cross referencing book names and authors.  
 
Genres of books in the ZHYD collection 
The contents of the Zhong Hua Yi Dian part of the CD is organised into 12 main sections according to 
genre, as listed below. 
1. Medical classics 醫經類 (49 titles): focuses on the Nei Jing and Nan Jing and commentaries on 
these 
2. Diagnostic methods 診法類 (43): mainly on pulse diagnosis with a few titles on tongue diagnosis 
3. Materia medica 本草類 (67 titles): see below for the sub-sections 
4. Formula books 方書類 (117 titles): arranged under dynasty and other subcategories 
5. Acupuncture, moxibustion and tui na 針灸推拿類 (50 titles): mostly on acupuncture 
6. Shang Han Jin Gui 傷寒金匱類 (71 titles): focuses on the two classics Shan Han Lun and Jin 
Gui Yao Lue and associated commentaries 
7. Warm disease 溫病類 (38 titles): includes the main works on Warm disease theory and 
therapeutics 
8. Comprehensive medical works 综合醫書類 (87 titles): contains a diverse selection of works 
9. Clinical and specialty works 臨証各科類 (277 titles): books on the treatment of diseases 
arranged under clinical specialty, such as internal medicine and pediatrics, but without a section for 
psychology 
10. Health preservation, diet and exercise 養生食療外治類 (40 titles): mostly on lifestyle and 
food with 5 titles in the exercise (dao yin qi gong) sub-category 
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11. Medical records and cases 醫論醫案類 (155 titles): contains a diversity of works by famous 
doctors 
12. Other其他類 (6 titles): includes medical history 醫史傳記 
Total: 1,000 titles 
 
Each section is also arranged into subsections but beyond this there is no system of indexing. The first 
page of each book contains its title and in most cases the author’s name and the dynasty but in a 
number of cases the last two items of information are missing or illegible. Some books contain 
prefaces which may include information pertinent to their identity or publication date but there is no 
consistent format for these and they are frequently absent. 
 
There is some duplication within the ZHYD but the total number of duplicates could not be 
determined since complete cross-referencing was not feasible. The following are illustrative examples. 
Separate entries can be found for the You Ke Zheng Zhi Zhun Sheng 幼科證治準繩 and the Zheng 
Zhi Zhun Sheng: You Ke 證治準繩: 幼科, both of which refer to the same book by Wang Ken-Tang 
王肯堂. Similarly, there are separate entries for the Shang Han Zheng Zhi Zhun Sheng 傷寒證治準
繩 and the Zheng Zhi Zhun Sheng: Shang Han 證治準繩:·傷寒. The other works in the Zheng Zhi 
Zhun Sheng corpus were consequently checked but no other duplications were evident.  
 
The Ben Cao Zheng 本草正 is usually incorporated into the Jing Yue Quan Shu 景岳全書 and it 
can be found in this location in the ZHYD. However, it is also listed as a separate work attributed, 
incorrectly, to Zhang Shan-Lei 張山雷 of the Min guo 民國 period (i.e. Chinese republic). The text 
was checked and it was found to be identical to the Ben Cao Zheng 本草正 section of the Jing Yue 
Quan Shu, so this work appears twice in the ZHYD. This would appear to be an error since Zhang 
Shan-Lei is the author of the similarly named Ben Cao Zheng Yi 本草正義 which is a work of the 
Min guo period and is also included in ZHYD as a separate entry. When the above duplications are 
taken into account, the total number of individual titles in the ZHYD falls to 997. 
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Another feature of the ZHYD is the splitting up of large books into their constituent titles. For 
example, the well known Qing dynasty work Yi Zong Jin Jian 醫宗金鑑 does not appear in the table 
of contents but each of its 15 constituent texts do. Similarly, the Shen Shi Juan Sheng Shu 沈氏尊生
書 comprises seven constituent works which are listed separately in the ZHYD. It would appear that 
this approach was to facilitate classifying works into the genres listed above but the lack of the 
principal title can be confusing. Also, this approach inflates the number of titles included. 
 
Summary search results for the whole ZHYD sample 
In the preliminary searches of the ZHYD, the terms chi 癡, dai 呆 and wang 忘 were used but 
singly they turned up too many hits, with 3,788 for wang alone, many of which proved to be 
irrelevant. It was impracticable to sort all these hits so more focussed terms were chosen for the final 
searches (see Table 5.4). Chi dai found 83 hits of which 34 referred to herbs or formulas. Jian wang 
produced by far the largest number of hits at 1,158 and also the largest number of useful formula 
entries (991).  
 
A number of the more unusual terms proposed in the specialist literature consulted (see chapter 3) did 
not prove to be productive. No hits were found for bai chi, dai zheng or dai sha and none of the 
instances of yu chi were in reference to this term as a disease or a symptom to be treated. Wen chi and 
wu chi were not evident as separate terms, only as the composite term wen wu chi 文武痴, and only 
in two entries. Dai chi appeared frequently in the acupuncture literature but not elsewhere. Of the jian 
wang synonyms, xi wang was the most frequent but shan wang was considerably more productive in 
locating relevant entries. The other terms were relatively low in frequency but each located relevant 
entries.  
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Table 5.4: Search results for the Zhong Hua Yi Dian (ZHYD) 
Search term: 
Pin yin 
characters No. 
hits 
No.FE 
extracted 
Comments 
Chi 
痴 
775 0 Not extracted, too many irrelevant hits 
Chi 
癡 
5 0 Included in 痴呆 etc 
Dai  
呆 
691 0 Not extracted, many irrelevant hits 
Chi dai 
痴呆 
83 34  
Dai chi  
呆痴 
57 1 All other hits were in acupuncture books 
Yu chi 
愚痴 
30 0 Term only occurred in general discussions 
Wen chi 
文痴 
Wu chi  
武痴 
2 2 In both cases the term was wen wu chi 文
武痴 
Bai chi  
白痴 
0 0 No hits 
Chi bing 
痴病 
5 2  
Dai bing 
呆病 
12 9  
Dai zheng  
呆証 
0 0 No hits 
Dai sha  
呆傻 
0 0 No hits 
Lao ren zhi bing 
老人之病 
6 5  
Lao ren jian wang 
老年健忘 
1 1  
Wang 
忘 
3788 0 Not extracted, too many irrelevant hits 
Jian wang 
健忘 
1158 991  
Shan wang 
善忘  
466 410  
Duo wang 
多忘 
290 273  
Hao wang 
好忘 
43 29  
Xi wang 
喜忘 
477 296  
Yi wang  
易忘 
13 9  
Yi wang 
遺忘 
45 11  
Qiang ji 
強記 
77 57  
Total extracted  2765 2130  
FE: Formula entry 
 
Following the removal of duplicates, 13,733 individual herb entries remained in the SPSS database. 
These represented 1,450 formula entries so the average number of herbs per formula was 10.5. It was 
not possible to determine which entry related to which search term due to the high level of duplication. 
In total, 239 different source books were included. Of these, 8 books were post 1911, and their 12 
formula entries were excluded from the analyses of classical works.  
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The earliest book was Shang Han Lun 傷寒論 (c. 206 AD) followed by the Mai Jing 脈經 (c. 280) 
and the most recent was the Lin Zhen Yi An 臨診醫案 which could not be reliably dated but was 
estimated to have been written no later than 1956. The top ten most frequently sourced books based 
on a combination of the total number of herb and formula entries are listed in Table 5.5. 
 
Table 5.5: Frequently sourced books in the Zhong Hua Yi Dian (ZHYD) 
Book title (Pin yin, characters) Year* No. HE No. FE 
Pu Ji Fang 普濟方 1406 3018 289 
Sheng Ji Zong Lu 聖濟總錄 1117 679 90 
Tai Ping Sheng Hui Fang 太平聖惠方 992 505 43 
Ji Yang Gang Mu 濟陽綱目 1626 411 38 
Zhen Zhi Zhun Sheng 證治準繩 1602 406 44 
Bei Ji Qian Jin Yao Fang 備急千金要方 652 286 25 
Gu Jin Yi Tong Da Quan 古今醫統大全 1556 267 30 
Wai Tai Mi Yao 外臺秘要 752 257 21 
Qi Xiao Liang Fang 奇效良方 1470 239 21 
Tai Ping Hui Min He Ji Ju Fang 太平惠民和劑局方 1107 217 18 
* According to the appendix in vol. 11; HE: Herb entry; FE: Formula entry 
 
As was the case in the ZYFJDCD, it was the large formula encyclopaedias that contributed large 
numbers of entries with the largest of them all, Pu Ji Fang, contributing 289 formula entries. Smaller 
books such as the Bian zheng lu 辨證錄, which was the most frequent in the ZYFJDCD, did not 
appear amongst the high frequency books but the Bian zheng lu did contribute 15 formulas to the data 
set.  
 
Around 60 formulas did not have specific names. Of those that were named, the highest frequency 
names are listed in Table 5.6. When high frequency formulas in the ZHYD data set were also 
included in the ZYFJDCD and in the CCM sample, these are marked in Table 5.6 together with the 
frequency of the formula in that data set. Gui pi tang was the most frequent formula in the ZHYD data 
set and was also a frequent occurrence in the CCM, but the second most frequent item Di dang tang, 
did not occur in the ZYFJDCD and appeared only once in the CCMs. This formula first appeared in 
the Shang han lun so it is the earliest of all the formulas but it was for jian wang as a symptom in 
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‘yang ming syndrome’ which refers to an acute febrile disorder. Its high frequency in the ZHYD 
reflected its citation over the centuries in this context. Since this formula was for an acute condition it 
was excluded in the subsequent analyses (see chapters 6 and 7). Tao ren cheng qi tang and Xi jiao di 
huang tang were similarly associated mainly with febrile diseases which accounts for their 
non-inclusion. In contrast, Tian wang bu xin dan and its variant Tian wang bu xin wan appeared in all 
three data sets.  
 
While there was a degree of overlap between the formulas used in the CCMs and those in the ZHYD, 
the most frequent formula in the CCMs, Tong qiao huo xue tang, did not appear in the ZHYD data set 
at all. As was the case with the ZYFJDCD sample, sharing a name did not necessarily indicate that the 
ingredients of the formulas were identical. Consequently, analysis at the level of formula name can be 
problematic so the focus of the results in subsequent chapters will be at the level of the individual 
herb. 
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Table 5.6: Most frequent formula names in the ZHYD 
Formula name (Pinyin, characters) F. in 
ZHYD 
Incl. in ZYFJDCD (F) Incl. in CCMs (F) 
Gui pi tang 歸脾湯 91 2 13 
Di dang tang 抵當湯 88 0 1 
Tao ren cheng qi tang 桃仁承氣湯 37 0 1 
Tian wang bu xin dan 天王補心丹 30 4 & 3 Tian wang bu xin wan 2 
Ding zhi wan 定志丸 26 4 1 & 1 Xiao ding zhi wan 
Xi jiao di huang tang 犀角地黃湯 24 0 0 
Er dan wan 二丹丸 22 1 1 
Yuan zhi wan 遠志丸 20 5 & 3 Yuan zhi san/tang 1 
Niu huang qing xin wan 牛黃清心丸 15 0 0 
Shou xing wan 壽星丸 14 1 0 
Fu shen wan 茯神丸 12 3 & 1 Fu shen tang 1 & 1 Fu shen tang 
Qian shi wan 芡實丸 12 0 0 
Zhu que wan 朱雀丸 11 1 1 
Yuan zhi san 遠志散 10 1 & 5 Yuan zhi wan 1 Yuan zhi tang 
Pai feng tang 排風湯 10 1 0 
Ren shen yang rong tang 人參養榮湯 8 0 3 
Ren shen tang 人參湯 8 1 & 4 Ren shen wan/san 1 Ren shen wan 
Zhen xin wan 鎮心丸 8 1 0 
Yang xin tang 養心湯 8 2 & 3 Yang xin dan/wan 1 & 1 Bo zi yang xin 
wan 
Jia wei fu ling tang 加味茯苓湯 8 1 1 Fu ling yin 
 
Characteristics of the ben cao data set 
The Ben cao section 本草類 of the Zhong Hua Yi Dian 4th edition is located in section 3 and 
contains 67 titles. It is organised into sub-sections as follows: 
 
Section 3. Ben cao section 本草類 (67 titles) 
3.1 Comprehensive ben cao 综合本草 (53 titles) 
 3.1.1 Ben cao from the Tang and earlier 唐以前本草 (7 titles) 
3.1.2 Ben cao from the Song and Yuan 宋元本草 (4 titles) 
3.1.3 Ben cao from the Ming 明代本草 (12 titles) 
3.1.4 Ben cao from the Qing 清代本草 (28 titles) 
3.1.5 Ben cao from abroad 國外本草 (2 titles) (from Japan) 
3.2 Food ben cao 食療本草 (3 titles) 
3.3 Ben cao in verse 歌訣便讀 (5 titles) 
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3.4 Books on herb preparation and processing 炮制 (1 title) 
3.5 Miscellaneous works 雜著 (5 titles) 
 
The collection spans the various ben cao genres as well as including key works across the dynasties 
beginning with the Shen Nong Ben Cao Jing 神農本草經 from the Han dynasty. There are, however, 
some oddities in the way the list is organised. In the Qing dynasty section are three works which 
would be more properly located under 3.4, namely the Lei Gong Pao Zhi Lun 雷公炮炙論, Pao Zhi 
Quan Shu 炮炙全書 and the Pao Zhi Da Fa 炮炙大法. Also, some post-Qing works, such as the 
Ben Cao Zheng Yi 本草正義, are included in the Qing section, presumably because there is no 
category for Min Guo period works and later. A surprising omission is the lack of the Famine/Wild 
food ben cao genre and the absence of the famous Ming dynasty work the Jiu Huang Ben Cao 救荒
本草 ‘Wild food plants for use in emergencies’. In contrast, a number of editions of this book appear 
in the ZGBCQS. Despite the above considerations, the 67 included works encompass the major works 
of the periods and included genres.  
 
Search results for Ben cao section of ZHYD 
In total, 318 hits on the search terms were found. These were sourced from 52 different ben cao 
spanning the period 220 to 1920 with only the Ben Cao Zheng Yi 本草正義 being from the modern 
era, even though it was classified within the Qing dynasty. The hits found 391 herb entries that were 
given as indicated for one or more of the search terms (see Table 5.7). Of the search terms, jian wang 
was by far the most productive, locating 247 references to herbs. This was followed by shan wang at 
52. The search found no herbs for treating chi dai or dai bing but the less common term chi bing 
found 2 entries. 
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Table 5.7: Search results for Ben cao section of ZHYD 
Search term: Pin 
yin 
characters No. hits* No of 
entries 
extracted 
Entries for 
treating the 
symptom 
Other Entries 
Chi dai 
痴呆 
1 1 0 1 令人痴呆 
Chi dai 
癡呆 
0 0 0 0 
Dai chi 
呆痴 
0 0 0 0 
Yu chi 
愚痴 
0 0 0 0 
Wen chi 
文痴 
0 0 0 0 
Wu chi 
武痴 
0 0 0 0 
Bai chi 
白痴 
0 0 0 0 
Chi bing 
痴病 
2 2 2 0 
Dai bing 
呆病 
0 0 0 0 
Dai zheng 呆証 0 0 0 0 
Dai sha 呆傻 0 0 0 0 
Lao ren zhi bing 
老人之病 
0 0 0 0 
Lao ren jian wang 
老年健忘 
0 0 0 0 
Jian wang 
健忘 
181 251 247 4 令人健忘 
Shan wang 
善忘  
47 52 51 1使人善忘 
Duo wang 
多忘 
44 44 20 24 令人多忘 
Xi wang 喜忘 21 20 20 0 
Hao wang 好忘 4 5 5 0 
Yi wang 
易忘 
0 0 0 0 
Yi wang 
遺忘 
1 0 0 0 
Qiang ji 
强記 
17 16 16 0 
Totals  318 391** 361** 30 
* there can be more than one hit per herb; also one hit can apply to a list of herbs; **incl 3 post 1911 books 
 
An unexpected feature of the search results was the 30 entries which referred to items of materia 
medica which can cause chi dai or jian wang. The Ben Cao Bei Yao 本草備要 of 1694 noted that 
frequent consumption of dan sha 丹砂 (cinnabar) causes chi dai (多服令人痴呆). The remaining 
references were to herbs which could cause jian wang, duo wang, or shan wang. The most commonly 
listed was hu sui 胡荽, which is the usual name for coriander (Coriandrum sativum) [133, 254], with 
15 ben cao listing it as causing jian wang (令人健忘) or causing duo wang (令人多忘). The next 
most frequent were shu jiao 蜀椒 and hu cong 胡蔥, with six listings each for causing jian wang. 
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Shu jiao occurs in the Zheng Lei Ben Cao and appears to be another name for hua jiao 花椒 or 
chuan jiao 川椒 (Zanthoxylum bungeanum) [254]. Hu cong appears to be Allium ascalonicum [254] 
about which Shi Liao Ben Cao says ‘long term consumption causes duo wang’ (久服令人多忘). Two 
items were listed in the Ben Cao Gang Mu alone. The herb fan lu 繁縷 (Stellaria media or S. 
chinensis) [133, 254] was said to cause duo wang (令人多忘) and in the entry on shells (bei zi 貝子), 
under a discussion on nine different kinds of shells, one called hui bei 慧貝 was reported to cause 
shan wang (使人善忘). Hui bei, which appeared to be a type of cowrie, could not be identified. 
References to items causing memory loss appear in the Tang dynasty with the first being in the Shi 
Liao Ben Cao 食療本草 of 739. However, only 17 of the 52 ben cao searched contained such 
references. However, none of the above herbs were major items of materia medica, so this is the likely 
reason why they are not mentioned in the smaller ben cao.  
 
When the above 30 entries were excluded, 361 entries which referred to the use of specific items of 
materia medica for one or more of the search terms remained. Of these, 3 were from a modern book 
the Ben Cao Zheng Yi 本草正義. In total, 86 different items of materia medica were found by the 
search terms. Of the 51 classical ben cao, those containing the greatest numbers of entries for the 
search terms are listed in Table 5.8. The most comprehensive of the ben cao, the Ben Cao Gang Mu, 
contained references to 55 different herbs as indicated for at least one search term, with a large 
proportion being found by two or more terms, as well as six entries for items causing jian wang (see 
Table 5.8).  
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Table 5.8: Ben cao from ZHYD by number of entries relating to search terms 
Book title (Pin yin, characters) Year Total No. entries No. causing jian wang 
Zheng Lei Ben Cao 證類本草 1082 27 3 
Ben Cao Pin Hui Jing Yao 本草品滙精要 1505 29 3 
Ben Cao Gang Mu 本草綱目 1578 61 6 
Shen Nong Ben Cao Jing Shu 神農本草經疏 1625 28 1 
Ben Cao Shu Gou Yuan 本草述鈎元 1832 28 0 
Yao Zheng Ji Yi 藥症忌宜 1872 14 0 
Ben Cao Cuo Yao 本草撮要 1888 10 1 
 
Prior to the Song dynasty only 4 items were indicated for memory loss (jian wang) but with the Zheng 
Lei Ben Cao the number rose dramatically to 24. The next increase was in the Ming dynasty with 26 
entries in the Ben Cao Pin Hui Jing Yao and numbers reached a peak at 55 in the Ben Cao Gang Mu. 
However, this appears more a measure of the comprehensiveness of the Ben Cao Gang Mu than of 
herb use or popularity. Throughout the whole period the smaller ben cao only contained a few 
mentions of jian wang or other terms. For example, 15 ben cao only included one entry and 7 
included only two entries.  
 
It is interesting to note that the term jian wang first appears in the Zheng Lei Ben Cao 證類本草 of 
1082, as do the terms xi wang and qiang ji. Prior to this, only the terms shan wang and duo wang were 
used. These earlier terms were not, however, necessarily superseded or replaced in later works. Rather, 
they continue to be referenced as later books quote verbatim sections from earlier books. For example, 
the Ben Cao Gang Mu uses the terms duo wang, shan wang and xi wang within the herb entries but 
only uses jian wang as an index term. 
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PART 2 
RESULTS OF COMPARISONS BETWEEN 
CLASSICAL COLLECTIONS 
 
Issues encountered when comparing classical collections 
Considerable difficulties were encountered when comparing the titles contained in different 
collections of classical literature to determine the degree of representativeness. Since these difficulties 
are illustrative of the range of issues confronting researchers in the field of classical literature, the 
main aspects are outlined below.  
 
Firstly, the same book can have variant titles and different books can have very similar titles, so it can 
be difficult to be certain whether two books are the same or different. Where possible, the texts were 
examined and the author and date checked against a range of sources but this was not possible for all 
comparisons. For example, the title Wei Sheng Yi Jian Fang 衛生易簡方 is listed in both the ZHYD 
and the ZYFJDCD but with different authors. Comparison of the texts revealed these were actually 
different books. Conversely, the ZYFJDCD also contains a book titled Yi Jian Fang 易簡方 by 
Wang Shuo 王碩 which has the same content as the Wei Sheng Yi Jian Fang in the ZHYD – in other 
words, these are the same book but under a longer and an abbreviated title. In another case, the ZHYD 
contains the Xue An Bian Shu 薛案辨疏 which is attributed to Xue ji 薛己, while the Su Ku Quan 
Shu collection contains the Xue Shi Yi An 薛氏醫案, also attributed to Xue ji 薛己, but neither 
provides a publication date. Since the author is the same and both works are in the case history genre, 
it appeared likely that they were the same book under variant titles. However, examination of the texts 
revealed quite different layouts with some overlapping content but also major differences, so they 
were not considered to be the same work.  
 
Secondly, books can be subsumed within other books and not necessarily appear on a list. For 
example, the Ben Cao Zheng is usually included with the Jing Yue Quan Shu but it can also appear as 
a separate work. A more perplexing example is the Yang Lao Feng Qin Shu 養老奉親書 and the 
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Shou Qin Yang Lao Shu 養老奉親書. Both appear in ZHYD and are attributed to the Song dynasty 
author Chen Zhi 陳直 but there are no publication dates. Examination of the texts revealed 
considerable overlap in content but differences in arrangement so they were considered to be different 
works. The Su Ku Quan Shu collection also contains a book titled Shou Qin Yang Lao Xin Shu 壽親
養老新書 but it is attributed to the Yuan dynasty author Zou Xuan 鄒鉉, so this appeared to be a 
later commentary on the Shou Qin Yang Lao Shu. However, the first part is identical to the Yang Lao 
Feng Qin Shu 養老奉親書 and the remainder is additional. So, as it turned out, there was overlap of 
content between the books that had differing titles, rather than between those with similar titles.  
 
To give yet another example, the major Qing dynasty work Yi Zong Jin Jian 醫宗金鑑 ‘Golden 
Mirror of Medical Tradition’ is not listed in the ZHYD. This appeared to be a major omission until 
cross referencing revealed that its 15 constituent works were included as separate titles. When a book 
is divided in this manner, this considerably alters the baseline figures for comparison. For example, it 
raises the number of books included in the Su Ku Quan Shu collection by 14 titles. 
 
Thirdly, books can appear in various editions with similar titles and contents but with editorial 
changes or additions. In such cases it can be difficult to decide whether these variant editions can be 
considered the same book or not unless the texts are examined closely. This is particularly the case in 
the Zhong Guo Ben Cao Quan Shu 中國本草全書 collection (ZGBCQS) which contains 14 variant 
editions of the Shen Nong Ben Cao Jing, 8 of the Xin Xiu Ben Cao 新修本草 and more than one 
edition of many other important ben cao. So while the ben cao section (本草專著) of this collection 
appears to contain 318 titles, a large proportion of these are variants of the same book. In contrast, 
there is no duplication amongst the 67 titles in the ben cao section of the ZHYD. 
 
Besides the difficulties in deciding whether titles from different collections refer to the same book or 
not, there is the issue of the relevance of the included titles to clinical herbal medicine. For example 
collections containing numerous books on acupuncture are not directly comparable with collections in 
173 
which such books are absent. In the ZHYD there are 50 titles in the acupuncture and tui na section, 43 
titles in diagnostic methods and 6 in miscellaneous works. There are 5 acupuncture titles in the Si Ku 
Quan Shu collection but none in the ZYFJDCD. 
 
Adjusting for baseline differences and comparing collections 
In order to arrive at meaningful comparisons between the collections, baseline adjustments were 
necessary. Firstly, the nominal total numbers of titles derived from the tables of contents were 
adjusted to account for duplications and inclusions. Since the ZHYD is the largest collection as well 
as the source of two of the data sets used in this study, all comparisons were made with the list of 
titles from the ZHYD. For example, the Si Ku Quan Shu 四庫全書 collection lists 104 titles but 
these include separate listings for separate sections of certain books, for example the Lei Jing 類經 
text and its illustrations (Lei Jing Tu 類經圖). When these are discounted, 101 titles remain. However, 
the Si Ku Quan Shu also includes both the Yi Zong Jin Jian 醫宗金鑑 and the Zheng Zhi Zhun Sheng 
證治準繩 as single titles while the ZHYD lists these as 21 separate titles. Therefore, based on the 
approach taken with the ZHYD, the Si Ku Quan Shu contains 120 titles. Similarly, the number of 
titles in the ZYFJDCD was adjusted to 712.  
 
Secondly, the adjusted totals needed to be further adjusted for relevance to clinical herbal medicine. 
This was a more approximate process since only those clearly irrelevant, such as books on 
acupuncture and diagnostics, could be identified and excluded. It is arguable that books in the section 
on health preservation, diet and exercise may also be irrelevant but some books in this genre do 
contain formulas, so identifying such titles would be problematic. Using this approach, the number of 
relevant titles in ZHYD was estimated at 898 whereas the ZYFJDCD remained unchanged at 712. 
Nevertheless, these two remained the largest collections. Even after the removal of duplicate editions, 
the ben cao section of the Zhong Guo Ben Cao Quan Shu 中國本草全書: 本草專著 (ZGBCQS: 
Ben cao) still contained 273 separate titles so it remained a considerably larger collection than the 
ZHYD ben cao section.  
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Table 5.9: Comparison of titles included in classical collections 
Sources Si Ku Quan 
Shu 
Ming Qing Ming 
Yi Quan Shu 
ZGBCQS: 
Ben cao 
ZHYD 
 
ZYFJDCD 
 
ZYFJDCD 66 NA NA 371 NA 
ZHYD: Ben cao 
section 
NA NA 55 67 NA 
ZHYD 109 202 NA NA 371 
Nominal totals 104 238 318 1000* 680** 
Adjusted totals 104-3+14+5 
= 120 
238-2 
= 236 
273*** 1000-3 
= 997 
680+7+14+6+5 
= 712 
Total relevant 
books 
120-5 
= 115 
236-2-10 
= 224 
273 997-50-43-6 
= 898 
712 
* the CD contains 1000 complete titles, but it also includes a section on famous formulas which includes 
material from additional books but there is no list of these books. 
** the appendix lists 680 titles, but this is not a complete list since 7 of the books found in the searches 
were not listed in the appendix. 
*** after removal of multiple editions 
 
Table 5.9 provides an estimate of the degree of overlap between the three collections searched and 
other collections of literature. When compared to the ZHYD, after adjustment for duplicates and 
inclusions, both the ZHYD and ZYFJDCD had 371 titles in common which is 52% of the total. This 
meant that there were 341 titles in the ZYFJDCD that were not included in the ZHYD. This was 
surprising, since it had been expected that the 1,000 titles of the ZHYD would have encompassed 
most of the 680 titles of the ZYFJDCD. However, when relevance was factored in, the difference in 
numbers between the two collections was estimated at 186 titles.  
 
When the Ming Qing Ming Yi Quan Shu 明清名醫全書 was compared with the ZHYD, 202 of 236 
titles were included in the ZHYD (86%). When the Si Ku Quan Shu was compared with the ZHYD, 
109 of 120 titles were included (91%). These comparisons indicate that both the Si Ku Quan Shu and 
Ming Qing Ming Yi Quan Shu are well represented in the ZHYD. In contrast, only 66 Si Ku Quan Shu 
titles (55%) were included in the ZYFJDCD.  
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In retrospect it was less surprising that the ZHYD and ZYFJDCD collections were considerably 
different. The ZHYD is a broad collection spanning numerous genres, whereas the ZYFJDCD focuses 
on herbal formulas. An examination of the titles indicated that most of the books in the ZYFJDCD fell 
into the genres of formula compendia, comprehensive medical works, clinical and specialty works, 
and medical records and cases. In the ZHYD these genres totalled only 636 titles, which was fewer 
than the adjusted total of 712 titles in the ZYFJDCD.  
 
In the case of the ben cao section of the Zhong Guo Ben Cao Quan Shu (ZGBCQS), when it was 
cross referenced to the ben cao section of the ZHYD 4th edition, 85% of the ZHYD ben cao were 
included in the ZGBCQS. Considering the size of the ZGBCQS ben cao section at 273 different titles, 
this was to be expected but it was surprising that 12 of the ben cao in ZHYD were not included in the 
ZGBCQS. 
 
Conclusions regarding representativeness of the sources 
The main conclusion that can be drawn from these analyses of the representativeness of the 
collections used in the searches is that the ZHYD is both representative of a wide range of genres of 
the CM literature as well as inclusive of large proportions of two other collections – the medical 
section of the Si Ku Quan Shu and the Ming Qing Ming Yi Quan Shu. Consequently, it seems that 
hand searches of these two collections would result in a high level of duplication and add little value 
to this project.  
 
On the other hand, the ZYFJDCD is narrower in scope than the ZHYD but it is a more specialized 
collection which is derived from a considerable number of works not found in the ZHYD. 
Consequently, there would appear to be considerable value in searching the ZYFJDCD in addition to 
the ZHYD.  
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With regard to the ben cao samples, it is evident that the majority of the ben cao works in the 
ZGBCQS are not included in the ZHYD. While the ZHYD does contain most of the well known ben 
cao, it is a selective collection which does not included lesser known works. Unfortunately, hand 
searching of the ZGBCQS for specific terms is a formidible task but if a practical method for 
sampling and searching the ZGBCQS could be developed, such as the digitalisation of a 
representative selection of works or the development of an indexing system, this would provide a 
more comprehensive approach to the ben cao literature in the future.  
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CHAPTER 6 
RESULTS FOR THE BEN CAO AND ZYFJDCD SEARCHES:  
FREQUENTLY USED INDIVIDUAL HERBS  
 
This chapter presents the results of the searches of two of the three populations of the classical 
literature at the level of the individual items of materia medica. The results from the collection of 
books on materia medica (ben cao) are presented in Part 1 and the results from the formula 
compendium (ZYFJDCD) are presented in Part 2. When listing the high frequency herbs, it proved 
impractical to include more than about 30 items in any one table, but since a number of items may 
share the same frequency, it was not feasible to end each list at 30 items exactly. In a number of the 
following tables, due to space considerations, it was impractical to include botanical names as well as 
the pin yin names in the tables. These can be found in the appendices. While the majority of items in 
the ben cao literature derive from plants, there are also considerable numbers of materia medica of 
mineral and animal origin. The focus of this project is upon plants, but other items were included in 
the tables and discussed since such items may also be of value for further research [315]. 
 
PART 1 
RESULTS FOR BEN CAO 
 
Individual herb results for the Ben Cao section of the ZHYD 
The search located 87 different items of materia medica sourced from 52 different ben cao spanning 
the period 220 to 1920. Of these, 6 items were listed as causing jian wang and not for its treatment. 
These were discussed in chapter 5. The search found no herbs for treating chi dai or dai bing but the 
less common term chi bing found 2 entries, both to the same herb fei zao jia 肥皂荚 (Gymnocladus 
chinensis) [254]. Of the remaining 80 items which were used for treating jian wang, 12 were of 
mineral origin and 13 were of animal origin, leaving 56 items derived from plants. The 27 items (of 
all types) with a frequency of 4 or more are presented in Table 6.1. All the included items were listed 
for treating at least one of the jian wang group of search terms in four or more different ben cao. As a 
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measure of how long the particular item was in use, the dates of the oldest and of the most recent ben 
cao in which the item occurs are given. 
 
The highest frequency item was the fungus fu shen (Poria cocos) which also had the longest history 
as a ben cao entry. Fu shen first appeared in the Ming Yi Bie Lu, which is of uncertain origin but can 
be dated to before the end of the Han dynasty (c. 220 AD), in which it was indicated for shan wang 
善忘. Closely related to fu shen is fu ling, but this herb first appeared for jian wang in the Ben Cao 
Pin Hui Jing Yao of 1505 and its frequency is considerably lower than that of fu shen in subsequent 
ben cao. Both fu shen and fu ling are from the same plant, Poria cocos, the only difference being that 
fu shen includes parts of the root of the pine trees upon which the fungus grows. The pine root itself 
was first included as a separate item called fu shen mu 茯神木 in the Ben Cao Pin Hui Jing Yao and 
appears in 12 subsequent ben cao (under this name or huang song jie 黃松節) indicated for jian wang. 
From this it appears that the combination of the fungus and the pine root in the form of fu shen or fu 
shen mu was considered more effective than the fu ling fungus alone. Fu ling typically grows on 
Pinus massoniana (ma wei song 馬尾松) and Pinus densiflora (chi song 赤松) as well as on other 
species of pine [254, 316]. When researching fu shen it may be productive to ensure there are 
significant root inclusions in the test samples and to identify the tree species. 
 
The second most frequent herb was yuan zhi 遠志 (Polygala tenuifolia) which first appeared in the 
Zheng Lei Ben Cao of 1082 and in 22 subsequent ben cao up to the modern era (1911). Also 
appearing in the Zheng Lei Ben Cao for the first time and continuing to the modern era was chang pu. 
This herb is designated as shi chang pu 石菖蒲 in modern ben cao and first appeared under this 
name as indicated for jiang wang in the Ben Cao Gang Mu (c. 1578). The species referred to in Li 
Shi-Zhen’s description appears to be Acorus graminus. However, the name chang pu may also include 
the related species A. calamus which is now more properly designated as shui chang pu 水菖蒲 
[254]. Since it was not always possible to determine which species the name chang pu referred to, 
these names were combined in the analyses. 
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Other plants that first appeared in the Zheng Lei Ben Cao and continued until at least the ben cao of 
the 19th century were yin yang huo 淫羊藿 (Epimedium spp) (from 1082-1920); gan cao 甘草 
(Glycyrrhiza uralensis or G. glabra) (from 1082-1872); and xian mao 仙茅 (Curculigo orchoides) 
(from 1082-1832). However, xian mao differs from all the 80 other items since it is the only one listed 
for memory enhancement (qiang ji 強記) and it is not indicated for jian wang.  
 
A number of herbs first appeared in the Ming period and recurred until at least the 19th century. Long 
yan rou 龍眼肉 (Dimocarpus longan) dates from the Ben Cao Gang Mu (c. 1578) and appeared in 
14 subsequent ben cao to 1888. Others include: ren shen 人參 (Panax ginseng) (from 1578-1888); 
dan shen 丹參 (Salvia miltiorrhiza) (from 1476-1872); suan zao ren 酸棗仁 (Ziziphus spinosa) 
(from 1578-1872); bai zi ren 柏子仁 (Biota orientalis) (from 1625 -1887); mai men dong 麥門冬 
(Ophiopogon japonicus) (from 1578-1872); mu tong木通 (Akebia quinata or Clematis armandii) 
(from 1505-1920); and gan di huang 干地黃 (Rehmannia glutinosa) (from 1578-1832). 
 
Another early inclusion was lu ru which first appears in the Ming Yi Bie Lu (c. 220) and appears in 8 
subsequent ben cao until the Shen Nong Ben Cao Jing Zan of 1850. The name appears synonymous 
with lan ru 蘭茹 but no herb under either of these names could be located in the modern ben cao 
consulted. However, Wright (2004) has tentatively identified lu ru as Euphorbia adenochlora [133].  
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Table 6.1: The 27 materia medica most frequently listed in the ZHYD ben cao section 
Chinese name* Genus & species (part used) or other name No. Ben cao** Year range 
Fu shen 茯神 Poria cocos (dried sclerotium with pine root 
inclusions) 
25 220- 1911 
Yuan zhi 遠志 Polygala tenuifolia (dried root) 23 1082-1920 
Chang pu 菖蒲  
Shi chang pu 石菖蒲 
Acorus calamus (dried rhizome) or 
A. graminus (dried rhizome) 
17 1082- 1911 
Long yan rou 龍眼肉 Dimocarpus longan (dried fruit) 15 1578-1888 
Fu shen mu 茯神木 
Huang song jie 黃松節 
Pinus massoniana or P. densiflora Seib. (dried 
root) 
13 1505 -1862 
Zhi zhu wang 蜘蛛網 Aranea ventricosa (spider web) 10 220-1578 
Xian mao 仙茅 Curculigo orchoides (dried root) 10 1082-1832 
Shan yao 山藥 Dioscorea spp (dried root) 10 1082-1773 
Yin yang huo 淫羊藿 Epimedium spp (dried herb) 10 1082-1920 
Lu ru Euphorbia adenochlora [unclear ID] 9 220-1850 
Sang piao xiao 桑螵蛸 Praying mantis egg case (various spp) 9 1082-1888 
(Bai) ma xin (白)馬心 Heart of a (white) horse 9 220-1705 
Gan cao甘草(炙甘草） Glycyrrhiza uralensis or G. glabra (dried root) 8 1082-1872 
Fu ling 茯苓 Poria cocos (dried sclerotium) 7 1505-1872 
(Bai) long gu (白)龍骨 Fossil bone 7 1082-1888 
Ren shen 人參 Panax ginseng (dried root) 6 1578-1888 
Dan shen 丹參 Salvia miltiorrhiza (dried root) 5 1476-1872 
Suan zao ren 酸棗仁 Ziziphus spinosa (dried seed) 5 1578-1872 
Niu huang 牛黃 Ox gall stone 5 1082-1637 
Xuan ming fen 玄明粉 Sodium sulphate 5 1082-1578 
Chai hu 柴胡 Bupleurum chinense (dried root) 4 1082-1578 
Bai zi ren 柏子仁 Biota orientalis (dried seed) 4 1625-1887 
Mai men dong 麥門冬 Ophiopogon japonicus (dried rhizome) 4 1578-1872 
Mu tong 木通 Akebia quinata (dried stem) 4 1505-1920 
Shang lu/ Shang lu hua 
商陸/商陸花 
Phytolacca acinosa Roxb. (root/flower) 4 1061-1578 
Bai shi ying 白石英 White quartz 4 1082-1695 
Gan di huang 干地黃  Rehmannia glutinosa (dried root) 4 1578-1832 
*Bold indicates inclusion in ZYFHDCD (see below);  
**Includes one post-Qing work, Ben Cao Zheng Yi (c. 1920).  
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Although the ben cao literature tends to be accumulative, there are examples of items dropping out of 
use. Shang lu 商陸 (Phytolacca acinosa) was an early inclusion (1061) but was last mentioned for 
jian wang in the Ben Cao Gang Mu. Chai hu 柴胡 (Bupleurum chinense) also dropped out of the 
record post-Ben Cao Gang Mu. Shan yao 山藥 (Dioscorea spp) received 10 mentions in the period 
1082 to 1773 but after this was not mentioned as being effective for jian wang. Of the non-plant items, 
the only ones that remained as inclusions into the nineteenth century were sang piao xiao 桑螵蛸 
(praying mantis egg case) (from 1082-1888) and long gu 龍骨 (fossil bone) (from 1082- 1888). 
 
Extract from the Ben Cao Gang Mu 
Considering the degree of influence the Ben Cao Gang Mu has had on the subsequent literature, it is 
of value at this point to examine what its author Li Shi-Zhen wrote in his chapter on the ‘principal 
medicines for the treatment of 100 diseases’ under jian wang (百病主治藥 健忘). The following is a 
summary translation which omits individual herbal actions, dosages and preparation instructions. The 
scientific names can be found in the appendices. 
 
The aetiology of jian wang can be divided into Heart Emptiness 心虛 and Excessive Phlegm and 
Fire 兼痰, 兼火. Similarly, the medicines used can be divided into those that Supplement 
Emptiness 補虛 and those that eliminate Phlegm Heat 痰熱. 
 
1. Medicines that Supplement Emptiness 補虛 (22 items) 
Category of herbs and trees (草木部): gan cao 甘草; ren shen 人參; yuan zhi 遠志; shi chang pu 
石菖蒲; xian mao 仙茅; yin yang huo 淫羊藿; dan shen 丹參, dang gui 當歸; di huang 地黃; 
yu zhi zi 預知子; ma bo 麻勃; shan yao 山藥; long yan 龍眼; lian shi 蓮實 [i.e. lian zi]; ru 
xiang 乳香; fu shen 茯神; fu ling 茯苓; bai shi 柏實 [i.e. bai zi ren]; suan zao 酸棗. 
Category of animals (鳞獸部): bai long gu 白龍骨; hu gu 虎骨; liu chu xin 六畜心.  
 
2. Medicines that eliminate Phlegm Heat 痰熱 (17 items) 
Category of herbs and trees (草木): huang lian 黃連; xuan shen 玄參; mai men dong 麥門冬; 
mu dan pi 牡丹皮; chai hu 柴胡; mu tong 木通; shang lu hua 商陸花; tao zhi 桃枝. 
Categories of metals, stones and animals (金石獸部): jiu tie hua 舊鐵鏵; tie hua fen 鐵華粉; jin 
bo 金薄; yin bo 銀薄; yin gao 銀膏; zhu sha 朱砂; kong qing 空青; bai shi ying 白石英; niu 
huang 牛黃 [252]. 
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Compared to modern CM categorisations of the etiology of jian wang (see Appendix 1 no. 4 for an 
example), Li’s two-way division seems simple but its basic feature of Empty (虛) and Full (實) types 
is retained in contemporary CM. Although the number of herbs mentioned is small these two lists are 
valuable in that they provide an indication of the general functions of individual herbs in treating jian 
wang which was, presumably, in accordance with contemporary thinking. Also, this was the only such 
list located in the ben cao search. 
 
Of the high frequency herbs listed in Table 6.1, the majority can be found in Li Shi-Zhen’s discussion 
and, of course, all of these items were found in the ben cao search. However, Li omitted from his 
discussion some high frequency items, such as lu ru, which may have already been archaic, and the 
insects zhi zhu wang 蜘蛛網 (Aranea ventricosa) and sang piao xiao 桑螵蛸 (Tenodera sinensis). 
There was also a tendency for the items in Li’s first list (i.e. bu xu補虛) to have a higher frequency in 
the search than the items in the second list. 
 
Summary of results 
In summary, the search of the population of ben cao in the ZHYD found that only one herb was 
indicated for a search term in the chi dai group whereas 80 different herbs were indicated for terms in 
the jian wang group. The first items appeared at the beginning of the history of the ben cao literature, 
with fu shen having the longest pedigree as well as the highest frequency. Of the 27 highest frequency 
herbs, 16 were still listed in ben cao dated post-1850. Of these, yuan zhi 遠志 (Polygala tenuifolia), 
chang pu 菖蒲 (Acorus graminus or A. calamus), yin yang huo 淫羊藿 (Epimedium brevicornum), 
sang piao xiao and gan cao recurred frequently since the Song dynasty, whereas herbs such as long 
yan rou龍眼肉 (Dimocarpus longan), fu shen mu and fu ling appear from the Ming dynasty onwards. 
Of the numerous ben cao, the Ben Cao Gang Mu was the most comprehensive.  
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PART 2 
RESULTS FOR ZYFJDCD 
 
Results for the ZYFJDCD data set 
For the 174 formula entries extracted to Excel from the ZYFJDCD search, each individual herb in 
each formula was entered into SPSS as a line of data. This resulted in 1,676 herb entries being 
extracted into SPSS for 396 different herbs. For each herb entry, data on a range of criteria were 
attached including the date of the entry, the conditions for which it was listed, general categorization 
criteria (if any), any mention of the patient’s age, and ratings according the DSM IV-TR criteria and 
the NPI categories (see chapter 4). These associated data allowed the entries to be sorted according to 
specific criteria. A step-wise sorting approach was adopted using the ‘select cases’ function in SPSS 
with the aim of determining a list of herbs which best satisfied the DSM IV-TR criteria. The results of 
this procedure are presented in Table 6.2 and outlined below. 
 
General categorisation criteria 
The data were coded according to a series of categorization criteria which allowed the exclusion or 
inclusion of items according to relevance to disorders such as AD, VaD and MCI. The total numbers 
of herb entries (HE) under each criterion for the full ZYFJDCD data set are presented in Table 6.2. 
 
Table 6.2: Frequencies of herb entries (HE) by general categorisation criteria 
Criterion Freq. of HE % of total HE 
1. Child, young person  18 1.1 
2. Acute condition e.g. associated with fever  55 3.3 
3. Mental disorder not consistent with dementia e.g. psychotic episode  62 3.7 
4. Physical disease unlike dementia e.g. seizures, head injury, range of 
physical symptoms  
0 0 
5. Modern literature i.e. from post-1911 book  155 9.2 
6. Indications of cerebro-vascular accident e.g. zhong feng, hemiplegia  33 2.0 
7. To improve memory only, not for disease, good for study, or disorder 
due to over reading/study  
86 5.1 
8. Woman’s disease i.e. specifically associated with gynaecological 
disease e.g. post-partum  
14 0.8 
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In the whole data set, the 12 modern books accounted for 9.2% of herb entries. Since the analysis 
aimed to identify classical books only, these items needed to be excluded in the further analyses. The 
next most common criterion was the ‘improve memory only’ section at 5.1%. Such items had been 
classified by the editors of the ZYFJDCD under jian wang but were not clearly indicated for an actual 
memory disorder. While these items may not all be relevant to the treatment of memory disorders, 
herbs that may assist in improving memory are of interest to this project so these items were retained 
in the final analyses.  
 
The level of detail provided about psychological symptoms was very variable, but in some cases the 
information indicated the disorder was not consistent with dementia. Such instances accounted for 
3.7% of items. For example, in the Zhang Shi Yi Tong 張氏醫通 of 1695, a condition called chi bing 
(癡病) was described as follows: ‘The person is crazily angry and shouts (狂怒叫號), there are 
seizures and loss of consciousness (失心風癲); s/he is sad and worried, doesn't want to talk (悲愁不
語).’ There was no mention of memory loss and this condition appears to have little in common with 
the modern conception of senile dementia (lao nian chi dai) and may have referred to an acute 
psychotic episode. Even so, it remains possible that a person with advanced AD may have presented 
with the above symptoms in addition to symptoms which were not recorded. In other cases, the 
situation was more ambiguous. For example, the Bian Zheng Lu 辨證錄 of 1687 described the 
following case of dai bing 呆病: ‘The person stays home alone all day (終日閉戶獨居); mumbles to 
her/himself (口中喃喃); most of what s/he says is not comprehensible (多不可解); sews own clothes 
very finely, in a strange way (將自己衣服用針線密縫); other people have to give her/him food and 
drink (與之飲食); s/he sometimes eats it and sometimes does not (時用時不用); does not eat for 
several days (嘗數日不食); does not feel hungry (而不呼飢); when s/he sees charcoal s/he wants to 
eat it (見炭最喜食之).’ In this case there was clearly a profound chronic psychological disturbance 
but a memory disorder was not mentioned, so there was no basis for this being a case of probable 
dementia. On the other hand, like most entries, there was not a complete description of the symptoms 
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so there may have been a memory deficit that was not mentioned. While these kinds of mental 
disorders were classified under criterion 3, they were retained until the final stages of the analysis due 
to the ambiguity of some cases.  
 
In 3.3% of entries the description pointed to an acute disorder. For example, in one case from the Bian 
Zheng Lu, a person was held hostage by robbers and threatened with death. As a result of the shock 
and fear, the person lost her/his mind and behaved as if demented (失心如癡) but after medicine the 
condition was cured. Since this study was concerned with chronic memory disorders, acute conditions 
such as this were excluded under exclusion 2. 
 
A number of entries were found to relate to disorders of children or young people. For example, an 
entry under jian wang which derived from the Shou Shi Bao Yuan 壽世保元 of 1615 referred to 
children suffering from psychological symptoms including jian wang as a result of shock or fright 
(bei jing 被驚). Since such entries were clearly not relevant to senile dementia, they were excluded. 
A small percentage (0.8%) of entries specified that the disorder was of women only, mostly referring 
to post partum disorders. Since, the conditions being investigated were not gender specific, such 
entries were excluded. However, entries that mentioned gynaecological symptoms in addition to more 
general symptoms were included. 
 
A few entries (2%) mentioned symptoms that were consistent with a cerebro-vascular accident (CVA) 
and may have been instances of VaD. For example, in the Sheng Ji Zong Lu 聖濟總錄 of 1111 a 
case of jian wang also mentioned: ‘stroke (中風), cannot use the arm and leg on one side (手足一邊
不收)’. Since VaD was included in the analyses for the clinical trial literature, these entries were also 
retained in the overall classical analyses but it was of interest to identify such disorders separately to 
determine their frequency and allow for separate analysis. 
 
The final criterion used for exclusion was ‘physical disease unlike dementia’ (exclusion 4) which 
aimed to identify any cases in which the symptoms indicated the disorder had no cognitive symptoms 
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beyond jian wang or chi dai, and appeared the result of trauma, sequelae of fever, epilepsy, or the 
symptom was incidental to a list of physical symptoms unlike those associated with dementia. As it 
turned out, no such cases were identified in the full ZYFJDCD beyond those excluded under acute 
conditions. 
 
Exclusion of entries according to categorisation criteria 
A step-wise series of exclusions of entries based on some of the criteria discussed above was 
conducted to arrive at a data set suitable for further analysis. The aim was to include all entries that 
could be relevant. The results of the exclusions are presented in Table 6.3 below, which includes the 
number of herb entries (HE), the number of formula entries (FE) from which they were derived, and 
the number of individual types of herbs (IH) following the SPSS recodes discussed previously. 
Finally the range of years for the source texts is listed. 
 
Table 6.3: Summary results for step-wise exclusions for ZYFJDCD 
Criteria No. HE No. FE No. IH Yr range 
1. Full data set 1,676 174 175 650-1985 
2. Exclude modern books 1,521 161 166 650-1892 
3. Exclude modern books & children 1,515 160 166 650-1892 
4. Exclude modern books & children & women only 1,501 159 166 650-1892 
5. Exclude modern books & children & women only & 
acute condition 
1,458 155 162 650-1892 
6. Exclude modern books & children & women only & 
physical disease unlike dementia 
1,458 155 162 650-1892 
HE: herb entries; FE: formula entries; IH: individual types of herbs; Yr; year 
 
Following these exclusions, 1,458 out of the original 1,676 herb entries remained in the data set. 
These were derived from 155 formulas in which 162 different herbs were represented. Once the 
modern books were removed, the range of years for the included classical books was 650 AD to 1892. 
Of the itemes that remained following the exclusions, the top 30 highest frequency herbs are listed left 
to right in Table 6.4 below.  
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Table 6.4: Highest frequency (F) herbs in the ZYFJDCD data set following exclusions  
Herb name  F.  Herb name F.  Herb name F. 
Yuan zhi 108  Zhu sha 35  Huang lian 18 
Ren shen 106  Bai zhu 30  Fang feng 15 
Chang pu  74  Long gu/chi 30  Dan shen 15 
Fu ling 70  Wu wei zi 29  Xuan shen 15 
Fu shen 68  Bai zi ren 26  Da zao 14 
Di huang 67  Tian dong 25  Ban xia 13 
Mai dong 58  Rou gui/Gui zhi 24  Chen pi 12 
Gan cao 55  Huang qi 22  Di gu pi 12 
Dang gui 47  Bai shao 20  Tu si zi 11 
Suan zao ren 46  Shan yao 19  Fu zi 11 
 
When compared with the total list for the ben cao search, 47 (54%) of the 87 herbs in ben cao were 
also included in the ZYFJDCD data set following the exclusions. The herbs that appeared on both 
lists are marked in bold in table 6.4 and in table 6.1. Amongst the high frequency herbs, a large 
proportion was on both lists but there were some notable exceptions. Fu shen mu 茯神木 (Pinus 
massoniana), xian mao 仙茅  (Curculigo orchoides) and yin yang huo 淫羊藿  (Epimedium 
brevicornum) were frequent in the ben cao but were not found in the ZYFJDCD list. 
 
The DSM IV-TR criteria 
The data remaining after the exclusions listed above formed the basis for further analyses according to 
the ratings for the DSM IV-TR criteria. Of these, the scores for memory are presented first, followed 
by those for ageing and then those for the group 2 symptoms.  
 
Results for memory scores 
Memory was scored on a four point scale (0-3). The frequency results for each score, as well as the 
consolidated results for memory scores 1 to 3, are presented in Table 6.5.  
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Table 6.5: Results for memory scores in ZYFJDCD data set 
Memory score No HE % HE No. FE. No. IH Yr range 
0. No mention of memory 134 9.2 13   
memory = 1,2,3 1324 90.8 142 149 650-1892 
1. Improve memory 139 9.5 13 50 650-1734 
2. Memory loss disorder 1094 75.0 118 137 650-1892 
3. Consistent with dementia 91 6.2 11 41 1111-1839 
Total 1458 100.0 155   
HE: herb entries; FE: formula entries; IH: individual types of herbs; Yr; year 
 
In 9.2% of herb entries derived from 13 formulas there was no explicit mention of memory. These 
included almost all the entries classified as chi dai but there were a few that had been classed under 
jian wang in the ZYFJDCD. These appear to have been included by the editors based on the section in 
the original text but the scoring system adopted only considered what was written in the ZYFJDCD 
entry. 9.5% of entries made reference to improving memory but did not clearly indicate they were for 
treating jian wang. Again, these appear to have been included by the editors on the inference that 
formulas that improve memory can also treat jian wang but some of these formulas were focused on 
memory improvement independent of any disorder. For example, a formula from the Qian Jin Yi 
Fang 千金翼方 of 680, called Peng zu yan nian bai zi ren wan 彭祖延年柏子仁丸, which was 
classified under jian wang in the ZYFJDCD, simply said: ‘if you consume [this formula] for a long 
time, it will strengthen your memory and you won't forget (久服强記不忘)’. The ingredients of this 
formula are listed in Appendix 3. 
 
The remaining 81.2% of herb entries were stated as indicated for jian wang. Of these, 75.0% simply 
mentioned the term jian wang without further details. In only 6.2% was the jian wang actually 
described in sufficient detail to indicate a disorder that was consistent with the type of episodic 
memory deficit found in probable AD or in MCI. For example, an extract from the Bian Zheng Lu 辨
證錄 of 1687 said of a formula indicated for jian wang called Shen jiao tang 神交湯: ‘When the 
person talks to someone, they soon forget what they said (對人說話，隨說隨忘); when someone 
speaks to the person, they cannot remember what they were told (人述其言，杳無記憶); it is as if 
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nothing had been said (如從前並不道及).’ In this case we were not told whether the person was aged 
or not, nor were any other symptoms given, so a tentative diagnosis of probable AD was not possible, 
but the memory disorder was clearly profound and consistent with probable AD and hence received a 
memory score of 3. The ingredients of the formula Shen jiao tang are listed in Appendix 3.  
 
Since memory loss is the most salient feature of AD, it was of interest to examine how the list of 
herbs was affected by the scoring system. Table 6.6 presents four parallel lists of the top 34 herbs in 
descending order of frequency, the first being for the combined memory scores (m=1-3), the second 
for improving memory (m=1), the third for jian wang (m=2), and the fourth for jian wang consistent 
with probable AD (m=3). 
 
Since the list for m=2 had by far the most entries, it was hardly surprising that it was very similar to 
the composite list (m=1-3). However, the other two lists could have been expected to differ 
considerably since one was for memory improvement (m=1) in the absence of the condition of jian 
wang, while the other (m=3) was for treating a profound memory disorder. However, both lists also 
proved similar with 12 of the 18 herbs (66.6%) in list 4 also being included in list 2. Somewhat 
surprisingly, the one herb in the ben cao search that was specifically indicated for memory 
improvement, xian mao, was not included in list 2. Considering that lists 2 and 4 were only derived 
from a small number of formulas, 13 and 11 respectively, these comparisons need to be considered 
cautiously. However it appears that in general, the main herbs for improving memory are also the 
main herbs for treating memory disorders. 
 
Since list 4 (m=3) derives from formulas used for memory loss consistent with AD it was of interest 
to compare this list with that found in the ben cao search. Of the 41 different herbs in list 4, 27 (66%) 
were also listed as specifically indicated for jian wang in the ben cao. So, only 14 different herbs were 
included in these formulas for other reasons with only bai zhu, shan zhu yu and bai jie zi having a 
frequency of 2 or above.
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Table 6.6: Lists of the highest frequency (F) herbs that received memory scores (m) from 1 to 3 
 
List 1 
m=1-3 
F. List 2 
m= 1 
F. List 3 
m=2 
F. List 4 
m=3 
F. 
1 Yuan zhi 107 Chang pu  11 Yuan zhi 91 Ren shen 8 
2 Ren shen 96 Yuan zhi 10 Ren shen 79 Di huang 7 
3 Chang pu 67 Ren shen 9 Fu ling 55 Mai dong 7 
4 Fu ling 66 Fu ling 8 Di huang 53 Yuan zhi 6 
5 Di huang 66 Bai zi ren 7 Fu shen 52 Chang pu 5 
6 Fu shen 62 Dang gui 6 Chang pu 51 Gan cao 4 
7 Mai dong 56 Di huang 6 Mai dong 45 Suan zao ren 4 
8 Gan cao 51 Fu shen 6 Gan cao 43 Fu shen 4 
9 Suan zao ren 45 Tian dong 5 Suan zao ren 38 Bai zi ren 4 
10 Dang gui 42 Xuan shen 5 Dang gui 34 Fu ling 3 
11 Zhu sha 34 Gou qi zi 4 Zhu sha 32 Tu si zi 2 
12 Long gu/chi 30 Wu wei zi 4 Long gu/chi 27 Dang gui 2 
13 Wu wei zi 26 Gan cao 4 Bai zhu 23 Bai zhu 2 
14 Bai zhu 26 Mai dong 4 Wu wei zi 22 Shan zhu yu 2 
15 Bai zi ren 24 Jie geng 4 Huang qi 20 Zhu sha 2 
16 Rou gui/Gui zhi 23 Rou gui/Gui 
zhi 
3 Rou gui/Gui zhi 20 Long gu/chi 2 
17 Tian dong 23 Du zhong 3 Tian dong 17 Xuan shen 2 
18 Huang qi 22 Dan shen 3 Bai shao 16 Bai jie zi 2 
19 Shan yao  18 Suan zao ren 3 Shan yao  15   
20 Bai shao 17 Shan yao 2 Fang feng 14   
21 Fang feng 15 Bai bu 2 Bai zi ren 13   
22 Xuan shen 14 Hou jiang 2 Huang lian 11   
23 Huang lian 13   Di gu pi 11   
24 Dan shen 13   Jiang 10   
25 Di gu pi 12   Chuan xiong 9   
26 Tu si zi 10   Dan shen 9   
27 Jiang  10   Da zao 9   
28 Hu po 10   Hu po 9   
29   Chen pi 8   
30 
Chuan xiong 
Chen pi, Da zao 
9 
  Mu xiang 8   
31 Mu xiang,  8   Long yan rou 8   
32 Jie geng, 8       
33 Long yan rou 8       
 Total: 1324 Total: 139 Total: 1094 Total: 91 
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Results for ageing scores 
Ageing was scored on a four point scale (0-3). The herb entry frequency results for each score are 
presented in Table 6.7. References to the elderly (老年人) or to the promotion of longevity (延年益壽) 
were infrequent with 89.0% of herb entries containing no references to these either directly or 
indirectly.  
 
Table 6.7: Results for ageing scores in ZYFJDCD data set  
Ageing score No. HE % HE No.FE No.IH Year range 
0. No reference to age or longevity 1297 89.0 139   
Ageing = 1,2,3 161 11.0 16 61 650-1839 
1. Indirect mention of longevity 32 2.2 3 19 1111-1615 
2. Promote longevity 72 4.9 7 43 650-1773 
3. Indicated for older people 57 3.9 6 31 1078-1839 
Total 1458 100.0 155   
 
In 2.2% of cases an inference was possible based on the book being aimed at longevity and in 4.9% 
the formula name or its indications mentioned the promotion of longevity or retaining youthfulness. 
For example, the Ci Xi Guang Xu Yi Fang Xuan Yi 慈禧光緒醫方選議, which is a collection of 
formulas used by the imperial household at the end of the Qing dynasty, contained a formula named 
Yan ling yi shou dan 延齡益壽丹 ‘Lengthen years and nourish long life elixir’ which, besides 
treating jian wang and having the actions its name indicates, is also ‘a good formula for women to 
lengthen life’ (是婦人長壽好方). The ingredients are listed in Appendix 3. 
 
In only 3.9% of cases were the formulas clearly indicated for older people. For example, the formula 
Zhen xin wan 鎮心丸 derived from the Yang Lao Feng Qin Shu 養老奉親書 of 1078 has the 
actions of ‘benefiting the Heart qi, nourishing the Heart Spirit, making the hearing acute and the 
vision bright (益心氣，養心神，聰明耳目)’, and is indicated for ‘elderly people with insufficiency of 
Heart qi and jian wang (老人心氣不足，健忘)’ (the ingredients of this formula are listed in Appendix 
3).  
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The frequencies of the herbs for the ageing scores are presented in Table 6.8. Overall, the numbers 
were low with the highest frequency being 13 for yuan zhi in list 1, so table 6.8 includes individual 
herbs down to a frequency of 3 for list 1 and a frequency of 2 for the other lists.  
 
There was considerable overlap between lists. When all the 19 different herbs in list 2 (ageing score = 
1) were compared with all herbs in lists 3 and 4, 13 were also in list 3, and 12 were also in list 4. The 
herbs that appeared on all lists are marked in bold. Not only were the lists very similar in composition, 
the higher frequency herbs were similar to those found for the memory scores (see Table 6.6).  
 
When the higher frequency herbs are compared between list 4 (memory=3) in table 6.6 and list 4 of 
table 6.8 (ageing=3), 100% of the herbs for ageing = 3 are also in the list for memory=3. Of the 31 
different items in list 4 of table 6.8 (ageing=3), 18 (58%) were also indicated for jian wang in the ben 
cao search, and of the 12 higher frequency items only shan zhu yu and bai jie zi were not indicated for 
jian wang. 
 
Considering these herbs were scored for ageing, differences it was expected that these lists would 
differ from those scored for memory. However, the whole dataset was selected based on the search 
terms chi dai and jian wang of which jian wang was by for the most productive. Therefore, in 
retrospect, it could have been expected that this list would be a subset of the jian wang list and, as 
such, reflect the characteristics of the main list. Also, memory loss is a disorder typically associated 
with ageing so the writers may have seen no need to explicitly mention age in the formula indications. 
Consequently, when jian wang is the condition, the addition of criteria for ageing appears not to have 
made much difference to the overall characteristics of the list.  
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Table 6.8: Frequencies (F) of herb entries for ageing scores (a) from 1 to 3 
 
List 1 
a=1-3 
F. List 2 
a=1 
F. List 3 
a=2 
F. List 4 
a=3 
F. 
1 Yuan zhi 13 Ren shen 3 Yuan zhi 6 Ren shen 5 
2 Fu ling 11 Fu ling 3 Fu ling 5 Di huang  5 
3 Di huang  11 Mai dong 3 Di huang  5 Chang pu  4 
4 Ren shen 10 Yuan zhi 3 Rou gui/gui zhi  4 Mai dong 4 
5 Chang pu  9 Suan zao ren 3 Chang pu  3 Yuan zhi 4 
6 Mai dong 8 Chang pu  2 Wu wei zi 3 Fu ling 3 
7 Suan zao ren 6 Bai zhu 2 Tian dong 3 Suan zao ren 3 
8 Rou gui/gui zhi  5 Chen pi 2 Ren shen 2 Shan zhu yu 2 
9 Dang gui 4   Tu si zi 2 Zhu sha 2 
10 Bai zhu 4   Rou cong rong 2 Fu shen 2 
11 Zhu sha 4   Dang gui 2 Bai zi ren 2 
12 Fu shen 4   Shan yao 2 Bai jie zi 2 
13 Tian dong 4   Di gu pi 2   
14 Wu wei zi 3   Xu duan 2   
15 Gan cao 3       
16 Shan zhu yu 3       
17 Shan yao 3       
18 Chen pi 3       
19 Bai zi ren 3       
 
Total:161 Total:32 Total:72 Total:57 
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Results for Group 2 symptoms 
The indications of the formulas were also coded for each of the four group 2 symptom categories: 
aphasia, apraxia, agnosia and disturbance in executive functioning. There were, however, very few 
matches to these categories (see Table 6.9).  
 
Table 6.9: Results for group 2 symptom scores in the ZYFJDCD data set 
Group 2 symptom categories No. HE % HE No. FE 
1. Aphasia 77 5.3 8 
2. Apraxia 0 0 0 
3. Agnosia 48 3.3 4 
4. Disturbance in executive functioning 0 0 0 
HE: herb entries; FE: formula entries; IH: individual types of herbs; Yr; year 
 
In only 5.5% of cases was there a reference to a language disturbance that was possibly an instance of 
aphasia. For example, the formula Jia wei fu ling tang 加味茯苓湯 from the Shi Yi De Xiao Fang 
世醫得效方 of 1337 was indicated for: ‘cannot remember anything, speaks as if demented (健忘失
事，言語如癡)’. The ingredients of this formula are in Appendix 3. 
 
Only a few entries were scored as possible agnosia and all of these were related to not recognizing 
what was proper food. For example, in the Shi Shi Mi Lu 石室秘錄 of 1687 it says: ‘if you give 
her/him food (與之食)， s/he doesn't like it and doesn't want to swallow it (則厭薄而不吞), if you do 
not give her/him food (不與食)，then s/he swallows charcoal and feels happy (則吞炭而若快).’ This 
condition was described as dai bing ru chi (呆病如癡) i.e. dai bing like chi (dai). This appears to 
distinguish the terms dai bing and chi dai but the nature of the distinction was not clear.  
 
In neither of the above entries was there a good match with the modern concept of dementia and the 
frequencies of the herb entries were too low to warrant listing  
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Step-wise analyses according to combined DSM IV-TR criteria 
When herb entries which made no reference to memory were excluded, 1,324 herb entries remained. 
This excluded all but one of the chi dai entries, since these typically did not refer to a disorder of 
memory. When entries that made no reference to ageing were excluded, this left only 161 herb entries. 
The basic features of AD or MCI according to the DSM IV-TR criteria are memory impairment and 
ageing, so the next step was to combine the above two exclusions (see Table 6.10).  
 
The first series of steps (1-8) examined all possible combinations of the three memory and three 
ageing scores. At the least restricted level (step 1) the number of herb entries was reduced to 148 
which included 51 different herbs derived from 15 different formulas from books dated between 650 
and 1839. These are presented in list 1 of Table 6.11). The next two steps (2-3) were to progressively 
restrict the memory score to 2 or 3, then to 3 only, whilst retaining the ageing score at 1 to 3. This 
procedure reduced the number of herb entries to 126 and 36 respectively. Following this, in steps 4 
and 5, the memory scores were progressively restricted to 2 or 3, then to 3 only, whilst retaining the 
ageing score at 1 to 3. This resulted in 116 and 44 herb entries being included respectively.  
 
The next stage (steps 6 & 7) was to restrict the memory score to 2 or 3 and the ageing score firstly to 
2 or 3, and then to 3 only. This produced 94 and 44 herb entries respectively. The list of 44 entries 
was the same as in step 5 and included 20 different herbs. When both the ageing and memory scores 
were set at 3 (step 8), only 36 entries and 4 formulas were retained. These are presented in list 2 of 
Table 6.11.  
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Table 6.10: Summary results for step-wise restrictions for ZYFJDCD according to DSM 4-TR 
criteria 
Inclusion Criteria No.HE No. FE No. IH Year range 
1. memory = 1, 2 or 3 & ageing = 1, 2 or 3 148 15 51 650-1839 
2. memory = 2 or 3 & ageing = 1, 2 or 3 126 14 43 650-1839 
3. memory = 3 & ageing = 1, 2 or 3  36 4 19 1687 & 1839 
4. memory = 1, 2 or 3 & ageing = 2 or 3 116 12 46 650-1839 
5. memory = 1, 2 or 3 & ageing score = 3 44 5 20 1078, 1687, 1839 
6. memory = 2 or 3 & ageing = 2 or 3 94 11 37 650-1839 
7. memory = 2 or 3 & ageing = 3 44 5 20 1078, 1687, 1839 
8. memory = 3 & ageing = 3 36 4 19 1687, 1839 
9. memory = 1, 2 or 3 & any Gp 2 symptom 44 5 31 992-1773 
10. memory = 2 or 3 & any Gp 2 symptom  44 5 31 992-1773 
11. memory = 3 & any Group 2 symptom  14 2 13 1337, 1602 
12. memory = 1, 2 or 3 & ageing = 1, 2 or 3, & any 
Gp 2 symptom  
15 1 15 1773 
13. memory = 2 or 3 & ageing = 1, 2 or 3, & any Gp 
2 symptom 
15 1 15 1773 
14. memory = 3 & ageing = 1, 2 or 3, & any Gp 2 
symptom 
0 0 0 0 
15. memory = 2 or 3 & ageing = 2 or 3, & any Gp 2 
symptom 
15 1 15 1773 
16. memory = 3 & ageing = 2 or 3, & any Gp 2 
symptom  
0 0 0 0 
17. memory = 2 or 3 & ageing = 3, & any Gp 2 
symptom  
0 0 0 0 
 
One of the four formulas was Fu lao wan 扶老丸 from the Bian Zheng Lu 辨證錄 of 1687 which 
was indicated for memory loss in old age (老年善忘). The book stated: ‘this formula can be taken by 
old and young (此方老少俱可服), but it is better for old people (而老年人尤宜), it has more herbs 
for strengthening kidney than for strengthening heart (蓋補腎之味多于補心); by strengthening jing it 
can produce fluid for/of heart (精足而心之液生), when the fluid has been produced the heart orifices 
are opened (液生而心之竅啟), when the orifices are opened the mind/spirit is clear (竅啟而心之神
清).’ The ingredients of this formula are listed in Appendix 3. 
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Since the presence of at least one of the group 2 symptoms - aphasia, apraxia, agnosia or disturbance 
in executive functioning - is a key aspect of the diagnosis of probable dementia, the scores for these 
were combined, firstly, with those for memory (steps 9-11), and then for various combinations of 
memory plus ageing scores (steps 12-17). When the presence of any group 2 symptom was combined 
with a memory score of 1 to 3, 44 herb entries remained (step 9). This list did not change when the 
memory score was restricted to 2 or 3, so these herbs are presented as list 3 in Table 6.11. However, at 
memory = 3, only 14 entries and two formulas remained (step 11).  
 
The last stage was to combine both memory and ageing scores with the presence of any group 2 
symptom (steps 12-17). At the lowest level of restriction, i.e. memory = 1, 2 or 3 and ageing = 1, 2 or 
3, only 15 herb entries satisfied all criteria (step 12) and this list remained the same when the memory 
scores were further restricted to 2 or 3. These herbs are presented as list 4 in Table 6.11. At memory = 
3, no entries remained (step 14). When memory = 2 or 3 and ageing = 2 or 3, the same 15 herbs again 
remained (step 15) but at higher levels of restriction, i.e. memory = 3 and ageing = 2 or 3, and 
memory = 2 or 3 and ageing = 3, no herb entries were retained.  
 
The list of herbs that satisfied all three DSM IV-TR criteria were the ingredients of one formula, Shou 
xing wan 壽星丸 ‘God of longevity pill’, from the Za Bing Yuan Liu Xi Zhu 雜病源流犀燭 of 1773, 
for which the indications were simply: ‘speaks as if demented, and memory loss’ (言語如癡而多忘). 
The ingredients of this formula are listed in Appendix 3.  
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Table 6.11: Herb frequency lists for combinations of DSM IV-TR criteria for ZYFJDCD 
List 1: memory = 1, 2 or 3 & ageing = 1, 2 or 3 
List 2: memory = 3 & ageing = 3 
List 3: memory = 1, 2 or 3 & any Gp 2 symptom 
List 4: memory = 1, 2 or 3 & ageing = 1, 2 or 3, & any Gp 2 symptom 
List 1 F. List 2 F. List 3 F. List 4 F. 
Yuan zhi 13 Di huang  4 Ren shen 4 Ren shen 1 
Di huang  11 Ren shen 3 Huang qi 1 
Fu ling 10 Chang pu  3 
Gan cao, Fu ling, Yuan 
zhi 
3 
Nan xing  1 
Ren shen, Chang pu 9 Mai dong 3 Wu wei zi 1 
Mai dong 8 Yuan zhi 3 
Di huang, Chen pi, 
Zhu sha, Fu shen 
2 
Gan cao 1 
Suan zao ren 6 Suan zao ren 3 Dang gui 1 
Rou gui/gui zhi 5 Shan zhu yu 2 Bai zhu 1 
Fu shen 2 Fu ling 1 
Bai zi ren 2 Di huang  1 
Wu wei zi, Dang gui, Bai 
zhu, Zhu sha, Fu shen, 
Tian dong 
4 
Bai jie zi 2 Rou gui/ 
gui zhi 
1 
Gan cao, Shan zhu yu, 
Chen pi, Bai zi ren 
3 
Chen pi 1 
Yuan zhi 1 
Zhu sha 1 
Bai shao 1 
Huang qi, Tu si zi, Rou 
cong rong, Shan yao, Di gu 
pi, Bai shao, Xu duan, 
Long gu/chi, Bai jie zi 
2 
Huang qi, Gan cao, 
Dang gui, Bai zhu, 
Fu ling, Zhu sha, 
Tian men dong, 
Long gu/chi, Xuan 
shen 
1 
Huang qi, Tu si zi, Nan 
xing, Wu wei zi, Rou 
cong rong, Dang gui, 
Bai zhu, Shan yao, Ban 
xia, Shi gao, Bai shao, 
Long gu/chi, Hu po, 
Rou gui/gui zhi, She 
chuang zi, Huang qin, 
Hei dou, Jing jie, Zi shi 
ying, Bai shi ying, Yi 
zhi ren, Xiang fu 
1 
Hu po 1 
Total:148 Total:36 Total:44 Total:15 
 
List 1 in Table 6.11 includes those of the 148 herb entries indicated for memory loss plus ageing that 
had a frequency greater than 1. List 2 is a subset of this for which the inclusion criteria were more 
restricted. In this sense, list 2 is a closer fit to these two criteria but in this process of restricting the 
data set, the numbers of herbs and formulas have been greatly reduced. This was largely due to the 
overall low frequency of references to ageing in the literature. Even so, all but three (in bold) of the 
19 different herbs were indicated for jian wang in the ben cao search and all were included in the list 
for memory=3. List 3, includes all the 44 herb entries that satisfied the criteria based on the DSM 
IV-TR for memory loss plus one of four sets of group 2 symptoms, and list 4 is a subset of this which 
also satisfied the ageing criterion. Again, the addition of criteria for which the overall frequency in the 
data set was low restricted the resultant herb lists to only a few formulas. While it was of interest that 
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one formula did satisfy all three sets of criteria, from the point of view of selecting herbs for further 
research, list 4 is overly restricted. At a much lower level of restriction, list 1 of Table 6.6 includes 
1,324 herbs indicated for improving memory or a memory disorder. Since list 4 of Table 6.11 is the 
most restricted subset of this much larger list, all of its component herbs were, of course, included. 
But more interestingly, all but one of the 15 herbs in the formula Shou xing wan, i.e. nan xing, was 
included in the top 34 highest frequency herbs in table 6.6 and all were in the top 55. Despite the terse 
indications of this formula, it was not only a good fit to the restriction criteria, but also included high 
frequency herbs. This suggested that the rating and exclusion processes were productive but there 
remained the issue of when to stop the exclusions. There appears no definitive answer to this question, 
since it depends upon how many herbs are required for ongoing research. However, when a criterion 
is highly restrictive, such as ageing or group 2 symptoms in this data set, its utility for sorting 
becomes questionable. On the other hand, as shown in the above example, very restrictive criteria can 
also locate best-fit examples that reflect many features of the data set as a whole. When a herb is both 
a high frequency item in the overall set and, following the necessary exclusions, also fits the most 
restrictive of the criteria, then it would appear to be a better candidate than one which scored a overall 
high frequency based on the primary criterion but was eliminated by more restrictive criteria. 
 
Of the four lists in Table 6.11, the one which combines the features of memory plus ageing, whilst 
still retaining a considerable list of herbs, is list 1 (memory = 1-3, ageing = 1-3). This list of herbs 
comprised the total ingredients of formulas that at least broadly satisfied these two criteria. In order to 
determine whether this list was comparable with that obtained from the ben cao search reported in 
Part 1 of this chapter, both lists were rank ordered in descending order. Of the 50 different herbs in 
list 1, 22 were also on the ben cao list as indicated for jian wang (see Table 6.12). The Spearman 
correlation was 0.531, p = 0.013 (2-tailed) which was significant. This indicated that the herbs with 
high frequencies in list 1 of Table 6.11 also tended to be high frequency items in the ben cao search. 
Of the top 20 items in list 1, all but a few are specifically indicated for jian wang, although they are 
also likely to have been used for other indications as well. Rou gui 肉桂, bai zhu 白術 and tian dong 
200 
天冬 are items that were not indicated for jian wang in the ben cao searches but had high frequencies 
in the formulas. Although the roles of individual herbs are not specified in any of the formulas 
included in the data set, it is likely that these herbs were included based on their functions and/or 
indications for other symptoms. For example, bai zhu 白術 is frequently used for debility, Spleen 
emptiness and dampness, all of which are conditions typical of elderly people with jian wang. 
 
Table 6.12: Herbs in Table 6.11 List 1 (L 1) and ben cao (BC) search according to rank 
Herb name L 1 BC 
Yuan zhi 1 2 
Di huang  2 38 
Fu ling 3 14 
Ren shen 4 16 
Chang pu 4 3 
Mai dong 6 23 
Suan zao ren 7 17 
Rou gui/gui zhi 8 - 
Wu wei zi 9 28 
Dang gui 9 28 
Bai zhu 9 - 
Zhu sha 9 28 
Fu shen 9 1 
Tian dong 9 - 
Gan cao 15 13 
Shan zhu yu 15 - 
Chen pi 15 - 
Herb name L 1 BC 
Bai zi ren 15 17 
Huang qi 19 38 
Tu si zi 19 54 
Rou cong rong 19 - 
Shan yao 19 6 
Di gu pi 19 54 
Bai shao 19 38 
Xu duan 19 - 
Long gu/chi 19 14 
Bai jie zi 19 - 
Nan xing  28 54 
Fu pen zi 28 - 
Che qian zi 28 - 
Du zhong 28 - 
Ze xie 28 - 
Ba ji tian 28 - 
Fang feng 28 - 
Herb name L 1 BC 
Zhi mu 28 - 
Chi shao 28 - 
Da zao 28 - 
Hu po 28 - 
She chuang zi 28 54 
Xuan shen 28 - 
Niu huang 28 - 
Long yan rou 28 3 
Jing mi 28 - 
Shi wei 28 - 
Shi hu 28 - 
Huang bo 28 - 
Shi zhong ru 28 - 
Zhi shi 28 - 
Niu xi 28 - 
Tian xiong 28 - 
 
There was again a tendency for the herbs in Li Shi-Jen’s first list (supplement emptiness) to be more 
prevalent amongst the higher frequency herbs in formulas for jian wang. These are marked in bold 
(13 items) in Table 6.12 with the herbs from the second list (eliminate phlegm heat) being marked in 
italics (2 items). The remaining items were listed in the ben cao search but not in Li’s discussion on 
herb functions. So in formulas for jian wang associated with ageing, the high frequency constituent 
herbs tended to be indicated for jian wang of the Empty (xu 虛) type.  
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Subgroup analyses for the ZYFJDCD data set 
The above analyses focused on jian wang as the condition but the data set also contained chi dai 
entries, entries coded as possible instances of CVA, and entries whose principal function was to 
enhance memory or aid study. These are examined in the subgroup analyses below. 
 
Chi dai (dementia) sub-group 
By adopting a memory score as the main criterion for sorting the data, most of the entries for chi dai 
were excluded in the early stages of the analysis. In order to examine this group in more detail the 
following procedure was adopted. Firstly the data were sorted using the same six criteria for exclusion 
as in Table 6.2 but only the formulas that mentioned chi dai were included. This resulted in 107 herb 
entries derived from 10 formulas (see Table 6.13). However, once a memory score was included all 
but one formula was excluded, and when combined with ageing the same formula remained. This was 
the same Shou xing wan as remained in the DSM IV-TR analyses above. It is disputable whether this 
formula should be considered as being indicated for chi dai since the indications were for ‘speaks as if 
demented’ but it received codes in the data set for chi dai as well as jian wang according to the 
established scoring criteria and hence was retained. 
 
Table 6.13: Frequency of entries for chi dai in ZYFJDCD data set 
Inclusion Criteria No. HE No. FEs No. IH Yr range 
1. Chi dai only, i.e. condition= 9 107 10 41 1687-1733 
2. Chi dai & memory score= 1, 2 or 3  15 1 15 1773 
3. Chi dai & ageing score= 1, 2 or 3  15 1 15 1773  
4. Chi dai & memory=1,2 or 3 & ageing = 1,2 or 3 15 1 15 1773 
HE: herb entries; FE: formula entries; IH: individual types of herbs; Yr; year 
 
The 41 different items of materia medica that appeared under chi dai are listed in Table 6.14. There 
are considerable similarities with the jian wang lists, with herbs such as ren shen 人參 (Panax 
ginseng), chang pu 菖蒲 (Acorus graminus or A. calamus) and gan cao 甘草  (Glycyrrhiza 
uralensis) having high frequencies. When compared with list 1 of Table 6.6, 16 of the items on the chi 
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dai list also appeared in the high frequency items for memory = 1-3 (in bold in Table 6.14). There 
were also some differences, with fu zi 附子 (Aconitum carmichaeli), shen qu 神麴 (fermented 
combination of herbs), nan xing 南星  (Arisaema erubescens) and chai hu 柴胡  (Bupleurum 
chinense) appearing in the higher frequency group on the chi dai list. However, the list was based on 
only 10 formulas and 21 of the entries only had a frequency of 1, so few inferences can be reliably 
made. When compared with the ben cao search, 18 (44%) of the 41 herbs for chi dai in ZYFJDCD 
were indicated for jian wang. However, the single herb indicated for dai bing, fei zao jia 肥皂荚 
(Gymnocladus chinensis), did not appear on the list. 
 
Table 6.14: Frequency of all 41 individual herbs for chi dai in ZYFJDCD data set 
Herb name F Herb name F Herb name F 
Ren shen 9 Chen pi 3 Mu xiang 1 
Fu zi  7 Zhu sha 2 Lu dou 1 
Ban xia 7 Zhi zi 2 Liang jiang 1 
Chang pu  6 Zhi shi 2 Jing jie 1 
Shen qu  5 Huang lian 2 Ji xing zi 1 
Nan xing  5 Bai jie zi 2 Huang qi 1 
Gan cao 5 Yuan zhi 1 Hu po 1 
Da zao 5 Yu jin (guang) 1 Rou gui / Gui zhi 1 
Fu shen 4 Xiong huang 1 Rou dou kou 1 
Fu ling 4 Wu wei zi 1 Di huang 1 
Dang gui 4 Tu si zi 1 Ci huang 1 
Chai hu 4 Tian hua fen 1 Bai zi ren 1 
Bai zhu 4 Shan zhu yu 1 Bai wei 1 
Bai shao 4 Pi Shuang, Bai Pi 1 Total 107 
 
CVA (zhong feng 中風) sub-group 
A number of entries were coded under general categorisation criterion 6 where the symptoms 
described were consistent with a possible CVA being responsible for the cognitive disorder. 
Following exclusions, 26 herb entries from 2 formulas remained and these also satisfied the criterion 
of memory disorder but not of ageing (see Table 6.15.). 
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Table 6.15: Summary results for step-wise restrictions for CVA sub-group in ZYFJDCD 
Inclusion Criteria No. HE No. FE No. IH Year range 
1. CVA only, i.e. category 6 = 1 26 2 24 992, 1111, 
2. CVA only & memory = 1, 2 or 3 26 2 24 992, 1111  
3. CVA only & ageing = 1, 2 or 3  0 0 0 0 
 
Since only two formulas were included in this subgroup a list of herbs was not provided. One of the 
two formulas, Fu shen tang 茯神湯 from the Sheng Ji Zong Lu 聖濟總錄 of 1111, was mentioned 
earlier. With the indications of: ‘stroke (中風), cannot use the arm and leg on one side (手足一邊不
收), and memory disorder (精神健忘)’, it appears a possible case of VaD. The ingredients of this 
formula are listed in Appendix 3. Beyond this, the list was too small for further analysis.  
 
Memory enhancement sub-group 
The next sub-group examined was that coded under general categorisation criterion 7 as formulas for 
memory enhancement and/or improving study. Following the general exclusions, 93 herb entries from 
10 formulas remained in the group. One formula was excluded once a memory score was applied 
since it was for improving reading and study but did not explicitly mention memory. When memory 
and ageing scores were combined only two formulas remained (see Table 6.16). Both of these have 
been mentioned above: Peng zu yan nian bai zi ren wan 彭祖延年柏子仁丸 from the Qian Jin Yi 
Fang 千金翼方 of 680, and Fu lao wan 扶老丸 from the Bian Zheng Lu 辨證錄 of 1687. 
 
Table 6.16: Summary results for step-wise restrictions for memory enhancement sub-group 
Inclusion Criteria No. HE No. FE No. IH Year range 
1. Memory enhancement only 93 10 49 650-1851 
2. Mem. enhance & memory = 1, 2 or 3  82 9 44 650-1851 
3. Mem. enhance & ageing = 1, 2 or 3  36 2 31 680, [f 159] 
1687 [f 103] 
4. Mem. enhance & memory = 1, 2 or 3 & ageing = 3 14 1 14 1687 [f 103] 
HE: herb entries; FE: formula entries; IH: individual types of herbs; Yr; year 
 
Herb entry frequency scores for the total memory enhancement sub-group from a frequency of 2 and 
above are presented in Table 6.17. The higher frequency herbs proved to be a similar list to that found 
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under memory score = 1, the herbs in bold being in the top ten of that list. It was plausible that there 
would be differences in the herbs indicated for ‘improve memory’ in general and those specifically 
used in formulas for improving memorization and aiding study, but the most frequent herbs appear the 
same. The main differences are that this list includes the kidney tonic herbs tu si zi 菟絲子 (Cuscuta 
chinensis), du zhong 杜仲 (Eucommia ulmoides) and ba ji tian 巴戟天 (Morinda officinalis), as 
well as three astringent herbs wu wei zi 五味子 (Schisandra chinensis), shan zhu yu 山茱萸 
(Cornus officinalis) and di gu pi地骨皮 (Lycium barbarum). 
 
Table 6.17: Frequency of the top 21 individual herbs for the memory enhancement sub-group 
Herb name F. Herb name F. Herb name F. 
Chang pu 8 Fu shen 3 Shan zhu yu 2 
Yuan zhi 7 Long gu/ chi 3 Rou gui/gui zhi 2 
Ren shen 6 Bai zi ren 3 Ba ji tian 2 
Fu ling 4 Huang qi 2 Mai dong 2 
Wu wei zi 3 Tu si zi 2 Di gu pi 2 
Dang gui 3 Du zhong 2 Suan zao ren 2 
Di huang 3 Bai zhu 2 Tian dong 2 
 
The Neuropsychiatric Inventory (NPI) criteria 
The Neuropsychiatric Inventory scores provided a different view of the symptoms described in the 
data set compared to the DSM IV-TR group 2 symptoms. They also proved less difficult for the raters 
to conceptualise and more straightforward to score, provided an inclusive view was taken. The 
approach was to include probable instances using the NPI descriptors and questionnnaire as a guide 
(see appendix 2). The frequencies of the incidence of the twelve NPI categories in the data set 
following general exclusions are presented in Table 6.18. The category of anxiety ranked highest with 
78 formula entries. This was largely due to the broad range of somatic symptoms that can be 
indicative of anxiety such as palpitations, shortness of breath, feeling of choking, chest pain or 
discomfort [3]. The approach taken was to include these unless there was an indication that they were 
due to a physical disease. 
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Table 6.18: Frequencies of NPI results in ZYFJDCD 
NPI category No. HE No. FE No. IH Year range 
1. Delusions 0 0 0 no entries 
2. Hallucinations 10 1 10 1337 
3. Agitation or aggression 76 8 47 1085-1695 
4. Depression or dysphoria 131 15 61 752-1695 
5. Anxiety 765 78 110 650-1892 
6. Elation or euphoria 12 1 12 1687 
7. Apathy or indifference 363 42 89 650-1751 
8. Disinhibition 25 2 21 1111, 1191 
9. Irritability or lability 22 2 20 1337, 1687 
10. Motor disturbance 32 3 21 1687 
11. Nighttime behaviours 293 31 69 650-1892 
12. Appetite and eating 129 11 62 650-1892 
 
Apathy or indifference also scored highly, mainly due to the inclusion of huang hu 恍惚 which, 
depending up on the context, can refer to dreaminess, absent mindedness, dissociation, or lack of 
interest in the world around and is commonly associated with jian wang in the literature. The main 
nighttime behaviours were insomnia and frequent dreaming. Depression and lack of joy were the next 
most frequent followed by eating disorders most of which were lack of interest in food or eating 
strange things. Agitation and aggression was broadly interpreted to include a range of symptoms such 
as agitation (fan zao 煩躁), manic behaviour (kuang 狂), madness (dian kuang 癲狂), and rage 
(kuang nu 狂怒) but these were relatively infrequent in the data set.  
 
To what extent the above list of symptoms reflected their incidence in persons with memory loss in 
pre-modern China is questionable but it is of interest to note that amongst modern populations of 
dementia patients, apathy, agitation, anxiety and irritability are high frequency symptoms while 
hallucinations, euphoria and delusions are less frequent [304].  
 
Due to the low frequencies of some symptoms, herb lists are only presented for NPI symptom 
categories 3, 4, 5, 7, 9, 11 and 12 in Table 6.19 below.  
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It was expected that there would be considerable differences between the lists in Table 6.19 since 
these NPI symptoms were quite distinct. However, there is a high level of similarity in the top ten 
herbs in each list, particularly in the higher frequency categories NPI 5, 7 and 11. The herbs in bold 
are also found in the high frequency herb list for memory score = 1-3 (Table 6.6). Of these, a number 
were the same herbs as in the more general lists for memory, i.e. yuan zhi 遠志 (Polygala tenuifolia), 
ren shen 人參 (Panax ginseng), di huang 地黃 (Rehmannia glutinosa), fu shen 茯神 (Poria cocos), 
chang pu 菖蒲 (Acorus graminus or A. calamus), fu ling 茯苓 (Poria cocos), zhu sha 朱砂 
(cinnabar) and gan cao 甘草 (Glycyrrhiza uralensis). Some distinctions between lists emerge within 
the top 20 herbs, with huang lian 黃連 (Coptis chinensis), appearing for anxiety (NPI 5), fang feng 
防風 (Saposhnikovia divaricata) for apathy (NPI 7), and hu po 琥珀 (amber) for apathy and sleep 
disturbance (NPI 11), but beyond these most of the distinctions only emerged in the lower frequency 
items. 
 
Step-wise analyses for NPI according to combined DSM IV-TR criteria 
The NPI scores were progressively resticted according to the DSM IV-TR criteria of memory and 
ageing (see table 6.20). Whereas the general exclusions resulted in entries for NPI categories 2-12, 
once a memory score of 1, 2 or 3 was introduced as a criterion, no entries remained in NPI categories 
2, 6, 9 or 10. At memory = 2 or 3 the results remained similar but at memory = 3, NPI categories 8 and 
12 were removed leaving only 91 herb entries (HE) in the data set. When memory and ageing scores 
were combined, the range of NPI symptoms was further restricted with only NPI 4 (depression), 5 
(anxiety) and 11 (nighttime behaviours) remaining at memory = 2-3 plus ageing = 1-3.  
 
Table 6.20: Step-wise exclusions according to memory and ageing scores (frequency of HE) 
NPI category 2 3 4 5 6 7 8 9 10 11 12 Total 
General Exclusions 10 76 131 765 12 363 25 22 32 293 129 1458 
Memory 1-3 0 70 103 755 0 342 25 0 0 284 72 1314 
Memory 2-3 0 70 103 699 0 342 25 0 0 284 72 1175 
Memory 3 0 9 10 28 0 10 0 0 0 2 0 91 
Memory 1-3 & ageing 1-3 0 0 7 39 0 0 0 0 0 15 0 147 
Memory 2-3 & ageing 1-3 0 0 7 39 0 0 0 0 0 15 0 125 
Memory =3 & ageing 1-3 0 0 0 0 0 0 0 0 0 0 0 0 
Memory 2-3 & ageing 2-3 0 0 0 15 0 0 0 0 0 15 0 94 
Memory 2-3 & ageing =3 0 0 0 0 0 0 0 0 0 0 0 0 
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At memory = 3 plus a score for ageing, no entries remained but at memory = 2-3 plus ageing = 2-3 
entries remained in NPI 4 and NPI 11 only, so this was the highest level of restriction possible in the 
NPI data set. What remained were two formulas as follows:  
 
1. Long yan rou zhou 龍眼肉粥 is a kind of porridge referenced to the Lao Lao Heng Yan 老老恒言 
of 1773 which comprised long yan rou 龍眼肉 (longan fruit), hong zao 红棗 (red jujube), and jing 
mi 粳米  (rice). It aims to strengthen Heart, Spleen and blood and treat disorders including, 
palpitations 心悸, insomnia 失眠, jian wang, loose stool due to digestive weakness 脾心虛腹瀉 etc 
and hence received scores for NPI 5 and 11. It received a score for ageing based on the book title.   
 
2. Long chi zhen xin dan 龍齒鎮心丹 is referenced to the Tai Ping Hui Min He Ji Ju Fang 太平惠
民和劑局方 of 1078 and also to Pu Ji Fang 普濟方. Comprising long chi 龍齒 (fossilized teeth), 
yuan zhi 遠志 (Polygala tenuifolia)，tian men dong 天門冬 (Asparagus cochinchinensis)，shu di 
huang 熟地黃 (Rehmannia glutinosa)，shan yao 山藥 (Dioscorea opposita)，fu shen 茯神 (Poria 
cocos)，mai men dong 麥門冬 (Ophiopogon japonicus)，che qian zi 車前子 (Plantago asiatica)，
bai fu ling 白茯苓 (Poria cocos)，gui xin 桂心 (Cinnamomum cassia), di gu pi 地骨皮 (Lycium 
barbarum)，and wu wei zi 五味子 (Schisandra chinensis) it aims to ‘nourish essence and marrow, 
blood and qi and’ (益精髓，養血氣) and also to ‘improve the complexion and make you look younger’ 
(悅色駐顏) which is why it received an ageing score. Its indications included palpitations 驚悸, jian 
wang and disturbed sleep 夢寐不安 which accounted for its NPI 5 and 11 scores.  
 
The book entries for these two formulas only use the term jian wang without any further description 
and their use for ageing is inferred from the context, so they are not strong matches to the AD criteria. 
Nevertheless, they do contain numerous herbs indicated for jian wang. The food formula is quite 
simple but its primary ingredient long yan rou 龍眼肉 is the third most common herb for jian wang 
according the the results of the ben cao search. This is illustrative of how a common therapeutic food 
item can be swamped in a data set derived from medical formulas. 
 
In the more complex second formula, nine of the twelve constituent herbs were indicated for jian 
wang in the ben cao search, including those with the two highest frequencies (fu shen and yuan zhi). 
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Therefore, although the list of herbs turned out to be overly restricted for the purpose of selecting a 
candidate list, both the remaining formulas were consistent with an age-related memory disorder.  
 
Summary and discussion of key findings of this chapter 
The ben cao search reported in part 1 of this chapter found that about 76 different items of materia 
medica have been indicated for jian wang and related terms over the span of the classical ben cao 
literature. It also found that about 6 items were reported to cause jian wang but these tended to be 
items seldom used in formulas. It was expected that the ben cao would tend to accumulate new items 
for jian wang over time. While this was generally the case, there was also a counter trend which saw 
items dropping out of use for jian wang. These trends may have been due the more general trend in the 
ben cao literature for a progressive increase in the total number of entries up to the monumental Ben 
Cao Gang Mu followed by a series of shorter, less detailed ben cao.  
 
With regard to the analyses of the individual herb data from the ZYFJDCD in part 2, following the 
removal of items based on the general exclusion criteria, a substantial data set of 1,458 items remained 
which included more than half of the herbs indicated for jian wang in the ben cao search. When the 
memory scores were progressively applied, the data set was considerably restricted to only 91 items 
(comprising 41 different herbs) at a memory score of 3, which represented a memory loss disorder 
consistent with AD. Of the herbs on this list 66% were found to be indicated for jian wang in the ben 
cao search and this proportion was higher amongst the higher frequency items. Therefore the 
frequency data from both the ben cao and ZYFJDCD searches tended to agree. Not only did formulas 
for jian wang mainly include materia medica which were individually indicated for jian wang, the 
most frequent herbs in the formulas were also the most frequent inclusions in the ben cao literature.  
 
The addition of ageing scores and scores for the group 2 symptoms further restricted the data set to 
only 36 and 15 items respectively. Nevertheless, the remaining herbs tended to be high frequency 
items for jian wang found under the less restrictive criteria for memory. While these lists of herbs 
were the ones that best satisfied the DSM IV-TR criteria for AD, the overall low frequencies of ageing 
scores and group 2 symptom scores meant that once all the criteria were applied, the remaining 
formulas were too small a subset of the total to produce lists of herbs suitable for further research.  
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Sub-group analysis of the chi dai entries found that few formulas aimed to treat both chi dai and 
memory loss (jian wang) so there was little overlap between these conditions. Even so, a sizeable 
proportion (44%) of the herbs in the chi dai formulas were individually indicated for jian wang in the 
ben cao search. This was probably due to these herbs having a wide range of applications in mental 
disorders. When the memory enhancement sub-group was investigated, a similar set of herbs to those 
for jian wang was found, so the same herbs were used to both treat memory loss and to improve 
memory in normal people.  
 
It had been expected that the NPI criteria would result in quite different sets of herbs since they cover 
a broad range of symptoms. This was partially the case but the higher frequency herbs for jian wang 
tended to dominate each of the NPI lists. The main reason for this was that the overall data set was 
mainly for jian wang so this characteristic tended to be reflected in the subsets. Consequently, even 
though there are differences associated with the NPI symptoms, these were mostly in the lower 
frequency herbs. When the NPI categories were restricted by the addition of scores for memory and 
ageing, the number of entries declined steeply since the the overall frequencies of items in these 
categories was relatively low. Neverthess, when memory and ageing were combined, the few 
remaining items were broadly consistent with age-related memory loss. 
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CHAPTER 7 
RESULTS FOR ZHYD: FREQUENTLY USED INDIVIDUAL HERBS  
 
This chapter presents the results of the analyses of the ZHYD data set at the level of the individual 
items of materia medica. This is the third and largest of the three sets of classical data included in this 
study. The method and reporting procedures are the same as those that were described for the 
ZYFJDCD (Chapter 6) to enable direct comparison between the data sets.  
 
General categorisation criteria 
The total numbers of herb entries under each criterion for the full ZHYD data set are presented in 
Table 7.1. Entries derived from modern books accounted for only 0.6% of the total data set (13,737 
herb entries) which was considerably lower than the 9.2% of the ZYFJDCD (see Chapter 6). At 4.9%, 
the ZHYD data set included a larger proportion of CVA related entries than the ZYFJDCD (2.0%). 
The probable reason was such entries were not included by the editors of the ZYFJDCD under the 
category of jian wang whereas the search procedure used for the ZHYD found and included them. The 
673 herb entries in this group were sufficient for a sub-group analysis. The proportion of diseases of 
children was even lower than in the ZYFJDCD (1.1%), whereas the proportion of acute conditions 
was considerably higher at 6.3% compared with 3.3% in the ZYFJDCD. Again, it is likely that the 
ZYFJDCD would have categorised many of the acute disease entries differently, particularly when 
they related to febrile diseases.  
 
Table 7.1: General categorisation criteria for ZHYD data set 
Criteria F. HE % of total data set 
1. Child, young person 12 0.1 
2. Acute condition e.g. associated with fever 871 6.3 
3. Mental disorder not consistent with dementia e.g. psychotic episode 59 0.4 
4. Physical disease unlike dementia e.g. seizures, head injury, range of 
physical symptoms  
253 1.8 
5. Modern literature i.e. from post-1911 book 84 0.6 
6. Indications of cerebro-vascular accident e.g. zhong feng, hemiplegia 673 4.9 
7. To improve memory only, not for disease, good for study, or disorder 
due to over reading/study 
371 2.7 
8. Woman’s disease i.e. specifically associated with gynaecological 
disease e.g. post-partum 
190 1.4 
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While the proportion of entries categorised as improve memory only (2.7%) was lower than in the 
ZYFJDCD data set (5.1%), due to the much larger size of the total set there were more than four times 
as many such entries, which made sub-group analysis more feasible. 
 
Exclusion of entries according to general categorisation criteria 
A step-wise series of exclusions of entries based on the criteria discussed above was conducted to 
arrive at a data set suitable for further analysis. The procedure was the same as for the ZYFJDCD and 
the aim was to include all entries that could be relevant to age-related dementias and to ensure both 
data sets were comparable. The results of the exclusions are tabulated in Table 7.2. 
 
Table 7.2: Summary results for step-wise exclusions for ZHYD data set 
Criteria No. HE No. FE No. IH Yr range 
1. Full data set 13,737 1450 370 206-1956 
2. Exclude modern books 13,653 1441 364 206-1911 
3. Exclude modern books & children 13,641 1440 364 206-1911 
4. Exclude modern books & children & women only 13,451 1412 363 206-1911 
5. Exclude modern books & children & women only 
& acute condition 
12,584 1234 348 543-1911 
6. Exclude modern books & children & women only 
& physical disease unlike dementia 
12,336 1209 346 543-1911 
 
The total ZHYD data set contained 13,737 herb entries. This was more than eight times the size of the 
full ZYFJDCD data set (1,676). These entries represented 1,450 formulas that comprised 370 different 
herbs, after the herb data had been recoded. The number of distinct herb names was considerably 
greater. Following the series of six exclusions detailed in Table 7.2 the data set retained 12,336 herb 
entries, 1,209 formula entries and 346 distinct herbs. Compared with the ZYFJDCD (1,458), the size 
of the ZHYD data set used in the subsequent analyses was over 8.4 times as large.  
 
The dates of the books in the complete set ranged from c. 206 AD to c. 1956, so a broad scope of the 
classical literature was included plus a very small proportion of books from the modern period. 
Following the exclusions, the most recent books were dated at c. 1911. Unlike the ZYFJDCD, which 
included an appendix that listed years for most books, dates were not provided in the ZHYD. 
Estimates were required in a number of instances and Qing dynasty works of unknown date were 
assigned a date of 1911 (the final year of the dynasty). Since the earliest entries, from the Shang Han 
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Lun 傷寒論 and Mai Jing 脈經, both referred to the use of Di dang tang 抵當湯 in a febrile disease, 
once the acute conditions were excluded the range of book dates was reduced to the period 543-1911. 
 
The main overall differences between the ZYFJDCD and the ZHYD data sets were in the proportions 
of modern books and acute conditions, both of which were removed from the subsequent analyses. 
The main remaining difference was the relatively higher proportion of CVA-related entries in the total 
ZHYD but following exclusions these entries accounted for only 0.2% of the total. 
 
Table 7.3: High frequency herbs in the ZHYD data set following exclusions (n=31) 
Herb Name F  Herb Name F  Herb Name F  Herb Name F 
Ren shen 752  Mai dong 303  Fang feng 183  Jie geng 115 
Yuan zhi 676  Bai zhu 292  Wu wei zi 182  Ban xia 107 
Fu ling 579  Rou gui/gui zhi 290  Bai shao 150  Rou cong rong 99 
Gan cao 522  Suan zao ren 262  Tian dong 146  Niu xi 98 
Di huang 427  Huang qi 244  Shan yao  145  Fu zi 96 
Dang gui 404  Zhu sha 233  Chuan xiong 142  Dan shen 94 
Fu shen 388  Jiang 194  Mu xiang 141  Long yan rou 94 
Chang pu 347  Long gu/chi 186  Bai zi ren 134  Total 12336 
F=Frequency 
 
The top 31 highest frequency herbs in the ZHYD data set, following the exclusions, are presented in 
Table 7.3 (from left to right). The similarity with the ZYFJDCD was striking with all but seven of the 
above herbs (marked in bold) also being in the top 30 highest frequency herbs in the ZYFJDCD (see 
Table 6.4). Of these, long yan rou 龍眼肉 (Dimocarpus longan) was an inclusion in the ben cao list 
for memory, jiang 薑 (ginger) was an additional ingredient in many formulas and rou cong rong 肉
蓯蓉 (Cistanche deserticola) is typical herb for ageing and debility, but herbs such as chuan xiong 
(Ligusticum chuanxiong), mu xiang 木香  (Aucklandia lappa), jie geng 桔梗  (Platycodon 
grandiflorus) and niu xi 牛膝 (Achyranthes bidentata) were unexpected high frequency inclusions. 
Nevertheless, the overall similarity in the lists suggests both data sets were from a similar population 
of formulas. 
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The DSM IV-TR criteria 
The 12,336 herb entries remaining after the exclusions listed above formed the basis for further 
analyses according to the ratings based on the DSM IV-TR criteria. The results for the memory scores 
are presented first, followed by those for ageing and then for the group 2 symptoms.  
 
Results for memory scores 
The results for each memory score are presented in Table 7.4. In 11.8% of the herb entries there was 
no mention of any of the search terms for memory loss or memory improvement. This was a 
somewhat greater proportion than the 9.2% in the ZYFJDCD data set, but the overall proportions of 
the three memory scores were comparable between the ZHYD and the ZYFJDCD data sets. As in the 
ZYFJDCD, the largest proportion (78.7%) was for a memory loss disorder without further relevant 
detail (memory = 2). The proportion (2.9%) that contained sufficient information for the memory 
disorder to be rated as consistent with dementia (memory = 3) was smaller than in the ZYFJDCD 
(6.2%). However, 31 formulas and 68 different herbs still satisfied this criterion compared with 11 and 
41 respectively in the ZYFJDCD data set.  
 
Table 7.4: Results for memory scores in ZHYD data set  
Memory score No. HE % herbs No. FE No. IH Yr range 
0. No mention of memory 1451 11.8 166   
memory = 1,2,3 10885 88.2 1043 316 543-1911 
1. Improve memory 815 6.6 86 127 543-1764 
2. Memory loss disorder 9713 78.7 926 311 543-1911 
3. Consistent with dementia  357 2.9 31 68 652-1883 
Total 12336 100.0 1209   
 
The year range indicates that references to memory loss disorders were found throughout the period 
encompassed by the data set. The first memory improvement formula, Kai xin san 開心散, appeared 
in the Ji Yan Fang 集驗方 (c. 543) of the Northern and Southern Dynasties period. It simply stated: 
‘a formula to prevent forgetting (令人不忘方),’ and its four ingredients were chang pu 菖蒲 (Acorus 
graminus or A. calamus), fu ling 茯苓 (Poria cocos), ren shen 人參 (Panax ginseng) and yuan zhi 
遠志 (Polygala tenuifolia), all of which were high frequency herbs in the ZYFJDCD data set.  
 
The first formula with a rating of memory = 2 was Huang qi jiu 黃耆酒 (also in the Ji Yan Fang 集
驗方) but it was indicated for a diversity of symptoms, most of which were associated with disorders 
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of movement and pain, with shan wang 善忘 being an additional symptom, so it was not a good 
exemplar (see appendix 3 for the ingredients of this formula). However, the Bei Ji Qian Jin Yao Fang 
備急千金要方 of c. 652 contained an unnamed formula which was the same as that in the Ji Yan 
Fang 集驗方, except for the addition of fu shen 茯神 (Poria cocos). It was for treating duo wang 多
忘 as well as preventing forgetting (令人不忘方). The book also added that frequent consumption 
would improve intelligence (常服令人大聰) (see appendix 3 for the ingredients of this formula). The 
first memory = 3 formula, Da ba feng tang 大八風湯 was also derived from the Bei Ji Qian Jin Yao 
Fang. In one of five sets of indications, it was indicated for: ‘dissociation, talks a lot but forgets, and is 
sometimes frightened (恍恍惚惚，多語善忘，有時恐怖)’.  
 
When the herbs were sorted according to any score for memory (Table 7.5 list 1 m=1-3) the overall 
characteristics of the list in Table 7.3 remained; removing the entries that made no reference to 
memory made little overall difference to the herb frequencies at the higher end. At a memory score of 
3, the list remained very similar with only seven different items on list 4 (in bold) compared with list 1, 
and all of these were lower frequency items. In the case of the herbs for improving memory but not for 
jian wang, there were greater differences, with the herbs tu si zi 菟絲子 (Cuscuta chinensis), du 
zhong 杜仲 (Eucommia ulmoides) and ba ji tian 白戟天 (Morinda officinalis) appearing in the top 
20 (in bold). There were other differences in the lower frequencies but the high frequency herbs were 
very similar across all lists. Thus the herbs that were used to treat memory disorders tended to be the 
same as those used to improve memory in the absence of a memory loss disorder, which is the same 
conclusion as was made for the ZYFJDCD.  
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Table 7.5: Lists of the highest frequency (F) herbs that received memory scores (m) from 1 to 3 
 
List 1 
m=1-3 
F. List 2 
m= 1 
F. List 3 
m=2 
F. List 4 
m=3 
F. 
1 Ren shen 661 Yuan zhi 62 Ren shen 581 Ren shen 25 
2 Yuan zhi 619 Ren shen 55 Yuan zhi 540 Gan cao 19 
3 Fu ling 510 Fu ling 50 Fu ling 442 Fu ling 18 
4 Gan cao 458 Chang pu  42 Gan cao 422 Yuan zhi 17 
5 Di huang 389 Di huang  34 Dang gui 347 Dang gui 13 
6 Dang gui 371 Rou gui/gui zhi 22 Di huang  345 Fu shen 13 
7 Fu shen 335 Tu si zi 21 Fu shen 307 Bai zhu 12 
8 Chang pu 309 Tian dong 20 Chang pu  257 Chang pu  10 
9 Bai zhu 263 Bai zi ren 20 Bai zhu 245 Di huang  10 
10 Rou gui/gui zhi 263 Rou cong rong 19 Mai dong 236 Suan zao ren 10 
11 Mai dong 260 Wu wei zi 18 Rou gui/gui zhi 234 Huang qi 9 
12 Suan zao ren 231 Gan cao 17 Suan zao ren 213 Mai dong 9 
13 Huang qi 226 Shan yao 17 Huang qi 210 Jiang 9 
14 Zhu sha 189 Du zhong 15 Zhu sha 176 Bai shao 8 
15 Wu wei zi 172 Mai dong 15 Fang feng 150 Rou gui/gui zhi 7 
16 Fang feng 163 Fu shen 15 Jiang 149 Chuan xiong 6 
17 Jiang 163 Ba ji tian 12 Long gu/chi 149 Wu wei zi 6 
18 Long gu/chi 162 Long gu/chi 12 Wu wei zi 148 Chen pi 6 
19 Shan yao 138 Dang gui 11 Mu xiang 123 Ban xia 6 
20 Tian dong 136 Zhu sha 11 Bai shao 122 Fang feng 6 
21 Bai shao 133 Gou qi zi 10 Chuan xiong 119 Bai zi ren 6 
22 Mu xiang 131 Xu duan 10 Shan yao 119 Shi gao 5 
23 Chuan xiong 129 She chuang zi 9 Tian dong 113 Dan shen 5 
24 Bai zi ren 122 Bai zi ren 96 Mu xiang 5 
25 Jie geng 103 Jie geng 91 Zi wan 5 
26 Niu xi 97 
Shan zhu yu, Dan 
shen, Suan zao ren, 
Jie geng, Mi jiao, 
Bing lang 
8 
Long yan rou 89 Xuan shen 5 
27 Niu xi 89 Long yan rou 5 
28 
Rou cong rong 
Long yan rou 
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Shan zhu yu 77 Yi zhi ren 5 
29 Dan shen 89 Dan shen 76 Xiang fu 5 
30 Shan zhu yu 87 
Huang qi, Feng mi, 
Qin jiao  
7 
Rou cong rong 75 Wu tou 5 
 Total: 10,885 Total: 815 Total: 9,713 Total: 357 
 
Results for ageing scores 
As in the ZYFJDCD data set, indications for older age were infrequent with 91.8% of herb entries 
providing no evidence, direct or indirect, that the formula was intended to promote longevity or was 
indicated for older people (see Table 7.6). At 4.9%, the proportion of promote longevity entries was 
exactly the same as in the ZYFJDCD and the proportion of entries indicated for older people (2.2%) 
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was slightly lower than in the ZYFJDCD (3.9%). Nevertheless, the overall proportions of ageing 
scores were similar between the two data sets.  
 
Table 7.6: Results for ageing scores in ZHYD data set 
Ageing score No. HE. Percent No. FE. No. IH Yr range 
0. No reference to age or longevity 11330 91.8 1109   
ageing = 1,2,3 1006 8.2 100 166 652-1866 
1. Indirect mention of longevity 131 1.1 12 58 1615, 1771 
2. Promote longevity 608 4.9 67 143 652-1866 
3. Indicated for older people 267 2.2 21 58 682-1839 
Total 12336 100.0 1209   
 
Even though the proportion of references to ageing was low, there were still 1,006 herb entries that 
satisfied the ageing criteria. One example of a promote longevity formula that scored ageing = 2, was 
the formula Gou qi zi jian 枸杞子煎 from Pu Ji Fang 普濟方 of 1107 which could: ‘extend your 
years and lengthen your life (延年長生),’ as well as ‘strengthen memory (強記)’ (see appendix 3 for 
the ingredients of this formula). An example of ageing = 3 was Xiao dan 小丹 from the San Yin Ji Yi 
Bing Zheng Fang Lun 三因極一病證方論 of 1174 which aimed to: ‘supplement exhaustions and 
improve blood (補勞益血),’ and was good for ‘old people with dried up essence and depleted spirit 
(老人精枯神耗),’ This book stated that ‘long term consumption can nourish longevity and prolong 
life (久服益壽延年)’ (see appendix 3 for the ingredients of this formula).  
 
Lists of the higher frequency herbs are presented in Table 7.7. The relatively small totals make 
comparisons between lists less convincing than for the memory scores, particularly since there were 
only 161 items that scored ageing = 1-3 in the ZYFJDCD. Even so, the lists were very similar across 
the samples, with all 19 of the high frequency herbs in the ZYFJDCD (see Table 6.9 list 1) appearing 
in list 1 of Table 7.7. As was the case for the ZYFJDCD, there was considerable overlap between the 
lists for memory, with most of the high frequency herbs appearing on both lists. When ageing = 3 was 
considered (Table 7.7, list 4), all of the top 10 herbs also appeared on the list for memory = 1-3 (Table 
7.5, list 1), but in the remainder of the list 12 herbs were different (in bold). Of these, ba ji tian 
(Morinda officinalis), tu si zi 菟絲子 (Cuscuta chinensis), du zhong 杜仲 (Eucommia ulmoides) and 
xu duan 續斷 (Dipsacus asperoides) are notable as common inclusions in formulas for debility and 
old age. Just as for the ZYFJDCD, the ageing scores produced lists of herbs that reflected the overall 
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characteristics of the herbs for memory, and the most likely reason for this was the original data set 
was dominated by formulas for treating jian wang.  
 
Table 7.7: Frequencies (F) of herb entries for ageing scores (a) from 1 to 3 
n. List 1 
Age =1-3 
F. List 2 
Age = 1 
F. List 3 
Age =2 
F. List 4 
Age =3 
F. 
1 Ren shen 58 Yuan zhi 9 Ren shen 33 Di huang  18 
2 Yuan zhi 52 Ren shen 8 Fu ling 32 Ren shen 17 
3 Fu ling 49 Dang gui 8 Yuan zhi 27 Chang pu  16 
4 Di huang 49 Suan zao ren 7 Di huang  25 Yuan zhi 16 
5 Chang pu 34 Di huang  6 Tu si zi 22 Fu ling 12 
6 Zhu sha 29 Gan cao 5 Zhu sha 22 Shan zhu yu 10 
7 Tu si zi 28 Fu ling 5 Nan xing 20 Tian dong 10 
8 Rou cong rong 27 Huang qi 4 Rou cong rong 20 Bai zi ren 10 
9 Nan xing 22 Bai zhu 4 Hu po 20 Mai dong 9 
10 Gan cao 22 Fu shen 4 Chang pu  15 Rou cong rong 7 
11 Bai zi ren 21 Long yan rou 4 Gan cao 14 Ba ji tian 7 
12 Wu wei zi 20 Chang pu 3 Wu wei zi 12 Tu si zi 6 
13 Hu po 20 Mai dong 3 Niu xi 12 Fu pen zi 6 
14 Tian dong 18 Bai shao 3 Xu duan 11 Wu wei zi 6 
15 Dang gui 17 Bai zi ren 3 Ba ji tian 10 Du zhong 6 
16 Shan zhu yu 17 Chuan xiong 2 Du zhong 9 Shan yao 6 
17 Ba ji tian 17 Nan xing 2 Shan yao 8 Ze xie 6 
18 Fu shen 17 Wu wei zi 2 Rou gui/gui zhi 8 Rou gui/gui zhi 6 
19 Xu duan 17 Huang lian 2 Bai zi ren 8 Fu shen 6 
20 Shan yao 16 Shan yao  2 Bing lang 8 Xu duan 6 
21 Du zhong 15 Jiang 2 Gou qi zi 7 She chuang zi 6 
22 Rou gui/gui zhi 15 Zhu sha 2 Fu pen zi 7 Shi hu 6 
23 Mai dong 15 Long gu/chi 2 Fu shen 7 Zhu sha 5 
24 Suan zao ren 15 Da zao 2 Tian dong 7 Bai jie zi 5 
25 Fu pen zi 13 Mu xiang 2 She chuang zi 7 
26 Bai zhu 13 Huang qin 2 Qin jiao 7 
Bai zhu, Suan zao 
ren, Tian xiong 
4 
27 She chuang zi 13 Gui jia 2 
28 Niu xi 13   
29 Huang qi 11   
30 Shi hu 10   
Dang gui, Shan 
zhu yu, Mi jiao, 
Tong cao 
6 Huang qi, Gan cao, 
Dang gui, Xuan 
shen, Shi zhong 
ru, Lu rong 
3 
 Total: 1006 Total: 131 Total: 608 Total: 267 
 
Results for group 2 symptoms 
Aphasia was the most common symptom category, as in the ZYFJDCD data set (5.3%). And whereas 
there were no entries for apraxia or disturbance in executive functioning in the ZYFJDCD data set, 
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8.5% of herb entries in the ZHYD received a score for apraxia (see table 7.8). This was largely due to 
the greater proportion of possible CVA entries in the total data set, since 75.9% of these were scored 
for apraxia.  
 
Table 7.8: Results for group 2 symptom scores in ZHYD data set 
Group 2 symptom categories No HE % No. FE No.IH  Yr range 
2.1. Aphasia 1767 14.3 109 194 682-1911 
2.2. Apraxia 1048 8.5 57 161 652-1911 
2.3. Agnosia 85 0.7 10 46 752-1883 
2.4. Disturbance in executive functioning 30 0.2 3 18 1481, 1591 
 
One example scored as agnosia was from the Yi Xue Jian Neng 醫學見能 of 1873, which stated: 
‘what they say is upside down, the person has chi [dai] and cannot recognise people (出言顛倒，其人
痴不識人者).’ In this case there was no mention of memory, so no memory score was given (see 
appendix 3). Examples of disturbance in executive functioning were rare and their inclusion required a 
broad view of the DSM IV-TR criteria. For example, in the Dan Xi Xin Fa 丹溪心法 of 1481 under a 
discussion of the formula Gui pi tang 歸脾湯 for jian wang, it is stated: ‘the person starts doing 
something but cannot finish it (為事有始無終), [you] cannot make head nor tail of what they are 
talking about (言談不知首尾), [jian wang] is the name of this disease (此以為病之名); the person is 
not being naughty or contrary, they just don’t know [what they are doing] (非比生成之愚頑不知人事
者).’ The other formula entry was for the same formula with a similar set of indications, but was from 
a later book, the Yun Lin Shen Gou 雲林神彀 of 1591.   
 
In neither of the above examples were all the criteria for probable dementia present, since ageing was 
missing in both cases and a memory disorder could only be inferred in the first example. Nevertheless, 
these descriptions do throw light on the kinds of disorders encountered in the past and how they were 
conceptualised. In both examples, the person had disordered speech but in the first case the condition 
was considered to be chi dai whereas in the second example the disorder was jian wang.  
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Table 7.9: Frequencies (F) of herb entries for group 2 symptoms (Gp 2) from 1 to 4 
n Gp 2.1. 
Aphasia 
F. Gp 2.2. 
Apraxia 
F. Gp 2.3. 
Agnosia 
F. Gp 2.4. 
Exec. Func. 
F. 
1 Ren shen 68 Rou gui/gui zhi 37 Ren shen 6 Gan cao 3 
2 Gan cao 65 Fang feng 35 Chang pu 5 Bai zhu 3 
3 Fu ling 57 Chuan xiong 34 Ban xia 4 Suan zao ren 3 
4 Dang gui 48 Gan cao 34 Gan cao 3 Ren shen 2 
5 Fang feng 48 Ren shen 33 Fu ling 3 Dang gui 2 
6 Rou gui/gui zhi 43 Fu ling 32 Fu zi 3 Fu ling 2 
7 Bai shao 41 Du huo 31 Suan zao ren 3 Yuan zhi 2 
8 Chuan xiong 40 Dang gui 29 Zhu sha 3 Mu xiang 2 
9 Yuan zhi 40 Ma huang 28 Fu shen 3 Long yan rou 2 
10 Huang qin 39 Bai shao 26 Bai shao 3 Chang pu 1 
11 Di huang 34 Di huang 23 Da huang 3 Huang qi 1 
12 Mai dong 34 Yuan zhi 22 Tao ren 3 Di huang  1 
13 Zhu sha 32 Wu tou 21 Chai hu 2 Chen pi 1 
14 She xiang 31 Huang qi 18 Dang gui 2 Mai dong 1 
15 Jiang 30 Qin jiao 18 Yuan zhi 2 Zhi mu 1 
16 Niu huang 30 Shi gao 17 Shen qu 2 Fu shen 1 
17 Bai zhu 29 Wu wei zi 15 Wu zhu yu 2 Bai shao 1 
18 Chai hu 28 Xing ren 15 Qian dan 2 Huang bo 1 
19 Fu shen 26 Cha ye 2   
20 Jie geng 25 
Bai zhu, Jiang, 
Huang qin 
14 
Zhu xin 2   
21 Xi jiao 24 Qiang huo 13 2   
22 Zhu sha, Shi hu 12 
Rou gui/gui 
zhi 
   
23     
24 
Jin bo, Ling yang 
jiao, Shen qu, 
Xiong huang 
23 
  
  
25 Shan yao, Long nao 22 
Du zhong, Fu zi, 
Xi xin, Niu xi, Bai 
zhi 
11 
    
26   
  
27 
Ban xia, Xing ren, 
Ma huang 
21 Ban xia, Di gu pi, 
Bai xian pi 
10 
    
 Total: 1,767 Total: 1,048 Total: 85 Total: 30 
 
The frequencies of individual herbs for each of the group 2 symptoms are presented in Table 7.9. Too 
few entries received scores for group 2 symptoms in the ZYFJDCD to allow comparison. Therefore 
the largest lists, for aphasia (list 1) and apraxia (list 2), were compared with those for memory = 1 to 3 
(Table 7.7, list 1), of which they were a subset. Both lists show considerable overlap of higher 
frequency items with those for memory, but there were also a number of different herbs on the lists 
(shown in bold). These were presumably the herbs that focussed on the additional symptoms of 
language disturbance (aphasia) or movement disorder (apraxia). There is insufficient space to examine 
the indications for each of these herbs, but what is apparent is that many of the additional herbs differ 
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between the two lists. What these lists appear to be reflecting is differences in treatment when memory 
loss is associated with different kinds of additional symptoms. Since the spectrum of these additional 
symptoms could only have been captured in a general manner by the group 2 symptom criteria, little 
can be inferred about the functions of these herbs. Nevertheless the herbs in bold tend to be those that 
are less focussed on improving memory or treating a memory disorder. 
 
Step-wise analyses according to combined DSM IV-TR criteria 
The procedure for progressively combining the scores for memory, ageing and group 2 symptoms 
(gp2 sx) was the same as for the ZYFJDCD data set (see Table 7.10). At the lowest level of restriction, 
memory = 1 to 3 and ageing = 1 to 3, 973 herb entries from 161 formulas found in books dated from 
652-1866 remained. This was only 9.2% of all the entries that received a memory score, so the effect 
of combining the relatively frequent memory scores with the infrequent scores for ageing drastically 
restricted the data set.  
When the memory score was restricted to memory = 3, while allowing an ageing score of 1 to 3, only 
38 entries and 4 formulas remained (step 3). This was the same set as for memory = 3 and ageing =3 
(step 8). One of the four remaining formula entries was Sheng hui tang 生慧湯 from the Bian Zheng 
Lu 辨證錄 of 1687 which was for: ‘an old person with jian wang (老年而健忘者) who frequently 
cannot remember recent events (近事多不記憶),’ about which the book stated: ‘even though someone 
tells him/her about the event (雖人述其前事), s/he are blank, with no knowledge of it (猶若茫然), 
this is truly and extreme case of jian wang (此真健忘之極也)’ (see appendix 3 for the ingredients of 
this formula).  
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Table 7.10: Summary results for step-wise restrictions according to DSM IV-TR criteria 
Inclusion Criteria No.HE No.FE No.IH Yr range 
1. Memory = 1, 2 or 3 & ageing = 1, 2 or 3 973 95 161 652-1866 
2. Memory = 2 or 3 & ageing = 1, 2 or 3 652 64 145 652-1866 
3. Memory = 3 & ageing = 1, 2 or 3  38 4 19 1622, 1687 
4. Memory = 1, 2 or 3 & ageing = 2 or 3 852 83 149 652-1866 
5. Memory = 1, 2 or 3 & ageing = 3 258 19 56 682-1839 
6. Memory = 2 or 3 & ageing = 2 or 3 540 53 132 652-1866 
7. Memory = 2 or 3 & ageing = 3 175 13 54 682-1839 
8. Memory = 3 & ageing = 3 38 4 19 1622, 1687 
9. Memory = 1, 2 or 3 & Group 2 symptom 1934 104 184 652-1911 
10. Memory = 2 or 3 & Group 2 symptom 1850 99 180 652-1911 
11. Memory = 3 & Group 2 symptom 131 10 51 682-1663 
12. Memory = 1, 2 or 3 & ageing = 1, 2 or 3 & Group 2 
symptom  
81 5 67 1170, 1406, 
1615, 1773 
13. Memory = 2 or 3 & ageing = 1, 2 or 3 & Group 2 
symptom  
68 3 61 1406, 1615, 
1773 
14. Memory = 3 & ageing = 1, 2 or 3 & Group 2 symptom. 0 0 0 0 
15. Memory = 2 or 3 & ageing = 2 or 3 & Group 2 symptom  65 2 58 1406, 1773 
16. Memory = 3 & ageing = 2 or 3 & Group 2 symptom 0 0 0 0 
17. Memory = 2 or 3 & ageing = 3 & Group 2 symptom 0 0 0 0 
 
Combining a memory score with the presence of any group 2 symptom (step 9) was less restrictive, 
leaving 1,934 herb entries and 104 formulas in the data set. Even when the memory score was 
restricted to 3, ten formula entries remained. One of these was the formula Bu xin tang 補心湯, from 
the Yun Lin Shen Gou 雲林神彀 of 1591, which stated: ‘the person has memory loss and does things 
with no purpose (健忘作事無終始), you cannot make head nor tail of what they say (言發不知首與
尾)’ (see appendix 3 for the ingredients of this formula).  
 
The herb entry frequencies for steps 1, 8, 9 and 12 are presented in Table 7.11. When compared with 
the ZYFJDCD, the higher frequency herbs in list 1 were very similar with the only notable differences 
being the presence of nan xing 南星 (Arisaema erubescens) and hu po 琥珀 (amber) on the ZHYD 
list (in bold).  
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Table 7.11: Herb frequency lists for combinations of DSM IV-TR criteria for ZHYD  
List 1: memory = 1, 2 or 3 & ageing = 1, 2 or 3 
List 2: memory = 3 & ageing = 3 
List 3: memory = 1, 2 or 3 & any Gp 2 symptom 
List 4: memory = 1, 2 or 3 & ageing = 1, 2 or 3, & any Gp 2 symptom 
n List 1 F. List 2 F. List 3 F. List 4 F. 
1 Ren shen 56 Ren shen 4 Ren shen 72 Fu zi 3 
2 Yuan zhi 49 Chang pu  4 Gan cao 72 Zhu sha 3 
3 Di huang 47 Di huang  4 Fang feng 64 Wu tou 3 
4 Fu ling 46 Yuan zhi 3 Fu ling 62 Ren shen 2 
5 Chang pu  32 Fu shen 3 Chuan xiong 57 Dang gui 2 
6 Zhu sha 28 Bai jie zi 3 Rou gui/gui zhi 57 Di huang  2 
7 Tu si zi 27 Shan zhu yu 2 Dang gui 54 Hu po 2 
8 Rou cong rong 26 Mai dong 2 Bai shao 45 She xiang 2 
9 Nan xing 22 Suan zao ren 2 Yuan zhi 44 Lu rong 2 
10 Gan cao 21 Bai zi ren 2 Huang qin 38 Wu ling zhi 2 
11 Bai zi ren 20 Chai hu 1 Bai zhu 36 Mo yao 2 
12 Hu po 20 Dang gui 1 Du huo 36   
13 Wu wei zi 19 Bai zhu 1 Ma huang 36   
14 Shan zhu yu 17 Fu ling 1 Di huang  32   
15 Ba ji tian 17 Dan shen 1 Xing ren 31   
16 Tian dong 17 Zhu sha 1   
17 Tian dong 1 
Jiang, Niu huang,  
She xiang 
30 
  
18 
Dang gui, Shan yao, 
Fu shen, Xu duan 
16 
Bai shao 1 Mai dong 29   
19 Xuan shen 1   
20   
Chai hu,  
Ling yang jiao 
27 
  
21 
Du zhong, Rou 
gui/gui zhi, Mai 
dong, Suan zao ren 
15 
  Zhu sha, Xi jiao 26   
22     
23 
Fu pen zi, Bai zhu, 
She chuang zi 
13 
  
Huang qi, Shan yao, 
Jie geng 
25 
  
24     Long nao 24   
 Total: 973 Total: 38 Total: 1934 Total: 81 
 
In the more restrictive list 2 (memory = 3 & ageing = 3), the similarities between the data sets were 
even more striking. Of the 19 herbs in list 2 of the ZYFJDCD (Table 6.11), all but three were also on 
list 2 of Table 7.11 (in bold). This was surprising since the total numbers in list 2 in both the 
ZYFJDCD and the ZHYD were low (36 & 38). When a memory score and a score for any of the 
group 2 symptoms were combined (List 3), the resultant list was larger than in list one. This was a 
very different result from that in the ZYFJDCD for which there were only 44 items in list 3. This was 
due to differences in the numbers of group 2 symptoms (discussed above). The higher frequency items 
common to both lists are marked in bold. All of these were items found on the list of high frequency 
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items for memory (see Table 7.5, list 1) but the differences in the size of the lists make further 
comparisons difficult. There were also similarities between the fourth lists for both data sets (in bold) 
but it appears that once the data was restricted by the addition of the group 2 criteria the similarities 
between the data sets were reduced.  
 
Subgroup analyses for the for ZHYD data set 
Due to the considerably larger size of the ZHYD data set, in comparison with the ZYFJDCD data set, 
there was more scope for examining the subgroups of chi dai (dementia), possible CVA and memory 
enhancement.  
 
Chi dai sub-group 
All of the entries that included at least one of the terms chi dai, dai bing or similar were coded 
separately. Whereas the ZYFJDCD contained only 10 formula entries of this type, 36 were found in 
the ZHYD (see Table 7.12). Overall, 6.5% of formulas in the ZYFJDCD treated chi dai compared 
with 3.0% of formulas in the ZHYD. In neither data set was chi dai a common condition, so the small 
number of chi dai entries relative to jian wang in the ZYFJDCD was not a negative selection bias on 
the part of the editors – it appears that this condition was actually infrequent throughout the literature. 
Even so, the instances did span the period 1146 to 1911.  
 
Table 7.12: Frequency of entries for chi dai in ZHYD data set 
Inclusion Criteria No. HE No. FE No.IH Yr range 
1. Chi dai only (condition = 9) 319 36 102 1146-1911 
2. Chi dai & memory = 1, 2 or 3  12 1 12 1883 [f 853] 
3. Chi dai & ageing = 1, 2 or 3  4 1 4 1146 [f 725] 
4. Chi dai & memory = 1-3 & ageing = 1-3 0 0 0 0 
 
As in the ZYFJDCD, the chi dai formulas seldom mentioned memory loss, with only one such 
occurrence. Similarly, only one formula received a score for ageing. While it may have been expected 
that this formula would have been the Shou xing wan found in the ZYFJDCD, this was not the case. 
Shou xing wan was found in the search, but since it was for a condition ‘like chi dai’ it was not scored 
as chi dai. In the ZYFJDCD search all formulas classified by the editors under the index term chi dai 
were scored as such in the database, whereas in the ZHYD the judgement of the raters was the 
criterion for assigning a chi dai score.  
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The earliest example of a chi dai formula was Yan Shou Dan 延壽丹 from the Bian Que Xin Shu 扁
鵲心書 c 1146 which stated that: ‘from middle age onwards it is natural for the body to progressively 
become weak (凡人至中年，天數自然虛衰), or a person can have unrealistic desires that lead to 
worry (或加妄想憂思), or a person can be disappointed in their quest for fame (或為功名失志), all 
these can use up the blood of the heart [mind] (以致心血大耗), and these can result in chi zui [i.e. chi 
dai] which is difficult to treat (癡醉不治), slowly the qi and essence run out and this leads to death (漸
至精氣耗盡而死). [To prevent this] you should moxa the acupoint guan yuan [Governor Vessel no 4 
in modern acupuncture] with 300 cones (當灸關元穴三百壯), and consume one jin [approx 700 g] of 
Yan Shou Dan (服延壽丹一斤).’ In this example it was evident that this was a mental disorder, and 
while it was associated with ageing there were insufficient symptoms to determine whether the 
disorder was an example of the modern conception of senile dementia, particularly since there was no 
mention of memory loss.  
 
Table 7.13: Frequency of top 34 individual herbs for chi dai in ZHYD data set 
Herb F  Herb F  Herb F  Herb F 
Gan cao 18  Fu zi  9  Huang lian 5  Yu jin 3 
Ren shen 16  Fu shen 9  Jiang 5  Fang feng 3 
Ban xia 14  Shen qu 8  Mu xiang 5  Shi gao 3 
Chang pu 11  Zhu sha 7  Zhi zi 4  Xuan shen 3 
Chen pi 10  Bai shao 7  Mai dong 4  Bai jie zi 3 
Suan zao ren 10  Chai hu 6  Niu huang 4  Ci shi 3 
Nan xing 9  Bai zhu 6  Huang qin 4  Meng shi 3 
Dang gui 9  Di huang 6  Zhi shi 4    
Fu ling 9  Yuan zhi 6  Da huang 4  Total 319 
 
Although the overall frequencies of the individual herbs for chi dai were fairly low for a meaningful 
comparison between the lists in the ZYFJDCD and ZHYD, the level of overlap was considerable (see 
Table 7.13). When the top 20 herbs of the ZYFJDCD were considered (i.e. those with a frequency of 
2-9), all but three appeared on the list above (marked in bold). Of course, this similarity would be 
expected since the samples were from the same overall population of literature, but it does indicate 
that the ZYFJDCD sample, although small, produced a list representative of the larger ZHYD sample. 
When compared to the high frequency herbs for memory (see Table 7.5, list 1), the similarities far 
outweighed the differences, with the high frequency memory herbs dominating the list. The few 
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differences were that nan xing 南星 (Arisaema erubescens), fu zi 附子 (Aconitum carmichaeli), 
shen qu 神麴 (fermented combination of herbs) and chai hu 柴胡 (Bupleurum chinense) appeared in 
the high frequency items for chi dai but not for memory, even though both nan xing and chai hu were 
on Li Shi-Jen’s lists of herbs for jian wang. This was the same as the result found in the ZYFJDCD.  
 
CVA (zhong feng) sub-group 
Whereas the CVA subgroup of the ZYFJDCD only contained 2 formulas, there were 31 in the ZHYD 
and 610 individual herb entries, of which a large proportion also received a memory score, but only 
one received an ageing score (see Table 7.14).  
 
Table 7.14: Frequency of entries for CVA subgroup in ZHYD data set 
Inclusion Criteria No. HE No. FE No. IH Yr range 
1. CVA only (criterion 6 = 1) 610 31 113 543-1883 
2. CVA & memory = 1, 2 or 3  586 28 109 543-1883 
3. CVA & ageing = 1, 2 or 3  12 1 11 1170 
4. CVA & memory = 1, 2 or 3 & ageing =1, 2 or 3 12 1 11 1170 
 
When the herb frequencies were examined, the CVA list was different to the previous lists in a number 
of respects (see Table 7.15). While a number of the herbs (in bold) were the same as the top 30 herbs 
for memory = 1-3 (list 1 of table 7.5), over half the list was different. Notable amongst these other 
herbs were herbs for disorders of: movement, for example du huo 獨活 (Angelica pubescens), qiang 
huo 羌活 (Notopterygium incisum), bai zhi 白芷 (Angelica dahurica) and qin jiao 秦艽 (Gentiana 
macrophylla); for pain: wu tou 烏頭  (Aconitum carmichaeli), chuan xiong 川芎  (Ligusticum 
chuanxiong), xi xin 細辛 (Asarum sieboldii); and for tremor: jiang can 僵蠶 (Bombyx mori), tian 
ma 天麻 (Gastrodia elata). To what extent this list would be similar to the list of herbs found in a 
search of the ZHYD under the term zhong feng was not investigated, but such herbs would be 
expected to be common in formulas for arthritis, paralysis and neurological disorders. 
 
Since the RCTs for dementia investigated in chapter 2, focussed on VaD, it was of interest to compare 
this list in Table 7.15 with the AD, VaD subset list in Table 2.8. However, the main similarities lay in 
the high frequency of chuan xiong on both lists and also the presence of tian ma. What was perhaps 
more notable was the absence of gou teng 鉤藤 (Uncaria rhynchophylla) and he shou wu 何首烏 
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(Polygonum multiflorum) from Table 7.13, whereas they appeared as high frequency items in the 
RCTs.  
 
Table 7.15: Frequency of the top 28 individual herbs for CVA subgroup in ZHYD data set 
Herb F  Herb F  Herb F  Herb F 
Rou gui/gui zhi 24  Ma huang 13  Fu zi 10  Bai zhi 8 
Fang feng 23  Wu tou 13  Qiang huo 10  Ban xia 7 
Gan cao 22  Dang gui 12  Shi gao 9  Mai dong 7 
Chuan xiong 20  Huang qi 11  Jiang 9  Xi xin 7 
Ren shen 18  Di huang  11  Niu huang 9  Total 610 
Du huo 18  Yuan zhi 11  Huang qin 9  
Bai shao 16  Zhu sha 11  Jiang can 9  
Fu ling 15  Qin jiao 11  Tian ma 8  
  
 
What this sub-group appears to demonstrate is that the same set of herbs is not always used when there 
is memory loss of any type. When the condition is different then the herbs do vary as well. Also, this 
demonstrates that the rating and classification critera were effective in isolating a sub group that had 
different characteristics. Assuming this group is similar to the modern conception of VaD, this group 
might be considered for further research into this field.  
 
Memory enhancement sub-group 
The memory enhancement and study formula sub-group contained over four times as many formulas 
as the ZYFJDCD data set (10). All received a memory score, as would be expected, but only seven 
received an ageing score (see Table 7.16).  
 
Table 7.16: Summary results for step-wise restrictions for memory enhancement sub-group 
Inclusion Criteria No. HE No. FE No. IH Yr range 
1. Memory enhancement only 371 44 68 682-1911 
2. Memory enhance & memory = 1, 2 or 3  371 44 68 682-1911 
3. Memory enhance & ageing = 1, 2 or 3  87 7 38 682-1625 
4. Memory enhance & memory = 1, 2 or 3 & ageing = 1, 2 or 3 87 7 38 682-1625 
 
When the higher frequency herbs were compared between the two data sets, despite the differences in 
overall frequency, there was considerable overlap in the lists (marked in bold), with all but one of the 
21 herbs from the ZYFJDCD also appearing in Table 7.17. It appears that the ingredients of such 
formulas were consistent across the two data sets.  
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Table 7.17: Frequency of top 27 individual herbs for memory enhancement sub-group 
Herb F  Herb F  Herb F  Herb F 
Yuan zhi 39  Tian dong 10  Long gu/chi 8  Di gu pi 6 
Chang pu  32  Mai dong 9  Bai zi ren 8  Gui jia 6 
Ren shen 23  Gan cao 8  Suan zao ren 7  Huang qi 4 
Fu ling 19  Dang gui 8  Fu shen 7  Ba ji tian 4 
Di huang  17  Bai zhu 8  Chuan xiong 6  Zhi mu 4 
Wu wei zi 13  Shan yao 8  Du zhong 6  Dan shen 4 
Tu si zi 12  Rou gui/gui zhi 8  Rou cong rong 6  Total 371 
 
When compared with the muich larger consolidated memory score list (m=1-3) (see Table 7.5, list 1), 
there was considerable similarity in the high frequency items with 20 of the items in Table 7.17 also 
appeared in the top 30 items in list 1. So, as in the ZYFJDCD the memory enhancement herbs tended 
to be the same as those for jian wang.  
 
The Neuropsychiatric Inventory (NPI) criteria 
The frequencies for each of the NPI symptom categories, following the general exclusions, for all 
items having a memory score are presented in table 7.18. As was the case for the ZYFJDCD, the 
highest frequency category was ‘Anxiety’ followed by ‘Apathy or indifference’. The lowest categories 
were again ‘Delusions’, ‘Hallucinations’ and ‘Elation and euphoria’. The main differences were the 
relatively higher frequency of scores for ‘Irritability or lability’, and relatively lower frequency for 
‘Motor disturbance’.  
 
Table 7.18: Frequencies of NPI results (m=1-3) 
NPI category No. HE No. FE % FE No. IH Yr range 
1. Delusions 0 0 0 0 No entries 
2. Hallucinations 70 12 1.2 35 1337-1911 
3. Agitation or aggression  1174 89 8.5 145 652-1911 
4. Depression or dysphoria 3161 273 26.2 177 543-1911 
5. Anxiety 5652 500 47.9 228 652-1911 
6. Elation or euphoria 0 0 0 0 No entries 
7. Apathy or indifference  3184 280 26.8 233 543-1911 
8. Disinhibition 88 8 0.8 51 1117-1664 
9. Irritability or lability 952 61 5.8 139 652-1911 
10. Motor disturbance 9 3 0.3 3 1107,1178,1406 
11. Nighttime behaviours 2743 228 21.9 162 652-1911 
12. Appetite and eating 2012 160 15.3 163 652-1911 
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The NPI scores for the ZYFJDCD were derived from a smaller data set which was based on types, so 
it was consequently difficult to draw any firm conclusions regarding their relative frequency. However, 
those from the ZHYD were from a much larger data set which was based on tokens so it should 
provide a better indication of the relative incidence of these symptoms in the population of ancient jian 
wang sufferers. However, any such an interpretation can only be tentative, since the relative 
frequencies may also reflect the priorities of the practitioners who may have focussed on certain 
symptoms and failed to notice others.  
 
The higher frequency herbs for NPI categories 3, 4, 5, 7, 9, 11 and 12 (following general exclusions 
and at m= 1-3) are presented in Table 7.19. Those in bold were also present in the NPI table for the 
ZYFJDCD (Table 6.18). There were considerable differences in the proportions of herbs in common 
between the ZHYD and the ZYFJDCD. For NPI 9 only 26% of the herbs on the high frequency 
ZYFJDCD list also appeared for NPI 9 in the ZHYD list. At the higher end, 74% of the ZYFJDCD 
higher frequency herbs for NPI 5 were also high frequency items in the ZHYD.   
 
As was the case with the ZYFJDCD, the individual NPI lists are mostly composed of herbs that are 
high frequency items for jian wang. The herbs also present in list 1 of Table 7.5 (i.e. higher frequency 
herbs for memory score = 1-3) are marked in italics in Table 7.19 and the proportions listed under P 2. 
These ranged from 52% in NPI 9 to 90% in NPI 4. This suggests that when a formula is indicated for 
jian wang, the same set of herbs tends to dominate its composition especially when the associated 
symptoms are depression or sleep disturbance but less so when they are agitation or irritability.  
 
When jian wang is associated with NPI 3 (agitation) or NPI 9 (irritability) herbs that were not found in 
amongst the high frequency items Table 7.19, such as chai hu 柴胡 (Bupleurum chinense), niu huang
牛黄 (cattle gall), huang qin 黃芩 (Scutellaria baicalensis), xing ren 杏仁 (Prunus armeniaca) and 
she xiang 麝香 (musk) appear on the lists. The first two of these were indicated for jian wang in the 
ben cao search but were on Li Shi-Jen’s second list (Phlegm Heat), the members of which tended to be 
lower frequency items in the classical ben cao search. The next three items were not indicated for jian 
wang in the classical ben cao, but their actions are also directed at Phlegm and Heat.   
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Step-wise analyses for NPI according to combined DSM IV-TR criteria 
The NPI scores were progressively resticted according to the DSM IV-TR criteria of memory and 
ageing (see table 7.20). Whereas under the general exclusions there were herb entries in all NPI 
categories, once a memory score of 1, 2 or 3 was introduced as a criterion, no entries remained in NPI 
categories 1 or 6. The individual herb entries for memory = 1-3 were presented in Table 19. At 
memory = 2 or 3 the results remained similar but at memory = 3, the NPI categories, 2, 3, 8, 9, 10 and 
11 were also removed.  
 
Table 7.20: Step-wise exclusions according to memory and ageing scores (frequency of HE) 
NPI category 1 2 3 4 5 6 7 8 9 10 11 12 
General Exclusions 4 75 1473 3461 6290 54 3452 148 1056 41 2925 2156 
Memory 1-3 0 70 1174 3161 5652 0 3184 88 952 9 2743 2012 
Memory 2-3 0 70 1174 3116 5438 0 3112 70 950 9 2706 1983 
Memory 3 0 0 0 54 145 0 153 0 0 0 0 72 
Memory 1-3 & ageing 1-3 0 28 85 86 191 0 189 6 42 9 85 49 
Memory 2-3 & ageing 1-3 0 28 85 86 163 0 189 6 42 9 85 49 
Memory 3 & ageing 1-3 0 0 0 0 0 0 0 0 0 0 0 0 
Memory 2-3 & ageing 2-3 0 28 49 71 71 0 129 6 42 9 55 49 
Memory 2-3 & ageing 3 0 0 7 0 7 0 0 0 0 0 7 7 
 
When memory and ageing scores were combined at the lowest level of restriction, entries remained in 
all but two of the NPI symptom categories and there was little difference at the next step (m=2-3, a= 
1-3) but no scores remained in the following step. However, when both memory and ageing were set 
at scores 2-3, entries remained in all but 2 categories and there were even a few entries remaining in 
NPI 3, 5, 11 and 12 when ageing was further restricted to a score of 3 but these all related to only one 
formula, Shen xiong wan 神芎丸, from the Yu Yao Yuan Fang 御藥院方 of 1267 which comprised 
the following seven herbs: da huang 大黃  (Rheum palmatum), huang qin 黃芩  (Scutellaria 
baicalensis), sheng qian niu 生牽牛 (fresh Pharbitis seed), hua shi 滑石 (talc), huang lian 黃連 
(Coptis chinensis Franch.), bo he ye 薄荷葉  (mint leaf) and chuan xiong 川芎  (Ligusticum 
chuanxiong Hort.). These herbs were rather different to the high frequency herbs in earlier lists. Also, 
compared with the NPI results in the ZYFJDCD a quite different type of formula remained in the 
ZHYD set at this most extreme level of restriction. Nevertheless, huang lian, hua shi and chuan xiong 
were all low frequency items indicated for jian wang in the ben cao search. Whereas most of the high 
frequency herbs tend to fall into Li Shi-Jen’s category of supplement emptiness, this formula aims to 
treat a wide range of symptoms related to the ‘Heart Fire’ that develops when the Yin and Water of the 
Kidney become empty (治腎水真陰本虛，心火狂) which is a condition frequently associated with 
ageing. Consequently, the included herbs were mainly of the ‘clear heat’ type.  
 
From the point of view of herb selection for research, very little can be read into these results, since 
they are purely the remainders when the selection processes are applied until the fewest number of 
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items remains. However, what they do illustrate is: 1. the range of formulas and associated treatment 
strategies used for jian wang plus NPI symptoms when associated with ageing is more diverse than 
might be inferred from the lists of high frequency herbs (which have turned out to be very similar); 
and 2. that lower frequency herbs can also satisfy the selection criteria and are not simply filtered out 
as the criteria are tightened. Although, the high frequency herbs would appear to be the most likely 
candidates for further research, particularly when they are also indicated for jian wang in the ben cao 
search, it is also likely that there are potentially useful herbs at the low frequency end of the list. 
Whereas determining the high frequency items is a straight forward task, statistical sorting procedures 
such as those applied above become more necessary when sorting the lower frequency items in large 
data sets which contain numerous low frequency items. For example, since Shen xiong wan ended up 
satisfying so many criteria, its constituents would seem worthy of further attention, however the 
constituent sheng qian niu 生牽牛 would not normally attract attention based on frequency data 
alone since it only occurs 3 times in the total ZHYD data set.  
 
 
Comparisons between ZHYD, ZYFJDCD, Ben Cao, CCM and CT search results 
List 1 of Table 7.11 (m=1-3, a=1-3) is a list of herbs which broadly satisfies the criteria of memory 
disorder plus ageing, and at 973 entries it was neither too large nor too restricted for statistical 
procedures. So this list was selected as a baseline in order to investigate the similarities and 
differences between the various sets of data on individual herbs.  
 
Six lists were compiled and the degree of overlap with the ZHYD list was calculated in terms of the 
number of individual herbs (IH) based on the SPSS code categories (see Table 7.22). The number of 
herbs that did not also occur in the ZHYD list is also presented. 
 
Table 7.22: Summary data for herb lists from ZHYD, ZYFJDCD, Ben Cao, CCM and CT 
Herb list Total HE Total IH IH incl in ZHYD: F (%) IH not incl in ZHYD: F 
ZHYD m=1-3, a=1-3 973 161 161 (100%) 0 
ZYFJDCD m=1-3, a=1-3 148 50 49 (98%) 1 
Ben Cao 322 75 48 (64%) 26 
Controlled trials (total set) 149 67 49 (73%) 18 
CCMs (jian wang) 548 88 66 (75%) 23 
CCMs (chi dai) 1545 136 83 (61%) 50 
 
For each list, the IH entries were ranked in descending order according to frequency and Spearman 
correlations (2 tailed) were calculated between each list. Pairwise exclusions were used to deal with 
missing values. The results are presented in Table 7.23. 
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Table 7.23: Spearman correlations between herb lists in Table 7.22 
 ZYFJDCD Ben Cao CCM jian wang CCM chi dai CTs all 
ZHYD 0.644 p< 0.000*  0.233 p=0.111 0.523 p<0.00* 0.618 p<0.00* 0.258 p=0.073 
ZYFJDCD  0.386 p=0.062 0.755 p<0.00* 0.460 p=0.003* 0.474 p=0.007* 
Ben Cao   0.558 p<0.00* 0.341 p=0.052 0.283 p=0.180 
CCM jian wang    0.731 p<0.00* 0.412 p=0.005* 
CCM chi dai     0.251 p=0.069 
* Correlation is significant at the 0.01 level (2-tailed) 
 
Although it was much smaller, the ZYFJDCD list for m=1-3, a=1-3 was directly comparable with the 
ZHYD list since it was also derived from a set of classical formulas indicated for jian wang and had 
been sorted according to the same rating systems as for the ZHYD list. When compared with the 
ZHYD list, the ZYFJDCD list was found to be subset in all but one individual herb. The Spearman 
correlation was also significant indicating that the ranking of the herbs on both lists was similar even 
though the ZYFJDCD listed each formula only once whereas the ZHYD contained multiple listings.  
 
In the ben cao search, 322 herb entries remained once the herbs that caused jian wang were removed. 
Of the resultant 75 different items of materia medica 64% appeared in the ZHYD list. These included 
18 of the 22 items on Li Shi-Jen’s list of herbs to Supplement Emptiness and 9 of the 17 herbs on the 
the list of herbs to treat Phlegm Heat, which together comprised 69% of the herbs on these two lists. 
This was surprisingly low considering that there were 161 different herbs in the ZHYD list and only 
39 on Li’s lists.  
 
It was expected that all Li’s recommendations would have appeared in at least one of the formulas 
found. As in the ZYFJDCD, the Supplement Emptiness herbs were the better represented but even 
amongst these a few did not appear. For example, yu zhi zi 預知子 (Akebia quinata fruit), ma bo 麻
勃 (Calvatia gigantea) and tao zhi 桃枝 (Prunus persica twigs) did not appear on the ZHYD list, or 
on any of the other lists. All of these were low frequency items in the ben cao list but it is still notable 
that the composers of formulas did not necessarily Li’s follow recommendations.  
 
In terms of ranking, the correlation between the ben cao list and ZHYD was insignificant. This would 
appear to be due to the large number of items not included on both lists and also the very different 
rankings for some items, for example, xian mao 仙茅 (Curculigo orchoides) ranked 6 on the ben cao 
list and 72 in the ZHYD list. With regard to the ZYFJDCD there was also an insignificant correlation, 
whereas in chapter 6 a postive correlation was found when only the higher frequency items from the 
ZYFJDCD were considered. This different result is most likely due the effect of removing outliers in 
the data set, most of which were low frequency items.  
 
In the case of the herbs used in the controlled trials (CTs), 73% were present in the ZHYD list so the 
degree of overlap was considerable even though the CT data were derived from formulas for a range 
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of conditions. A few of the CT items occurred on none of the other lists, including chi ling zhi 赤靈芝
(Ganoderma lucidium), yi mu cao 益母草 (Leonuris heterophyllus) and huai hua 槐花 (Sophora 
japonica), so the researchers were including some novel herbs in their formulations. It was also 
notable that Gingko biloba did not appear in any of the classical lists.   
 
The relative rankings of the CT herbs did not correlelate with those of the ZHYD. There was, however, 
a significant correlation with the ZYFJDCD list. So, even though the CT list was relatively small and 
the source population was quite different to the two classical data sets, there was still a tendency for 
the same herbs to rank highly on both the classical and CT lists.  
 
The data from the contemporary clinical manuals (CCM) were separated into formulas for jian wang 
and for chi dai. Not surprisingly, the data for the jian wang group was a better match to the ZHYD list 
with a 75% overlap in herb entries. At 61%, the level of overlap between the chi dai group was much 
lower but the overall data set was also much larger so a greater diversity in herbs could be expected. 
There were signicant correlations between the rankings of herbs on both CCM lists with both the 
ZHYD and ZYFJDCD, as well as with each other. This indicates that the higher frequency herbs in the 
two classical data sets also tend to be higher frequency herbs in the formulas recommended in the 
CCMs for both jian wang and lao nian chi dai. The CCM list for jian wang also correlated 
significantly with both the ben cao and CT lists, whereas the CCM chi dai list did not. So the 
recommendations of the classical ben cao appear to be best reflected in the herbs derived the formulas 
recommended in the CCMs for jian wang. Also, the herbs frequently used in the CT formulas tend to 
be those used frequently in the CCM jian wang formulas.  
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CHAPTER 8 
GENERAL DISCUSSION AND RECOMMENDATIONS 
 
In this chapter the issues encountered in each of the components are discussed, the main findings are 
examined and recommendations for future research are made.  
 
Summary and discussion of the findings of the components of this study 
 
Systematic reviews of RCTs 
The two systematic reviews of the clinical research literature found a considerable body of clinical 
trials of herbal medicines for AD, VaD, MiD and for unspecified senile dementia, as well as for MCI 
and AAMI. The majority of these trials were conducted in China, with a much smaller number from 
Japan, and CHMs in the form of multi-ingredient formulas were the main kinds of test interventions. A 
large number of trials, mostly conducted in Europe and America, investigated single herbal medicines. 
Of these, extracts of Gingko biloba were by far the most frequent in clinical trials. Since reviews of 
Gingko biloba already exist these were not duplicated.  
 
The CHM studies in China mostly investigated VaD whereas those from Japan and elsewhere 
focussed on AD. The reasons for this difference in research focus were not determined although 
population studies in China suggest VaD may be more the prevalent kind of dementia in that country. 
It was found MCI and AAMI had received comparatively little research attention. 
 
Numerous clinical studies on senile dementia (AD, VaD, MiD) were located in the searches but the 
majority were of low methodological quality. Following methodological assessment, out of 125 
articles that reported clinical trials, only 14 satisfied all the inclusion criteria and received a score of 3 
or above on the Jadad scale. These reported on 13 RCTs. As with the overall focus of clinical trials of 
dementia in China, the majority were for VaD. Where possible, meta-analyses were conducted on 
MMSE scores and these suggested an overall benefit for the CHMs used but not necessarily any 
benefit in excess of the other test interventions.   
 
MCI and AAMI had received relatively less research attention but when compared with the broad 
scope of dementia trials these RCTs tended to be of more recent origin. Following methodological 
assessment, 12 articles reporting on 10 RCTs were included. Meta-analyses were again performed 
where sufficient data were reported for common outcome measures and these suggested an overall 
benefit for these CHMs.  
 
The results of these reviews need to be considered with caution for a number of reasons. Since the 
results were generally positive, there may have been a bias towards the publication of positive studies 
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only. Although such a bias may be present within the clinical trial literature as a whole, in the case of 
the dementia review, which only included higher quality studies, there was no apparent evidence for 
this. Also, a number of studies reported equivalence, rather than superiority, of the CHM compared 
with the other intervention. However, the overall number of RCTs was small and in only four of the 17 
formulas investigated was there evidence from two RCTs for the particular formula.  
 
At the level of the formula there was no overlap between the formulas investigated for dementia (AD, 
MiD, VaD) and those for MCI/AAMI, however at the level of the individual herb there were 
considerable commonalities, with about 50% of the herbs used in the formulas for MCI/AAMI also 
occurring in the formulas for the dementias. The most commonly used herbs were: shi chang pu 
(Acorus graminus), chuan xiong (Ligusticum chuanxiong), ren shen (Panax ginseng), he shou wu 
(Polygonum multiflorum), gou qi zi (Lycium barbarum), fu ling (Poria cocos), tu si zi (Cuscuta 
chinensis), yuan zhi (Polygala tenuifolia), gou teng (Uncaria rhynchophylla), and di huang 
(Rehmannia glutinosa). 
 
This suggested that when comparing CHMs, analysis at the level of the individual herb may be a more 
productive approach than at the level of the formula name. Nevertheless the above comparison has a 
number of limitations. Firstly it is from a sample of only 21 formula entries and whereas the formulas 
used for MCI/AAMI can be considered representative of the scope of the RCTs for MCI and AAMI 
the list for the dementias is derived from a subset of clinical trials for dementias selected on the basis 
of higher reporting quality. Had the herbs used in all the excluded dementia trials been included in the 
RCT list, this would have produced a much larger list which may have had different characteristics. 
This was not done because the broad scope of dementia trials included many of highly questionable 
quality in both methodology and reporting quality. Also, it was difficult to determine which herbs 
were included in the formulas in a large number of these trials. As was the case in the classic literature, 
the formula name alone was not a reliable guide to the constituents and many trials did not include full 
lists of the ingredients. Consequently, data entry for the herbs from the lower quality dementia trials 
was abandoned. In contrast, most of the MCI and AAMI trials included ingredient lists, so herb data 
extraction for the full list was feasible. 
 
Despite the above limitations of the herbs lists, the high frequency herbs found in the RCTs were 
similar to those found in the classical data for memory loss with shi chang pu (Acorus graminus), ren 
shen (Panax ginseng), fu ling (Poria cocos), yuan zhi (Polygala tenuifolia), and di huang (Rehmannia 
glutinosa) also being high frequency items in the classical literature. Even so, some of the differences 
were also notable. For example, he shou wu (Polygonum multiflorum) and gou teng (Uncaria 
rhynchophylla) appear frequently in the RCT formulas but only have frequencies of 5 and 7 
respectively in the total ZHYD data set.  
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Review of CCMs 
Since clinical manuals are a primary source of information for clinicians of CM, it was of interest to 
obtain a measure of the extent to which the recommendations presented to CM practitioners in these 
books were congruent with both the clinical trial research literature and the practice of CM in the 
classical period. Since, contemporary traditional Chinese medicine is rooted in the classical literature 
and discussions of the classical sources typically form an introduction to the discussion of a particular 
disease, it was expected that the selection of formulas in CCMs would be highly congruent with their 
classical use. With regard to the clinical research literature it was expected that due to its relative 
infancy only a small proportion of the formulas recommended for contemporary use would have 
received research attention.  
 
While the review was based on only 23 books, these were collected from a variety of locations and the 
14 books included in the analyses can be considered representative of the contemporary CM literature 
in the specialist fields of psychology and brain disorders. Although all 14 books contained sections on 
senile dementia only five discussed jian wang as a separate category. This was quite different to the 
classical literature in which jian wang was by far the most common diagnostic category. It was found 
that 99 different formulas were recommended for senile dementia and/or jian wang according to the 
specific syndrome. In most cases there were four or five syndromes given in the disease differentiation 
and a different formula was presented for each but some books provided greater levels of 
differentiation and multiple formulas (see Appendix 1).  
 
Considering the large number of different formulas, it was hardly surprising that most had not received 
research attention in the RCTs considered in the reviews. However, when the high frequency formulas 
were considered, it was found that there was little overlap between the formulas most commonly 
recommended for clinical use and those which had received clinical research attention, For example, 
the formula Tong qiao huo xue tang appeared in 13 of the 14 books but in none of the included clinical 
trials. This suggests there is a disjunction between clinical practice and research efforts in the field of 
CM dementia research, at least when the higher quality studies are considered. Consequently there 
appears to be a need to examine the more frequently recommended formulas in future clinical trials. 
Therefore it is recommended that future clinical trials consider investigating the formulas most 
frequently used in clinical practice and that CCMs include in their clinical recommendations, those 
formulas for which the best research evidence is available.  
 
When the RCTs and CCMs were compared at the level of the individual herb, the level of difference 
was reduced and it became evident that whereas the formulas in the RCTs tended to be more novel, a 
similar set of herbs still dominated their composition.  
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Selection of sources for the classical literature and the retrieval of data 
It did not prove feasible to use a sampling approach to selecting items for analysis from the classical 
literature for a number of reasons. The population of this literature is difficult to define, it exists in a 
largely unstructured format and, since disease of the elderly or psychological disorders were not 
distinct genres of the classical literature, references to dementia are unevenly distributed in the 
population. Consequently the approach taken was to examine and compare extant collections of the 
literature and select those which best satisfied the needs of this project.   
 
Based on analyses of the available representative collections of classical CM books and formulas, two 
collections, the ZHYD and the ZYFJDCD, were selected for searching. These both had the features of 
being derived from or contained large numbers of classical books (nominally 680 and 1000 books). 
Although there was considerable overlap between these sources, there were also significant 
differences between the collections so that their combination was complementary. When compared 
with other available collections this combination was found to provide the largest and most relevant 
spread of the literature, particularly since herbal formulas were the primary aim of the searches. 
 
It was concluded that the ZHYD encompassed the majority of books found in other collections, and 
even when compared with the much larger Zhong Guo Ben Cao Quan Shu, it still contained a broad 
sample of ben cao drawn from across the classical period and was therefore a suitable source for 
searching the ben cao literature.  
 
However, there were significant distinctions between the ZHYD and the ZYFJDCD in terms of the 
sources from which the formulas in the ZYFJDCD were drawn. 341 books sources in the ZYFJDCD 
were not included in the ZHYD. Also, these collections differed in that the ZYFJDCD was an 
organised collection of formulas for which the processes of selection and editing may have introduced 
biases whereas the ZHYD contained the full texts of each of the included books with no apparent 
editorial input beyond that required to select an appropriate edition, digitalise it, ensure the text was 
accurate, assign headings and sub-headings and organise the books into genres. Another important 
difference was the formulas entries in the ZYFJDCD only appeared once for a particular symptom so 
the resultant search results represented types. In contrast, the same formula could appear many times 
for the same symptom in the ZHYD so the resultand search was one of tokens. Therefore, it was 
conceivable that the range of formulas, and consequently the lists of herbs, would differ considerably 
between these two collections. 
 
The ZYFJCD is a structured collection of formulas in paper format which required digitisation to 
enable searching and data classification. The ZHYD is an electronic collection in a largely 
unstructured format with a simple search function that allowed the location of single words or phases 
within the collection but no option for Boolean operators or other means of data restriction. 
Consequently, neither of these collections was suitable for text mining in the formats in which they 
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presented and each had to be converted into a structured digitalised format. This involved a two stage 
process by firstly extracting the text data into Excel spreadsheets and secondly converting relevant 
aspects of the data into numerical format suitable for analysis in SPSS.  
 
It was found that the extraction and conversion of data from the ZYFJCD was a relatively straight 
forward process since this was an edited collection of formulas and the key search terms were also 
index terms. This produced a total data set of 174 formula entries in Excel and 1,676 herb entries in 
SPSS which represented all the entries under the index terms chi dai and jian wang with no overlap 
between entries. In contrast the ZHYD required a series of searches under groups of terms broadly 
synonymous with chi dai and jian wang which turned up 2,765 hits, each of which required 
examination to determine whether it was relevant and contained herbal formulas suitable for entry into 
the Excel data base. Of these, 2,130 were extracted to Excel and following editing, sorting, 
comparison and the removal of duplicates, 1,450 formula entries and 13,733 individual herb entries 
remained in SPSS. These resulted in a much larger data set than that derived from the ZYFJCD. It 
represented to total population of formulas indicated for the search terms in the collection of 1000 
books.  
 
When the two search processes were compared, it was evident that searching the indices of the 
ZYFJDCD and extracting the data from the pages of this compendium was a much faster approach to 
generating a data set than the electronic searches of the ZHYD. There were a number of reasons for 
this. The main reason was the difference between using a structured and an unstructured data source. 
In the ZYFJDCD, all the hits were relevant even though some were subsequently filtered out, whereas 
the searches of the ZHYD produced numerous irrelevant hits as well as numerous duplications. The 
other reason was the large difference in the volume of data generated by the electronic searches which 
included all instances of the same formula in different books. As the search results demonstrated, the 
inclusion of such repetitions in the ZHYD data set versus their non-inclusion in the ZYFJDCD had 
little effect on the overall results at the high frequency end. Therefore, for future projects when a 
disease is included in the ZYFJDCD, this appears a suitable source for formula information, 
particularly when time is a consideration.  
 
While this may presently be the case, it is expected that databases of books in electronic format along 
the lines of the ZHYD but which employ more advanced search and text extraction functions will 
become available. When this happens, text mining of the classical Chinese literature will be 
considerably streamlined and the electronic search option will become the method of choice. However, 
even with a more flexible database that allows restrictions of searches there will still be a need for 
approaches to rating the results of the searches.   
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Development of methods for assessing the classical literature 
In the present project the approach taken to rating the entries involved a series of categorisation 
criteria that were designed to be employed by the raters to classify the items in the data set, in order to 
facilitate the filtering and selection of data. Unlike the systems or scales used in modern clinical 
settings, there was no conceivable method of evaluating whether any sets of criteria could reliably or 
validly differentiate dementia patients from non-dementia patients in the classical literature. Nor was 
there any imperative for such a scale to be developed, since it would have little practical application 
outside the present project. In the approach taken, the DSM IV-TR criteria were adapted into a series 
of inclusion (memory loss, ageing and group 2 symptoms) and exclusion criteria (children, acute 
condition, CVA etc) which approximated the approach taken by a psychiatrist to the clinical diagnosis 
of probable AD. There were, however, a number of limitations to this approach. There was, of course, 
no possibility of explorative questioning of the patient to obtain all relevant information, so the 
resultant data was always going to be incomplete, particularly since the nature of the descriptors for all 
but one of the group 2 symptoms did not match well with the information found in the classical 
literature.  
 
Nevertheless, a system had was sufficiently simple to be used by a non-psychiatrist and applied as 
quickly as possible to a large data set was needed. The system also needed to be able to filter the data 
set so that only items that fit the established diagnostic criteria for dementia remained. Of the possible 
options the DCM IV-TR best combined the features of simplicity and international acceptance. It also 
proved the best method for generating lists of herbs that were easily compared across data set. The 
NPI, while providing a better match to the symptoms found in the classical clinical literature, the 
resultant multiple lists proved difficult to interpret.  
 
Comparisons of the classical data sets and general results for classical searches 
Based on the comparisons between the ZHYD and the ZYFJDCD, it was evident that the much 
smaller data set of the ZYFJDCD reflected the characteristics of the much larger ZHYD data set. Even 
though neither was the total population of formulas for chi dai or jian wang in the classical literature, 
as collections they were different in a number of aspects, so the similar results suggest that if an even 
larger collection were searched the result would be similar.  
 
In the case of the subgroups, an even larger collection may allow more fine grained analyses of 
particular groups of symptoms but as shown in the NPI groups, such an approach only resulted in 
differences in the lower frequency items. There is also the issue of the meaningfulness of the analysis 
of items which have low frequencies in the population. In such cases it may be more productive to 
analyse the individual items separately. As some of the examples have shown, even individual 
formulas can reflect the general characteristics of the larger set. 
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Another issue was the selection of search terms. In this case the approach taken was broad and 
inclusive. However, had the modern term for senile dementia (lao nian chi dai) been taken at face 
value and the data searched for variants on lao nian (old age) and chi dai (dementia) and the results 
combined, the overall result would have been considerably different. As the examination of individual 
entries has demonstrated, the modern concept of lao nian chi dai is considerably different from the 
conception of chi dai in the classical literature. In almost all cases of chi dai in the classical literature 
there was no mention of memory loss, but when the focus was on the symptom jian wang, a large 
number of instances were found.  
 
Undertaking an historical analysis of the epidemiology of dementia in ancient China was not the 
purpose of this thesis and the methods employed here cannot determine when AD first appeared in 
China. Nevertheless, statistical methods such as these are effective in selecting instances that fit 
general criteria and can thereby considerably reduce the search space for such a study. While this 
approach is not sufficient for investigating the historical development of or first occurrence of this 
disease in ancient China, it is effective for filtering a large data set and selecting possible cases. Each 
of these requires translation and interpretation to determine their exact nature, and work of this kind 
was beyond the scope of this study. In this sense this study is preliminary to a more detailed analysis 
of the frequency and nature of dementia in China.  
 
While it cannot be concluded that on the basis of this data that AD was present, what this study has 
demonstrated is that conditions consistent with dementia, it least with regard to suffering 
age-associated memory loss were present in the classical period in China. Also the findings of the NPI 
ratings suggest that with regard to the neuropsychiatric symptoms that were present in addition to the 
memory loss, the relative incidence of such symptoms was similar to that of modern populations. This 
lends some credence to these being instances of more general cognitive deficit but again, there is no 
definitive answer. It is also probable that a considerable number of the entries retained in the data set 
referred to instances of other diseases, such as VaD, MiD, brain tumours, trauma etc but the symptoms 
that would allow further differentiation were not recorded. This problem cannot be solved using these 
methods. All than can be determined is that there were numerous possible cases and there were 
consistencies in the treatments used.  
 
Selecting herbs for future research 
In selecting which of the numerous herb lists is the most useful for further research, there is also no 
definitive answer. It was expected that there would be considerable differences between the lists of 
herbs when they were sorted, according to whether they were intended to improve memory in the 
absence of a clear pathology or whether the herbs were used for the more severe cases. However, the 
lists were very similar (see Table 7.5). Similarly, the lists for ageing were similar to the general list, 
but the relative infrequency of scores for ageing may have reduced the reliability of these lists. 
Similarly, the addition of the group 2 symptoms produced even greater reductions in the herb 
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frequencies with few items remaining. While these filtering processes were useful in selecting cases 
that satisfied the criteria for probable dementia, they also reduced the reliability of the data as the 
frequencies declined. The comparison of the two data sets proved useful in this regard. Since they both 
had different characteristics, the level of overlap could be considered at least tentative evidence for 
reliability.  
 
Issues in interpreting these data 
While it seems reasonable the conclude that the lists of herbs produced from the ZYFJDCD and the 
ZHYD data sets did represent the constituents most commonly found in formulas for memory loss, 
these lists are likely to include not only the herbs considered by the classical authors to be effective for 
memory loss but also herbs that had other functions in the formulas. For example, a herb such as gan 
cao (licorice) is a component of many classical and modern formulas since it is considered to have the 
function of harmonising the combined effects of the other herbs. Ren shen (ginseng) is a common 
component of many formulas for debility and is also a common inclusion in formulas for the aged. 
Both jiang (ginger) and zao (jujube) were often added to prescriptions to make them more palatable 
and to ease the effects of harsh ingredients on the stomach. Consequently herbs such as these could be 
expected to be frequent in formulas for many conditions other than memory loss.  
 
In the procedures used in this project it was not possible to remove herbs from the analyses based on 
criteria other than those that could be determined by the systems of rating. It is likely that in the total 
population of Chinese herbal formulas from the classical period, certain herbs would have high 
frequencies irrespective of what the formulas were indicated for. Since the logic of formula 
construction involves the combination of multiple ingredients to achieve a range of outcomes some of 
which are general. For example, a formula may contain herbs that aim to ‘improve digestion’ (bu pi 
補脾) or ‘calm the mind’ (an shen 安神), as well as those which focus on a specific symptom such as 
memory loss (jian wang). Therefore an analysis of formula ingredients will include herbs with both 
general and specific actions. In the classical sources consulted, discussions of the roles of the 
individual herbs in an individual formula were seldom found. Some books do provide general 
discussions of this kind and modern books on formulas provide discussions on the roles of ingredients 
in common formulas, but there was no conceivable method of retrospectively scoring specific formula 
ingredients to determine which were intended for jian wang or chi dai.  
 
At present, such baseline data does not appear to be available so it was not possible to use any 
procedures to correct for this characteristic of the data sets. Such a procedure could involve, for 
example, subtracting the high frequency herbs in the total population of formulas from the sets for 
herbs found in the searches for jian wang to determine which herbs remained as specific for jian wang. 
However, as can be seen in the results, some of the herbs that would be expected to be high frequency 
items in the population of all formulas, such as can cao (licorice) and ren shen (ginseng), were also 
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specific for jian wang. Therefore subtraction of baseline characteristics, had they been available, may 
not have been an appropriate procedure. Nevertheless, by consulting the ben cao literature it was 
possible to determine which individual herbs were indicated for jian wang and these data were used 
for comparison with the data for formula use.  
 
Another option that was considered was cluster analysis to determine which combinations of herbs 
best suited the sorting criteria. In some preliminary attempts at this approach, it was found that the 
total number of individual herbs in the data set made the process too unwieldy and when a reduced 
data set was used the output was similar to that for the frequencies. Since the original data was from 
clusters, i.e. formulas, the outputs of these cluster analyses produced combinations which 
approximated the most common of the simple formulas. Therefore the approach was abandoned in this 
study but it is possible that the synergistic effects of herbs may be of importance in these formulas so 
in future research the principal herb combination should be examined and not just the herbs singly. 
 
Future directions 
The present study represents an approach to using the classical literature to generate lists of herbs that 
not only have a history of use for specific conditions, and for combinations of conditions/symptoms. 
For example, the frequency data for herbs for memory loss and depressive symptoms is now available. 
The next stage is to apply these data in further research. Such research could take a number of forms. 
At the clinical research level, the classical lists indicate which herbs and formulas were the most 
popular during the classical period, the lists for the clinical trials indicate which herbs and formulas 
have received research attention, and the lists for the contemporary clinical manuals (CCMs) indicate 
which formulas and herbs are currently recommended for clinical use by practitioners. With this 
information it is possible to determine the extent to which these sets of data are congruent and identify 
areas that require further investigation.  
 
In cases where a particular formula or particular individual herbs have a high frequency of use in the 
classical literature, it would be expected that modern clinical manuals would include these in their 
recommendationsn, unless there is a reason for their abandonment. Moreover, the reasons for the 
inclusion or exclusion of herbs and formulas that are frequent in the classical literature, from the 
clinical recommendations of CCM also need to be made explicit. Conversely, when a formula is 
included in a CCM has little or no pedigree in the classical literature, there needs to be an explicit 
reason for its inclusion, such as evidence from clinical research.  
 
In the case of clinical research, when selecting herbs and formulas for use in clinical trials the 
selection could be informed not only by the research literature but also by the frequency that the 
formulas is recommended by CCMs and its pedigree in the classical literature. Moreover, it appears 
imperative that RCT be conducted to evaluate the formulas that most frequency receive 
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recommendations in CCMs since these are the treatments being applied in contemporary clinical 
settings and are consequently those for which evaluation is most urgently required.  
 
The electronic and hand searches amassed a considerable body of clinical and experimental literature 
on dementia and associated conditions in addition to the controlled clinical trials. This includes animal 
studies, in vitro studies, chemical analysis and clinical studies of other forms. For reasons of scope and 
time, this considerable mass of data has not been reported in this study. However, in order to provide a 
more complete assessment of the research base into these disorders, these types of studies need to be 
further examined and evaluated. Approaches to classifying and rating non RCT clinical trials for 
methodological quality exist for cohort studies and case series studies. Therefore these studies could 
be evaluated in a similar fashion to the RCTs and larger data sets generated for further analysis anmd 
comparison. 
 
From the point of view of drug discovery, the frequency lists from the classical literature could be 
used to inform the selection of items for screening in assays. Another approach would be to investigate 
the chemical constituents of the herbs on these lists for commonalities in structure to determine 
whether similar compounds recur throughout the lists. As databases of the chemical constituents of 
natural products expand in size and depth, approaches to searching and extracting useful information 
are required. These searches of the classical literature may provide an additional approach to 
investigating the molecules present in these plants to determine their therapeutic potential. For 
example, are there commonalities in the chemical constituents of the higher frequency herbs on these 
lists? Are these also present in lower frequency items that are also indicated for jian wang?  
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CHAPTER 9 
CONCLUSIONS 
 
General conclusions in relation to the research questions 
 
The general conclusions in relation to the research questions are as follows: 
 
What is the state of the modern clinical research evidence for the use of CHM in the 
management the prevention of the age-related dementias Alzheimer’s disease (AD) and Vascular 
Dementia (VaD) as well as for Mild Cognitive Impairment (MCI) and Age Associated Memory 
Impairment (AAMI)? 
 
The systematic reviews found that there is high quality research evidence in the form of 13 RCTs for 
AD and VaD as well as a smaller body of evidence for MCI and AAMI. However, the range of 
formulas investigated was considerably more limited than the formulas used in contemporary clinical 
practice. Therfore, this evidence only applies to specific aspects of the CM management of these 
disorders. Also there was a mismatch between the formulas most often investigated in the RCTs and 
those most commonly used in clinical practice. Therefore there are considerable research gaps in this 
field and further high quality clinical research is required to assess the safety end efficacy of the range 
of formulas used for these disorders with particular priority on the higher frequency formulas 
idenfified in this study.  
 
What instances are there in the classical Chinese medicine literature of the use of CHM in the 
management of signs, symptoms and conditions that are similar or analogous to the modern 
clinical entities of AD, VaD, MCI or AAMI? 
 
Instances of memory disorders characterised under a range of classical terms broadly synonymous 
with jian wang were found throughout the classical literature from the Tang dynasty onwards. While 
most of these instances did not provide sufficient detail for identification as probable cases of senile 
dementia, there were still a considerable number for which the descriptions were sufficiently clear for 
them to be probable cases of dementia consitent with AD as well as cases of probable VaD.  
 
Examples, of AAMI were also evident but the data sorting procedures used were not specific enough 
to isolate this group or to identify likely examples of MCI from this group. Since a retrospective 
diagnosis of AD is not possible, it remains unknown whether any of these cases were actually AD, 
only that they may have been AD. 
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How can the evidence in the classical literature be evaluated in terms of quality, reliability and 
relevance to a specific disease and in particular to dementia and related conditions? 
 
The rating systems that were developed based on the DSM IV-TR criteria proved to be a practical 
means of classifying and filtering the data in the two databases that were derived from the classical 
collections according to relevence. These criteria were able to determine which instances were the 
likely to have been cases of AD and related disorders. The rating systems based on the DSM IV-TR 
also produced broadly consistent results across both data bases which suggested that the procedures 
were reliable. The second approach which adapted the NPI proved similarly reliable but the results 
proved complex and difficult to interpret.  
 
With regard to the quality of the classical literature, or the quality of the individual items, no practical 
method for evaluating quality could be determined. A number of rating systems were developed based 
on whether the source text was well regarded, officially supported, or frequently cited but these proved 
too difficult to implement and were of questionable validity. Consequently, evaluation was eventually 
based on frequency and relevance alone.  
 
What are the relationships between the classical CM literature, modern CM clinical practice 
and the modern clinical research literatures in terms of their approaches to the management of 
dementia and related disorders?  
 
There proved to be number of disjunctions between the modern RCT evidence and the 
recommendations of contemporary clinical manuals (CCMs), particularly at the level of the formulas 
in common use. The RCTs had tested formulas not commonly recommended and commonly used 
formulas had not been subject to RCTs. When the classical literature data sets were compared with the 
modern CCM data sets, both similarities and differences in formulas usage were found. So while there 
is continuity between classical and modern CM, there have also been changes in practice. However, at 
the level of the individual herb, greater similarities between the data sets emerged. These indicated 
that while formula preferences varied across the classical and modern data sets, the same herbs were 
often included in these formulas. Even so, the RCTs tended to include herbs seldom found in classical 
formulas. 
 
Which herbs and formulae demonstrate the greatest potential for further research for AD based 
on these analyses of the classical and modern clinical data? 
 
The lists of herbs and formulas that proved most frequently used in each of the data sets proved to be 
lengthy and are tabulated in the relevant chapters. Other herbs were also noted based on satisfying the 
selection criteria (i.e. DSM IV-TR etc). There was considerable consistency between the resultant herb 
lists of the two classical data sets (see chapter 7). The level of congruence was somewhat less when 
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the modern CCM and RCT herb lists were compared with those of the classical literature. These 
differences have now been identified and quantified but further investigation will be required to 
evaluate their significance. It cannot be assumed that there is a direct relationship between the 
frequency at which a herb occurs in the literature and its likely efficacy for dementia. Nor can it be 
assumed that the herbs used in the formulas that were associated with the entries from the classical 
literature that most closely matched the AD diagnostic criteria were likely to have been effective. All 
than can be concluded is that such herbs are worthy of further attention. What form such attention 
should take is a matter for future researhers. For example, if high-throughput screening is the desired 
approach, then it may be possible to investigate all the approximately 370 different herbs identified in 
the ZHYD search and to include any extra items from the other searches. Obtaining good samples may 
be problematic but such an approach is at least feasible. However, if is only possible to investigate a 
limited number of herbs, then these could be selected from one or more of the more resticted lists.  
 
Limitations of this study 
Although a number of the limitations of aspects of this study have been discussed elsewhere, the main 
limitations are reiterated and discussed in this section by way of a conclusion and to draw attention to 
caveats on the interpretation of the results of the various sections of the study. 
 
Clinical trial section 
As indicated in the introduction the scope of this study was intentionally limited in a number of ways. 
Since the overall focus is on the clinical management of dementia and related disorders, the scientific 
evidence was limited to that derived from clinical trials. However, not all forms of clinical trials were 
included in the analysis. Case series and case control studies were included in the searches and the 
papers were retrieved but these were not included in the systematic reviews. Had these been included, 
the resultant frequency lists may have been different to those for the controlled trials (CTs). 
Examination of the consolidated results of these kinds of clinical studies was considered worthwhile 
but given the constraints of time and the volume of controlled trials located in the searches, it was 
decided to focus on the CTs since these are generally perceived as constituting higher levels of 
scientific evidence compared with the other forms of clinical trials.  
 
With regard to the systematic review of CTs for dementia, the reported data derived from the higher 
quality studies only. Had the large number of lower quality CTs been included in the analyses the 
results would have been different, but since the aim was to determine the best available evidence, and 
there were a reasonable number of higher quality studies available, it was decided that focussing on 
these was the more productive approach. From the point of view of selecting herbs for further research, 
the herb lists are relatively short and the meaningfulness of the frequencies is limited. However, they 
do highlight a number of herbs than only appear at low frequencies in other lists. 
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Contemporary CM practice 
The examples of the contemporary clinical literature of CM were all derived from one genre. All were 
clinical manuals with a specialist focus that conformed to the structure and content generally found in 
tertiary level textbooks in China. It was considered that this genre should provide the best available 
clinical recommendations as well as provide a good indication of contemporary practice by tertiary 
educated CM practitioners who would be likely to have used such CCMs during their education or in 
their subsequent practice. However, this remains an assumption since no surveys of the books used in 
CM university courses or the treatments used in CM hospitals in China were undertaken.  
 
Another approach to generating a sample of contemporary practice would have been to collect all the 
review and discussion articles on the CM treatment of dementia published in CM journals and extract 
their recommendations. Such articles were located in the literature searches of the databases and 
copies retrieved but they were found to have a diversity of formats, to vary in level of detail and 
comprehensiveness, and did not necessarily provide clear recommendations regarding treatment. 
Moreover there appeared to be no plausible approaches to rating the quality of these articles or 
effective approaches to extracting the data contained therein.  
 
An additional genre of the contemporary CM literature that was considered was the case history. 
Examples of this genre were located in the journal searches and books were obtained from libraries 
and book stores. While items in this genre would appear to to demonstrate good validity as exemplars 
of contemporary practice it was difficult to determine how to obtain a representative sample since the 
genre is spread across journals, books and book chapters, and there were difficulties in determining 
how to extract data. For example, when a case history reports a sequence of formulas and formula 
modifications, which should be included? Should this be considered a single treatment or multiple 
treatments? In the case of the CCMs, formula modifications were usually listed separately and were 
excluded unless they were particular to dementia but such an approach was not feasible for case 
histories. 
 
As lists of herbs for further research, those derived from the CCMs may only derive from a small 
number of titles, but these contain considerable detail and variety, and were compiled by experts in the 
CM field, so it is likely that they contain numerous herbs worthy of further investigation but the value 
of the individual herb may have little to do with their frequency in this data set. These books are not 
compilations of cases but summaries of the spread of formulas applicable for a variety of types and 
sub-types of chi dai and jian wang.  
 
Classical literature 
For the classical literature the searches were generally considered to be both comprehensive and 
representative since they encompassed both a wide selection of books from all eras and across all 
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genres. The scope was, of course, limited by the books included in the two collections, so an unknown 
component of the classical literature was excluded, but these two collections were the two largest 
available and encompassed the majority of works in other collections, except in the case of the ben cao 
literature.  
 
Had a practical method for searching the Zhong Guo Ben Cao Qian Shu been found, the ben cao data 
set would have been more comprehensive and may have demonstrated different features. Even so, 
since the ben cao literature tends to be accumulative and repetitive, it is likely that while additional 
low frequency items would have been located, the general features of the data set would still have 
been present since the ben cao component of the Zhong Hua Yi Dian (ZHYD) did include a wide 
spread of this literature.  
 
In the selection of items for inclusion in the ZHYD data set, a specific set of search terms were used. 
Therefore, the processes used for selecting these terms limited the data available for analysis. Since it 
remains unknown whether diseases such as AD, VaD and MCI were actually present in the 
pre-modern Chinese population and there is no way of verifying whether a case described in the 
literature was an actual instance of one of these conditions according to modern diagnostic categories, 
the selection of cases must necessarily rest on a number of assumptions and logical inferences.  
 
Based on preliminary searches which located disease descriptions of memory loss in older persons that 
were consistent with that observed in dementia patients, it was assumed that such cases could have 
been AD, VaD or MCI and would at least be considered AAMI from a modern perspective. In cases 
were there were also symptoms of stroke or hemiplegia, VaD seems a reasonable assumption but there 
was no plausible way of isolating likely instances of AD.  
 
The clinical symptoms demonstrated by modern AD sufferers are diverse, so it would appear likely 
that this would also have been the case in pre-modern times. Assuming this, such cases may have 
received a wide variety of disease and symptom names depending upon the view of the doctor. These 
would be likely to include those used in contemporary CM, i.e. chi dai and jian wang but also archaic 
terms synonymous with these and terms referring to other presenting symptoms such as mental 
dullness (dai bing 呆病), madness (dian kuang 癲狂), dissociation (huang hu 恍惚), depression (yu
鬱) and a wide range of others. However, it was impractical to search and extract data for all of these 
terms and, unless there was a memory impairment, there was no basis for assuming that senile 
dementia was a possible diagnosis, even when all the other symptoms were consistent.  
 
Had vascular dementia (VaD) been the focus of the investigation there would have been a need to 
consider adding terms such as stroke (zhong feng 中風) but in such a case this may still have turned 
up too many unclear cases to be worthwhile. In the ZHYD search, since all entries that included the 
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search terms in the symptom lists were extracted, rather than just the entries for which the search term 
was a subject heading or other classifier, all instances that could be retrospectively classified as 
possible dementia should have been included.  
 
The coding of terms found in the classical entries according to the symptoms and signs specified in the 
DSM IV-TR and NPI presented a major challenge and required a number of assumptions to be made. 
The translation of terms and concepts across languages as different as English and Chinese is difficult 
even within a contemporary context and this is evident when the descriptors used in these two 
diagnostic systems are viewed in the modern English and Chinese versions. Such difficulties are 
compounded when terms in classical Chinese from various eras require interpretation according to the 
conceptual framework of modern psychiatry.  
 
In one sense, this issue is insoluble since it is not possible that doctors in pre-modern China could have 
conceived of their patient’s conditions in a manner comparable to the modern day psychiatrist. Even 
so, in either case the practitioner must attempt to describe the behaviour, distress and apparent mental 
state of a patient in a manner that allows the reader to form a meaningful mental image of their 
situation. Assuming this, parallels can be drawn between, for example, ‘episodic memory impairment’ 
and ‘cannot remember what they have just said’. However, when single terms are used it can be 
difficult to determine the scope of the meaning intended. For example, the condition huang hu can 
refer to a broad scope of mental states and behaviours including dissociation, disorientation, lack of 
attention, uninvolvement in the world around, dreaminess, ‘spacyness’, apathy, lack of drive etc 
depending upon the context, and does not necessarily imply a pathology. Since the scope of meaning 
of huang hu has a degree of overlap with ‘apathy’ which can also be interpreted in a range of senses, it 
was scored as such in the NPI. A similar approach was used for the other terms and a running list of 
terms compiled to assist in decision making consistency.  
 
There are a number of limitations with this approach. It is likely that language change has resulted in 
variation in the meaning of terms over the scope of the classic literature, so the usage and meaning of 
terms during one dynasty may not be the same as in another dynasty. In fact, it became evident that the 
meaning of the term chi dai, as in the lao nian chi dai of modern CM, was not equivalent to chi dai as 
used in some classical sources. Since no practical method for verifying the scope of meaning of terms 
over time could be determined, the approach used was to err on the side of inclusion when the context 
suggested the classical term overlapped with the modern concept based on the judgement of the two 
Chinese raters, the investigator and other advisors as required.  
 
If more a stringent approach had been taken to rating, fewer entries would have received a score and 
this would have impacted upon the results derived from the data sets. However, these limitations 
mainly apply to the NPI symptom categories and the group 2 symptoms. In the case of jian wang and 
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its associated terms, these appear to have referred to some type of forgetfulness or memory loss across 
the span of the literature.  
 
Issues in data extraction and analysis 
The general approach taken to data extraction and entry was to extract all instances of a formula that 
was indicated for the search terms and enter each of its constituent herbs in the SPSS data editor. The 
frequencies of the herbs and formulas could thereby be determined in the total data set and in any 
subsets generated by eliminating cases using the ‘select cases’ command.  
 
Since a primary aim of the study was to select herbs as candidates for further research, analysis at the 
level of the individual herb was the logical option. Also, it was assumed that the higher the frequency 
a herb had in a data set derived from instances of possible or probable age-associated dementia, the 
better it was as a candidate for further research. Such an assumption is, however, limited by a number 
of features of CHM practice.  
 
One is that in a multi-herb formula, different herbs have different actions, so even though the formula 
may be principally indicated for jian wang, not all the herbs included would be indicated for this 
condition. Another is that certain herbs are more common than others in formulas in general, so these 
are likely to have a high frequency across a broad range of conditions. For example, gan cao (licorice) 
is frequently included due to its function of harmonising the action of other herbs and reducing their 
toxicity, ren shen (ginseng) has a general function of improving energy level so it is included in a wide 
range of formulas for debility, and jiang (ginger) ‘warms’ the stomach and assists digestion so it can 
counter the ‘cold’ effects of other herbs and aid the absorption of the formula. Therefore, just because 
a herb has a high frequency in a data set derived from formulas indicated for jian wang, this does not 
mean it is itself intended to treat jian wang.  
 
One option investigated for dealing with this issue was coding herbs according to their role in a 
formula based on classical formula theory and considerable time was spent on investigating this option. 
However, the roles of herbs are seldom made explicit in the classical or even in the modern CM 
literature. Also, a herb may have multiple roles. While it is possible to make inferences as to a herb’s 
role in a modern formula, there is no way to verify these unless the information is included in the entry. 
In a classical formula such inferences become even more problematic, since there were differing views 
on formula construction whuc were difficult to reconcile.  
 
In the study, this issue was partially addressed by compiling a separate data set for herbs individually 
indicated for jian wang and chi dai in the ben cao literature. Therefore when such herbs appeared in a 
formula it could be inferred that they were intended for these conditions. However, the issue of 
overlap in roles could not be fully resolved. Since herbs such as gan cao and ren shen are also 
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individually indicated for jian wang, so their high frequencies in data sets are likely to be a product of 
these two factors.  
 
The meaningfulness of frequency data is further limited by the balance between generality and 
specificity. When the selection criteria are relaxed, such as memory score = 1-3, the data set is very 
large and the high frequency items dominate, particularly when the number of items examined is 
limited to the top 30, as was frequently done in the tables. However, when selection is tightened to 
only include items that satisfy a narrower range of conditions, such as memory score = 3 and ageing 
score = 3, the resultant data set is a better match to the diagnostic criteria, but it may contain only a 
few formulas and numerous items that had low frequencies in the previous data set.  
 
In the end, there is no definitive answer as to which list is better. From the point of view of generating 
candidates for further research, it would seem that both approaches should be combined. High 
frequency items in the broader data set that are also indicated for jian wang in the ben cao should 
certainly be investigated further, However, it is also possible that other high frequency items may have 
activity but had been overlooked by the compilers of ben cao so these should not be ignored. It is also 
likely that some of the low frequency items that satisfied stringent criteria may have been effective but 
they were not taken up by enough other practitioners to enter common practice.  
 
Statistical procedures can only sort and classify data, decisions on how to use the results depend on 
human priorities such as how many herbs is it practical to investigate and for what properties. 
Nevertheless, the use of frequency scores, restriction according to rating systems and comparisons 
between data sets do offer the means for generating meaningful lists of research candidates providing 
the caveats on interpretation are considered.  
 
Comparison of data sets 
Separate data sets were generated for the two classical searches (ZYFJDCD and ZHYD), the ben cao 
in the ZHYD, the CCMs and the clinical tials (CTs). Comparisons have been drawn between the 
results derived from these data sets but these need to be interpreted with caution due to the differing 
features of the data sets.  
 
Although the two classical searches are both based on large selections of the classical literature and 
there is considerable overlap in the titles included, the resultant data sets differ in two important ways. 
The ZYFJDCD is mostly derived from formula compendiums and includes each formula once, 
whereas the ZHYD is derived from a broader spectrum of genres and includes repeated instances of 
the same formula in different books.  
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Interestingly, the results for high frequency single herbs were very similar between these two data sets. 
However, when the ZHYD was tightly restricted the resultant herb lists can become dominated by 
repeated instances of the same formula which affects the frequencies of individual herbs, so 
comparisons between the relative frequencies of individual herbs need to be made with caution when 
overall frequencies are low. 
 
The ben cao data have the same basic characteristics as the ZHYD set, so these are directly 
comparable, and since they derive from classical sources spanning a similar timeframe to those in the 
ZYFJDCD, there would appear to be few difficulties in making comparisons between these. In both 
cases, one issue that could be considered is year range, since certain herbs only become indicated for 
jian wang after a particular date so this may have affected their inclusion in formulas. Similarly, some 
items drop out of ben cao after certain dates.  
 
The CCM data were derived from a restricted genre of the modern literature so there are questions 
regarding the generalisability of the results to the modern literature in general. With regard to 
comparisons with the classical literature, these data appear most comparable with that of the ZHYD 
since both are derived from formula tokens. However, the ZHYD data set is dissimilar in that it 
derives from a variety of genres. In this sense the ZYFJDCD, which is mainly derived from formula 
compendiums and other clinical manuals, may constitute a better source for comparison between 
classical and modern herb usage.  
 
CT data set is comparatively small and also subject to change as new CT literature is published. Like 
the CCM and ZHYD data, is is based on tokens but it is derived from a very different genre of the 
literature. In theory, it should have a relationship with both the CCM and classical data sets since these 
would appear the most likely sources of formulas for research. There were some similarities to the 
ZYFJDCD and jian wang subset of the CCTs but the differences were also notable. It is possible to 
speculate on a number of reasons for these differences. However, these data were derived from such 
diverse sources (i.e. RCTs in electronic data bases) that any comparisons with more consistent data 
sets need to be viewed with caution. 
 
Traditional diagnostic categories 
As the CCM data illustrate, both chi dai and jian wang have numerous sub-types within CM and each 
can receive distinctive treatment. This suggests that data analysis should take the diagnostic 
sub-category into account. Consideration was given to this issue and it was initially proposed to code 
each formula according the syndrome (zheng) it treated, as well as for the symptom.  
 
However this proved impractical for a number of reasons. Even though the CCMs do specify zheng, 
the terminology is inconsistent and overlapping so the allocation of codes proved difficult and multiple 
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codes would have been required. Eventually, a tabular approach was taken for reference purposes (see 
Appendix 1).  
 
In the CT data, only a few trials specified the zheng and zheng were seldom explicitly stated in the 
classical literature as well. Consequently the allocation of zheng to the majority of the classical 
formulas would have involved considerable interpretation and assumption.  
 
Consequently, this aspect of the traditional CM approach to therapy has become submerged in the 
consolidated data. Nevertheless, in interpreting the results it needs to be borne in mind that jian wang 
was not a unitary concept and one reason for the variation in the formulas used and in the selection of 
herbs was the different zheng involved.  
 
Herb combinations 
According to traditional formula theory, combinations of herbs can have therapeutic actions not 
achievable by the herbs individually and this is one of the reasons for prescribing multi-herb formulas. 
The analyses presented throughout this study have been at either the level of the total formula or the 
individual herb. No attempt has been made to examine which pairs of herbs recur within formulas in 
the data sets. Just because two herbs have the same frequency, it does not mean that they were used in 
combination so frequency data cannot resolve this question, further analyses would be required to 
determine such relationships but these have proven to be beyond the scope of this study.  
 
Herb identification 
Herbs can have a range of names and the correspondence between traditional names and botanical 
names is not always clear. Materia medicas such as the Ben Cao Gang Mu have devoted considerable 
space to resolving confusions in herb identity and nomenclature but these still remain issues in modern 
CM.  
 
Although the botanical identities of most commonly used herbs are well established this cannot be said 
for all herbs across the span of the literature. When allocating a botanical name to a Chinese herb 
name, the procedure used was to select the name most commonly used in contemporary ben cao and 
dictionaries of herbs. Such an approach is subject to uncertainly and inaccuracy since the same 
Chinese name may apply to a number of species and there has been variation in the species used as a 
particular herb over time and region.  
 
It was beyond the scope of this study to undertake detailed investigations of the species that were the 
most likely referents for each herb entry. Such a task is both complex and time consuming. 
Nevertheless, this issue needs to be carefully considered when investigating the properties of plants on 
these lists. In such cases the most appropriate approach would be to work from the Chinese name and 
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determine which species have been known by this name and to investigate each of these species, not 
just the one now considered primary.  
 
The issue of efficacy 
One assumption underlying this research is that at least some of the herbal formulas used in CM have 
been effective in treating dementia or memory loss or can improve memory. Another implicit 
assumption is that treatments used repeatedly across the span of the classical literature, are likely to 
have had an effect, otherwise they would have been abandoned. Conversely, treatments that were 
abandoned were either ineffective or less effective than an available alternative or were associated 
with an undesirable effect. The results of the CTs suggest that some formulas conferred a cognitive 
benefit on at least some patients but it was not known which herbs produced these effects. The CCMs 
provide expert opinion on the applicability of certain formulas for certain groups of symptoms and 
may also provide some backup to some of these recommendations based on research, but most of the 
formulas recommended have not been the subjects of clinical trials.  
 
Although the herb frequency lists do indicate which herbs have been used most frequently for certain 
conditions over certain periods of time, these results cannot be interpreted as evidence of their efficacy 
for dementia. As discussed earlier, some of these herbs are high frequency items in a wide range of 
formulas. Others may provide nutritional benefits and thereby produce an improvement in health but 
have little effect on memory. Some herbs may have antioxidant properties and consequently assist in 
slowing decline in a wide range of degenerative disorders. However, such investigations are beyond 
the scope of this study and it can only be hoped that some herbs can assist in the management of 
dementia and some may provide leads for the development of new, more effective therapies. 
 
.
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APPENDIX 1: Summary of disease names, syndromes and formulas in contemporary CM clinical manuals (CCM) 
 
 Book name, editor, year Disease Syndrome (zheng) Formula name (pin yin) Formula name 
1 Zhong Yi Lao Nian Bing Xue 
中醫老年病學 
Zhang Xian-Yuan 張賢媛 
1992 
Lao nian xing 
chi dai  
老年性痴呆  
Tan zhuo zu qiao zheng 痰濁阻竅 
Yu zu nao luo zheng   瘀阻腦絡 
Gan yu xue xu zheng  肝郁血虛 
Xin pi liang xu zhang  心脾兩虛 
Gan shen kui sun zheng 肝腎虧損 
Wen dan tang 
Tong qiao huo xue tang 
Xiao yao san / Gan mai da zao tang 
Gui pi tang 
Huan shao dan 
溫膽湯 
通竅活血湯 
逍遙散/甘麥大棗湯 
歸脾湯 
還少丹 
Chi dai 痴呆 Bing fu bu zu  稟賦不足 
Jing qi kui xu  精氣虧虛 
Tan shi zu qiao 痰濕阻竅 
Qi xue yu zu   氣血瘀阻 
Qi fu yin 
Huan shao dan 
Zhi mi tang 
Tong qiao huo xue tang 
七福飲 
還少丹 
指迷湯 
通竅活血湯 
Jian wang 健忘 Nao sui kui xu 腦髓虧虛 
Jing qi bu zu 精氣不足 
Tan zhuo shang meng 痰濁上蒙 
Yu zu nao fu 淤阻腦府 
He che da zao wan 
Ren shen yang rong tang 
Dao tan tang 
Xue fu zhu yu tang 
河車大造丸 
人參養榮湯 
導痰湯 
血府逐瘀湯 
2 Shi Yong Zhong Yi Nao Bing 
Xue 
實用中醫腦病學 
Chen Hui 陳輝 
1993 
Lao nian xing 
chi dai  
老年性痴呆 
Sui hai bu zu 髓海不足 
Gan shen kui sun 肝腎虧損 
Xin gan huo wang  心肝火旺 
Tan zhuo zu qiao 痰濁阻竅 
Qi zhi xue yu  氣滞血瘀 
Bu tian da zao wan 
Zuo gui wan / Jia wei ding zhi wan 
Huang lian jie du tang 
Zhuan dai wan / Zhi mi tang 
Tong qiao huo xue tang 
補天大造丸 
左歸丸/加味定志丸 
黃蓮解毒湯 
轉呆丹/指迷湯 
通竅活血湯 
3 Shi Yong Zhong Yi Lao Nian 
Nei Ke Bing Xue 
實用中醫老年內科病學 
Gao Fu-An 高福安  
1995 
Lao nian xing 
chi dai  
老年性痴呆 
Empty syndromes 虛症 
Sui hai bu zu, shen jing kui sun  
髓海不足,腎精虧損 
Gan shen yin xu , xu feng nei dong  
肝腎陰虛,虛風內動 
Pi wei qi xu , tan zhuo zu qiao  
脾胃氣虛,痰濁阻竅 
 
Bu shen yi sui tang 
 
Ding zhi tang 
 
Xi xin tang 
 
 
補腎益髓湯 
 
定智湯 
 
洗心湯 
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3 Shi Yong Zhong Yi Lao Nian 
Nei Ke Bing Xue 
實用中醫老年內科病學 
Gao Fu-An 高福安  
1995 
Lao nian xing 
chi dai  
老年性痴呆 
Pi shen liang kui, sui ye kong xu  
脾腎兩虧.髓液空虛 
Xin gan yin xu , shen she bu an  
心肝陰虛,神舍不安 
Full syndromes 實症 
Gan yang shang kang 肝陽上亢 
Xin huo kang sheng 心火亢盛 
Tan shi zu qiao  痰濕阻竅 
Gan yu qi zhi 肝郁氣滯 
Zuo gui yin / Gui pi tang 
 
Er yin jian 
 
 
Tian ma gou teng yin / Zhen gan xi feng tang 
Zhu sha an shen wan jia wei 
Zhuan dai wan / Zhi mi tang 
Xiao yao san 
左歸飲 / 歸脾湯 
 
二陰煎 
 
 
天麻鉤藤飲 / 鎮肝熄風湯 
朱砂安神丸加味 
轉呆丸 / 指迷湯 
逍遙散 
Shen xu jing kui 腎虛精虧 Er zhi wan / Liu wei di huang wan 
Zuo gui wan / Jia jian gu ben wan  
Jian wang wan / Du shu wan / Er dan wan 
二至丸 / 六味地黃丸 
左歸丸 / 加減固本丸 
健忘丸 / 讀書丸 / 二丹丸 
Xin pi liang xu 心脾兩虛 Si jun zi tang / Gui pi tang 
Ren shen yang rong tang 
Ren shen yuan zhi wan / Bu wang san 
四君子湯 / 歸脾湯 
人參養榮湯 
人參遠志丸 / 不忘散 
Xin xu shen qie 心虛神怯 Fu shen wan / Bu xin shen xiao wan 
Da cding xin tang / Yuan zhi tang 
Fu ling bu xin tang 
Zhuang yuan wan / Da gui shen dan 
茯神丸 / 補心神效丸 
大定心湯 / 遠志湯 
茯苓補心湯 
狀元丸 / 大歸神丹 
Xin shen liang xu 心腎兩虛 Cong rong san / Xiao ding zhi wan 
Tian wang bu xin dan 
Ba ji tian wan / Da yi zhi san 
Zhu que wan / Yang xin tang 
蓯蓉散 / 小定志丸 
天王補心丹 
巴戟天丸 / 大益智散 
朱雀丸 / 養心湯 
4 Zhong Yi Lao Nian Bing Lin 
Chuang Yan Jiu 
中醫老年病臨床研究 
Zhou Wen-Quan 周文泉 & 
Gao Pu 高普 
1995 
Jian wang 健忘 
Tan zhuo nei zu 痰濁內阻 Kai xin bu wang san / Er chen tang 
Di tan tang / Dao tan tang / Fu ling yin 
Jia wei ding zhi wan / Gui shen dan 
開心不忘散 / 二陳湯 
涤痰湯 / 導痰湯 / 茯苓飲 
加味定志丸 / 歸神丹 
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Jian wang 健忘 Yu xue nei zu 瘀血內阻 Tao hong si wu tang / Bu yang huan wu tang 
Xue fu zhu yu tang / Di dang tang 
Dai di dang wan / Chang pu yi zhi tang 
桃紅四物湯 / 補陽還五湯 
血府逐瘀湯 / 抵當湯 
代抵當丸 / 菖蒲益智丸 
Shen xu sui jian 腎虛髓減 
Shen yin xu  腎陰虛 
Shen yang xu 腎陽虛 
 
Zuo gui wan 
You gui wan 
Bu tian da zao wan 
Bu tian guang si wu lei you qing dan 
Chang chun zhi bao dan / Bu nao wan 
 
左歸丸 
右歸丸 
補天大造丸 
補天廣嗣物類有情丹 
長春至寶丹 / 補腦丸 
Xin gan yin xu 心肝陰虛 Suan zao ren tang / An shen bu xin dan 
Tian wang bu xin dan / Bo zi yang xin wan 
Si wu an shen tang / Kong sheng zhen zhong dan 
酸棗仁湯 / 安神補心丹 
天王補心丹 / 柏子養心丸 
四物安神湯 / 孔聖枕中丹 
Xin pi liang xu 心脾兩虛 Qi fu yin / Xuan zhi tang / Fu shen tang 
Ding zhi wan / Ren shen wan / Gui pi tang 
七福飲 / 宣志湯 / 茯神湯 
定志丸 / 人參丸 / 歸脾湯 
Tan zhuo zu qiao 痰濁阻竅 Xi xin tang / Di tan tang 
Qing xin gun tan wan / Qi xin jiu wei tang 
Su xin tang / Qing xin dao tan tang 
洗心湯 / 涤痰湯 
清心滾痰丸 / 啟心救胃湯 
蘇心湯 / 清心導痰丸 
4 Zhong Yi Lao Nian Bing Lin 
Chuang Yan Jiu 
中醫老年病臨床研究 
Zhou Wen-Quan 周文泉 & 
Gao Pu 高普 
1995 
Chi dai 痴呆 
Qi zhi xue yu 氣滯血瘀 Tong qiao huo xue tang / Xue fu zhu yu tang 
Tao ren cheng qi tang / Tao hong si wu tang 
Fu yuan huo xue tang / Bu yang huan wu tang 
通竅活血湯 / 血府逐瘀湯 
桃仁承氣湯 / 桃紅四物湯 
復元活血湯 / 補陽還五湯 
5 Zhong Yi Zhi Liao Lao Nian 
Bing 
中醫治療老年病 
Hou & Geng 
1997 
Senile dementia Stagnation of phlegm and qi 
Deficiency of heart and spleen 
Deficiency of brain 
Type of heart disorder 
Type of liver yang 
Type of qi depressio 
Shun qi dao tan tang 
Bao yuan tang 
Liu wei di huang tang (with additions) 
No formula name 
No formula name 
No formula name 
順氣導痰湯 
保元湯 
加味六味地黃湯 
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5 Zhong Yi Zhi Liao Lao Nian 
Bing 
Senile dementia Type of yin deficiency 
Type of yang deficiency 
No formula name 
No formula name 
 
Jian wang 健忘 Empty syndromes 虛症 
Xin pi liang xu  心脾兩虛 
Xin shen bu jiao  心腎不交 
Jing jie shen shuai 精竭神衰 
Full syndromes 實症 
Tan zhuo shang meng 痰濁上蒙 
Yu zu nao zang 瘀阻腦臟 
 
Gui pi tang 
Xin shen liang jiao tang 
Ren shen yang rong tang 
 
Xin shen liang jiao tang 
Xue fu zhu yu tang 
 
歸脾湯 
心腎兩交湯 
人參養榮湯 
 
心腎兩交湯 
血府逐瘀湯 
6 Zhong Yi Nao Bing Xue  
中醫腦病學 
Xu Pei-Hu 許沛虎 
1998 
Chi dai 痴呆 Bing fu bu zu  稟賦不足 
Jing qi bu zu  精氣不足 
Pi shen kui xu  脾腎虧虛 
Tan zhuo zu qiao  痰濁阻竅 
Qi zhi xue yu  氣滯血瘀 
Re du chi sheng  熱毒熾盛 
Qi xue xu ruo  氣血虛弱 
Qi tong yin 
Huan shao dan 
Jin gui shen qi wan 
Xi xin tang 
Tong qiao huo xue tang 
Huang lian jie du tang 
Ba zhen tang / Chang pu wan 
七痛飲 
還少丹 
金匱腎氣丸 
洗心湯 
通竅活血湯 
黃蓮解毒湯 
八珍湯/菖蒲丸 
7 Lao Nian Chi Dai Zheng De 
Zhong Xi Yi Zhen Duan Yu 
Zhi Liao  
老年痴呆症的中西醫診斷與
治療 
Li Qiu-Bing 李求兵 & Mei 
Rong 梅嶸 
1999 
Lao nian chi dai  
老年痴呆 
Common syndromes 常見症型 
Sui hai bu zu 髓海不足 
Gan shen kui sun 肝腎虧虛 
Pi shen liang xu 脾腎兩虛 
Tan zhuo zu qiao  痰濁阻竅 
Yu xue zu qiao 瘀血阻竅 
Gan yang shang kang 肝陽上亢 
Xin huo kang sheng 心火亢盛 
Other syndromes 其它症型  
Qi xu xue yu 氣虛血瘀 
Shen xu xue yu 腎虛血瘀 
 
Bu tian da zao wan / Bu shen yi sui tang 
Zuo gui wan / Qi ju di huang wan 
Jin gui shen qi wan / Huan shao dan 
Zhi mi tang / Di tan tang 
Tong qiao huo xue tang / Tao hong si wu tang 
Tian ma gou teng yin / Zhen gan xi feng tang 
Xie xin tang / Huang lian jie du tang 
 
Bu yang huan wu tang 
Bu tian da zao wan / Tong qiao huo xue tang 
 
補天大造丸 / 補腎益髓湯 
左歸丸 / 杞菊地黃丸 
金匱腎氣丸 / 還少丹 
指迷湯 / 涤痰湯 
通竅活血湯 / 桃紅四物湯 
天麻鉤藤飲 / 鎮肝熄風湯 
瀉心湯 / 黃蓮解毒湯 
 
補陽還五湯 
補天大造丸 / 通竅活血湯 
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7 Lao Nian Chi Dai Zheng De 
Zhong Xi Yi Zhen Duan Yu 
Zhi Liao  
老年痴呆症的中西醫診斷與
治療 
Li Qiu-Bing 李求兵 & Mei 
Rong 梅嶸 
1999 
Lao nian chi dai  
老年痴呆 
Tan yu hu zu 痰瘀互阻 
Qi yin liang xu 氣陰兩虛 
Qi xue kui xu 氣血虧虛 
Yin yang liang xu 陰陽兩虛 
Jing xue kui xu 精血虧虛 
Xin pi liang xu  心脾兩虛 
Tan huo rao xin 痰火擾心 
Xin shen bu jiao 心腎不交 
Dao tan tang / Tao hong si wu tang 
Shen di huanf qi tang / Qi fu yin 
Dang gui bu xue / Ba zhen tang 
Zuo gui wan / You gui wan 
Jia wei si wu tang 
Gui pi tang 
Qing xin gun tan wan / Chang pu yu jin tang 
Jiao tai wan jia wei 
導痰湯 / 桃紅四物湯 
參地黃蓍湯 / 七褔飲 
當歸補血湯 / 八珍湯 
左歸丸 / 右歸丸 
加味四物湯 
歸脾湯 
清心滾痰丸 / 菖蒲郁金湯 
交泰丸加味 
8 Xin Bian Zhong Yi Lao Nian 
Bing Lin Chuang Shou Ce  
新编中醫老年病臨床手冊 
Wang Fa-Wei 王發渭 & 
Hao Ai-Zhen 郝愛真, 1999 
Lao nian xing 
chi dai  
老年性痴呆 
Gan shen kui sun 肝腎虧損 
Tan mi xin qiao 痰迷心竅 
Xin pi liang xu  心脾兩虛 
Xue yu qi zhi 血瘀氣滯 
Huan shao dan 
Xi xin tang 
Gui pi tang 
Tong qiao huo xue tang 
還少丹 
洗心湯 
歸脾湯 
通竅活血湯 
Jian wang 健忘 Xin pi liang xu  心脾兩虛 
Nao sui kong xu 腦髓空虛 
Xin shen bu jiao 心腎不交 
Tan zhuo rao xin 痰濁擾心 
Yu zu nao qiao 瘀阻腦竅 
Tan yu bi zu 痰瘀痹阻 
Jing qi shuai wei 精氣衰微 
Gui pi tang 
He che da zao wan 
Xin shen tong yuan fang 
Dao tan tang 
Tong qiao huo xue tang 
Zhi mi tang 
Huan shao dan 
歸脾湯 
河車大造丸 
心腎同源方 
導痰湯 
通竅活血湯 
指迷湯 
還少丹 
9 Zhong Yi Shen Jing Jing 
Shen Bing Xue  
中醫神經精神病學 
Zhang Deng-Ben 張登本 
2000 
Chi dai 痴呆 Bing fu bu zu 稟賦不足 
Jing qi kui xu 精氣虧虛 
Tan shi zu qiao 痰濕阻竅 
Qi zhi xue yu 氣滯血瘀 
Sui hai bu zu 髓海不足 
Gan shen yin xu 肝腎陰虛 
Xin gan huo wang 心肝火旺 
Qi fu yin 
Huan shao dan 
Zhi mi tang 
Tong qiao huo xue tang 
Bu tian da zao wan 
Zuo gui wan 
Huang lian jie du tang 
七福飲 
還少丹 
指迷湯 
通竅活血湯 
補天大造丸 
左歸丸 
黃蓮解毒湯 
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9 Zhong Yi Shen Jing Jing 
Shen Bing Xue  
Chi dai 痴呆 Pi shen liang xu 脾腎兩虛 
Qi xue xu ruo 氣血虛弱 
Jin gui shen qi wan 
Ba zhen tang / Chang pu wan 
金匱腎氣丸 
八珍湯 / 菖蒲丸 
10 Shi Yong Zhong Yi Lao Nian 
Bing Xue  
實用中醫老年病學 
Zhou Wen-Quan 周文泉 & 
Li Xiang-Guo 李祥國 
2000 
Lao nian qi chi 
dai  
老年期痴呆 
Lao nian xing chi dai 老年性痴呆 
Shen jing xu shuai 腎精虛衰 
Qi xue liang xu 氣血兩虛 
Qi zhi xue yu 氣滯血瘀 
Tan zhuo zu qiao 痰濁阻竅 
Xue guan xing chi dai 血管性痴呆 
Gan yang shang kang 肝陽上亢 
Yin xu yang kang 陰虛陽亢 
Tan zhuo zu qiao  痰濁阻竅 
Yu zu qing qiao 瘀阻清竅 
Gan shen kui xu 肝腎虧虛 
Qi xue bu zu 氣血不足 
 
Zuo gui wan / Gui lu er zian jiao 
Gui pi tang / Dan gui shao yao san 
Xue fu zhu yu tang 
Di tan tang 
 
Tian ma gou teng yin 
Zhen gan xi feng tang 
Ban xia bai zhu tian ma tang 
Xue fu zhu yu tang 
Da bu yin wan jia wei 
Ba zhen tang jia wei 
 
左歸丸 / 龜鹿二仙膠 
歸脾湯 / 當歸芍藥散 
血府逐瘀湯 
涤痰湯 
 
天麻鉤藤飲 
鎮肝熄風湯 
半夏白術天麻湯 
血府逐瘀湯 
大補陰丸加味 
八珍湯加味 
11 Shi Yong Zhong Yi Lao Nian 
Bing Xue  
實用中醫老年病學 
Zhang Min 張暋 
2000 
Lao nian chi dai 
zheng  
老年痴呆症 
Gan shen jing kui 肝腎精虧 
Tan zhuo zu qiao 痰濁阻竅 
Qi zhi xue yu 氣滯血瘀 
Qi xu xue yu 氣虛血瘀 
Xue xu 血虛 
Zhen zhu mu wan 
Zhi mi tang / Di tan tang 
Xue fu zhu yu tang / Tong qiao Huo xue tang 
Bu yang huan wu tang 
Xiao yao san / Gan cao da zao tang 
珍珠母丸 
指迷湯 / 涤痰湯 
血府逐瘀湯 / 通竅活血湯 
補陽還五湯 
逍遙散 / 甘草大棗湯 
12 Chinese Medical Psychiatry  
中醫精神病學 
Bob Flaws & James Lake 
2001 
Impaired 
memory (jian 
wang) 
Heart-spleen dual vacuity pattern 
Kidney essence insufficiency pattern 
Non-interaction between the heart & 
kidneys pattern 
Phlegm qi depression & binding pattern 
Blood stasis internally obstructing pattern 
 
Gui pi tang jia jian 
He che da zao wan jia jian 
Liu wei di huang wan jia wei 
 
Wen dan tang jia jian 
Xue fu zhu yu tang jia jian 
 
歸脾湯加減 
河車大造丸加減 
六味地黃丸加味 
 
溫膽湯加減 
血府逐瘀湯加減 
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12 Chinese Medical Psychiatry  
中醫精神病學 
Bob Flaws & James Lake 
2001 
Senile dementia 
(chi dai) 
Kidney essence insufficiency pattern 
Yin vacuity-internal heat pattern 
Spleen-kidney yang vacuity pattern 
Qi & blood dual vacuity pattern (also 
called Heart-spleen dual vacuity pattern) 
Phlegm misting the clear orifices pattern 
Stasis stagnating in the brain network 
vessels pattern 
Toxins damaging the brain network 
vessels pattern 
Liver depression qi stagnation pattern 
Da zao wan jia jian 
Zhi bai di huang wan jia wei 
Jia wei shen qi wan 
Gui pi tang 
 
Wen dan tang jia wei 
Tong qiao huo xue tang jia jian 
 
Huang lian jie du tang 
 
Xiao yao san jia wei 
大造丸加減 
知柏地黃丸加味 
加味腎氣丸 
歸脾湯 
 
溫膽湯加味 
通竅活血湯加減 
 
黃蓮解毒湯 
 
逍遙散加味 
13 Shen Jing Ke Zhuan Bing 
Zhong Yi Lin Chuang Zhen 
Zhi 神經科專病中醫臨床診
治, Huang Pei-Xin 黃培新 
& Liu Mao-Cai 劉茂才 
2005 
Lao nian chi dai  
老年痴呆 
Sui hai bu zu 髓海不足  
Gan shen kui sun 肝腎虧損  
Pi shen liang xu 脾腎兩虛 
Xin gan huo wang 心肝火旺  
Tan zhuo zu qiao  痰濁阻竅  
Qi zhi xue yu  氣滞血瘀  
Bu tian da zao wan 
Zuo gui wan / Jia wei ding zhi wan 
Huan shao dan 
Huang lian jie du tang 
Zhi mi tang 
Tong qiao huo xue tang 
補天大造丸 
左歸丸 / 加味定志丸 
還少丹 
黃蓮解毒湯 
指迷湯 
通竅活血湯 
14 Gu Jin Zhong Yi Nao Bing 
Bian Zhi Jing Yao  
古今中醫腦病辨治精要 
Li Yong 李勇.& Xie 
Dong-mei 謝冬梅  
2007 
Lao nian qi chi 
dai 
老年期痴呆 
Sui hai bu zu 髓海不足 
Gan shen kui sun 肝腎虧損 
Pi shen liang xu 脾腎兩虛 
Xin pi liang xu 心脾兩虛 
Xin gan huo wang 心肝火旺 
Tan zhuo zu qiao 痰濁阻竅 
Qi zhi xue yu 氣滯血瘀 
Bu tian da zao wan 
Zuo gui wan 
Huan shao dan 
Gui pi tang 
Huang lian jie du tang 
Zhi mi tang 
Tong qiao huo xue tang 
補天大造丸 
左歸丸 
還少丹 
歸脾湯 
黃蓮解毒湯 
指迷湯 
通竅活血湯 
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APPENDIX 2: Rating Sheets 
 
1. Scoring the Diagnostic Criteria for Dementia of the Alzheimer’s Type (DSM-IV-TR) 
 
Column 1: Memory 
The key symptom is:  
Memory impairment (impaired ability to learn new information or to recall previously learned 
information) particularly episodic memory 記憶的損傷 (無法學習新事物或無法回憶以前學習的事
物).  
The course is characterized by gradual onset and continuing cognitive decline 認知的衰退過程是漸
近並且持續地. 
 
Scoring instructions 
• When there is no mention of jian wang or similar term, or any mention of improving memory, then 
score 0. 
• When there are no symptoms of memory loss given, but the treatment principle or function of the 
formula or formula name is to improve memory, then score 1. This includes cases where the 
formula is for improving memorisation for exams. 
• When there are symptoms of memory impairment (jian wang, duo wang, shan wang, xi wang etc) 
but no additional information to indicate its nature then score 2. This should be done even when 
there are other symptoms that could indicate that the condition is not AD. 
• When there are symptoms of memory loss that are consistent with AD, score 3. 
 
Scoring for memory 
No mention of memory 0 
Function of improve memory (qiang ji etc) without explicit indication that there is a memory 
disorder 
1 
Memory impairment (jian wang, duo wang, shan wang, xi wang etc) as a disease or 
symptom 
2 
Description of memory disorder consistent with dementia 3 
 
 
Column 2: Age 
Since AD is a disorder of aging, it is important to determine whether the particular entry relates to 
older people. 
 
Scoring instructions 
• When there is no reference to old age, or longevity in the text, formula, book name etc, and the 
context does not allow us to infer that an older person is being referred to, score 0.  
• Also score 0 when there is reference to a young person. 
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• When we can infer from context that the formula is probably intended for older people, rather than 
for young people or people of any age, then score 1. For example, if the book makes reference to 
longevity or is intended for use by older people. 
• When there is a clear reference to promoting longevity either in the section heading, formula 
actions, or formula name, then score 2. In such cases we cannot be sure that it is only for old people, 
since longevity promotion may be an enterprise of younger people as well. 
• When the instance clearly refers to an elderly person, or the formula is clearly indicated for older 
people, then score 3. 
 
Scoring for Age 
No reference to old age or longevity 0 
Longevity referred to book name 1 
Promote longevity as a formula action/function, or in the formula name 2 
Indicated for older people 3 
 
 
Column 3: Group 2 symptoms 
In addition to the above, for a diagnosis of AD, there needs to be: one (or more) of the following 
cognitive disturbances: 至少有下列一個的認知障礙 
 
1. Aphasia (language disturbance) 失語症 (言語障礙) 
Deterioration of language function (aphasia) may be manifested by difficulty producing the names of 
individuals and objects. The speech of individuals with aphasia may become vague or empty, with 
long circumlocutory phrases and excessive use of terms of indefinite reference such as "thing" and 
"it." Comprehension of spoken and written language and repetition of language may also be 
compromised. In the advanced stages of dementia, individuals may be mute or have a deteriorated 
speech pattern characterized by echolalia (i.e., echoing what is heard) or palilalia (i.e. repeating sounds 
or words over and over).  
 
2. Apraxia (impaired ability to carry out motor activities despite intact motor function) 失用症 (雖無
運動中心損傷，但有運動能力有障礙) 
Individuals with dementia may exhibit apraxia (i.e., impaired ability to execute motor activities despite 
intact motor abilities, sensory function, and comprehension of the required task). They will be 
impaired in their ability to pantomime the use of objects (e.g., combing hair) or to execute known 
motor acts (e.g. waving goodbye). Apraxia may contribute to deficits in cooking, dressing, and 
drawing.  
 
3. Agnosia (failure to recognize or identify objects despite intact sensory function) 認識不能 (感覺中
心雖無損傷，但認識或分辨事物有障礙) 
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Individuals with dementia may exhibit agnosia (i.e., failure to recognize or identify objects despite 
intact sensory function). For example, the individual may have normal visual acuity but lose the ability 
to recognize objects such as chairs or pencils. Eventually they may be unable to recognize family 
members or even their own reflection in the mirror. Similarly, they may have normal tactile sensation, 
but be unable to identify objects placed in their hands by touch alone (e.g. a coin or keys).  
 
4. Disturbance in executive functioning (i.e. planning, organizing, sequencing, abstracting) 執行功能
障礙 (即計劃、組織、排序、摘錄) 
Disturbances in executive functioning are a common manifestation of dementia and may be related 
especially to disorders of the frontal lobe or associated subcortical pathways. Executive functioning 
involves the ability to think abstractly and to plan, initiate, sequence, monitor, and stop complex 
behaviour. Impairment in abstract thinking may be manifested by the individual having difficulty 
coping with novel tasks and avoiding situations that require the processing of new and complex 
information. The ability to abstract can be formally assessed by asking the person to find similarities 
or differences between related words. Executive dysfunction is also evident in a reduced ability to shift 
mental sets, to generate novel verbal or nonverbal information, and to execute serial motor activities. It 
is also useful to determine (from the individual and informants) the impact of the disturbances in 
executive functioning on the individual's daily life (e.g. ability to work, plan activities, budget).  
 
Identifying and scoring group 2 symptoms 
• These four symptoms represent broad abstract concepts, so you have to use your judgement in 
determining whether a particular symptom or description from the classical source can fit within 
one of these categories. In general, you should aim to be inclusive. 
• Only score each of the group 2 symptoms once, so when a symptom in the classic source seems to 
overlap, you have to choose the group 2 symptom that is best fit.  
• Unlike the scores for memory and age you can score more than one number in this column. 
 
Scoring group 2 symptoms 
Aphasia 1 
Apraxia 2 
Agnosia 3 
Disturbance in executive functioning  4 
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2. NPI Criteria  中文版本: 症狀定義及說明 
 
Code 
No. 
Chinese terms English terms Chinese explanation Examples 
1 妄想 
Delusions 
病人的行為和/或語言表明
病人相信某些不存在或者真
實的事實 
1. 病人相信他正處於危險中嗎？即其他人正計劃去傷害他？ 
2. 病人相信其他人正在偷他的東西嗎？ 
3. 病人相信他的配偶正與其他人有染嗎？ 
4. 病人相信不速之客正住在他的屋嗎？ 
5. 病人相信他的配偶或其他人並不是他們所聲稱的那些人嗎？ 
6. 病人相信他的房子不是他的家嗎？ 
7. 病人相信家人計劃拋棄他嗎？ 
8. 病人相信電視或雜誌的人物正處身在他的家嗎？(他試圖同他們談話或交往嗎？) 
9. 病人有沒有其他不尋常的信念，是我未曾問及的呢？ 
2 幻覺 
Hallucinations 
病人的行為和/或語言表明
病人出現幻覺或者幻聽，能
看到不可能存在的东西或者
聽到别人没有聽到的聲音,
或者有其他異常感覺 
1. 病人有描述他的幻聽或表現得像聽到聲音嗎？ 
2. 病人有同不存在的人談話嗎? 
3. 病人有描述看到一些東西，是其他人看不見的或病人的舉止好像表現出他/她看到東西，是其
他人看不見的嗎(如：人、動物、光等)？  
4. 病人有提及聞到氣味是其他人嗅不到的嗎？  
5. 病人描述感到有東西在他/她的皮膚上或有東西爬行或觸摸他/她嗎？  
6. 病人有描述一些不知來由的味度(指味覺)嗎？  
7. 病人有描述不正常的感官經歷嗎？ 
3 煩燥/攻擊行
為 
Agitation or 
Aggression 
病人情绪激動，躁動不安，
無法放鬆或者平静下來，無
法接受别人的意见，喜歡爭
辯，有攻擊别人的傾向。 
1. 病人有向照顧者發脾氣/或對活動例如洗澡/換衣服表現不合作的態度嗎？ 
2. 病人很頑固，堅持依他/她的方法處事嗎？  
3. 病人不合作，拒絕接受別人的幫助嗎？  
4. 病人有其它行為使人難於處理嗎？  
5. 病人有憤怒地大聲叫或詛咒嗎？  
6. 病人有大力關門，踢傢俬和扔東西嗎？ 
7. 病人有試圖傷人或打其他人嗎？  
8. 病人有其他的攻擊行為或煩燥不安的行為嗎？ 
4 抑鬱/情緒低
落 
Depression or 
Dysphoria 
病人情绪低落，默默不語，
悲傷欲哭，自我否定，有自
殺傾向。 
1. 病人有一段時期哭泣，似乎顯示他/她的悲傷嗎？  
2. 病人在言語或行為上有表現他/她很傷感或情緒低落嗎？  
3. 病人有貶低自己或說感覺他/她是個失敗者嗎？  
4. 病人有說他/她是壞蛋或應受處罰嗎？ 
5. 病人有表現得沮喪或說他/她沒有前途嗎？  
6. 病人說他/她對家庭是個包伏或說若家裏沒有他/她，境況將會更好嗎？  
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Code 
No. 
Chinese terms English terms Chinese explanation Examples 
7. 病人有尋死的念頭或談及自殺嗎？  
8. 病人有其它顯示抑鬱或悲傷的徵象嗎？ 
5 焦慮 
Anxiety 
(inc fear, panic) 
病人表現為情緒緊張，焦慮
不安，過度擔心或不必要的
恐懼。常伴随軀體不適症状
如呼吸困難，胸悶，心悸，
胃部不適。 
1. 病人說他/她擔心已計劃好的事情嗎？ 
2. 病人有段時期感到恐懼震顫，不能放鬆或感到特別緊張嗎？  
3. 病人有段時期(或投訴)呼吸困難，氣喘，嘆氣等，無緣故的焦慮徵狀嗎？  
4. 病人有投訴胃部隱隱不適，與焦慮有關的心跳加快或加重嗎？(徵狀不是因疾病引起的)  
5. 病人有避免去某些引起她/他焦慮的地方或場合，例如乘車，會見朋友或去人多擠擁的地方
嗎？  
6. 當同你(或他/她的照顧者)分開，病人有變得緊張和不安嗎？(他/她有沒有緊貼著你不願分
開？)  
7. 病人有顯示其他焦慮的徵象嗎？ 
6 情緒高漲/欣
快 
Euphoria 
病人情绪過度高漲，異常欣
快，甚至有不適當的行為
（如不適應場合的大笑或唱
歌）。 
1. 病人呈現過度高興或愉快，與平常的他/她不同嗎？  
2. 病人有發現幽默和好笑的東西，而其他人卻沒有此感的嗎？  
3. 病人好像有幼稚的幽默感，且有不恰當的傻笑或大笑的傾向嗎例如當有不幸事發生在某人身上
時)？ 
4. 病人講笑話或給評論，對其它人來說一點也不幽默，而他/她本人覺得很好笑嗎？  
5. 病人有玩小孩的惡作劇例如扭人一下或玩捉迷藏嗎？ 
6. 病人把自己抬舉或聲稱自己有很多才能或財富而實際則不是這樣嗎？  
7.  病人有否顯示其他過度高興或快樂的徵象嗎？  
 
7 情緒淡漠/冷
漠 
Apathy or 
indifference 
病人表情淡漠，對周圍人、
事或環境失去興趣。 
1. 病人似乎比平常少了主動和活躍嗎？  
2. 病人較少主動交談嗎？  
3. 與病人平時比較，他/她較少顯露情感或缺乏感情嗎？  
4. 病人做家務少于平時嗎？ 
5. 病人對於別人的活動和計劃，顯得減少了興趣嗎？ 
6. 病人已對朋友和家庭成員失去興趣嗎？ 
7. 病人對平時興趣相比減退了熱心嗎？ 
8. 病人有任何徵象顯示他/她對做新事物不關心嗎？ 
8 抑制解除 
Disinhibition 
病人無法抑制自己的一些不
符合社交習惯的行為和言
語，且無法判斷這些行為和
言語的社會後果。 
1. 病人表現不考慮後果而作出衝動行為嗎？ 
2. 病人有跟陌生人談話，好像是認識他們的嗎？  
3. 病人有說一些不體貼或傷害別人感情的話嗎？  
4. 病人說粗魯或與性有關的話題，是病人以往不常說的嗎？ 
5. 病人開放地談論一些通常不會在公共場所說的，有關個人或非常隱私的事嗎？ 
6. 病人一反常態，表現過份熟落，或觸摸，擁抱其他人嗎？ 
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Code 
No. 
Chinese terms English terms Chinese explanation Examples 
7. 病人有顯示失去控制他/她的衝動的其它徵象嗎？ 
9 易怒/情緒波
動 
Irritability or 
lability 
病人容易被激怒，情緒不稳
定，脾氣暴躁，缺乏耐心。 
1. 病人有發脾氣，且很易為些小事情失控嗎？  
2. 病人的情緒很易改變，喜怒無常嗎？  
3. 病人有突然地發怒嗎？  
4. 病人無耐心，不能容忍拖延或等候安排好的活動嗎？ 
5. 病人有脾氣暴躁(忕憎)和易怒嗎？  
6. 病人好爭辯和很難與人相處嗎？  
7. 病人有其它顯示易怒的徵象嗎？  
10 異常的動作
行為 
Motor disturbance 
病人異常地反覆做一些行
為。 
1. 病人無目的地在房子中踱步嗎？  
2. 病人重覆打開抽屜或衣櫥拿物件出來嗎？ 
3. 病人反覆地穿衣或脫衣嗎？  
4. 病人有重覆的行為或習慣嗎？  
5. 病人有重覆行為例如把弄衣鈕，拾東西，縛繩等嗎？ 
6. 病人過度的坐立不安，似乎不能安坐，或雙腳蹦蹦跳跳，或經常用手指輕敲嗎？  
7. 病人反覆地做其它的行為嗎？  
11 睡眠 
Night time 
behaviour 
病人睡眠習慣或夜晚行為出
現異常。如失眠，早醒，日
夜反常行為等。 
1. 病人有困難入睡嗎？  
2. 病人有晚上起床嗎？(下列情形不計在內：如病人每晚只單純地起床一至二次去 洗手間，然後
很快入睡)  
3. 病人在晚上遊蕩、踱步或有不適當的行為嗎？  
4. 在晚上病人有把你弄醒嗎？  
5. 病人在晚上醒來，穿衣，並且計劃出外當作是早上，是時候開始新的一天嗎？  
6. 病人在早晨過早醒來嗎(比他/她以往的習慣更早)？  
7. 病人在白天睡得太多嗎？  
8. 病人在晚上有其它的行為打擾你，是我們沒有問及的嗎？  
12 食慾或飲食
失調 
Appetite and eating 
病人食欲、飲食習慣發生異
常改變。 
1. 他/她已失去食慾嗎？  
2. 他/她有食慾增加嗎？  
3. 他/她有體重減輕嗎？  
4. 他/她有體重增加嗎？  
5. 他/她進食行為改變了，例如在同一時刻將太多食物放進嘴嗎？  
6. 他/她在自己喜歡的食物種類上有改變，例如吃太多的甜食或其它特別種類的食品嗎？ 
7. 他/她有以下的進食行為，例如每天吃同樣的食物或堅持以固定的次序進食嗎？  
8. 有沒有其他在食慾或飲食的改變，是我未曾問及的？ 
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3. Scoring Policy and procedure for NPI 
The NPI is a modern system written in modern Chinese, so there are a number of difficulties when applying it to an historical record. Also, when the NPI is used it is 
administered by a trained person who questions a caregiver. In such a situation it is possible to ask for clarification on any point in order to arrive at a decision about 
the appropriate symptom category. This is not possible when the only information is what is written in the entry in the classical text. Therefore, when deciding upon 
whether to score a particular word or phrase as one of the NPI categories, you will have to make a judgement. In doing this the following need to be considered: 
1. The main aim is to identify possible or probable cases of dementia based on the scores included in the database. In general, it is better to include a symptom 
in the database than leave it out and have it lost to the statistical analysis. So the general rule is to include all likely examples.  
2. The NPI descriptions are not complete lists of all possible instance of that category of symptom and rely upon the person scoring the test making their own 
judgements. When scoring these entries you also need to judge whether an instance constitutes an example of an NPI category. In doing this you may need 
to take the whole context into account. For example, many symptoms of anxiety can also have a physical cause. If the context indicates that a physical cause 
is very likely, then these should not be included under anxiety. Otherwise, they should be included. The reason is that the majority of the entries under the 
disease categories of chi dai and jian wang relate to disorders that have at least some psychological component, so the default judgement is to include these 
symptoms unless the evidence is to the contrary. 
3. When scoring, the aim is to determine whether any symptoms belong to an NPI category, not how many symptoms belong to that category. For example, 
when there are three symptoms in the entry that could indicate anxiety, you still only score the entry once as 5. 
4. It can be difficult to distinguish between some NPI categories, so you may have difficulty deciding how to score an item. In such cases, choose the category 
you think is closest. The main criterion for inclusion is that the scope of meaning of the term at least overlaps with the meaning of the NPI category. If it is 
possible to include it, you should include it. But only include it once in one category. 
5. Some terms may seem to belong in two or more NPI categories. In such cases you have to decide upon which is the best fit. Also, when there are a number 
of different symptoms that could belong in either of two categories the approach is to allocate one to each category. Otherwise the data is lost since there is 
only one score allowed for any one NPI category. 
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APPENDIX 3: Selected classical formulas 
 
Book name: Ji Yan Fang 集驗方 (c. 543) 
Formula name: Kai xin san 開心散 
Ingredients: 
Chang pu 菖蒲     Acorus graminus or A. calamus L., 
Fu ling 茯苓    Poria cocos (Schw.) Wolf 
Ren shen 人參    Panax ginseng C.A. Mey.  
Yuan zhi 遠志    Polygala tenuifolia Willd., 
 
Book name: Ji Yan Fang 集驗方 (c. 543) 
Formula name: Huang qi jiu 黃蓍酒 
Ingredients: 
Huang qi 黃蓍 Astragalus membranaceus (Fisch.) Bge. var. mongholicus 
(Bge.) Hsiao 
Du huo 獨活    Angelica pubescens Maxim. f . biserrata Shan & Yuan 
Fang feng 防風    Saposhnikovia divaricata (Turcz.) Schischk. 
Xi xin 細辛    Asarum sieboldii Miq. Var. seoulense Nakai 
Niu xi 牛膝    Achyranthes bidentata Blume 
Chuan xiong 川芎   Ligusticum chuanxiong Hort. 
Fu zi 附子    Aconitum carmichaeli Debx. 
Gan cao 甘草    Glycyrrhiza uralensis Fisch.   
Shu jiao 蜀椒    Zanthoxylum bungeanum Maxim. 
Chuan wu 川烏    Aconitum carmichaeli Debx. 
Shan zhu yu 山茱萸   Cornus officinalis Sieb. & Zucc.  
Qin jiao 秦艽    Gentiana macrophylla Pall. 
Ge gen 葛根    Pueraria lobata (Willd.) Ohwi 
Guan gui 官桂    Cinnamomum cassia Presl 
Dang gui 當歸    Angelica sinensis (Oliv.) Diels   
Da huang 大黃    Rheum palmatum L. 
Bai zhu 白術     Atractylodes macrocephala Koidz. 
Gan jiang 乾薑    Zingiber officinale (Willd.) Rosc. 
 
Book name: Bei Ji Qian Jin Yao Fang 備急千金要方 (c. 652.) 
unnamed formula 
Ingredients: 
Chang pu 菖蒲    Acorus graminus or A. calamus L. 
Yuan zhi 遠志    Polygala tenuifolia Willd. 
Fu ling 茯苓    Poria cocos (Schw.) Wolf 
Fu shen 茯神    Poria cocos (Schw.) Wolf 
Ren shen 人參    Panax ginseng C.A. Mey. 
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Book name: Bei Ji Qian Jin Yao Fang 備急千金要方 (c. 652.)  
Formula name: Da ba feng tang 大八風湯 
Ingredients: 
Dang gui 當歸    Angelica sinensis (Oliv.) Diels   
Wu wei zi 五味子   Schisandra chinensis (Turcz.) Baill.  
Sheng ma 升麻    Cimicifuga foetida L. 
Wu tou 烏頭    Aconitum carmichaeli Debx. 
Huang qin 黃芩    Scutellaria baicalensis Georgi 
Shao yao 芍藥    Paeonia lactiflora Pall. 
Yuan zhi 遠志    Polygala tenuifolia Willd. 
Du huo 獨活    Angelica pubescens Maxim. f . biserrata Shan & Yuan 
Fang feng 防風    Saposhnikovia divaricata (Turcz.) Schischk. 
Chuan xiong 川芎    Ligusticum chuanxiong Hort. 
Ma huang 麻黃    Ephedra sinica Stapf 
Qin jiao 秦艽    Gentiana macrophylla Pall. 
Shi hu 石槲    Dendrobium loddigesii Rolfe. 
Ren shen 人參    Panax ginseng C.A. Mey.  
Fu ling 茯苓    Poria cocos (Schw.) Wolf 
Xing ren 杏仁    Prunus armeniaca L. 
Huang qi 黃蓍 Astragalus membranaceus (Fisch.) Bge. var. mongholicus 
(Bge.) Hsiao 
Zi wan 紫菀    Aster tartaricus L.f.  
Shi gao 石膏    Crystalline gypsum 
Gan cao 甘草    Glycyrrhiza uralensis Fisch. 
Gui xin 桂心    Cinnamomum cassia Presl  
Gan jiang 乾薑    Zingiber officinale (Willd.) Rosc. 
Da dou 大豆    Glycine max (L.) Merr. 
 
Book name: Qian Jin Yi Fang 千金翼方 (680) 
Formula name: Peng zu yan nian bai zi ren wan 彭祖延年柏子仁丸 
Ingredients: 
Bai zi ren 柏子仁   Biota orientalis L., Platycladus orientalis (L.) Franco. 
She chuang zi 蛇床子   Cnidium monnieri (L.) Cuss. 
Tu si zi 菟絲子    Cuscuta chinensis Lam. 
Fu pen zi 覆盆子   Rubus chingii Hu 
Shi hu 石槲    Dendrobium loddigesii Rolfe. 
Ba ji tian 巴戟天   Morinda officinalis How 
Zhi du zhong 炙杜仲    Eucommia ulmoides Oliv. 
Fu ling 茯苓    Poria cocos (Schw.) Wolf 
Tian men dong  天門冬   Asparagus cochinchinensis (Lour.) Merr. 
Yuan zhi 遠志    Polygala tenuifolia Willd. 
Tian xiong 天雄   Aconitum carmichaeli Debx. 
Xu duan 續斷    Dipsacus asperoides C.Y. Cheng & T.M.Ai 
Gui xin 桂心    Cinnamomum cassia Presl 
Chang pu 菖蒲     Acorus graminus or A. calamus L. 
Ze xie 澤瀉    Alisma orientalis (Sam.) Juxep. 
Shu yu 薯蕷    Dioscorea opposita Thunb. 
Ren shen 人參    Panax ginseng C.A. Mey. 
Gan di huang干地黄   Rehmannia glutinosa Libosch. 
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Shan zhu yu 山茱萸   Cornus officinalis Sieb. & Zucc. 
Wu wei zi 五味子    Schisandra chinensis (Turcz.) Baill. 
Zhong ru 鐘乳     Stalactitum tubuliform 
Rou cong rong肉蓯蓉   Cistanche deserticola Y.C. Ma 
 
Book name: Yang Lao Feng Qin Shu 養老奉親書 (1078) 
Formula name: Zhen xin wan 鎮心丸  
Ingredients: 
Chen sha 辰砂    Cinnabar 
Gui 桂     Cinnamomum cassia Presl 
Yuan zhi 遠志     Polygala tenuifolia Willd. 
Ren shen 人參    Panax ginseng C.A. Mey. 
Fu ling 茯苓    Poria cocos (Schw.) Wolf 
Mai men dong 麥門冬   Ophiopogon japonicus (Thunb.) Ker-Gawl. 
Shi chang pu 石菖蒲   Acorus tatarinowii Schott.  
Gan di huang 干地黄   Rehmannia glutinosa Libosch. 
 
Book name: Pu Ji Fang 普濟方 (1107 ) 
Formula name: Gou qi zi jian 枸杞子煎 
Ingredients: 
Gou qi zi 枸杞子   Lycium barbarum L. 
Xing ren 杏仁    Prunus armeniaca L. 
Sheng di huang 生地黃   Rehmannia glutinosa Libosch. 
Ren shen 人參    Panax ginseng C.A. Mey. 1  
Fu ling 茯苓    Poria cocos (Schw.) Wolf 
Tian men dong 天門冬   Asparagus cochinchinensis (Lour.) Merr. 
Bai mi 白蜜    Honey  
Niu sui 牛髓    Ox marrow 
Su酥     Butter 
 
Book name: Sheng Ji Zong Lu 聖濟總錄 (1111)  
Formula name: Fu shen tang 茯神湯 
Ingredients: 
Fu shen 茯神    Poria cocos (Schw.) Wolf 
Fang feng 防風    Saposhnikovia divaricata (Turcz.) Schischk. 
Niu xi 牛膝    Achyranthes bidentata Blume 
Zhi ke 枳殼    Citrus aurantium L. 
Fang ji 防己    Stephania tetrandra S.Moore 
Qin jiao 秦艽    Gentiana macrophylla Pall. 
Xuan shen 玄參   Scrophularia ningpoensis Hemsl. 
Shao yao 芍藥    Paeonia lactiflora Pall. 
Huang qi 黃蓍 Astragalus membranaceus (Fisch.) Bge. var. mongholicus 
(Bge.) Hsiao 
Bai xian pi 白鲜皮   Dictamnus dasycarpus Turcz. 
Ze xie 澤瀉    Alisma orientalis (Sam.) Juxep.， 
Du huo 獨活    Angelica pubescens Maxim. f . biserrata Shan & Yuan 
Gui 桂     Cinnamomum cassia Presl 
Wu wei zi 五味子    Schisandra chinensis (Turcz.) Baill.， 
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Ren shen 人參    Panax ginseng C.A. Mey.， 
Yi Yi Ren 薏苡仁    Coix lacryma-jobi L. var. ma-yuen (Roman.) Stapf 
Mai men dong 麥門冬   Ophiopogon japonicus (Thunb.) Ker-Gawl. 
Ling yang jiao羚羊角，  Saiga tatarica Linnaeus 
Shi gao 石膏    Crystalline gypsum    
Zhi gan cao 炙甘草   Glycyrrhiza uralensis Fisch.， 
Ci shi 磁石    Magnetite 
 
Book name: Bian que xin shu 扁鵲心書 (1146) 
Formula name: Yan Shou Dan 延壽丹 
Ingredients: 
Bai zi ren柏子仁   Biota orientalis L., Platycladus orientalis (L.) Franco. 
Gan ju hua甘菊花   Chrysanthemum morifolium Ramat. 
Fu ling茯苓    Poria cocos (Schw.) Wolf 
Song zhi 松脂    Pinus massoniana Lamb 
 
Book name: San Yin Ji Yi Bing Zheng Fang Lun 三因極一病證方論 (1174) 
Formula name: Xiao dan 小丹 
Ingredients: 
Shu di huang 熟地黃   Rehmannia glutinosa Libosch. 
Rou cong rong 肉蓯蓉   Cistanche deserticola Y.C. Ma 
Wu wei zi 五味子    Schisandra chinensis (Turcz.) Baill. 
Tu si zi 菟絲子    Cuscuta chinensis Lam. 
Bai zi ren 柏子仁   Biota orientalis L., Platycladus orientalis (L.) Franco. 
Tian men dong 天門冬   Asparagus cochinchinensis (Lour.) Merr. 
She chuang zi 蛇床子   Cnidium monnieri (L.) Cuss.  
Fu pen zi 覆盆子   Rubus chingii Hu 
Ba ji 巴戟    Morinda officinalis How 
Shi hu 石槲    Dendrobium loddigesii Rolfe. 
Xu duan 續斷    Dipsacus asperoides C.Y. Cheng & T.M.Ai  
Ze xie 澤瀉    Alisma orientalis (Sam.) Juxep.  
Ren shen 人參    Panax ginseng C.A. Mey. 1   
Shan yao 山藥    Dioscorea opposita Thunb. 41  
Yuan zhi遠志    Polygala tenuifolia Willd. 56  
Shan zhu yu 山茱萸   Cornus officinalis Sieb. & Zucc. 40   
Chang pu 菖蒲     Acorus graminus or A. calamus L.  
Gui xin 桂心    Cinnamomum cassia Presl  
Bai fu ling 白茯苓   Poria cocos (Schw.) Wolf 
Du zhong 杜仲    Eucommia ulmoides Oliv.  
Tian xiong 天雄   Aconitum carmichaeli Debx. 
Zhong ru fen鐘乳粉   Stalactitum tubuliform 
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Book name: Shi Yi De Xiao Fang 世醫得效方 (1337) 
Formula name: Jia wei fu ling tang 加味茯苓湯 
Ingredients: 
Ren shen 人參    Panax ginseng C.A. Mey. 
Ban xia 半夏    Pinellia ternata (Thunb.) Breit. 
Chen pi 陳皮    Citrus reticulata Blanco 
Bai fu ling 白茯苓   Poria cocos (Schw.) Wolf 
Fen cao 粉草    Glycyrrhiza uralensis Fisch. 
Yi zhi ren 益智仁   Alpinia oxyphylla Miq. 
Xiang fu zi 香附子   Cyperus rotundus L. 
 
Book name: Dan Xi Xin Fa 丹溪心法 (1481)  
Formula name: Gui pi tang 歸脾湯  
Ingredients: 
Bai zhu 白術    Atractylodes macrocephala Koidz. 
Fu shen 茯神    Poria cocos (Schw.) Wolf 
Huang qi 黃蓍 Astragalus membranaceus (Fisch.) Bge. var. mongholicus 
(Bge.) Hsiao 
yuan yan rou 圓眼肉   Dimocarpus longan (Lour.) Steud.  
Suan zao ren 酸棗仁   Ziziphus spinosa Hu 
 Ren shen 人參    Panax ginseng C.A. Mey.  
Mu xiang 木香    Aucklandia lappa Decne. 
Gan cao 甘草    Glycyrrhiza uralensis Fisch. 
 
Book name: Yun lin shen gou 雲林神彀 (1591) 
Formula name: Bu xin tang 補心湯 
Ingredients: 
Bai shao 白芍    Paeonia lactiflora Pall  
Ren shen 人參    Panax ginseng C.A. Mey.  
Dang gui 當歸    Angelica sinensis (Oliv.) Diels  
Bai zhu 白術     Atractylodes macrocephala Koidz. 
Fu ling 茯苓    Poria cocos (Schw.) Wolf 
Zhi mu 知母    Anemarrhena aspheloides Bge. 
Gan cao 甘草    Glycyrrhiza uralensis Fisch.  
Chen pi 陳皮    Citrus reticulata Blanco 
Sheng di huang 生地黃   Rehmannia glutinosa Libosch. 
Huang bo 黃柏    Phellodendron amurense Rupr. 
Shi chang pu 石菖蒲   Acorus tatarinowii Schott.   
Mai men 麥門    Ophiopogon japonicus (Thunb.) Ker-Gawl. 
Suan zao ren 酸棗仁   Ziziphus spinosa Hu 
Yuan zhi 遠志    Polygala tenuifolia Willd.  
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Book name: Bian Zheng Lu 辨證錄 (1687) 
Formula name: Shen jiao tang 神交湯 
Ingredients: 
Ren shen 人參    Panax ginseng C.A. Mey. 
Mai dong 麥冬     Ophiopogon japonicus (Thunb.) Ker-Gawl. 
Ba ji tian 巴戟天   Morinda officinalis How 
Bai zi ren 柏子仁   Biota orientalis L., Platycladus orientalis (L.) Franco. 
Shan yao 山藥    Dioscorea opposita Thunb. 
Qian shi 芡實    Euryale ferox Salisb. 
Xuan shen 玄參   Scrophularia ningpoensis Hemsl. 
Dan shen 丹參    Salvia miltiorrhiza Bge. 
Fu shen 茯神    Poria cocos (Schw.) Wolf 
Tu si zi菟絲子     Cuscuta chinensis (fried dried seed) 
 
Book name: Bian Zheng Lu 辨證錄 (1687) 
Formula name: Fu lao wan 扶老丸  
Ingredients: 
Ren shen 人參    Panax ginseng C.A. Mey. 
Bai zhu 白術    Atractylodes macrocephala Koidz. 
Fu shen 茯神    Poria cocos (Schw.) Wolf 
Huang qi 黃蓍 Astragalus membranaceus (Fisch.) Bge. var. mongholicus 
(Bge.) Hsiao 
Dang gui 當歸    Angelica sinensis (Oliv.) Diels 
Shu di 熟地    Rehmannia glutinosa Libosch. 
Shan zhu yu 山茱萸   Cornus officinalis Sieb. & Zucc. 
Xuan shen 玄參   Scrophularia ningpoensis Hemsl. 
Chang pu 菖蒲     Acorus graminus or A. calamus L. 
Bai zi ren 柏子仁   Biota orientalis L.,  
Sheng zao ren 生棗仁   Ziziphus spinosa Hu 
Mai dong 麥冬    Ophiopogon japonicus (Thunb.) Ker-Gawl. 
Long chi 龍齒    Fossilized teeth 
Bai jie zi 白芥子.   Brassica juncea (L.) Czern. & Coss. 
 
Book name: Bian zheng lu 辨證錄 (1687) 
Formula name: Sheng hui tang 生慧湯 
Ingredients: 
Shu di 熟地    Rehmannia glutinosa Libosch. 
Shan zhu yu 山茱萸   Cornus officinalis Sieb. & Zucc.  
Yuan zhi 遠志    Polygala tenuifolia Willd. 
Sheng zao ren生棗仁   Ziziphus spinosa Hu 
Bai zi ren 柏子仁   Biota orientalis L., Platycladus orientalis (L.) Franco.  
Fu shen 茯神    Poria cocos (Schw.) Wolf. 
Ren shen 人參    Panax ginseng C.A. Mey.  
Chang pu 菖蒲     Acorus graminus or A. calamus L.  
Bai jie zi 白芥子   Brassica juncea (L.) Czern. & Coss. 
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Book name: Za Bing Yuan Liu Xi Zhu 雜病源流犀燭 (1773)  
Formula name: Shou xing wan 壽星丸  
Ingredients: 
Jiang yuan zhi 姜遠志   Polygala tenuifolia Willd. 
Ren shen 人參    Panax ginseng C.A. Mey. 
Huang qi 黃蓍 Astragalus membranaceus (Fisch.) Bge. var. mongholicus 
(Bge.) Hsiao 
Bai zhu 白術    Atractylodes macrocephala Koidz. 
Gan cao 甘草    Glycyrrhiza uralensis Fisch. 
Dang gui 當歸    Angelica sinensis (Oliv.) Diels 
Sheng di 生地    Rehmannia glutinosa Libosch 
Bai shao 白芍    Paeonia lactiflora Pall. 
Fu ling 茯苓    Poria cocos (Schw.) Wolf 
Chen pi 陳皮    Citrus reticulata Blanco 
Rou gui 肉桂    Cinnamomum cassia Presl 
Dan xing 膽星    Arisaema heterophyllum Bl. 
Hu po 琥珀    Amber (fossil resin) 
Zhu sha 朱砂    Cinnabar 
Wu wei zi 五味子    Schisandra chinensis (Turcz.) Baill. 
 
Book name: Yi Xue Jian Neng 醫學見能 (1873) 
Formula name: Zhu sha dan fan wan 朱砂丹矾丸 
Ingredients: 
Huang dan黃丹   Lead Tetraoxide (Pb3O4) 
Bai fan白矾    Alumite  
Cha ye 茶葉    Camellia sinensis O.Ktze 
Zhu sha朱砂    Cinnabar 
Zhu xin xue 豬心血   Blood and heart of a pig  
 
Book name: Ci Xi Guang Xu Yi Fang Xuan Yi 慈禧光绪醫方選議 
Formula name: Yan ling yi shou dan 延齡益壽丹  
Ingredients: 
Fu shen 茯神    Poria cocos (Schw.) Wolf 
Yuan zhi rou 遠志肉   Polygala tenuifolia Willd. 
Hang bai shao 杭白芍   Paeonia lactiflora Pall. 
Dang gui 當歸    Angelica sinensis (Oliv.) Diels 
Dang shen 黨參   Codonopsis pilosula(Franch.) Nannf. 
Huang qi 黃蓍 Astragalus membranaceus (Fisch.) Bge. var. mongholicus  
(Bge.) Hsiao 
Ye bai zhu 野白術    Atractylodes macrocephala Koidz. 
Fu ling 茯苓    Poria cocos (Schw.) Wolf 
Ju pi 橘皮    Citrus reticulata Blanco 
Xiang fu 香附    Cyperus rotundus L. 
Guang mu xiang 廣木香  Aucklandia lappa Decne. 
Guang sha ren 廣砂仁   Amomum villosum Lour. 
Gui yuan rou 桂圓肉   Dimocarpus longan (Lour.) Steud.  
Zao ren 棗仁    Ziziphus spinosa Hu 
Shi chang pu 石菖蒲   Acorus tatarinowii Schott. 
Zhi gan cao 炙甘草   Glycyrrhiza uralensis Fisch. 
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